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Abstract 
This thesis falls within the field of chemical biology, describing a selective modification (with controlled 
reversibility) of primary amines of biomolecules.  
Selective conjugation of species to the surface of biomolecules is extremely important in that it allows 
an endless number of biological applications, leading to modify the properties of biomolecules. As 
examples of these modifications, the mimicry of post-translational modifications of proteins, artificial 
glycosylation and immobilization of biomolecules to certain surfaces, incorporation of molecules for 
bioimaging, enhancement of pharmacokinetic properties of biomolecules and drug-delivery possibilities.  
Based on published literature, a selective modification (with controlled reversibility) of primary amines 
on the surface of native proteins and other biomolecules was found and optimized. Its theoretical 
foundations were elucidated with DFT calculations and its reversibility proven with a select set of 
endogenous molecules.  
After the above-mentioned discovery and optimized conjugation, various synthetic modifications have 
been made to induce specific chemical properties to the molecule, keeping the core structure that allows 
conjugation. Several compounds with different properties were synthesized and important biological 
studies were performed. Particularly, a study from which it was concluded that these iminoboronates are 
stable enough to go through cellular internalization and that the conjugation of a cytotoxic drug with a 
biomolecule can possibly increase the selectivity of the internalization of the drug. The study of 
intracellular reversibility of the conjugate is currently in progress through the development of an "ON-OFF" 
probe that is specific for this type of conjugation.  
Nevertheless, in this work it was found that the conjugation system has a deficient reversibility, and for 
that reason experiments were initiated (ongoing work) to improve this bioconjugation to the point that a 
broader number of biological applications can be applied. 
 
 
Keywords:  Lysine functionalization, boronic acids, Iminoboronates, reversible
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Resumo 
A tese apresentada insere-se no campo de química biológica, descrevendo uma modificação selectiva 
(e com reversibilidade controlada) de aminas primárias em biomoléculas. 
A conjugação selectiva de espécies à superfície de biomoléculas é extremamente importante na 
medida em que permite um infindável número de aplicações biológicas, podendo até modificar as 
propriedades inerentes da biomolécula. Como exemplos destas modificações, salientam-se a 
mimetização de modificações pos-translaccionais de proteínas, a glicosilação artificial e a imobilização a 
determinadas superfícies de biomoléculas, a incorporação de moléculas para bioimaging, a alteração de 
propriedades farmacocinéticas de biomoléculas e a possibilidade de distribuição selectiva de compostos 
com propriedades farmacológicas. 
Baseado na literatura publicada, uma modficação selectiva e com reversibilidade controlada de 
aminas primárias à superfície de proteínas naturadas e outras biomoléculas foi encontrada e optimizada. 
As suas fundamentações teóricas foram elucidadas com um estudo de cálculos de DFT e a sua 
reversibilidade comprovada utilizando um conjunto selecto de moléculas. 
Depois de descoberta e optimizada a conjugação supracitada, diferentes modificações sintéticas 
foram feitas para conferir propriedades químicas específicas à molécula, mantendo a estrutura nuclear 
que permite a conjugação. Sintetizados vários compostos com diferentes propriedades, importantes 
estudos biológicos poderam ser feitos. Nomeadamente, o estudo que permitiu concluir que os 
iminoboronatos são estáveis o suficiente a um processo de internalização celular e que a conjugação de 
um fármaco citotóxico a uma biomolécula poderá aumentar a selectividade da internalização do fármaco. 
O estudo de reversibilidade intracelular do conjugado está neste momento a decorrer, através do 
desenvolvimento de uma sonda “ON-OFF” específica para este tipo de conjugações. 
Ainda assim, no decorrer do trabalho, verificou-se que o sistema de conjugação tem uma 
reversibilidade deficiente, pelo que, foram iniciadas experiências (ainda em curso) para melhorar esta 
bioconjugação ao ponto de potenciar as suas aplicações biológicas. 
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ABSTRACT 
Proteins are biomolecules that carry out the majority of cell’s functions, acting as their structural blocks, 
as catalysts and regulators of all processes concerning cell cycle or cellular metabolism. Not to mention, 
therapeutic peptides or proteins that show pivotal importance to some pathologies. However, since these 
molecules are unstable to several conditions, peptide and protein enhancing technologies are being 
developed in order to stabilize such biomolecules or to create more efficient delivery systems, either by 
conducting the protein itself or acting as a carrier for a given drug.  
Selective modification of native proteins is one of the approaches to change a protein’s properties 
without varying its function or natural structure. Usually, selective reactions that take place under naturing 
conditions are studied with the intention of modifying one amino acid, in the presence of several functional 
groups of a peptide/protein. Selective bioconjugation relies on amino acids’ properties, whether for their 
reactivity, as much as for their occurrence in proteins or their accessible surface area. 
In this chapter, a state of the art of chemical modification of proteins will be presented.
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Chapter I.   
State of the Art 
I.1. Protein Modification 
Proteins are biomolecules that are responsible for a wide variety of functions, namely as catalysts in 
cellular metabolism as regulators of cell cycle, differentiation, growth, division, motility, death, among 
others.1 Moreover, proteins are vital members of a cell communication system that controls cellular 
activities and actions, called cell signalling. Considering the three most important classes of signalling 
molecules: hormones, neurotransmitters and cytokines, amino acid based biomolecules are the base for 
two of them. For example, peptide/protein hormones like TRH, vasopressin, insulin or growth hormone 
are invaluable molecules for a living organism, as well as cytokines that are a large group of small proteins 
that represent the core of all immune system.2  
Many of those functions, crucial for the signalling network, are dependent on a tightly controlled system 
of in vivo chemical modifications of proteins, which are called post-translational modifications (PTMs). 
Examples of such reactions are phosphorylations, glycosylations, ubiquitinations, methylations or 
acetylations, each with its important role to perform a given function.3 A clear example of the importance 
that these modifications have to a living organism are those operated on histones. 
Histones are proteins found in eukaryotic cell nuclei that are wrapped around by the DNA helix creating 
cored structures named nucleosomes. These are, subsequently, folded into higher order structures called 
chromosomes.  Despite the clear organization induced by these proteins to an otherwise disorderly DNA, 
they are also quite relevant in terms of gene regulation, and at this point is where PTMs play a substantial 
role. For example, histone acetylation and deacetylation are processes that occur at the ε-amine of the 
side chain of lysine residues within the N-terminal tail protruding from the histone core of the nucleosome. 
Acetylation removes the positive charge on the histones, thereby decreasing the interaction of the 
N-termini of histones with the negatively charged phosphate groups of DNA. As a consequence, the 
condensed chromatin is transformed into a more relaxed structure that is associated with greater levels 
of gene transcription.4,5 
Other examples of important PTMs are those occurring on proline residues in the transcription factor 
HIFα, which are involved on oxygen-sensing mechanisms within cells and, also, the phosphorylation 
cascades that occur on different amino acids which are crucial for intracellular signalling.6 All of which 
demonstrate the function modulation that is stressed by these “simple” peptide or protein modifications. 
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Nonetheless, to fully comprehend the biological role of PTMs and to determine precise structure-activity 
relationships, access to pure protein derivatives is crucial.7 Natural protein production methods usually 
lead to complex PTM mixtures, making it difficult to determine which derivative is causing what effect. 
Therefore, chemical modification of proteins that allow the production of artificial post-translational 
modification mimics can be a useful tool to achieve pure mimics of complex PTMs or to create artificially 
modified proteins.8 
Historically, chemical modification of proteins started with the chemistry of amino acids themselves 
and, only later, concerning the amino acid side chains of intact proteins. In the early 20th century, 
experiments were done based on empirical observations and as a result, determinant data was gathered, 
for instance, for the tanning industry or for toxicology. During this period a significant number of proteins 
were also crystallized. Before World War II, few analytical data of individual amino acid was available. 
After this historical landmark, identification of which amino acid was responsible for the biological activity 
of proteins (active sites) started to be the object of study. During the next twenty years, some techniques 
were studied that allowed a greater knowledge of these biomolecules: cation-exchanger amino acid 
analyser; radioactively labelled reagents; amino acid analysers or ion-exchange and gel exclusion 
chromatography. In 1962, the first selective modification was performed by Wofsey et al., modifying a 
chymotrypsin’s histidine that, consequently, eliminated its catalytic activity. During the 80’s and 90’s there 
was a large improvement of bioconjugation reagents and techniques, mainly enhanced by the evolution 
of mass spectrometry.9  
More recently, with the production of recombinant proteins and their constant improvement, these 
biomolecules have become commercially interesting (estimated in $90+ billion U.S. market share in 
2009).10 This procedure allied with bacteria or yeast engineering to incorporate site-selective natural or 
non-natural amino acids on a protein sequence led to relevant developments on synthetic biology.1 
Protein modifications enable the modulation of the biomolecule’s properties and the tracking of its 
distribution in vitro or in vivo, using, for instance, fluorescence based techniques or affinity tagging. 
Moreover, therapeutic and signalling protein conjugates have become very promising constructs for 
studying pathologies, such as: HIV,11,12 cancer,11,13,14 malaria,11,15 neurodegenerative diseases like 
Alzheimer’s disease,15 acromegaly13 or Angina Pectoris.12 The most ambitious goal in the field of protein 
modification is to create conjugates and biomarkers relevant for the development of new therapeutic 
molecules or systems that lead to a more effective and targeted therapy.16 
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I.2. Site-Selective Modification 
Selective chemical modification of proteins is a very wide area of research that can be divided into 
three different groups, each facing different limitations: modification of natural amino acid side chains, 
modification of terminal residues or modifications of non-natural amino acids. Each of these groups will 
be discussed in detail. When considering a site-selective modification, the functionalization of a single 
residue in the presence of multiple unprotected functionalities is a remarkable chemical challenge. 
Particularly, in order to have broad applicability, these methodologies need to operate in conditions that 
prevent unfolding of the protein, namely these reactions need to be fast at low temperature and at near 
neutral pH. Furhermore, proteins are only available in low concentrations, and therefore the modification 
reactions have to occur at high dilution. All these requirements limit the choices of chemical reactions that 
can be used for this purpose.11 Nevertheless, several examples have already been studied and will be 
presented below. 
 
I.2.1. Modification of Natural Amino Acids 
With the development of techniques such as genetic engineering, a new possibility for modification of 
proteins has emerged. Site-selective modification of proteins through reaction with amino acids 
incorporated at specific sites of a protein’s sequence makes it possible to overcome a number of 
limitations that conjugation to non-recombinant proteins usually face. These limitations are often related 
with the latent properties of the amino acids, whether for their natural occurrence and accessible surface, 
as for their chemical reactivity (Table 1). 
Nine of the canonical amino acids can be referred as chemically active, and, thus suitable for natural 
amino acids modification (highlighted in Table 1), namely, acidic residues (aspartic acid and glutamic 
acid), aromatic amino acids (tyrosine and tryptophan), sulfur containing amino acids (methionine and 
cysteine) and nitrogen containing side chains (histidine, lysine or arginine, as well as N-terminal function). 
Of all the properties mentioned in the table, reactivity of the amino acid side chain is the most efficiently 
explored. Exactly for this reason, cysteine and lysine, having the best nucleophiles in their side chains, 
are the residues most commonly modified.1,10 Less often, carboxylate or hydroxyl functionalities can also 
be targeted, as being nucleophiles, though a lack of selectivity is often observed due to the frequent 
presence of functional groups with similar characteristics.17 For this reason, modification of cysteines and 
lysines will next be discussed in more detail, while the functionalization of other groups will be briefly 
summarized. 
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Table 1 – Amino acids’ propertiesa  
Amino Acid 
pKa of ionizing 
side chain 
Occurrence in 
proteins (%) 
Buried 
residues (%) 
Accessible 
surface area (A2) 
Alanine  
(Ala, A)  
- 7.5 38 (12) 67 
Arginine  
(Arg, R)  
12.5  
(>12) 
5.2 0 196 
Asparagine 
(Asn, N)  
- 4.6 10 (2) 113 
Aspartic Acid 
(Asp, D)  
3.9  
(4.4 – 4.6) 
5.2 14.5 (3) 106 
Cysteine  
(Cys, C)  
8.3  
(8.5 – 8.8) 
1.8 47 (3) 104 
Glutamic Acid 
(Glu, E)  
4.3  
(4.4 – 4.6) 
4.1 6.3 (2.2) 144 
Glutamine  
(Gln, Q)  
- 6.3 20 (2) 138 
Glycine  
(Gly, G)  
- 7.1 37 (10) - 
Histidine  
(His, H)  
6.0  
(6.5 – 7.0) 
2.2 19 (1.2) 151 
Isoleucine  
(Ile, I)  
- 5.5 65 (12) 140 
Leucine  
(Leu, L)  
- 9.1 41 (10) 137 
Lysine  
(Lys, K)  
10.8  
(10.0 – 10.2) 
5.8 4.2 (0.1) 167 
Methionine 
(Met, M)  
- 2.8 50 (2) 160 
Phenylalanine 
(Phe, F)  
- 3.9 48 (5) 175 
Proline  
(Pro, P)  
- 5.1 24 (3) 105 
Serine  
(Ser, S)  
- 7.4 24 (8) 80 
Threonine  
(Thr, T)  
- 6.0 25 (5.5) 102 
Tryptophan 
(Trp, W)  
- 1.3 23 (1.5) 217 
Tyrosine  
(Tyr, Y)  
10.9  
(9.6 – 10.0) 
3.3 13 (2.2) 187 
Valine  
(Val, V)  
- 6.5 56 (15) 117 
a For more detail, see reference 18 
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I.2.1.1. Cysteine 
Cysteine has a sulfhydryl group on its side chain, which makes it the strongest natural nucleophile of 
a protein. Therefore, this functionality is the easiest to manipulate selectively with chemical reagents, even 
at neutral pH.13 Another important characteristic of cysteines that allows the site-selective functionalization 
of proteins is its scarce occurrence in proteins (1.8%)19,20 conferring cysteine modification a very high 
specificity but a limited number of applications without resorting to genetic manipulation of proteins or 
reducing agents (used to disrupt natural occurring disulfide bridges). 
The first reaction that modified the side chain of cysteine was an alkylation using an appropriate 
electrophile, which goes back to 1935. Goddard and Michaelis used iodoacetamides to alkylate cysteines 
of queratine.21 The reaction had its flaws (crossed reactivity with other nucleophiles, such as lysine), but 
it was an important starting point in research of different electrophiles suitable for this purpose. From 
these, other α-halocarbonyls emerged (2, Scheme 1), such as chloroacetamide or α-bromoacetophenone 
derivatives, which were more selective and permitted the alkylation of the active center of papain, 
transforming this cysteine protease into an inactive enzyme.22 
 
 
+ 
 
 
 
1  2  3 
Scheme 1 – Cysteine modification – α-Halocarbonyls, X = Cl, Br or I and R = NHR’ or Ar 
 
Nucleophilic substitution for protein modification continued to be evaluated over the years, leading to 
other interesting studies, such as the production of lysine mimics by aminoethylation (Scheme 2), or the 
introduction of chemical haloaryl functions (Scheme 3) or the generation of glycoproteins using halo-
glycosyl donors.23 
The lysine mimetics were obtained via reaction of the cysteine thiol group with aziridines, prepared in 
situ with β-haloethylamines, 4, producing a thioether with a terminal primary amine (5, Scheme 2).11 
 
 
+ 
 
 
Base 
 
1  4  5 
Scheme 2 – Cysteine modification – β-Haloethylamines, X = Cl or Br 
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Later, the cysteine thiol group was modified to incorporate a halogenated aromatic moiety that was 
subsequently used to perform a Suzuki-Miyaura cross-coupling reaction (Scheme 3). By using 
1-bromomethyl-4-iodobenzene, 6, for the nucleophilic substitution and palladium (0) complex, 8, to 
catalyze the cross-coupling, Davis et al. modified a recombinant protein under mild conditions (phosphate 
buffer, pH 8.0, at 37 ºC) leading to the formation of a glycoprotein, among other examples.24  
 
 1.PMSF    
 2.DTT  R-B(OH)2 or R-BPin  
1 
3.  
6 
7  
8 
9 
Scheme 3 – Cysteine modification leading to cross-coupling Suzuki-Miyaura  
 
Another example of alkylating agents that have been largely used for cysteine modification are Michael 
acceptors like acrolein, vinyl sulfones, alkynoic amides  and maleimides.11,13,19,25–28  
Acrolein being one of the strongest electrophiles among all α,β-unsaturated aldehydes was shown to 
be unselective, exhibiting cross-reactivity with histidine and lysine. Nevertheless, it was used to promote 
structural modifications of soy protein.29 
Over the years, maleimides (10) have been the most used scaffold to label cysteine residues. These 
Michael acceptors can react rapidly and selectively with thiols at slightly acidic to neutral pH (6.5-7.5), 
generating a thioether bond, 11 (Scheme 4). Above pH 8.0, maleimides are hydrolytically labile, forming 
nonreactive maleamic acids (12, Scheme 4) and present cross-reactivity with amino groups. The construct 
hydrolysis is also dependent on the chemical nature of the maleimide N-substituent.30 Furthermore, recent 
studies on the stability of maleimide-conjugates in human plasma and in vivo assays, highlight a cross-
reactivity of these conjugates with reactive thiols from albumin, free cysteine or glutathione, if the 
maleimide conjugation site is highly solvent accessible or if the hydrolysis is promoted by a positively 
charged environment at partially accessible cysteines.31 
 
 
+ 
 
 
 
>pH 8.0 
 
1  10  11  12 
Scheme 4 – Cysteine modification  –  Maleimides 
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This Michael addition is one of the most studied and understood reactions for bioconjugation and has 
been used in the construction of several bioconjugates.  
The extensive use of this bioconjugation scaffolds resulted in a detailed knowledge of the properties 
of this molecule in terms of conjugation and stability of the constructs and now, maleimides are often used 
as reference when designing new reagents for protein modification.32–36 Moreover, maleimides are 
currently commercially available to apply different biological applications. 
Due to the large number of applications in which maleimides have been used, an organization based 
on the recurrence of the application was made. The three most important groups of applications either 
use maleimides to develop potential diagnostic tools and therapeutic agents, or to grant certain biological 
properties into biomolecules or as one of the counterparts of heterobifunctional linkers. 
Several strategies have been pursued for developing novel therapeutic agents based on maleimide 
conjugation, though two are particularly important. PEGylated maleimides have been used to improve the 
pharmacokinetics properties of biomolecules such as therapeutic peptides or proteins. In another field, 
maleimides have been extensively used to conjugate drugs to biomolecules that are selectively 
recognized by a specific target. The synthesis of antibody-drug conjugates (ADCs) is one of the most 
important examples. Drugs combined to an antibody by means of maleimide conjugation are one of the 
most recurring methods and led to the development of an Food and Drug Administration (FDA) approved 
ADC, named brentuximab vedotin (Adcetris®).37–41  
As examples of maleimides that have been conjugated to proteins to grant some originally absent 
biological properties, artificial glycosylation by means of glycosylmaleimides can be mentioned or even 
the incorporation of biotin-maleimides in order to have a recognizable agent for surface 
immobilization.16,42–44 
Lastly, another common application that uses maleimide conjugation is based on the development of 
bifunctional linkers that attach molecules through different conjugation systems. There are two main 
strategies with these maleimide heterobifunctional linkers: one that introduces bioorthogonal groups (such 
as azides, alkynes or olefins) on the opposite end of maleimides and another that introduces amine 
reactive groups (e.g. N-hydroxysuccinimide (NHS) esters) for the same purpose.45–49 
 
As an alternative for maleimides, bromomaleimides (13) were described in 2009 as reagents for 
selective and reversible modification of cysteine (Scheme 5). This reversibility feature was introduced to 
an otherwise irreversible reaction, which could be extremely useful for temporary modifications. According 
to the authors, this reversible modification of cysteine could be used for transitory blockage of an active 
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cysteine residue, cysteine conversion into dehydroalanine (Dha, 15, Scheme 5), protein purification, 
quantitative proteomic analysis, probing of binding sites, possibility of structural studies or even drug 
delivery. 
 
 
+ 
 
 
TCEP or GSH 
 
 
Base 
 
1  13  14  15 
Scheme 5 – Cysteine Modification  –  Monobromomaleimides 
 
A year later, Caddick, Baker et al. reported a system to reversibly modify a cysteine residue 
incorporated in a mutant protein, enabling a controlled separation between the conjugation molecule and 
labeled protein. In the same study, bromomaleimides were proven as plausible molecules to create pro-
drugs, since they, presumably, present a controlled release in the cell’s interior, when in the presence of 
higher concentrations of glutathione.13 
Exploring the structural versatility of bromo and thiomaleimides,50–52 these molecules have been used 
in artificial glyscosylation, biotinylation, PEGyaltion, development of fluorescent bromomaleimides and, 
more recently, ADC’s production.51,53–58 
 
Oxidation of cysteine is an additional method that can be used to modify this residue in a protein, in 
order to form disulfide bridges between the thiol-side chain and alquilated reagents of 
methanethiosulfonate (MTS, 16, Scheme 6) or other thiol-disulfide exchange reagents, such as pyridyl 
disulfides or 5-thio-2-nitrobenzoic acid (TNB)-thiol-activated species.11,30  
 
 
+ 
 
 
 
1  16  17 
Scheme 6 – Cysteine modification  –  Alquilated reagents of methanethiolsulfonate 
 
Through derivatization with MTS, Jones et al. varied the specificity of two pockets (S1 e S1’) of subtilisin 
in Bacillus lentus and Davis et al., using this approach was able to modify important substrates that were 
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shown to be sensitive systems to detect inflammatory illnesses of mammal brains, like Malaria or 
Alzheimer’s disease.15,59  
Remarkably, using another thiol-disulfide exchange reagent (a TNB-thiol-activated species), Neri et 
al. recently applied this approach for the development of linkerless ADCs where a thio-drug was directly 
conjugated with antibody fragments. These ADCs, in the presence of reducing agents such as glutathione, 
unconjugate without any trace of linker attached to either counterpart, thus developing a traceless 
conjugation method.60–62 
 
Since the disulfide bridge formed during the oxidation of cysteine is sensitive to reducing environments 
and this can be a limitation for some applications, it was important to find a procedure to reduce this 
linkage to more stable thioethers (Scheme 7). With this purpose, Davis et al. developed  such procedure 
using phosphines and applied it in the reduction of an oxidized form of cysteine in a mutant protein 
(SBL-S156C) at basic conditions (phosphate buffer pH 9.5).63 
 
 
 
Several Steps 
 
98  18 
Scheme 7 – Cysteine modification – Reduction of previously forms of oxidized cysteines 
 
Apart from the already discussed additions, substitutions, oxidations and reductions of cysteine and 
derivatives, there is a strategy that converts the most nucleophilic residue among all natural amino acids 
(Cys) into an electrophilic species (Dha). Since proteins do not have natural occurring electrophiles this 
new formed species becomes a valuable synthetic precursor to a wide collection of protein 
modifications.64  There are different methods to install Dha on the protein surface based on the elimination 
of cysteine, which include the reduction-elimination of cysteine-disulfides, the base-mediated elimination 
of cysteine-disulfides, the oxidative-elimination of cysteine and the bis-alkylation-elimination of cysteine.65 
The first two strategies are based on the previously described method of oxidation of cysteines to 
generate disulfides, which can then be reacted with phosphines (regioselective reduction with 
tris(dimethylamino)phosphine (HMPT)) or bases (e.g. 1,8-Diazabicycloundec-7-ene (DBU)) to further 
convert these residues.  
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The oxidative-elimination of cysteine to obtain Dha uses O-mesitylenesulfonylhydroxylamine (MSH, 
19) as the oxidizing agent in a phosphate buffer pH 8.0, during 20 min, at 4 ºC (Scheme 8).66 Later, some 
side-reactions of this method were presented with other nucleophilic amino acids (Asp, Glu, Met, Lys, and 
His) and with the N-terminal amino group.65  
 
 
+ 
 
 
 
1  19  15 
Scheme 8 – Cysteine modification – Dehydroalanine generation (1) 
 
In order to avoid this cross-reactivity, the same authors tested a potentially more selective 
transformation: the bis-alkylation–elimination of cysteine to dehydroalanine. Several reagents were tested 
to achieve a fast formation of the 5-membered ring sulfonium intermediate and subsequent elimination to 
generate Dha. Different water-soluble reagents with the required 1,4-dihalobutane moiety were evaluated 
in order to grasp the optimal intended modification (Scheme 9), which led to the modification of 
SBL-S156C with bisamide of the 1,4-dibromobutane core, at pH 8.0. However, this procedure requires 
incubation for one h at 37 ºC in order to induce cyclization and elimination. 
 
 
+ 
 
 
 
 
 
1  20  21  15 
Scheme 9 – Cysteine modification – Dehydroalanine generation (2) 
 
Later, Caddick et al. reported an unexpectedly stable cyclic sulfonium intermediate, which was 
explored as a different strategy to modify cysteines, enabling a site-selective dual labelling of a mutant 
green fluorescent protein (GFP) using the same cysteine modifying reagent 
(2,5-dibromohexanediamide).67,68 The ring opening of the stable cyclic sulfonium intermediate was 
selectively obtained by treatment of the construct with sodium azide (which was then reacted with a 
commercially available strained alkyne dye) and Dha was reacted with a thiol dummy in order to show 
selective reactivity for both electrophiles.68 
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Regarding other methods to modify cysteine, it is worth mentioning a click process based in addition 
reactions of thiols to alkenes or alkynes, designated as thiol-ene coupling (TEC) and thiol-yne coupling 
(TYC). These processes rely in a radical mechanism, in order to give anti-Markovnikov-type thioether.69 
Dondoni and Davis developed a system based in this free-radical hydrothiolation of alkynes to give a 
dithioether derivative with exclusive 1,2-addition, showing as applications artificial glycosilation and 
fluorescent labeling of proteins.70 
 
A series of new reagents for selective modification of cysteine residues were recently reported and 
they present interesting characteristics that show promising applications. These reagents include 
perfluoroaromatic molecules, 2-cyanobenzothiazole, methylsulfonylbenzothiazole, phenyloxadiazole and 
allenamides. 32,71–80 
Pentelute et al., in 2013, reported the discovery of a nucleophilic aromatic substitution (SNAr) between 
perfluoroarenes and cysteine residues from unprotected peptides, at room temperature (Scheme 10). 
These authors describe their conjugation system as a method to access rigid perfluoroaromatic staples 
that fulfils several requirements of “click” chemistry.79 Nevertheless, the insolubility and low reactivity of 
such reagents in aqueous media led them to turn their attention to an enzymatic “click” ligation promoted 
by glutathione S-transferase (GST) which is responsible for cellular xenobiotics detoxification in vivo. This 
enzyme recognizes the glutathione moiety and performs a site-specific modification of its cysteine residue 
with an activated perfluoroaryl electrophile in the presence of other unprotected cysteine residues, as well 
as other reactive functional groups.72 
 
 
+ 
 
 
GST 
 
1  22  23 
Scheme 10 – Cysteine modification – Perfluoroaromatic Molecules 
 
In 2009, Rao et al. described the modification of an N-terminal cysteine residue with 
2-cyanobenzothiazole (25, CBT) derivatives (Scheme 11) by transposition from a reaction used in the last 
step of the synthesis of D-luciferin (a common substrate for firefly luciferase) that occurs smoothly in 
aqueous media. During this first assay, the authors synthesized three CBT derivatives, two fluorescent 
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ones and a biotin-derivative, which were used to show that this condensation proceeds with a high degree 
of specificity and efficiency, at physiological conditions, in vitro and on cell surfaces.77  
A year later, the same authors described an interesting study that allowed direct imaging of the 
condensation products generated by glutathione reduction and proteolytic hydrolysis inside cells revealing 
their different subcellular locations, demonstrating the feasibility of a controlled and localized reaction in 
living cells. This intracellular condensation process enabled the imaging of the proteolytic activity of furin 
which can be a good indication for in vivo molecular imaging of cancer and selective drug delivery to 
tumor cells that often overexpressed proteases like furin and cathepsins.80 In 2012, Rao, Chin et al. 
presented an efficient method for site-specific 18F-labeling of cysteine-bearing peptides and proteins, by 
developing 18F-CBT which was used to show good in vivo tumor targeting efficiency for positron emission 
tomography (PET) imaging. However, the increased accumulation of their conjugate in livers showed that 
this structure needs to be optimized in order to increase hydrophilicity.73 
 
 
+ 
 
 
 
24  25  26 
Scheme 11 – N-terminal cysteine modification – 2-Cyanobenzothiazole 
 
Following this work, Chin et al. were  able to genetically encode an unnatural amino acid featuring 
1,2-aminothiols (as mimetics of N-terminal cysteines) in the side chain, thus facilitating this bioorthogonal 
condensation75 and Lin et al. were  able to promote such condensation to apply a novel site-selective 
protein immobilization method.74  
In 2013, Chang et al. developed an ingenious strategy for dual analyte detection in living systems that 
was mostly based on this condensation. Peroxy Caged Luciferin-2 (28) was developed, bearing a H2O2-
responsive boronic acid probe that releases CBT-6-OH upon reacting with reactive oxygen species, which 
in turn reacted with a N-terminal D-cysteine released from a peptide-based probe (27) in the presence of 
active caspase 8, to generate firefly luciferin in situ (Scheme 12). In this case, the bioluminescent signal 
from luceferin represents the presence of reactive oxygen oxygen species and caspase 8 activity. This 
shrewd method offers a potentially powerful tool for studying simultaneous oxidative stress and 
inflammation processes in living animals during injury, aging and other pathological abnormalities.76,81 
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LPS 
 
27  28  29 
Scheme 12 – Dual-Analyte Luciferin Imaging; LPS - Lipopolysaccharides 
 
In 2012, Xian et al. described the use of similar probes as electrophiles in a selective nucleophilic 
substitution. After attempting different leaving groups at the position two of the benzothiazole, the authors 
described methylsulfonyl benzothiazole reagent (30) as a selective protein thiol blocking agent (Scheme 
13). This study evaluated the selectivity when using this reagent at different pHs and against different 
amino acids with different nucleophilic side chains (namely, tyrosine, serine, lysine, histidine, methionine 
and tryptophan), revealing that the substitution occurs faster in basic pHs, though, at the same time, it 
promotes cross-reactivity with amines.82 
 
 
+ 
 
 
 
1  30  31 
Scheme 13 – Cysteine modification – Methylsulfonyl benzothiazole 
 
Inspired by this work, a year later, Barbas III et al. synthesized a series of methylsulfonyl-functionalized 
monocyclic compounds to be used as selective thiol alkylating reagents. This study revelead that 
phenyloxadiazole (32) reacts with cysteine-protected amino acids to afford quantitatively the conjugate in 
less than 5 minutes (Scheme 14). The authors also demonstrated that such scaffolds are amenable to 
synthetic manipulation allowing the site-selective introduction of fluorophores, azides and 
poly(ethylene)glycol chains at the surface of proteins. The phenyloxadiazole diapoles were also shown to 
produce more stable constructs than the ones obtained with maleimides.32 
 
 
+ 
 
 
 
1  32  33 
Scheme 14 – Cysteine modification – Phenyloxadiazole 
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Finally, very recently, allenamides (34) have been described as novel orthogonal handles for selective 
modification of cysteine in fully unprotected peptides and proteins (Scheme 15). These reagents show 
great promise due to a combination of factors, such as the fast kinetics of C-substituted allenamides 
towards thiols, its unreactivity towards amine and hydroxyl nucleophiles and their stability in aqueous 
media. This conjugation method also permit the synthesis of stable and irreversible conjugates with 
interesting characteristics.78  
 
 
+ 
 
 
 
1  34  35 
Scheme 15 – Cysteine modification – Allenamides 
 
These novel modifications of cysteine residues are expected to produce valuable applications in a 
near future and shouldn’t be disregarded while thinking about alternatives to more classic methods of 
conjugation, such as the one with maleimides. 
 
To close the topic of cysteine modification it is required to mention the disulfide bridging reduction-
alkylation strategy, since a vast portion of relevant natural proteins do not have free unpaired cysteines, 
available for modification. Usually, proteins present an even number of cysteines that pair up to form 
disulfides, which are considered to be crucial for tertiary structure and biological activity, thus, seen as 
unsuitable targets for chemical modification. However, since usually one has to use recombinant 
engineering to introduce a free cysteine for further modification, a strategy that reduces selectively 
naturing occurring disulfides using mild reducing conditions presents a valuable alternative for selective 
and efficient addition chemistry of thiols.83,84 
By separating disulfide bridges according to their solvent accessibility, Shaunak, Brocchini et al. 
showed that it was possible to use dithiothreitol (DTT) or tris(2-carboxyethyl)phosphine (TCEP) to reduce 
a disulfide bridge to its two free cysteine sulfur atoms, maintaining the protein’s tertiary structure, as the 
buried disulfides remained intact. This would only be possible without using denaturants in order to ensure 
that inaccessible disulfides are not reduced. After reduction, a bis-alkylation conjugation is performed to 
reconnect the two cysteine sulfur atoms via a three-carbon bridge or a two-carbon bridge.83 
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In 2005, Alley et al., members of Seattle Genetics, studied the possibility of achieving precise control 
over the location of the conjugation in the preparation of homogenous ADCs. This was obtained by 
chemical reduction and oxidation methods that lead to preferential cleavage of particular monoclonal 
antibody interchain disulfides and subsequent alkylation with maleimides.85 This pioneer study set the 
basis for selective bioconjugation on disulfide rebridging using chemical reagents specially designed for 
this purpose. 
 
In 2006, Shaunak, Brocchini et al. described one of those rebridging disulfide procedures using cross-
functionalized PEG monosulfone (37) to generate a three-carbon bridge between two sulfur atoms that 
were previously reduced from a disulfide bridge (Scheme 16). The α,β-unsaturated ketone present in 
compound 37 is require to initiate the sequence of addition-elimination reactions, which starts from the 
1,4-addition of the thiol leading to an elimination of sulfinic acid, generating another conjugated double 
bond for the second thiol addition.84 Several PEGylation systems were developed by this group in the 
following years for different applications, leading to the production of a stable ADC.35,83,86–89 
 
 
 
1. DTT or TCEP 
 
2.   
36  37  38 
Scheme 16 – Disulfide bridge modification – Monosulfone 
 
In 2010, Caddick, Baker et al. developed a different rebridging disulfide procedure using 
dibromomaleimides (39) to generate a two-carbon bridge without the requirement of an additional 
asymmetric carbon (Scheme 17). The authors started from synthesizing N-fluoresceindibromomaleimides 
to conjugate somatostatin’s disulfide bridge in order to demonstrate this idea, then the authors tried to 
optimize this conjugation by changing bromo for other good leaving groups, like chloro, iodo, 
dimercaptoethanol and dithiophenol substituents.51,53 Dibromo and dithiomaleimides proved to be the 
most efficient reagents for this procedure.54,55,90 
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DTT or TCEP 
 
36  39  40 
Scheme 17 – Disulfide bridge modification – Dibromomaleimides 
 
In conclusion, several reagents have been used to selectively modify cysteine residues, since this 
amino acid has singular characteristics ideal for chemical modification. From simple nucleophilic 
substitutions and conjugate additions, through thiol-dissulfide exchange reagents and their reduction, as 
well as dehydroalanine generation and transition-metal-catalysed C-C bond-forming reactions, not to 
mention the novel chemical reagents for selective modification of cysteine and the disulfide bridge 
reduction-alkylation procedure, all show promising results to obtain even more selective and homogenous 
protein and peptide conjugates. Probably, there are still new cysteine modification agents yet to emerge 
as the demand for specificity of conjugation sites becomes firmer over the time. This requirement is even 
amplified when therapeutic strategies and fundamental biological studies are envisioned. 
 
I.2.1.2. Lysine 
Another natural amino acid (NAA) that is largely used for protein modification due to its natural 
characteristics is lysine. This is an amino acid with a primary amine on its side chain, making lysine the 
second best nucleophile of a protein, apart from cysteine.28 It has been reported that this ε-amine can be 
distinguished from other α-amines on a protein’s surface through its pKa  (pKa of 9.3–9.5 for lysine versus 
pKa of 7.6–8.0 for α-amines), but depending upon the reaction’s selectivity, cross-reactions can occur 
with other nucleophilic residues, such as the imidazol group of histidine, or the hydroxyl function of serine, 
threonine or tyrosine, and the thiol group from cysteine, as well as, the most common interferent, the 
α-amine group of N-terminal functions.12 In addition to this, lysines are also often positioned on the 
surface, making it available to be simply derivatize.30 The modification of lysines typically generates 
heterogenous constructs, which depending on the application, may be considered as a limitation. 
Although lysine is a considerably more abundant amino acid than cysteine, this residue is a common 
target for modification due to its nucleophilicity, surface exposure and abundance of methods to 
selectively aim primary amines.91 The most common reagents to modify these amines proceed via the 
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acylation or alkylation of the ε-amine group, yielding stable amides or secondary amines, respectively. 
Examples of such reagents are: acyl azides, activated esters (NHS and fluorophhenyl esters), 
carbodiimides and anhydrides that form amide bonds and aldehydes and glyoxals (with subsequent 
reduction), epoxides and oxiranes, arylating agents that yield secondary amines. Other groups of reagents 
to obtain different or the same linkages are: iso(thio)cyanates, sulfonyl chlorides, carbonates, imidoesters, 
hydroxymethyl phosphine derivates, O-alkylisoureas, diketene,92 ethyl squaramyl group,93 
imidazole-1-sulfonyl azide,94 aldehyde terpenoids (such as (E)-3-methoxycarbonyl-2,4,6-trienal) and 
reductive alkylation with iridium.28,30,95  
Despite having this much modifications reported, some are more recurrent then others. For that 
reason, anhydrides, isocyanates, activated esters and different aldehydes will be discussed in further 
detail, together with other very promising studies for future application. It is of note that most of these 
reagents can additionally modify the N-termini of proteins, though since usual heterogeneity is already 
obtained (due to a high abundance of lysine), this modification does not add crucial relevance.91 
Anhydrides (42) were one of the first lysine derivatization group of reagents to be used. These reagents 
perform an acylating reaction with amines (preferentially at pH ~8 or above, Scheme 18), but present 
cross-reactivity with residues bearing hydroxyl functions.96  
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Scheme 18 – Lysine modification – Anhydrides 
 
In the late sixties, several anhydrides were described as reversible blocking agents of amino groups, 
starting from maleic and citraconic, moving to acetic, trifluoroacetic, succinic and tetrafluorosuccinic 
anhydrides.97 Other examples could be named to demonstrate the vast applicability of these molecules,98 
but it is far more pertinent to give an impression of their evolution. This group of reagents started by using 
symmetric anhydrides (where R1=R2, 42, Scheme 18), as the ones aforementioned, and evolved for more 
complex structures of mixed anhydrides (where R1≠R2, 42, Scheme 18), in which mixed carbonic 
anhydrides and cyclic anhydrides are the representative sets.99 However, this does not mean that 
symmetric anhydrides are not used currently, since, even to this day, a common method for protection of 
amino groups in solid phase peptide synthesis (SPPS) is to use an excess of a symmetric anhydride 
(acetic anhydride) to avoid side reactions.100,101 As for all well-known reagents for protein modification, 
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these agents also present a vast number of applications already tested. Freeman et al. presented a study 
of protein modification with different anhydrides that led to changes in the crystals’ porosity, which in turn 
made  significant differences in terms of solubility or crystals shape.98 Other applications for anhydrides 
include the study of changes in enzymatic activities, PEGylation of biomolecules or the introduction of 
chelating agents to an antibody.37,38,102–106 
Alongside with anhydrides, isocyanates (X= O, 44, Scheme 19) and isothiocyanates (ITC, X= S, 44, 
Scheme 19) were also reported as reagents that rapidly modify primary amines, forming an urea or 
thiourea bond, respectively (Scheme 19). Despite differences in cross-reactivity, both classes of reagents 
are susceptible to react with other nucleophiles of a protein. However, both of these cyanates are mainly 
used to modify primary amines since that is the only reaction that leads to stable products.30 This reaction 
has an optimal pH higher than the physiological pH, requiring a more basic medium to react preferentially 
with amines (pH 9.0 to 9.5), which makes them unsuitable to modify alkaline-sensitive proteins.28 
 
 
+ 
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Scheme 19 – Lysine modification – Isocyanates, X=O or S 
 
Isocyanates and isothiocyanates present as a major difference the different reactivity towards hydroxyl 
and thiol groups. Isocyanates are reagents that modify hydroxyl bearing amino acids, forming urethane 
linkages, and this has been used to perform the PEGylation of several biomolecules.37 ITCs are known 
to react with cysteine forming dithiocarbamates, which are unstable at physiological conditions. 
Nevertheless, they have been reported as modifying agents of Cys347 of α-tubulin (inhibiting cell growth) 
and Cys79 of a binding pocket from a bacterial quorum-sensing regulator, LasR.107,108  
Both cyanates mentioned are known to form many adducts with nucleophilic molecules and their 
toxicity towards living organisms is well known. A large number of studies were performed in order to 
justify isocyanates’ toxicity.107,109–111 Despite this, several applications for bioconjugation with these 
reagents have been disclosed in the literature. These include artificial glycosylation,42 modification of virus’ 
capsids,112 antibody conjugation to introduce chelating agents,113,114 incorporation of radioactive labeling 
agent (18F) to lysine-containing proteins115 and last, the most common application for these molecules, 
protein (e.g. antibodies) modification to introduce high quantum yields fluorochromes, such as the 
commercially available fluorescein-5-isothiocyanate (FITC) or rhodamine-B-isothiocyanate (RITC). These 
probes are known to maximize the detection sensitivity in binding assay or cell imaging.116,117 
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Later, in the mid seventies, activated esters were reported as acylating agents, and they rapidly 
became one of the most used molecules for protein bioconjugation. Among these activated esters, 
N-hydroxysuccinimide (NHS) esters (46) are the most explored acylating compounds and they were first 
described as homobifunctional crosslinkers.30 Such reagents have an improved reaction specificity and a 
roughly 1000-fold lower required concentration when compared with a symmetric anhydride.118 These 
reactive esters form an amide bond in the presence of unprotonated amines, using an aqueous 
environment of pH 8.5 ± 0.5 (Scheme 20).119,120 At lower pHs, N-terminal function and tyrosine can react 
preferably.119 Over the years, several studies of chemical cross-linking have been reported using this 
functionality and they highlight cross-reactivity of NHS esters with N-termini, tyrosines, serines and 
threonines, which can be enhanced by basic amino acids (such as histidine) in their proximity.119,121 
Moreover, from the improvement of these reagents and the bioconjugation system, efficient 
heterobifunctional cross-linkers were developed and sulfonated derivatives of NHS esters were 
synthesized, enhancing the hydrosolubility of these species.28,122–124 
 
 
 
+ 
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Scheme 20 – Lysine modification  – NHS esters 
 
As the most used cysteine’s reactive agent (maleimide), also NHS esters present numerous 
bioconjugation applications. The readly synthesis of NHS esters, a functionality that is commonly prepared 
by reacting a given acid with N-hydrosuccinimide and carbodiimide, also explains the wide variety of 
applications reported using these reagents. These applications include cell imaging and fluorescence 
studies,125,126 constituent in numerous heterobifunctional linkers with maleimides,127,128 hydrazines,129,130 
alkynes and alkenes (terminal and cyclic),131–134 cyclic nitrone135 and other bioorthogonal functions,136 as 
well as, a reference molecule for different comparative studies with amine modifying reagents (ketenes, 
glutaldehydes)137,138 and thiol modifying agents (dibromomaleimides).55 
From all applications of NHS esters, available in the literature, probably, the ones that permit a direct 
intervention in a living system can be considered as the most interesting ones, whether as a diagnostic 
tool or a therapeutic agent.  
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As a representative example some FDA/EMA approved drugs with different indications based on NHS 
methodology can be mentioned, such as: two ADCs (Mylotarg® and Kadcyla®) and two PEGylated 
cytokynes (PegIntron® and Pegasys®).139  
Apart from those compounds many other studies relying on NHS conjugation can be given as 
examples, such as PEGylation methods of different proteins and hormones37,140–142 (even providing an 
orally bioavailable form of insulin);143 some antibody modification strategies, either for surface 
immobilization,144,145 or for ADC’s development (Genentech’s TDM1 and Immunogen’s 
Mylotarg®);123,146,147 virus’s capsids modification148,149 and, finally, incorporation of different chelating 
agents for bioimaging, either for nuclear imaging with a sarcophagine ligand or polyaminopolycarboxylic 
ligands,150,151 as for optical imaging, with quantum dots or rhodamine derivatives.152,153 
Reductive amination is one of the earliest alkylations procedures of lysines described. Aldehydes and 
ketones are known to react selectively with primary and secondary amines to form Schiff bases. However 
these imines are considered to be unstable in aqueous media, suffering hydrolysis and thus, regenerating 
the starting materials. Usually the imine formation is enhanced by alkaline pH values, but still a reducing 
agent is required to stabilize this alkylation (Scheme 21). Reducing reagents known to perform this 
transformation are: sodium boro hydride (NaBH4) or sodium cyanoboro hydride (NaBH3CN), which react 
preferentially at pH ~9 and ~7, respectively.30 
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Scheme 21 – Lysine modification – Aldehydes and subsequent reduction 
 
In the last century, several improvements of this reaction have been made, leading to mild reducing 
conditions and the main advantage of this reductive alkylation, which is the lack of cross-reactivity. This 
modification will be discussed in further detail in Chapter II. where the selectivity issue will be thoroughly 
discussed. Similarly to the other amine modifying reagents, this strategy was also used in important 
applications that induced surface immobilization,154,155 artificial glycosylation42,156 and PEGylation of 
 
Chapter I. State of the Art 
 
23 
several biomolecules,157,158 the synthesis of a FDA/EMA approved drug (Neulasta®), which is a 
PEGylated pro-drug indicated to decrease the risk of infection for patients under chemotherapy, 
stimulating neutrophile generation.159 
Two very interesting studies based on Schiff base formation and subsequent stabilization through 
catalyzed reduction or 6-azaelectrocyclization show an important evolution for the reductive alkylation 
strategy. These reports showcase the potentialities of this selective reaction with lysines or N-terminal 
function, where the overall charge state of the protein is maintained (minimizing effects in protein 
solubility) and competitive hydrolysis pathways that occur with some activated esters are avoided.  
First, Francis and McFarland present an evolution of the wide-known reductive amination by replacing 
the harsh reducing reagents with an efficient water-stable iridium complex (Figure 1), that can achieve the 
same results as hydrides at room temperature and at a wider pH window (from 5 to 7.4). According to the 
authors, this reaction has shown a wide tolerance in terms of protein and aldehyde component, however 
this complex performs poorly when ketones are used.95 This study will be discussed in further detail in 
Chapter II. since it was one of the core studies that support the work described in this thesis. 
 
 
Figure 1 – Iridium Catalyst for Reductive Amination 
 
Another study that presents a major advantage for reductive amination is based in Katsumara’s 
findings that described aldehyde terpenoids as selective reagents to modify protein’s amine groups.160 In 
2008, Fukase et al. presented a rapid 6-azaelectrocyclization, as a way of stabilizing a Schiff base 
formed between lysine and unsaturated (E)-ester aldehydes (Scheme 22). This new lysine-based labeling 
method allowed the modification of several biomolecules and the incorporation of several bioimaging 
agents, within 30 minutes, at room temperature.161 Later that year, the same group presented an evolution 
of their work by reporting a site-selective modification of Lys137 attained by directing reactive groups to 
a specific site using a small-molecule ligand of human serum albumin (HSA). In the end, the auto-oxidation 
of the 1,2-dihydropyridine led to the hydrolysis of the ester linkage connecting this ligand.162 
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Scheme 22 – Lysine modification – Unsaturated (E)-ester aldehydes 
 
Site-selective strategies to modify lysine residues are of paramount importance, though only a very 
few number of studies to achieve this have been reported. This is justified due to the availability of multiple 
lysine residues on a protein, which upon modification often leads to heterogeneous mixtures of 
conjugates.36 Apart from the study just described, a study from Weil et al. is worth highlighting since it 
reports a site-selective lysine modification via kinetically controlled labeling. According to the authors, the 
NHS methodology can be developed towards synthesizing monofunctionalized conjugates.163  
In this revolutionizing study, Weil et al. describe a “kinetically-controlled protein labeling” (KPL) 
approach, where common commercially available biomolecules (ribonuclease A, lysozyme C and 
somatostatin) are monoconjugated through an established methodology of 6 steps, namely:  
1- Bioconjugation step (conjugation of biomolecule with the NHS ester) 
2- Quenching step (addition of ethanolamine to quench unreacted NHS ester) 
3- First biotin-removal step (filtration with a 1.5kD cut off to remove biotin-small molecules) 
4- Protein recovery step (loading mixture to a monomeric avidin resin column to recover excess of 
native protein) 
5- Affinity elution step (eluting this column with biotin to recover the monobiotinylated protein) 
6- Second biotin-removal step (another filtration to purify the final product) 
According to the authors this KPL approach leads to a more selective labeling since more reactive and 
accessible residues should react faster. Thus, the authors provide a preliminary computational study in 
which it was highlighted the importance of solvent accessibility, as well as interaction with adjacent amino 
acids to justify the differences in reactivities from K1 of ribonuclease A and lysozyme C. Furthermore, the 
synthesis of bioorthogonal linkers bearing a terminal alkyne and an azide were incorporated in 
ribonuclease A via this “chemical” approach, and then subsequently reacted with an azidocoumarin (which 
is a very useful fluorophore for click labeling since it only emits fluorescence after the triazol ring formation) 
and a rhodaminephosphine, respectively.163,164 
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Although the latest study to be mentioned did not start as a site-selective modification of lysine, like 
the reductive amination from Francis and McFarland, it introduces a novel metal-mediated modification of 
lysine that can be very useful in a near future. In this case, an azide is introduced through direct diazo 
transfer to lysine, showing an alternative for Dha generation, since it introduces a bioorthogonal agent 
that can be used for extra modification, without altering the native protein’s surface with long linkers. Thus, 
van Hest et al. reported an insertion of azide groups in proteins through diazo’s transfer with copper (II), 
in aqueous medium. The introduction of an azide function is a very interesting protocol, since the azide is 
the partner for invaluable Huisgen [3+2] cycloadditions (click reaction). Therefore, an alternative to avoid 
genetic incorporation of non-natural amino acids is presented through this direct diazo transfer to lysine 
residues, using imidazole-1-sulfonyl azide hydrochloride (53) and copper (II), which was successfully used 
to modify the enzyme horseradish peroxidase and an engineered red fluorescent protein from Discosoma 
striata.165 Later, the authors acknowledge the concern of modifying all amino functions of a proteins and, 
thus, reported a protocol without copper at lower pHs that improved the method to a site-selective 
procedure where only a single azide function was introduced at the α-amine of N-terminal function.166 
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Scheme 23 – Lysine modification – Imidazole-1-sulfonyl azide 
 
In conclusion, numerous reagents have been reported to selectively modify lysine residues, since, like 
cysteine, lysine possesses chemical advantages that grant some level of selectivity in the presence of 
other chemical functionalities. Although the modification of this amino acid has been slightly neglected 
due to the high heterogeneity that the most common methods (acylations and alkylations) often lead to, 
recent reports that described site-selective modifications of lysine residues, either by kinetic labelling as 
much as for ligand-affinity guidance show great promise in a near future. 
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I.2.1.3. Other Natural Amino Acids 
By contrast to cysteine and lysine, the other canonical amino acids have been scarcely modified, 
although some present promising advantageous in terms of site-selective modifications.  
The acidic residues have been mostly targeted via coupling with amines through carbodiimides 
(though cross-linking is a common limitation of this strategy).91 Some strategies have been pursued in 
order to circumvent this limitation of modifying acidic residues with carbodiimides and amines, such as 
the use of hydrazides, hydrazines or weakly basic amines (that react preferentially with activated 
carboxylic acids), as well as controlled pH.167–169 
Tyrosine has a phenolic side chain, which gives an amphiphilic nature to this residue , determining its 
common localization in a protein (partially buried in the surface of proteins).170 This residue has been 
modified based on two different strategies involving aromatic electrophilic substitution and metal-mediated 
modifications.171,172 Due to the nature of the side chain (activated aryl group) the phenol ortho position 
can be modified using electron-rich anilines and aldehydes in a selective three-multicomponent Mannich 
reaction,170,173,174 or using iodination or diazonium-coupling reagents (diazonium salts or 
diazodicarboxamides) to perform hetero-Diels-Alder reactions.167,171,175 Barbas III et al., using 
diazodicarboxamides, was able to modify chymotrypsinogen A and a therapeutic antibody herceptin 
without changing its affinity to Erb B-2.171  
Tryptophan is the rarest amino acid among all proteinogenic amino acids. Still, approximately 90% of 
proteins (depending on the species) possess, at least, one Trp in their constitution.176 Metabolic reactions 
or disorders of tryptophan may lead to pathologies, such as cataract, emphysema, rheumatoid arthritis, 
blue diaper syndrome and purple urine bag syndrome.177–179 There are two main approaches concerning 
the selective modification of Trp residues. One is based on the formation of metallocarbenoids from diazo 
species catalyzed by dirhodium (II) complex177,180,181 and the other reaction takes advantage of the high 
reactivity between secondary amines and dialdehydes.176,182 
As far as site-selective modifications of the other 18 proteogenic amino acids goes, few have been 
targets of modification. Nevertheless, tyrosine seems to be the most promising residue for this purpose. 
The reported aromatic electrophilic substitutions and metal-mediated modifications of tyrosine show a 
high selectivity regarding other amino acids, though some procedures can be somewhat toxic to some 
biological systems as well as having a limited applicability. 
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I.2.2. Modification of Terminal Amino Acids 
In terms of general site-selective modification of native proteins, apart from targeting accessible 
disulfide bonds, specific modification of terminal functions of a protein can be seen as a promising 
approach that avoid resorting to genetic engineering. 
Proteins’ terminal chains have some specific reactions to modify them, either by exploring the reactivity 
of specific terminal amino acids, as by modifying them based on their singularity. Targeting the terminal 
amino acid offer several advantages when comparing with other exposed residues. This includes a high 
flexibility and solvent accessibility, rare or none implication in biological activity and single function (of 
each) per protein.183 Their resemblance with side chains of some amino acids justifies their limited 
application, though a restriction of modifications towards specific terminal amino acids can increase 
selectivity. The reactions that are performed in these terminal functions can be divided in: modifications 
that do not require a specific amino acid to occur, in opposition to the ones that do require a specific amino 
acid. It is also important to mention that these modifications play a huge role in peptide coupling strategies, 
since modifications that lead to general amidations are of crucial importance to chemically combine 
peptides.  
Regarding modifications of general terminal endings, two scenarios can be considered. In the case of 
C-terminal functions, they are hard to selectively modify without resorting to recombinant technology.183 
The N-terminal function, on the other hand, is easier to modify because it is distinguishable from other 
amines based on its different pKa.184–187 
Different amino acids (or sequences) can be mentioned as being required on a protein N-terminal 
ending for a modification to proceed. As examples aspartic acid,184 serine,188 proline,189 cysteine,77 
alanine, glycine/serine and proline sequence,190 among others (that can be found in an excellent review 
from Bertozzi and Sletten)91 were used to perform site-selective modifications.  
Nevertheless, the most crucial work performed in terminal modifications of specific N(C)-terminal 
peptides and proteins is the one that leads to native bonds between two amino acid chains. This work 
has been decisive for the recent development of synthetic biology, since it is a vital part for chemical 
protein synthesis.  
Although it is not the central topic of this thesis, due to its relevance in terms of applications, a brief 
discussion of chemical ligation of peptides and proteins will be presented. Since this methodology usually 
requires specific N-terminal and C-terminal functions to be performed, it can be included in this topic, 
though it can not  hardly be considered as a modification of natural proteins in their native state. 
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Nevertheless, it finds in peptide and protein synthesis a huge field of applications that shouldn’t be 
disregarded. 
 Chemical ligation is a field of research that has its foundations on a chemical reaction between a 
N-terminal cysteine and a C-terminal thioester, which was first described in 1953, by Wieland et al., where 
the S,N-acyl shift is highlighted for this transthioesterification.191  From this study, in 1994, Kent et al. 
developed a methodology to combine different unprotected peptides that fulfilled the aforementioned 
requirements for their terminal functions. Stephen B.H. Kent named this process native chemical ligation 
(NCL, Scheme 24) and since then it has been an extensively used strategy for the total chemical synthesis 
of peptides and proteins.192 
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Scheme 24 – N-terminal cysteine modification – NCL mechanism 
 
In the following years, much research has been done in NCL methodology using synthetic chemistry 
to elucidate the molecular basis of protein function, and particularly enzyme catalysis. For instance, in 
vivo compatibility was reported, allowing to promote protein’s biotinylation, solid support immobilization 
(maintaining protein’s biological activity) and biosignaling.193  
Stephen Kent disclosed several studies that improved this technology and demonstrated its vast 
applicability. In 2004, Kent et al. showed, for the first time, the total synthesis of a folded protein (crambin) 
by combining three unprotected peptides through NCL. In this study, 1,3-thiazolidine-4-carboxo moiety 
was introduced as a protecting group for N-terminal Cys, in order to guide the right sequence of a protein 
through a protection/deprotection system. This deprotection was achieved by using methoxyamine.194 In 
2005, Kent and co-workers reported the total synthesis of ubiquitin.195 A year later, after an extensive 
study of the reaction’s mechanism, a relationship between the thiol’s pKa and its reactivity in NCL was 
established,196 Kent et al. reported a fully convergent protein synthesis based on kinetically controlled 
ligation based on the use of different thioesters.197 In the same year, a method of direct on-resin synthesis 
of protein through NCL was described, highlighting a fast production of α–thiophenylesters peptides.198 
Among other reports of total proteins synthesis, in 2008, the same group, reported the total synthesis of 
the enzyme ribonuclease A and its biochemical characterization.199  
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In 2009, Stephen Kent wrote an excellent review on this topic, in which is discussed the most important 
limitation of this methodology which is to proceed only with a N-terminal cysteine residue. In this review, 
the author also emphasized the attempts on chemically expanding NCL to N-terminal non-Cys 
unprotected peptides, which were based on two different methodologies (Scheme 25).200 
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Scheme 25 – Methodologies to expand NCL to N-terminal non-Cys unprotected peptides.  
A.- desulfurization of cysteine; B.- Mimetics of cysteine (N(α)-auxiliaries) 
 
One being the desulfurization of cysteine in the NCL product, enabling the production of Ala peptides 
where a cysteine would originally be (Scheme 25A). This reduction procedure with palladium or nickel 
was first described by Dawson and Yan, but it has been extended to other β-mercapto amino acids, like 
phenylalanine.200 Later, Danishefsky and Wan, concerned with the lack of chemoselectivity of the metal-
mediated reduction, developed a procedure using TCEP based reduction, applying it to generate peptides 
with alanine or valine in the final products.11 Later on, trifluoroethanethiol was also described as an 
additive for the same purpose leading to an aspartic acid and an alanine instead of their β-mercapto amino 
acids.201 Recently, other amino acids (like tryptophan, arginine or proline) were used as a mercapto amino 
acids to perform the NCL and then reduced.202–204 
The second attempt to expand NCL to N-terminal non-Cys peptides is based on using thiol containing 
N(α)-auxiliaries that mimic the presence of cysteine and that can be selectively removed once the ligation 
has occurred (Scheme 25B). This strategy was first reported by Macmillan et al. and ideally it could be 
applied to any terminal amino acid, however, these molecules tend to be highly sensitive to the nature of 
the amino acid and to substitutions on the α-carbon atom of the thioester, and for those reasons proved 
to be less efficient than regular NCL.205  
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On the other hand, in terms of the C-terminal thioester for NCL, its requirement has also been 
discussed and, among other developments, in 2007, Danishefsky et al. replaced this function for a 
phenolic ester with an ortho protected thiol group with a simpler synthetic pathway.206 
Early applications of the NCL were based on the formation of microproteins, cyclic proteins, 
neoglycoproteins and artificial proteins with non-natural amino acids (NNAA) or with artificial post-
translational modifications. Furthermore it was one of the most used tools in order to combine different 
peptides through solid-phased peptide synthesis (SPPS).207 
From this methodology, others have emerged to enhance NCL’s applications, combining chemical and 
biochemical tools to achieve better results.  
Based on the resemblance of NCL’s mechanism and the natural mechanism of protein self-splicing 
(where a domain of a protein, referred as intein, is extruded in a post-translational process), two other 
techniques were developed to make use of recombinant proteins. First, expressed protein ligation (EPL) 
was described, which is based in a chemical process between a recombinant protein (intein) with a 
thioester and a chemically synthesized N-terminal cysteine peptide, that can occur under a wide range of 
reaction conditions. And then, the protein-trans splicing (PTS) technique was reported, where, in contrast, 
has to be performed under naturing conditions since the process involves the functional reconstitution of 
a split intein. This splicing occurs when the two complements of inteins meet each other, since a part of 
the split intein is fused to the target recombinant protein and its complementary portion is connected to 
another synthesized peptide (Figure 2).91,191,208 
 
 
Figure 2 – Expressed protein ligation (EPL, A) and protein trans-splicting (PTS, B) mechanism. Image adapted 
from a review from Sletten and Bertozzi91 
  B. 
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Apart from these ingenious strategies directly descendants of NCL, other ligations have been purposed 
to combine peptides under naturing conditions. Despite the fact that some ligations are more general than 
others five examples have been successfully implemented (Table 2): 
1 – Traceless Azide-Staudinger Ligation – reaction between an azide and a thioester that uses a 
thiophosphino auxiliary that yields an amide product without any residual atoms;209 
2 – Peptide Hydrazides Ligation – reaction between a C-terminal peptide hydrazide and a N-terminal 
cysteine to yield a native peptide bond, by using an oxidant in a first step and a thiol in the final step;210 
3 – α-Ketoacid-hydroxylamine (KAHA) Ligation – decarboxylative amidation of a hemiaminal 
intermediate produced from an α-keto acid and a N-alkylhydroxylamine;211,212 
4 – Acyltrifluoroborate-hydroxylamine (ATHA) Ligation – improved KAHA ligation with increased 
reaction speed and nonacidic conditions between O-benzoyl hydroxylamines and acyltrifluoroborates 
under aqueous solvents;213 
5 – Serine and Threonine Ligation (STL) – reaction between a C-terminal salicylaldehyde ester and a 
N-terminal serine or threonine that forms an imine with its α-amine group and leads to an irreversible 
amide bond formation (through a 1,5 O→N acyl shift).214,215 
 
Table 2 – Alternatives for Native Chemical Ligation 
Ligation Reaction 
Traceless Azide 
Staudinger  
+ 
 
 
 
Peptide 
Hydrazydes 
 
+ 
 
1. pH 3.0-4.0, 
NaNO2 
 
2. pH 7.0  
α-Ketoacid-
Hydroxylamine 
(KAHA)  
+ 
 
pH 3.0-4.0; 40 ºC 
 
50 min  
Acyltrifluoroborate-
hydroxylamine 
(ATHA)  
+ 
 
r.t., 30 min 
 
 
Serine and 
threonine (STL) 
 
+ 
 
1. org. solv, r.t. 
 
2. TFA/H2O 
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Apart from individual examples of modification of general terminal endings, functionalization of specific 
terminal endings of peptides and proteins tend to be the most followed strategy within these parameters. 
Although this methodology is highly selective its applicability is quite scarce without resorting to genetic 
engineering. In that sense, introduction of non-natural amino acids is the competitive methodology in 
terms of selectivity. 
 
I.2.3. Modification of Non-natural amino acids 
In terms of site-selective modification of peptides and proteins, it is practically impossible to compete 
with the selectivity that the introduction of non-natural amino acids (NNAA) permits. The incorporation of 
a chemical functionality that has no match in biology and exhibits a specific chemical reactivity, allows 
unprecedented levels of selectivity and specificity. This methodology faces a major limitation related with 
the incorporation of the NNAA. This has been achieved via translational or semi-synthetic incorporation.1 
Translational incorporation is based in different methods, such as: use of auxotrophic strains, stop 
codon suppressor tRNA, orthogonal aminoacyl-tRNA synthetase, non-natural base pairs or by expanding 
the size of codons. In contrast, semi-synthetic incorporation is mainly based in a single methodology 
named solid-phase peptide synthesis (SPPS).1,27 Excellent reviews, as well as two recent letters from 
Schultz et al. and Liu et al.,  can be consulted to show the diversity of NNAA that have been incorporated 
throughout the years.1,216–222  
Incorporation of NNAA led to the possibility of using chemical species that allow reactions that neither 
interact with nor interfere with biological systems. In 2003, Bertozzi et al. described these reactions as 
bioorthogonal reactions, though some reactions with those properties have been described prior to that 
term. According to these authors, the functional groups for this type of reaction have to respect two major 
requirements, which are the inertness towards biological moieties and exclusive reactivity against its 
counterpart under biocompatible conditions. Moreover, for in vivo applications, they also shall be nontoxic 
to cells and organisms.223 
Despite the difficulties inherent with the development of such biocompatible reactions, several 
bioorthogonal reactions have been described, as it is shown in Table 3 (adapted from two recent 
reviews).135,224 One or both of the reaction’s counterparts have already been directly incorporated into 
proteins or, in alternative, indirectly attached by means of chemical modification of natural amino acids, 
as it has been described in I.2.1. Modification of Natural Amino Acids. From these reactions, the most 
recurring modifications rely on cycloaddtions between azides and alkynes (whether terminal or cyclic), 
condensations of aldehydes/ketones and some metal-mediated reactions with halogenated amino acids. 
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Table 3 – Bioorthogonal Reactions 
Chemical 
Reporter 
Reaction 
counterpart and 
catalyst 
Product 
Reaction 
Type 
 
Chemical 
Reporter 
Reaction 
counterpart and 
catalyst 
Product 
Reaction 
Type 
    
 
 
Aniline can be 
used as catalyst  
Aldehyde/ 
ketone 
aminooxy  
condensation 
 
 
 
Inverse 
Electron-
Demand Diels-
Alder (iEDDA) 
 
Aniline can be 
used as catalyst 
 
Aldehyde/ 
ketone 
hydrazide 
condensation 
 
 
iEDDA 
 
 
Strain-promoted 
[4+2] 
Cycloaddition 
 
 
Aldehyde/ 
ketone 
condensation 
Pictet-Spengler 
 
 
iEDDA 
 
 
 
Strain-
promoted 
Azide-Alkyne 
Cycloaddition 
(SPAAC) 
 
 
[4 + 1] 
Cycloaddition 
reaction 
  
Staudinger 
Ligation  
 
iEDDA 
  
Copper Azide- 
Alkyne 
Cycloaddition 
(CuAAC)   
 
Strain-
Promoted 
Alkyne–Nitrone 
Cycloaddition 
  
Tandem [3+2] 
Cycloaddition 
retro-Diels-
Alder 
 
  
UV light 
 
Photoinduced 
Cycloaddition 
reaction 
 
 
 
Strain-
promoted 
Azide-Nitrile 
Oxide 
Cycloaddition 
(SPANOC) 
 
UV light 
 
Photoinduced 
Cycloaddition 
reaction 
  
UV light 
 
Photoinduced 
Cycloaddition 
reaction 
  
 SPANOC 
  
 SPANOC 
 
 
 
[2+2+2] 
Cycloaddition 
reaction 
  
SPANOC 
 
  
Click hetero-
Diels−Alder 
Cycloaddition 
 
 
 
Strain-
promoted 1,3-
dipolar 
Cycloaddition 
 
  
Sonogashira 
Coupling 
   
Cross- 
Metathesis   
Suzuki 
Coupling 
  
 
Of these cycloadditions between azides and alkynes, 1,3-dipolar Huisgen cycloaddition is one of the 
oldest reactions described and meets the majority of criteria to selectively modify a protein. Both 
counterparts have been incorporated into proteins as analogues of different amino acids, such as Phe, 
Tyr, Ala and Met.10,15,225–227 As it is easy to comprehend, the labeling agent has the complementary 
termination for such reaction to occur, whether is mediated by a metal (copper (I)), when a terminal alkyne 
is one of the counterparts, or without metals, when cyclooctyne is the reaction’s counterpart (where ring 
strain release acts as the driving force of this reaction). 10,27,225–227 Although the final product is always a 
1,4-disubstituted triazole (66), the name of the reaction depends upon the driving force of the reaction, 
which can be copper – copper azide-alkyne cycloaddition (CuAAC) – or, ring strain release – strain-
promoted azide-alkyne cycloaddition (SPAAC). In Scheme 26, an example of such reaction is presented, 
where the azide was introduced to a protein and the labeling agent has an alkyne in its constitution.135,224 
 
 
+ 
 
Cu (I) cat, when  
R1 =alkyl and R2=-H 
 
No catalyst, 
R1,R2 = -(CH2)6-  
64  65  66 
Scheme 26 – NNAA Modification – Azide-alkyne cycloaddition 
 
When incorporating aldehydes or ketones to a peptidic based structures, a series of selective 
condensations can be made with these functional groups. Of those, the most broadly used is the reaction 
with hydrazides, which are chemical species that can be added to fluorescent probes or biomolecules. 
For instance, Schultz et al. selected a translational incorporation of NNAAs and reported a successful 
selective labeling, in vivo, of LamB protein with hydrazide-fluorescein.228  
For reactions with incorporated halo-amino acids, there are two different approaches worth 
mentioning. One, which is not bioorthogonal since the reaction’s counterpart is a nucleophile that can 
react with other electrophiles using a simple bimolecular nucleophilic substitution (SN2) as its 
foundation,229 and another that takes advantage of palladium (II) to perform a Suzuki coupling between a 
boronic acid and a halogenated amino acid which allows the conjugation with several arenes.230 
In recent years, with the significant development of bioorthogonal reactions, an increased concern has 
been directed to the kinetics of these reactions that can limit their effectiveness under highly dilute reaction 
conditions, such as the ones required for in vivo applications.231 This is the guideline that is promoting the 
development of new bioorthogonal reactions, where iEDDA and SPAAC reactions present the fastest 
reactions rates (Figure 3). 
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Figure 3 – Reported reaction rates of tetrazines and azide with different counterparts. XX values are logaritmic 
values of second order rate constant in M-1s-1. Figure adapted from two reviews.224,231 
 
Apart from the aforementioned functionalities that enable bioorthogonal reactions, there are also other 
functional groups that have been incorporated into proteins that promote selective reactions with certain 
counterparts. The incorporation of selenium amino acids that lead to Dha through oxidative elimination is 
the best example of such methodology, since it introduces an electrophilic species otherwise absent from 
a peptidic structure. Seebeck and Szostak successfully incorporated selenium amino acids that were 
genetically encoded.232  
 
In terms of site-selective modification of proteins, the simplification of non-natural amino acids 
incorporation is promoting this field of research into one of the most promising areas of bioconjugation. 
Although there are still some conservative doubts regarding the use of these abiotic species mainly due 
to unexpected changes that these functionalities can acquire in a recombinant protein or in a living 
organism, a major growth of this area is to be expected in a near future as an alternative of the well-
established modification of natural amino acids (mainly, cysteine and lysine). 
-2 -1 0 1 2 3 4 5
Tetrazine Azide
  
 
 
 
 
General Objectives of the Thesis 
In recent years, the site selective functionalization of proteins entered into the limelight of synthetic 
organic chemistry and many research groups are now actively looking for new ways to create bonds with 
proteins. In Chapter I. an overview of the state of the art for this area of research was given and based 
on such information, the objectives established for this project will now be presented. 
The main goal of this project is the development of several new reagents for manipulation of non-
recombinant proteins. To achieve this objective, a selective and reversible modification of primary amines 
was studied, looking to overcome some of the gaps in the present state of the art. 
Based on the fact that aldehyde/ketone condensation has a great advantage among other lysine 
modifying agents, since it presents lack of cross-reactivity in a wide pH range, this reaction was taken as 
a starting point. However, the reported studies of this methodology indicated the instability of the final 
product as a drawback that required a subsequent reduction to form a stable protein modification.  
To overcome this limitation we envisioned to stabilize the imine linkage towards hydrolysis and, at the 
same time, have a tunable reversibility. With this purpose in mind, a search of different boronic acids’ 
based reagents was developed to have a selective (with a controlled reversibility) primary amine 
modification of biomolecules, which will be discussed in Chapter II.  
Once the conjugation was fully described, the synthesis of derivatives with specific chemical properties 
was crucial. Therefore, in Chapter III. the search to develop an adjustable core structure of the novel 
modifying agent will be presented. Followed by the description of the installation and biological 
applications of fluorescent labels, “clickable”, PEGylating and cytotoxic agents in Chapter IV.  
Finally, in Chapter V. an ongoing project will be presented, in which, chemical improvements to the 
core structure are being developed to synthesize a molecule that can have a more controlled reversibility 
upon specific pH conditions. 
 
 
 
 
  
Chapter II 
Searching Conjugation with Controlled Reversibility 
 
 
 
 
ABSTRACT 
Protein modification has entered the limelight of chemical and biological sciences, since, by appending 
small molecules into proteins surfaces, fundamental biological and biophysical processes may be studied 
and even modulated in a physiological context.  
In this chapter, a new strategy to modify the lysine’s ε-amino group and the protein’s N-terminal will be 
presented, based on the formation of stable iminoboronates in aqueous media. This functionality enables 
the stable and complete modification of these amine groups, which can be reversible upon the addition 
of fructose, dopamine, or glutathione. A detailed DFT study is also presented to rationalize the observed 
stability of the iminoboronate constructs toward hydrolysis. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter II. Searching Conjugation with Controlled Reversibility 
   
39 
Chapter II.   
Searching Conjugation with Controlled Reversibility 
II.1. Introduction 
II.1.1. Reductive Amination 
As mentioned in Chapter I. reductive amination is one of the available tools to modify lysine residues 
of natural proteins. This procedure is based on a selective reaction between a carbonyl group and a 
primary or secondary amine to form Schiff bases that are hydrolytically unstable and, thus, need to be 
reduced. The lack of cross-reactivity is one of the most appealing aspects of this methodology, although 
the highlighted instability and subsequent requirement for reduction constitutes important limitations that 
needed to be overcome.  
Two different strategies were developed in order to overcome this limitation: one being the 
development of water-soluble iridium catalysts for transfer hydrogenation (to avoid harder reducing 
agents) and the other being based on the development of reagents that stabilized this unstable linkage, 
once it is formed, mainly through intramolecular reduction. 
The study of Francis and McFarland that developed water-soluble iridium catalysts has been briefly 
described in I.2.1.2 Lysine,95 however some features of this work remained unstated, namely the 
activation of the aforementioned catalyst to reduce the imine, as it is illustrated in Figure 4, which explains 
the required stoichiometric amount of sodium formate. The authors classified their strategy as being able 
to functionalize proteins with similar efficiencies to NHS-ester and sodium cyanoborohydride-based 
techniques, without using water-sensitive or harsh reagents. This study served as basis for the 
methodology described in this chapter, by delineating reaction conditions and outlining model proteins 
that can be used to evaluate a lysine modifying agent. 
 
 
Figure 4 – Iridium’s catalyst activation 
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Apart from this study of transfer hydrogenation, a more common strategy to take advantage of this 
selective reaction is to use specific aldehydes or ketones that lead to a stable and irreversible final product 
through intramolecular rearrangements, even in aqueous media. An example of such approach is the use 
of unsaturated (E)-ester aldehydes (51, Scheme 27). 
 
 
 
  
41 51 52 
Scheme 27 – Lysine modification – Unsaturated (E)-ester aldehydes 
 
In 1999, aldehyde terpenoids were described as agents to modify lysine residues that inhibited bovine 
pancreatic phospholipase A2, by irreversible formation of dihydropyridine derivatives.160 Using the same 
core structures, Fukase et al., in 2008 reported unsaturated (E)-ester aldehyde derivatives, which led to 
the development of an efficient PET protocol.  
Once the mechanism of the above-mentioned procedure was explained, the authors synthesized 
different derivatives that could be used for bioimaging applications. On one hand, having the same core 
structure, the authors synthesized rhodamine and coumarin derivatives available for optical fluorescence 
imaging, on the other hand, the same authors, developed a derivative of a chelating agent 
(dota-O-succinimidyl ester), which was used to chelate gadolium (68Ga). This compound was then used 
for nuclear imaging by conjugation with somatostatin, showing images that grounded the accumulation of 
this conjugate in the liver, kidney and pancreas, as it was expected.161 Later that year, the same authors 
also reported a site-selective modification of Lys 137 of HAS by ligand directing strategy.162  
Inspired by these results, which reported a new lysine-based labeling method with Schiff bases as 
intermediaries, we have developed a method in which the Schiff base would be the final product, once it 
was stabilized by another functional group (a boronic acid) present in the same molecule. This strategy 
would have an advantage in that we would be able to have a controlled reversibility mechanism induced 
by certain molecules. If successful this strategy would have promising applications in terms of drug 
delivery. This hypothesis is majorly based on the intrinsic characteristics of boronic acids, which will now 
be discussed in further detail as a support of what will be described in this chapter.  
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II.1.2. Boronic Acids 
Boronic acids are organic compounds that have a sp2-hybridized boron atom attached to one alkyl, 
vinyl or aryl substituent, two hydroxyl groups and a vacant p orbital as a consequence of having only 6 
valence atoms (67, Scheme 28). These compounds have interesting physicochemical properties that 
makes them ideal for some biological application, namely, their known low toxicity (with the 
environmentally friendly boric acid as their ultimate degradation product), their absence in nature and their 
relative stability to atmospheric oxidation. Boronic acids are also considered to be amphiphilic species 
since the apolar carbonated chain balances the polarity set through the hydrogen bond donating ability 
(of their hydroxyl groups) and their Lewis acidity. Due to their unique properties as mild organic Lewis 
acids and unparalleled reactivity, in the past three decades boronic acids have passed from being rather 
neglected compounds to valuable synthetic intermediates of modern organic chemistry.233 
Generally, boronic acids present trigonal planar geometry, where the boron empty orbital is 
perpendicular to the boron substituents. The exception for this rule is the case of ortho susbtittuted 
aromatic moieties, where the aromatic ring is perpendicular to minimize the steric strain.  However, in 
order to complete boron’s octet, boronic acids can also coordinate basic molecules, existing as stable 
tetracoordinated adducts with tetrahedral geometry. This coordination caused by boron’s deficient 
valence results in a negative charge that is formally drawn on this atom (69, Scheme 28). This 
complexation explains its unique properties as mild organic Lewis acids in opposition to a usual Brønsted 
base formed in the equilibrium of hydroxyl groups in water. In other words, the boronic acids ionize water 
and form hydronium ions by “indirect” proton transfer instead of direct proton removal from their hydroxyl 
groups.233 
 
 
+ 
 
 
 
+ 
 
 
67  68  69  70 
Scheme 28 – Ionization equilibrium of boronic acid in water 
 
Due to the importance of boronic acids and derivatives, over the past decade, several attempts were 
made in order to incorporate these molecules in proteins. Even because, this is one of the chemical 
entities that can act as chemical reporters for bioorthogonal reactions, as it has been mentioned in I.2.3 
Modification of Non-natural amino acids. 
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In 2002, through a maleimide reaction it was possible to introduce a fluorescent tag containing BODIPY 
(boron-dipyrromethene) into a protein, due to the high affinity of this molecule with cysteine.234 Several 
years later, different studies were made to fruitfully incorporate similar dyes into a protein by translational 
modification.235–237 Nevertheless, these derivatives did not confer many of the advantages that boronic 
acids could give to biomolecules. So, in 2008, Schultz et al. were  able to successfully encode a boronate-
containing amino acid in a protein of E.Coli,238  as well as, two years later, do the same in Mycobacterium 
tuberculosis organism.239 Apart from these translational incorporations, another approach uses a semi-
synthetic procedure in order to incorporate a boronic acid in the N-terminal function of peptides. Like so, 
Santos et al. were  able to find selective inhibitors of human ClpXP, which is an ATP-dependent serine 
protease present in the mitochondrial matrix.240  
The translational introduction of this molecule into biomolecules allows a bioorthogonal reaction to 
occur at mild conditions (Suzuki Miyaura cross-coupling) and many experiments were made to perform it 
either in peptides241,242 or in proteins.238,243 However, a chemical incorporation of boronic acids using 
reagents of chemical modification of biomolecules and subsequent cross-coupling is yet to be proven. 
Boronic acids are useful reagents available for synthetic organic chemistry. Their uses expands from 
traditional organic and organometallic chemistry, in which they are used to establish new bonds, to sugar 
sensing, material sciences and medicinal chemistry. Notwithstanding, this family of compounds has been 
almost neglected in what concerns their use as protein modifying reagents.  
 
II.1.3. Interaction between Boron and Nitrogen 
Aiming at proving our hypothesis that alkylic imine stabilization could occur through interactions with 
a proximal boronic acid, we initiated this study by evaluating reagents that allow for that N-B interaction 
to occur. Ortho-carbonyl benzene boronic acids have been reported in the literature as synthetic 
intermediaries to obtain different diazaborines (by reaction with hydrazine),244,245 macrocycles246–248 or 
even as counterparts for Suzuki couplings.249,250 However, in terms of iminoboronates that highlight the 
interaction between boron and nitrogen, work from two different authors is worthy of emphasizing. These 
authors are named Eric V. Anslyn and Tony D. James. 
 
Eric V. Anslyn and co-workers reported a significant number of interesting 11B-NMR, reporting no 
significant differences between secondary and tertiary amines in terms of complexation geometry and pH 
dependence.251 In 2006, important conclusions from these compounds were obtained, namely the 
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difference between N-B interaction depending on the solvents and on their complexation with diols. If the 
solvent is aprotic N-B dative bond is present, but on the contrary, if the solvent is protic, the boronate 
species dominates and a hydrogen-bonded zwitterionic species is the most predominant species. 
Moreover, if the boronic acid is complexed with a vicinal bifunctionalized, electron-withdrawing substrate 
to generate a boronate ester, N-B bond formation is promoted, as it is true for solvent insertion due to the 
increased electrophilicity/Lewis acidity of the boronate.252 Three years later, the same group performed 
another study where the N-B bonding was evaluated in opposition to solvent insertion, depending upon 
the degree of substitution from the amine group. This study proved that there is a slender increase in the 
N-B dative bonding when using tertiary amines instead of secondary or primary amines, though solvent 
insertion is the dominant process in all boronate esters formation.253 
 
Tony D. James and co-workers developed several applications of 2-formylbenzeneboronic acid 
derivatives (2-FBBA, 72) as an element of a three-component chiral derivatizing protocol for enantiopurity 
NMR determination of different chiral products.254–258 In these studies, an enantiomeric pure chiral ligand, 
(S)- or (R)-BINOL (73), would be complexed to the boronic acid of 2-FBBA and the amine-based chiral 
product would form an imine from reaction between the formyl group of FBBA and the racemic amine 
(Scheme 29). From these structurally rigid diastereoisomeric iminoboronate esters, a significant 
difference in the 1H-NMR spectrum of the amines is obtained depending upon the different amine 
enantiomers. 
 
 + 
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amine 
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72 
 
(S)-BINOL 
73 
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74 
 
(S,S)-
Iminoboronate 
75 
Scheme 29 – James’s protocol for NMR analysis of the enantiomeric purity of different amines 
 
Apart from this very complete study on enantiomeric purity determination of amines, other studies have 
been reported from this group which were focused on boron and nitrogen interaction. In 2008, James et 
al. reported dynamic covalent self-assembled macrocycles between 2-FBBA and 1,2-amino alcohols, 
which is a common application for these compounds.259 A few years later, an interesting review from the 
same authors mentioned a very attractive dynamic covalent bonding for what we intended from the 
reversible modification of lysine residues.260 According to the authors, the Lewis acidity of boronic acids 
is enhanced whenever boronate esters are formed in the presence of 1,2-, 1,3- or 1,4-diols, in aqueous 
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media, and, thus the fast and stable bond formation between these chemical species could be the basis 
of reversible molecular assemblies.  
Although these studies of N-B interaction proved to be important milestones for the development of 
this project, it is crucial to highlight that the majority of the conclusions were taken in aprotic solvent 
conditions. Moreover, some of these studies gave assumptions based on aminoboronates, which differ 
from iminoboronates in the C-N bond order. Regardless, all this data concerning N-B interaction gave us 
momentum to outline our objectives to develop a conjugation system with controlled reversibility. 
 
II.1. Goals 
This chapter’s purpose is to describe all the chemical reactions developed to demonstrate a selective 
conjugation with alkylic amines in the presence of other functional groups and under naturing conditions. 
In parallel with the experimental data collected, a theoretical elucidation was developed to highlight the 
role of the ortho boronic acid group in terms of aiding the imine formation and stabilizing the final product. 
Moreover, once the conjugation had been well established with several biomolecules, the envisioned 
reversibility was evaluated using different endogenous molecules that can lead to controlled delivery 
under certain physiological conditions. 
 
II.2. Exploratory Results and Optimization 
We hypothesize in this study that boronic acids, due to a close proximity with the imine would form a 
potentially stable iminoboronate by forming a N-B dative bond, as depicted in Scheme 30. In addition, 
once the conjugation is settled, the disruption of this newly-formed dative bound, would reverse 
conjugation and regenerate the starting materials. Therefore, the formation of stable imines in aqueous 
media would allow a direct, selective and potentially reversible strategy to modify lysine residues and 
N-terminus. 
 
+ 
 
 
 
41  72  76 
Scheme 30 – Hypothesis - lysine modification with 2-FBBA 
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To test this hypothesis, we studied the imine formation using 1-butylamine as a model to mimic the 
ε-amino group of lysine residues. With this amine, we performed several mild reactions with aldehydes 
and ketones (77-80) without the boronic acid functionality (under naturing conditions, i.e. performed in 
neat water and mixed for 18 h at room temperature). The results are resumed in Table 4 and will serve 
as controls for the results obtained with molecules bearing boronic acids. 
Considering the dynamic feature of the constructs, we decided not to perform any purification 
processes that could tamper our conclusions. Therefore, all conversions presented in this chapter are 
based on the crude 1H-NMR spectra. 
  
Table 4 – Aboronated aldehydes and ketone as control reactions 
Aldehyde/Ketone 
Conversion of 
imine formed 
Aldehyde/Ketone 
Conversion of 
imine formed 
 
77 
20% 
 
78 
0% 
 
79 
9% 
 
80 
0% 
 
Based on the aforementioned studies, we performed the synthesis of the imine from 1-butylamine and 
2-FBBA in organic solvents to have a pure form of the iminoboronate. The imine was obtained 
quantitatively in dichloromethane. Having the product isolated, finally we could test our hypothesis by 
adding 2-FBBA to a butylamine aqueous solution. Very pleasingly, the iminoboronate was formed at room 
temperature in 49% and 52% conversion when the reaction proceeded in neat water or in a phosphate 
buffer solution (50 mM, pH 8.02), respectively. 
Encouraged by these results that dictated an increase of imine conversion to almost the triple of what 
was obtained with the aboronated species (Table 4), we carried on our study to comprehend this reaction 
and improve its efficiency.  
First, to highlight the importance of the boronic acid with a vacant p orbital in an ortho-position relatively 
to the formyl compound, we test two different boronated compounds that are unable to establish a N-B 
dative bond. A formylbenzene boronic acid para substituted (4-FBBA, 81) was used to prove the 
importance of the boronic acid’s at ortho-position and a substituted benzaldehyde with an ortho-potassium 
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trifluoroborate (82) was used to show the importance of the vacant p orbital centered on boron. As 
expected, both species were unable to yield the desired imine in aqueous media as shown in Table 5. 
 
Table 5 – Boronated aldehydes reaction with 1-butylamine 
Aldehyde/Ketone 
Conversion of imine 
formed 
Aldehyde/Ketone 
Conversion of imine 
formed 
 
81 
0% 
 
82 
0% 
 
 
Aiming at improving the formation of the iminoboronate in aqueous media, several reaction parameters 
were evaluated, namely the reagent stoichiometry and dilution, buffer concentration and reaction time. 
However, all modifications had little effect on the iminoboronate formation. Apart from the reactions with 
unfunctionalized 2-FBBA, commercially available formylbenzeneboronic acids with different substituents 
(83-85) were also evaluated, yet, none significantly improved the conversion obtained before while using 
2-FBBA (Table 6). 
 
Table 6 – 2-Formyl boronic acid derivatives’ reaction with 1-butylamine 
Aldehyde/Ketone 
Conversion 
of imine 
formed 
Aldehyde/Ketone 
Conversion 
of imine 
formed 
Aldehyde/Ketone 
Conversion 
of imine 
formed 
 
83 
18% 
 
84 
53% 
 
85 
0% 
 
Based on the results obtained, a different approach was pursued to improve the imine formation with 
2-FBBA, exploring the increase of the boronic acid electrophilicity/Lewis acidity upon complexation with 
cathecol, p-nitrocathecol and glucose as suggested in organic solvents by Ansyln et al.. However, in our 
study, the addition of these vicinal diols led to a considerable decrease of the imine formation. This fact 
may be related with the solvent insertion that disabled the possibility of N-B dative bond formation, by 
occupying more effectively the vacant p orbital of the boron atom. 
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In the course or these studies with 2-FBBA, a competing reaction enhanced by the pH increasing was 
observed (Scheme 31).261 This tautomeric cyclization between the aldehyde and boronic acid was 
observable by 1H-NMR, which led to a peak disappearance, related with the formyl proton, and the 
appearance of a new one at ~6.0 ppm, associated with the proton in the tertiary carbon in compound 86. 
Thus, these results suggested that in this cyclized form (86), 2-FBBA becomes unable to react with 
1-butylamine and this is probably the reason why throughout the optimization studies the yields of 
iminoboronates were never improved. After thorough NMR studies with 2-FBBA and 1-butylamine under 
acidic, neutral and basic pHs, it was possible to conclude that high pHs drive this equilibrium towards the 
unreactive compound 86 and acidic conditions protonate the amino group of 1-butylamine hampering this 
way the imine formation. Therefore, this dilemma couldn’t be solved by tuning the reaction. 
 
 
 
 
72  86 
Scheme 31 – Tautomeric equilibrium of 2-FBBA 
 
In order to reduce the impact of the competing reaction that leads to tautomeric compound 86, the 
2-acetylbenzeneboronic acid (2-ABBA, 88) was tested as a substitute for 2-FBBA. It was hypothesized  
that the steric hindrance imposed by the methyl group could block the “reduction” of the carbonyl (Scheme 
32). Very gratifyingly, using 2-ABBA, the iminoboronate (89) was readily obtained in 88% conversion, 
either in neat water as in phosphate buffer solution (50 mM; pH 8.02). As expected, the para-isomer 
(4-ABBA, 90), which is unable to establish the same envisioned N-B interaction was incapable to deliver 
the imine. Hence, compound 88 was selected as lead scaffold to develop protein modification of lysine 
residues. 
 
 + 
 
 
 
87  88  89 
Scheme 32 – Reaction between 2-ABBA and 1-butylamine 
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Table 7 – 4-Acetylbenzeneboronic acid reaction with 1-butylamine 
Aldehyde/Ketone 
Conversion of 
imine formed 
 
90 
0% 
 
Once identified, 2-ABBA (88) was evaluated in these different studies involving the iminoboronate 
formation: kinetic evaluation and pH range assessment.  
Considering the results obtained with the kinetic study, a high reaction rate was observed and the 
iminoboronate was already formed in 81% in deuterated water when the first 1H-NMR was performed 
(after 15 minutes of reactants addition to the NMR tube). The iminoboronate’s stability was also evaluated 
during this study, which demonstrated the construct’s stability in water for up to 24 h (Figure 5). 
 
 
Figure 5 – Kinetics and stability of reaction between 2-ABBA and 1-butylamine 
 
The formation of the iminoboronate 89 was also evaluated at pHs ranging from 6.0 up to 9.2 (Table 
8). This study showed a remarkable stability of the imine over 7 days under such conditions (room 
temperature and phosphate buffer solution, 50 mM). 
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Table 8 – Conversion from the reaction of  
1-butylamine and 2-ABBA at different pHs 
pH 1 day 7 days 
6.0 67% 67% 
7.0 79% 80% 
8.0 84% 88% 
9.2 87% 87% 
 
Once the reaction conditions for the imine formation with 2-ABBA and 1-butylamine were well-
established, we synthesized an α-protected lysine (91, Boc-Lys-OCH3) which was then reacted with 
different 2-carbonyl boronic acids to determine the feasibility of this methodology when using more 
complex amines. Very gratifyingly, as shown in Table 9, the reaction proceeded similarly to what was 
observed when using the model 1-butylamine, and again the 2-ABBA (88) proved to be the most efficient 
reagent yielding the iminoboronate in 71%. 
 
 
+ 
 
 
 
91  92  93 
Scheme 33 – Reaction between 2-ABBA and Boc-Lys-OCH3 
 
Table 9 – Conversions from 2-carbonylbenzeneboronic acid derivatives’ reaction with Boc-Lys-OCH3 
Compound -R1 -R2 -R3 -R4 Conversion 
2-FBBA, 72 -H -H -H -H 61% 
83 -H -F -H -H 33% 
84 -H -H -OCH2O- -OCH2O- 56% 
2-ABBA, 88 -CH3 -H -H -H 71% 
 
Taking these results in consideration, the functionalization of more complex biomolecules was then 
pursued. Somatostatin (SST) is a short-life hormonal neuropeptide, which inhibits the secretion of various 
hormones including the growth hormone. In tumor cells, membrane receptors for somatostatin are over-
expressed, making it an excellent candidate to append and deliver cytotoxic agents.262   
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The 14 amino acid active form of this peptide was employed as a target, which presents two lysine 
residues in its sequence. SST-14 reacted with 2-ABBA (50 mM) for five minutes, in ammonium 
bicarbonate buffer (10 mM, pH 7.8) and the reaction was analysed by ESI-MS (Scheme 34 and Table 
10). Gratifyingly, the conjugates with one and two modifications were readily obtained with almost 
complete conversion of the peptide. Similarly, conjugation between 2-FFBA and SST-14 was evaluated, 
affording products with one, two and three modifications (N-terminal also modified). Once confirmed the 
successful formation of the constructs, MS2 analysis of the conjugate with three modifications obtained 
with 2-FBBA (m/z 1996.8) was performed and lead to the identification of a construct with one less 
appended boronic acid. 
 
 
+ 
 
 
 
94  95  96 
Scheme 34 – Reaction between 2-ABBA and SST 
 
Table 10 – ESI-MS results from reaction 2-FBBA/2-ABBA with SST 
Compound -R1 +1 BA (m/z) +2 BA (m/z) +3 BA (m/z) 
2-FBBA, 72 -H 
1750.7 
(-H2O) 
1863.8 
(-2H2O) 
1996.8 
(-2H2O) 
2-ABBA, 88 -CH3 1781.8 1927.8 - 
 
Following the successful modification of somatostatin, the reaction was then attempted with a native 
protein under naturing conditions. Lysozyme (Lyz) is one of the most well characterized proteins with a 
single amino acid chain of 129 residues (six of which are lysines) and a molecular weight of 14.5 kDa. 
This enzyme is a glycoside hydrolase and it is known for reacting with peptidoglycans present in bacterial 
cells, which is why it has been successfully applied as a biopharmaceutical.163,263 
As for the previous example, modification of Lyz with 2-ABBA took place smoothly at room temperature 
in ammonium acetate buffer (20 mM, pH 7.0), rendering up to six modifications evaluated with FTICR-MS 
(Figure 6).  
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Figure 6 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified Lyz; Black – Reaction between Lyz 
(10.0 µM) and 20.0 mM of 2-ABBA in ammonium acetate buffer (20.0 mM, pH 7.0) 
 
Since lysozyme is rather stable and readily available,264 it was used as a model protein for further 
studies, namely for the pH range assessment, the reaction’s kinetic evaluation with 2-ABBA and 2-FBBA 
and also in an attempt to isolate the conjugates. 
Remarkably, as it was true for the amine’s alkylic model, the reaction is fairly tolerant to pH and stable 
through time. Successful modifications were obtained in neat water or in ammonium acetate buffer (20 
mM) at pHs between 5.0 and 9.0, as well as insignificant changes were detected in the mass spectra from 
one up to four hs of reaction (under neutral pH).  
Moreover, using the optimized conditions, lysozyme was reacted with 10 mM of 
3-fluoro-2-formylphenylboronic acid (83), 2-formyl-4,5-methylenedioxyphenylboronic acid (84) and 
3-formyl-2-thienylboronic acid (85) in ammonium acetate buffer (20 mM, pH 7.0) at room temperature 
(Figure 7). Though quantitative measurements can not  be directly accessed from the mass spectra, the 
herein reported results are in line with the ones obtained with the model 1-butylamine. The later boronic 
acid failed to react while the former two readily led to iminoboronate species, demonstrating the system 
tolerance towards different functionalities on the aromatic moiety. 
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Figure 7 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified Lyz; Black – Reaction between Lyz 
(10.0 µM) and 10.0 mM of compounds 83 or 84 or 85 in ammonium acetate buffer (20.0 mM, pH 7.0)  
83 
84 
85 
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Despite the several attempts of purifying the conjugates obtained from 2-ABBA and Lyz were 
performed, its isolation was not achieved. Techniques such as dialysis (with D-tubeTM dialyzers or 
Amicon® ultra diafilters), size exclusion gravity columns (with Thermo Scientific™ Pierce™ dextran 
desalting columns) and centrifugal filtration (with Vivaspin® 2 centrifugal concentrator) were 
unsuccessfully executed.  
 
Finally, after the unproductive attempts of isolating the iminoboronate conjugates with lysozyme, other 
model proteins were targets of this conjugation method to show the vast applicability of this procedure. 
With the optimized conditions obtained for lysozyme, cytochrome c, ribonuclease A and myoglobin were 
also fully converted with 2-FBBA (72) in less than 5 min after addition of this boronic acid at room 
temperature, as depicted in Figure 8, Figure 9 and Figure 10, respectively. 
 
 
Figure 8 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified cytochrome C; Black – Reaction 
between cytochrome C (10.0 µM) and 10.0 mM of 2-FBBA in ammonium acetate buffer (20.0 mM, pH 7.0) 
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Figure 9 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified ribonuclease A; Black – Reaction 
between ribonuclease A (10.0 µM) and 10.0 mM of 2-FBBA in ammonium acetate buffer (20.0 mM, pH 7.0) 
 
 
Figure 10 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified myoglobin; Black – Reaction 
between myoglobin (10.0 µM) and 10.0 mM of 2-FBBA in ammonium acetate buffer (20.0 mM, pH 7.0) 
 
Hence, based on all the reported experimental data, it is fair to state that a new conjugation system 
selective for primary amines has been developed. In order to further understand the importance of the 
boronic acid in this conjugation system, the reaction mechanism was studied using DFT calculations. 
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II.3. Computational Studies 
Taking into account the experimental results discussed in II.2 Exploratory Results and Optimization, 
it is comprehensible that further information regarding the mechanism of iminoboronate formation and the 
N-B interaction should be of great value and an excellent complement to the previously discussed results. 
With that purpose, the well-known reaction of imine formation was studied by means of DFT calculations, 
using 1-butylamine as the amine model counterpart and different acetyl compounds to support the claim 
of a remarkable stability of the iminoboronate towards hydrolysis. First, acetophenone was used showing 
a well-known two step mechanism of hemiaminal formation and subsequent dehydration to generate the 
imine. Secondly, the same mechanism was applied for a boronic acid derivative, 4-ABBA, showing that 
the relative position of this chemical group makes a difference in terms of aiding imine formation, as well 
as the final product stabilization. Finally, 2-ABBA was used as a carbonyl counterpart to verify the role of 
the boronic acid in the ortho position to the acetyl group. Different mechanisms are purposed for this last 
reaction and all will be discussed in detail. 
 
It is important to highlight that for all mechanisms studied, there are two representations of each 
compound corresponding to diferent cis and trans imine stereoisomers. While the acetyl reagent 
(compound 97, Figure 11) does not present any isomer about the double bond, in the imine double bond, 
butylamine acts as a third substituent in this double bond, having an assigned priority, defined by a set of 
priority rules made by Cahn-Ingold-Prelog. Thus, two diastereoisomers are formed and this will have a 
crucial importance, in terms of possible N-B interactions between the boronic acid in the aryl group (Ar) 
and the nitrogen atom from 1-butylamine. When the aryl and the butyl group are on the same side of the 
double bond, the bond is assigned the configuration Z, like demonstrated in Figure 11 with compound 98. 
When these higher priority groups are faced on opposite sides of the double bond, this linkage is assigned 
with the configuration E, as shown with compound 99 (Figure 11).  
 
   
97 98 99 
Figure 11 – Acetyl reagent and different diastereoisomers for Imine product 
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II.3.1. Acetophenone and 1-Butylamine 
As aforementioned and as it was done with the presented experimental data, DFT calculations were 
performed focusing on the reaction between an aboronated carbonyl compound, acetophenone (80) and 
1-butylamine (87). Within the objective of this thesis, these results could be later compared with the ones 
obtained for the iminoboronate formation. 
This textbook mechanism of imine formation is based on two fundamental steps, which are two proton 
transfers from the nitrogen of an amine to the oxygen of a carbonyl compound driven by a nucleophilic 
attack from the amine to the electrophilic carbon of the carbonyl group. In opposition to iminoboronates, 
after imine formation, there is no possible stabilization in any of the isomers. Both isomers of this reaction 
are represented in Figure 12 and Figure 13 highlighting their similar energy. 
The mechanism for each isomer, starts with A, where the reactants (1-butylamine (87) and 
acetophenone (80)) interact in the presence of an additional water molecule that facilitates the proton 
transfers between these species. In the first step, from A to B, there is an approach made by the nitrogen 
to the carbonyl’s C-atom (from dAN–C = 3.73 Å to dBN–C = 1.58 Å), which leads to a simultaneous 
protonation of the oxygen atom, forming the expected hemiaminal B. This proton transfer is aided by a 
neighbour water molecule that exchanges one N-H proton from the amine to the water molecule. 
Simultaneously, one of the water O-H protons is transferred to the O-atom of the carbonyl group. In 
intermediate B, a new C-N bond is formed, as attested by the distance between these atoms (dBN–C = 
1.43 Å). 
From B to C there is a rearrangement of the geometry of the pair hemiaminal-water and of the 
corresponding H-bond network, which is required in order for the same water molecule to transfer another 
N-H proton from the now secondary amine to the newly formed secondary alcohol. In this following step 
(from D to E) a second molecule of water is formed, while a C-O bond is broken (dDC–O = 3.35 Å) and 
the C-N imine D double bond formed (dDN–C = 1.28 Å).  
Considering the thermodynamics of the process, these results highlight an unfavourable reaction 
pointing out a reversible character generally associated with a well-known tendency of imines to suffer 
hydrolysis. For instance, the last O-protonation step is highly unfavourable, even though a solvent 
molecule was considered to assist the process, TSC-D still presents 30-31 kcal/mol above the reactants 
(A). Moreover, this step is slightly endo-energetic (ΔE = 3-5 kcal/mol), indicating that there is a stability 
loss between the hemiaminal and the resulting imine. Additionally, an overall energy balance of 3-5 
kcal/mol and an energy of activation for this reaction of 35-36 kcal/mol also support the claims of a 
reversible and unfavourable reaction.  
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Figure 12 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the Z-isomer of 
N-butylmethylphenylimine from 1-butylamine (87) and acetophenone (80). Relevant changes are highlighted in red. 
 
 
 
 
Figure 13 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the E-isomer of the 
N-butylmethylphenylimine from 1-butylamine (87) and acetophenone (80). Relevant changes are highlighted in red. 
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Isomers Z and E only vary on 1-2 kcal/mol per step and therefore, all that it has been mention from 
A-D it is also true for A-D’. 
In conclusion, this far, all theoretical data is coherent with the preliminary experimental results obtained 
upon reaction of 1-butylamine (87) and acetophenone (80) in water, at room temperature, with a detected 
conversion of 0% (Table 4). 
 
II.3.2. 4-Acetylbenzeneboronic acid and 1-Butylamine 
Furthermore, in the same line of thought as the one applied with the experimental data, the reaction 
mechanism between 1-butylamine (87) and 4-ABBA (90) was also evaluated by means of DFT 
calculation, and as shown in Figure 14 and Figure 15, no significant changes were detected when 
comparing with the mechanism of 1-butylamine and acetophenone.  
This mechanism elucidation serves the purpose of stressing the importance of the position of the 
boronic acid within the aromatic ring for stabilizing the newly-formed imine. Considering the experimental 
and theoretical studies, solubility issues are unlikely responsible for the differences in reactivity of 2-ABBA 
and butylamine when compared with acetophenone. 
As a general remark, the steps depicted in Figure 14 and Figure 15 follow exactly the same routes as 
the previous mechanism, so they will not be discussed in detail. Summarizing, this mechanism also 
describes a thermodynamic unfavourable process and stresses the same reversible character. Similar 
energies as the ones from the last mechanism were obtained, like the slightly endo-energetic last step 
(ΔE = 3-4 kcal/mol) and the energy activation calculated for this reaction of 34-35 kcal/mol. Again, both 
mechanisms for isomers Z- and E- also have little variations. 
In conclusion, these theoretical studies support the experimental results obtained with the reaction of 
1-butylamine (87) and 4-ABBA (90) in water, at room temperature, where the imine was not formed (Table 
7). 
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Figure 14 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the Z-isomer of the 
iminoboronate obtained from 1-butylamine (87) and 4-ABBA (90). Relevant changes are highlighted in red. 
 
 
 
 
Figure 15 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the E-isomer of the 
iminoboronate obtained from 1-butylamine (87) and 4-ABBA (90). Relevant changes are highlighted in red. 
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II.3.3. 2-Acetylbenzeneboronic acid and 1-Butylamine 
Finally, the mechanism of the reaction between 1-butylamine (87) and 2-ABBA (88) was studied by 
means of DFT calculations. However, in this case, different interactions between the reactants led to the 
development of three different hypothetic mechanisms.  
In both hypothetic mechanisms 1 and 2, imine formation is the last step and the boronic acid’s role is 
the most noticeable difference between the two mechanisms. In the first case, boron acts as a Lewis acid 
forming a zwitterionic species between a hydroxylated benzoxaborole and a protonated secondary amine 
(TSJ-K, Figure 17), although boron is not directly involved in the protonation step. In the second 
mechanism, boron acts as a Brønsted acid, directly protonating a hydroxyl function of the newly formed 
secondary alcohol (TSQ-R, Figure 20), which is known to be a highly unfavourable process. Regarding the 
hypothetic mechanism 3, the boronic acid also acts as a Lewis acid, but the iminium is formed in early 
steps of the mechanism, leading to a zwitterionic species where a free boronate is its counterpart (TST’-U’, 
Figure 24). Also, it is worth highlighting that in any of the studied mechanisms there is always a final step 
of N-B coordination in all E-isomers, a bond that due to steric hindrance can not be formed in the 
Z-isomers. 
Hypothetic mechanism 3 was found to most effectively explain the observed results and for that 
reason, only this mechanism will be compared with the previous ones. 
 
II.3.3.1. Hypothetic Mechanism 1 
Regarding the first hypothetic mechanism of the reaction between 1-butylamine (87) and 2-ABBA (88), 
the ortho-boronic acid relatively to the carbonyl function acts as a Lewis acid. This leads to the formation 
of an intermediary benzoxaborole, which upon protonation regenerates the boronic acid functionality, as 
represented in Figure 16 and Figure 17. In this case, the mechanisms representing Z- and E-isomers 
formation present significant energetic differences and will be discussed in detail. 
The formation of the Z-isomer of iminoboronate N involves four consecutive steps, starting from the 
reagents I, 1-butylamine (87), 2-ABBA (88) and an additional water molecule to mediate proton transfers. 
In the first step, from I to J, there is a coordination of the O-atom of the carbonyl group to the boron 
(dTSI-JB-O = 1.87 Å), while the nitrogen attacks the electrophilic carbon from the carbonyl group (dTSI-JN-C 
= 2.64 Å). This step leads to a zwitterionic species between a protonated secondary amine (dJN-C = 1.6 
Å) and a hydroxylated benzoxaborole (dJB-O = 1.54 Å) and not the usual hemiaminal as one might expect.  
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Figure 16 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the Z-isomer of the 
iminoboronate obtained from 1-butylamine (87) and 2-ABBA (88) – Mechanism 1. Relevant changes are highlighted 
in red. 
 
 
 
Figure 17 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the E-isomer of iminoboronate 
(89) from 1-butylamine (87) and 2-ABBA (88) – Mechanism 1. Relevant changes are highlighted in red. 
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This step is followed by a process of proton transfer aided by the neighbour water molecule, from the 
N-H of the protonated amine to one hydroxyl groups of the cyclic boronate. This step leads to a neutral 
species where the water molecule remains coordinated to the boron atom (dKB-O = 1.64 Å). In the 
consecutive step a water molecule is loss and the oxygen and the boron atoms are incoordinated (dLB-O 
= 3.26 Å). The optimized geometries of tetrahedral coordinated benzoxaborole in K and the trigonal 
uncoordinated benzoxaborole in L are depicted in Figure 18. 
 
 
 
Figure 18 – Illustrations of the optimized geometry (PBE0/6-31G**) of K (left) and L (right) to highlight boron’s 
coordination 
 
From L to M there is the already mentioned H-bond rearrangement using the same water molecule to 
transfer another proton. This transfer is the fourth and last step of the iminoboronate Z-isomer’s 
mechanism 1 (from M to N) and it is assisted by the neighbour water molecule to move another N-H 
proton from the newly formed secondary amine to the cyclic O-atom of the benzoxaborole structure. This 
procedure finally leads to imine formation (dNN-C = 1.28 Å), by cleavage of the C-O bond and subsequent 
regeneration of the boronic acid (dNB–O = 1.36 Å). Overall, the formation of the iminoboronate Z-isomer 
in mechanism 1 is exo-energetic, as product N is 6.0 kcal/mol less stable than the reactants in I. 
Due to the rigidity associated with a double bond, no subsequent stabilization can occur in the 
Z-isomer, justifying the product instability when compared to the reactants. In the case of iminoboronate 
E-isomer’s mechanism 1 (Figure 17), once the imine is formed due to a favourable internal geometry 
adjustment, the N-atom and the boron are close enough to establish a N-B bond (dON-B= 1.71 Å) greatly 
enhancing the stability of the product O. In fact, the last step is strongly exo-energetic (ΔE = –7.5 kcal/mol), 
indicating the stability gain resulting from the formation of the N-B bond. This also reflects in an overall 
thermodynamic favourable energy balance of –7.2 kcal/mol. 
Despite being a thermodynamic favourable process , the energy activation calculated for the reaction 
(23.7 kcal/mol) that corresponds to the highest barrier in the mechanism (from M to N) is similar to the 
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previous species evaluated by DFT calculations. Therefore, this mechanism does not support the 
experimental results. In fact, the transition state for the second O-protonation, TSM’-N’, although assisted 
by a solvent molecule, is 19-21 kcal/mol less stable than the reactants I. Such high energy for a reaction 
that occurs smoothly at room temperature led us to investigate other mechanisms, aiming to unveil new 
roles of the boronic acid to stabilize the second O-protonation. 
Before moving on to the next hypothetic mechanism though, it is important to summarize the role that 
the boronic acid took in this mechanism 1, since it is considered to be the driving force of this reaction 
and also the reason for stabilization of the final product. Thus, in the first step, boronic acid establishes a 
B-O bond with the oxygen from the carbonyl group in order to activate this group towards a nucleophilic 
attack from the amine’s N-atom. Then it forms a benzoxaborole group (coordinated or not with water) that 
will be present until the second O-protonation that leads to imine formation. As expected also in the 
E-isomer formation, the establishment of the N-B dative bond that stabilizes the final product.  
 
II.3.3.2. Hypothetic Mechanism 2 
Aiming at discovering a reaction mechanism between 1-butylamine (87) with 2-ABBA (88) that 
supports the results obtained experimentally, an alternative mechanism was studied by means of DFT 
calculations. In Figure 19 is presented the calculated mechanism for the Z-isomer and Figure 20 for the 
E-isomer. 
This mechanism for iminoboronate formation presents two major differences from the ones presented 
before. First, it leads to the expected hemiaminal, though it requires overcoming higher energy barriers 
(8.5 kcal/mol) to achieve the intermediary R. Also in contrast with the previous mechanism, where water 
loss is driven by an uncoordination between the boron atom and the water molecule (from K to L), in 
hypothetic mechanism 2, the water loss is driven by the direct protonation from one of the hydroxyl groups 
of the boronic acid to the hydroxyl group of the newly formed secondary alcohol (from S to M’’). Therefore, 
in this mechanism the boronic acid plays a role of a Brønsted acid, which is not a thermodynamic 
favourable process, as confirmed by the energy requirements.  
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Figure 19 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the Z-isomer of the 
iminoboronate obtained from 1-butylamine (87) and 2-ABBA (88) – Mechanism 2. Relevant changes are highlighted 
in red. 
 
 
 
 
Figure 20 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the E-isomer of iminoboronate 
(89) from 1-butylamine (87) and 2-ABBA (88) – Mechanism 2. Relevant changes are highlighted in red. 
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Hypothetic mechanism 2 involves four consecutive steps with an extra one of N-B coordination for the 
E-isomer as described before in mechanism 1. With either isomer, this mechanism starts with P, the 
reactants and an additional water molecule, which then through a nitrogen’s nucleophilic attack to the 
electrophilic carbon of the carbonyl (dQN–C = 1.59 Å) leads to a coordination of the oxygen to the boron 
atom (dQB–O = 1.63 Å). 
From Q to R, the aforementioned nucleophilic attack is completed with the formation of a new N-C 
bond (dRN–C = 1.48 Å) and simultaneous protonation of the oxygen atom from the previous carbonyl 
group, leading to hemiaminal R. As in the case of the other mentioned mechanisms, a neighbour water 
molecule assists the proton transfer from the amine group to the oxygen atom of the carbonyl group. 
From R to S there is a rearrangement of the geometry of the hemiaminal-water pair and of the 
corresponding H-bond network, in a way that the proton from one of the hydroxyl groups of the boronic 
acid forms a strong H-bond with the newly formed secondary alcohol (dSBOH-O = 1.76 Å).  
From intermediate, S, based on the close proximity between the hydrogen and the alcohol, the 
subsequent step is established by breaking the C-O bond and releasing a second water molecule. In the 
corresponding high energy transitory state, TSS-M’’ (Figure 21), the former C–O bond is practically cleaved 
(dTSS-M’’C–O = 2.34 Å) and comprises a boronic acid acting as a Brønsted acid. The boronic acid yields a 
proton to promote the release of a new molecule of water, instead of the normal path of proton transfer 
from the second proton of the amine. This last step has a high energy barrier showing a step strongly 
endo-energetic (ΔE = 13.8 kcal/mol) and indicating that this is not a suitable role for this organic group, 
as expected and commented in II.1.2 Boronic Acids. This step also leads to the formation of a 
benzoxaborole group mentioned in mechanism 1, M’’, since the boronic acid is not stable when bearing 
an unprotonated hydroxyl group. 
 
 
Figure 21 – Water loss promoted by boronic acid in the fourth step of hypothetic mechanism 2 – Optimized geometry 
(PBE0/6-31G**) of TSS-M’’ 
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From M‘‘ to M there is another rearrangement of the geometry and corresponding H-bond network, 
though in this case between the benzoxaborole-water pair, since with the previous step of water loss, the 
heminaminal no longer exists. This reorganization gives the proper geometry for the final step of this 
mechanism to occur, a second O-protonation. This last step, from M to N, is based on a proton transfer 
from the second proton of the nitrogen atom to the benzoxaborole group, which is assisted by the 
neighbour water molecular forming the imine and regenerating the boronic acid.  
All the steps described so far are based on the iminoboronate Z-isomer’s mechanism 2, though all 
descriptions are also applicable to the E-isomer with slight energetic changes from M’ to N’, as the 
rearrangement of the geometry of the pair benzoxaborole-water and corresponding H-bond network is 
different to afford this different diastereoisomer. 
Moreover, the E-isomer has an additional step of N-B coordination, which is mainly related with an 
internal geometry adjustment of a NC–C(phenyl) bond rotation that brings the imine’s N-atom into closer 
proximity of the boron atom, allowing the formation of a new N-B bond (dON-B = 1.71 Å). This last step is 
once again, strongly exo-energetic (ΔE = –7.5 kcal/mol) representing a stability enhancement for this 
bond formation. 
The overall energy balance of –10.0 kcal/mol represents a favourable thermodynamic process, though 
the high activation energy calculated for this reaction (26.2 – 28.3 kcal/mol) corresponding to the highest 
barrier along the path (from M to N) demonstrates the same drawback as in the last hypothetic 
mechanism. The protonation step of the cyclic oxygen from benzoxaborole is a high energy step that once 
more is not supported by the experimental data. Furthermore, in this hypothetic mechanism there is 
another high activation energy step to obtain the benzoxaborole, which is related with the unusual acidic 
nature of the boronic acid. Thus, the corresponding transitory state TSS-M’’ is 15.2 kcal/mol less stable 
when compared to the reactants P. For these reasons, once again this hypothetic mechanism 2 is believed 
to be unsuitable to describe the smooth reaction between 1-butylamine and 2-ABBA that occurs at room 
temperature. Once more, other roles for the boronic acid were investigated. 
As performed in the hypothetic mechanism 1, due to its importance the boronic acid’s part in this 
mechanism will now be summarized before moving to the next hypothetic mechanism. As before, in the 
first step, the boronic acid forms a B-O bond with the O-atom from the carbonyl group to activate it towards 
the nucleophilic attack from the amine’s N-atom. However, in the water loss step the boronic acid plays a 
direct role in O-protonation of the newly formed secondary alcohol and also one of its oxygens forms a 
C-O bond that did not exist previously. This is the major difference between this mechanism and the 
previous one. The other functions performed by this group are the same as in hypothetic mechanism 1 – 
benzoxaborole formation and stabilization of the final product (for the E-isomer). 
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II.3.3.3. Hypothetic Mechanism 3 
Based on the aforementioned results a third hypothetic mechanism for the reaction between 
1-butylamine (87) and 2-ABBA (88) was studied by means of DFT calculations, again for the Z- and 
E-isomer depicted in Figure 22 and Figure 24, respectively. 
Differently from all the calculated mechanisms presented until now, the diastereoisomers presented 
significant energy differences, whether for its final product as for some steps along the path. For that 
reason, both will be fully discussed with the exception of heminal formation and steps from P to R (which 
are the same described in hypothetic mechanism 2). 
Considering the mechanisms presented in Figure 22 and Figure 24, when going from R to N’ (for 
Z-isomer) or from R to O (for E-isomer), these paths proceed through formation of an iminium species 
and a boronate group forming different zwitterionic intermediaries. Benzoxaborole group was not detected 
in these mechanisms calculated for both isomers. 
 
 
 
Figure 22 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the Z-isomer of the 
iminoboronate obtained from 1-butylamine (87) and 2-ABBA (88) – Mechanism 3. Relevant changes are highlighted 
in red. 
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Regarding the mechanism calculated for the Z-isomer (Figure 22), when going from R to T there is a 
rearrangement of the geometry of the hemiaminal-water pair and of the corresponding H-bond network. 
Then, in the following step, from T to U, there is cleavage of a C-O bond, transferring the newly formed 
hydroxyl group to the boron atom, in line with the true character of this mild Lewis acid. Here the resulting 
negative charge is formally drawn on the boron atom but, in fact, it is spread out on the three heteroatoms. 
In parallel with boronate formation there is also formation of an iminium ion, which then forms the first 
abovementioned zwitterionic species, U. The corresponding transition state, TST-U, represents several 
characteristics that corroborate these claims, namely the former C–O bond practically cleaved (dTST-UC-O 
= 2.13 Å), the new B-O bond (dTST-UB–O = 1.55 Å) and the new C=N+ bond (dTST-UN–C = 1.32 Å) newly 
formed. 
From U to W two reorganization of the H-bonds between the boronate-water-iminium triad occur, which 
lead to the release of a water molecule and the final iminoboronate in the Z-isomer form (from W to N’). 
This second O-protonation represents one of the major energetic differences between the mechanisms 
of both isomers, mainly due to a stereochemical arrangement around the C=N bond of TSW-N’ that prevents 
the proper organization for the water molecule to mediate a proton transfer, as depicted in Figure 23. 
However this limitation might be overcome by using two water molecules (instead of one) that would 
facilitate this proton transfer, which is reasonable considering that water is the reaction’s solvent. 
 
 
Figure 23 – Illustrations of the optimized geometry (PBE0/6-31G**) of TSW-N’ (left) and TSU’-V’ (right) to highlight 
steric hindrance  
 
Regardless of that fact, the Z-isomer of the iminoboronate N’ can not establish the N-B interation due 
to its stereochemical arrangement. The lack of this property leads to an intermediate 4.8 kcal/mol less 
stable than the initial reactants P, and hence 15 kcal/mol less stable than O. Thus, suggesting that 
Z-isomer of this iminoboronate corresponds to a thermodynamically unfavourable reaction and 
consequently, easily reversible. 
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Figure 24 – Energy profile (kcal/mol) calculated (PBE0/6-31G**) for the formation of the E-isomer of iminoboronate 
(89) from 1-butylamine (87) and 2-ABBA (88) – Mechanism 3. Relevant changes are highlighted in red. 
 
In the case of the E-isomer, from R to U’ there is also the same H-bond rearrangements that lead to 
the formation of the same species as in Z-isomer (iminium and boronate zwitterion), which can be 
confirmed by some distances registered from TST’-U’ (depicted in Figure 24): iminium (dTST’-U’N–C = 1.29 
Å) and boronate formation (dTST’-U’B–O = 1.50 Å), with prior C-O bond cleavage (dTST’-U’C–O = 2.26 Å). 
However, from this point on, there are significant changes in the two mechanisms that demonstrate a 
more thermodynamically favourable mechanism for the E-isomer. 
In the fourth step of this path, from U’ to V’, the second proton from the iminium ion is transferred to 
one of the hydroxyl groups coordinated with the boron atom, which is supported by the neighbour water 
molecule. Thus, in V’ boron is coordinated to the aromatic substituent, two hydroxyl groups and the 
resulting water molecule. This protonation results in a clear weakening of the B-OH2 bond, as confirmed 
by the corresponding bond lengths (1.50 Å, in U’, and 1.64 Å, in V’). 
After a second rearrangement of the H-bonds involving the water molecule, there is loss of a water 
molecule by uncoordination with the boron atom, and consequently iminoboronate formation N’’. In the 
corresponding transition step, TSW’-N’’, cleavage of the B–OH2 bond is finished, as shown by the 
corresponding distance (2.72 Å). 
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From N’’ to X there is a final rearrangement of the H-bonds, involving two different water molecules, 
one being the solvent molecule present in the molecule since the beginning of the mechanism and the 
other corresponds to the reaction’s side product obtained in the previous step (from W’ to N’’). 
Similarly to the previous mechanisms calculated for the E-isomer, in the last step of this mechanism, 
from X to O, there is an internal geometry adjustment that corresponds mainly to a rotation around the 
NC-C(phenyl) bond. This leads to a close proximity between the imine’s N-atom and the boron, thus 
establishing a N-B bond (dON-B= 1.71 Å) greatly enhancing the stability of product O. In the same line 
with the previous hypothetic mechanisms 1 and 2, this last step is strongly exo-energetic (ΔE = –7.4 
kcal/mol) demonstrating an increase of stability due to N-B bond formation, which also reflected in an 
overall energy balance of –10.0 kcal/mol, which is indicative of a thermodynamically favourable reaction. 
Finally, the energy activation calculated for this reaction (12.4 kcal/mol) is in agreement with the 
experimental conditions employed. This energy corresponds to the highest barrier along the path (from 
T’ to TSW’-N’’) which is related with one of the most difficult steps along the entire path – the second proton 
transfer between N–H to O–H. Despite the assistance of the solvent molecule in both proton transfer, the 
corresponding transition states TSQ-R and TSW’-N’’ are both 5.9 kcal/mol above the reactants P. 
Once again, it is important to highlight the crucial role of boronic acid along the mechanism. As before, 
the boronic acid group started by establishing a B-O bond with the carbonyl’s oxygen, promoting the 
nucleophilic attack from the amine’s N-atom. Further along, respecting the true nature of this mild Lewis 
acid, it coordinates a hydroxyl group that is retained throughout the mechanism (from U’ to W’). In the 
end, it has promoted two protonation steps, assisting the formation and loss of the water molecule (the 
leaving group in this reaction). 
By comparison with the aboronated species or the mechanism between 1-butylamine and 4-ABBA, it 
is clear that this boron assistance along the reaction justify a significantly smaller energy barrier for the 
formation of the iminoboronate O (89), from 35-36 kcal/mol to 12.4 kcal/mol as aforementioned. Moreover, 
both mentioned mechanisms without N-B interaction led to slightly endo-energetic reactions (ΔE = 3–5 
kcal/mol) versus the one where N-B interaction exists. In such case a strongly exo-energetic reaction (ΔE 
= –7.4 kcal/mol) was determined suggesting a reversible character for the first two species and an 
increase of stability. Such statements clearly justify the iminoboronate smooth formation in aqueous 
media. 
Finally, the observed iminoboronate stability towards hydrolysis or in other words, the diminished 
reversibility of the corresponding reaction when compared with simple imine formation is a direct 
consequence of the N-B bond established between the boron atom and the imine N-atom, as shown by 
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 1.70 Å 
WI = 0.48 
a 7.4 kcal/mol energy gain in the final product (O) compared with intermediate X where the N-B bond is 
absent. In the optimized structure of O (89) the presence of the N-B bond is represented by a distance of 
1.70 Å and it is confirmed by a Wiberg index of 0.48, indicative of a covalent bond (Figure 25). Such 
observations support the stability of the product as much as the role of the boronic acid along this 
mechanism. 
 
 
Figure 25 – Optimized geometry (PBE0/6-31G**) of the iminoboronate O (89). The N-B bond distance (Å) and the 
corresponding Wiberg index (WI, italics) are indicated.  
 
 
II.4. Reversibility 
Since the theoretical elucidation of the mechanism and stability of the final product was established by 
means of DFT calculations and it was in agreement with the experimental results, demonstrating an 
expected bioconjugation based on the formation of hydrolysis-stable iminoboronates, the following step 
relied on studying the possibility of controlled reversibility.  
As aforementioned, it was envisioned that N-B dative bond could be disrupted by the influence of an 
external molecule, offering a mechanism to promote the imine hydrolysis and thus, revert the protein’s 
modification. With that purpose in mind, several endogenous molecules (glucose, fructose, lactose, 
sucrose, ephedrine, thymine, adenine, cytosine, dopamine and glutathione) were added to iminoboronate 
89 and a kinetic 1H-NMR evaluation was performed.  
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Figure 26 - Reaction of iminoboronate 89 with 1 equivalent of endogenous molecules (EM): glucose, fructose, 
lactose, sucrose, ephedrine, thymine, adenine, cytosine, dopamine and glutathione. 
 
As shown in Figure 26, most of the molecules tested had an almost negligible effect on the percentage 
of the preformed imine. Nevertheless, fructose and dopamine considerably reduced the concentration of 
iminoboronate 89 in 56% and 79% respectively, probably due to the formation of boronate esters which 
increased the electrophilicity/Lewis acidity of the boronate and thus amplified solvent insertion. 
Furthermore, glutathione decomposed the iminoboronate 89 in up to 7% in less than 2 h. This constitutes 
a very promising result when envisioning the design of delivery systems into cells because in the cell’s 
cytoplasm glutathione exists in an increased concentration (milimolar range) and this fact may be targeted 
to promote the conjugate dissociation only when internalized.39  
Taking in consideration the aforementioned results, the hydrolysis potential on biomolecules was 
evaluated using the well-established 2-FBBA-Lyz conjugates in an ammonium acetate buffer solution (20 
mM) at pH 7.0. After mass spectrometry evaluation of these constructs, 1 equivalent of dopamine (102), 
fructose (101) and glutathione (100) were added separately to 2-FBBA-Lyz conjugates and the results 
obtained with ESI-FTICR-MS were recorded immediately (Figure 27). Similarly to what occurred when 
using the model iminoboronate 89, the addition of dopamine, fructose and glutathione rapidly induced the 
hydrolysis of the constructs. These results clearly support a controlled reversible modification of primary 
amines, which can be used as a new tool for protein modification. 
 
0
10
20
30
40
50
60
70
80
90
100
0 100 200 300 400 500
%
 P
ro
d
u
ct
t (min)
1400 1420 1440
Fructose
Dopamine
Glutathione
Chapter II. Searching Conjugation with Controlled Reversibility 
   
73 
 
Figure 27 - Reaction of lysozyme constructs with equimolar amount of endogenous molecules (EM): dopamine, 
fructose and glutathione. A zoom of the ESI-MS spectra of the lysozyme constructs is displayed. The 
ESI-FTICR-MS spectra a, b and c were recorded immediately after the addition of dopamine, fructose and 
glutathione, respectively. 
 
II.5. Conclusion 
In the end, an innovative strategy to modify a protein’s lysine ε-amino and N-terminal groups based 
on the generation of stable imines in aqueous media with 2-carbonylbenzeneboronic acids was presented.  
Several experimental data, as well as theoretical elucidation of the reaction’s mechanism and on the 
hydrolytic stability of iminoboronates was demonstrated, which led to the fast and efficient modification of 
different biomolecules. Moreover, these iminoboronates allow a controlled reversibility upon the presence 
of certain endogenous molecules, such as glutathione, dopamine and fructose.  
 
1193.1
12+ (A)
1202.6
12+ (B)
1212.0
12+ (H)
1224.6
12+ (I)
1234.1
12+ (M)
1245.0
1256.0
1265.2
1190 1200 1210 1220 1230 1240 1250 1260 1270 1280m/z
0
20
40
60
80
100
Intens.
[%]
LZ_w ss_FBA_more_000001.d: +MS
 
(12+) 
1202.6 
(12+) 
1212.0 
(12+) 
1224.6 
(12+) 
1234.1 
.  
1256.0 
.  
1210 1220 1230 1240 1250 1260 1270 m/z 
(12+)
12 .6
(12+)
1212.0
(12+)
1224.6
(12+)
1234.1
1245.0
1256.0 1265.2
a
b
c
 
1184.5
1193.1
12+ (A)
1202.5
1212.3
1223.9 1233.1
1244.5 1252.5 1260.5
1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 m/z
0
5
10
15
20
25
Intens.
[%]
LZ_w ss_FBA_reversB_000001.d: +MS1200 1210 1220 1230 1240 1250 1260 m/z 1190 
(12+) 
1193.1 
1184.5 
1202.5 
12 .9 
1233.1 1252.5 
1244.5 1212.3 1260.5 
(12+)
1193.1[%]
25
20
15
10
5
0
 
1184.3
1193.1
12+ (A)
1202.5
1212.3
1229.4
1+ (J)
1240.4
1251.3
1+ (C)
1267.3
1+ (I)
1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 m/z
0
2
4
6
8
Intens.
[%]
LZ_w ss_FBA_reversA_000002.d: +MS
8 
 
0 
2 
 
4 
 
6 
[%] 
 
1200 1210 1220 1230 1240 1250 1260 m/z 1190 
1244.5 
1260.5 
m/z 
 
1200 
 
210 
 
20 
 
1230 
 
40 
 
1193.0
12+ (A)
1208.1
12+ (F)
1216.3
12+ (B)
1222.5
12+ (G)
1240.5
1261.5
1190 1200 1210 1220 1230 1240 1250 1260 1270 1280 m/z
0
20
40
60
80
Intens.
[%]
LZ_w ss_FBA_reversC_000001.d: +MS1200 1210 1220 1230 1240 1250 1260 m/z 1190 
60 
0 
20 
 
[%] 
 
40 
 
80 
 
(12+) 
1216.3 
(12+) 
11 .0 
(12+) 
1208.
1 
(12+) 
22.5 
12 .5 
12 .5 
(12
9 .0
(12+)
1216.3
(12+)
1222.5
(12+)
1208.1
1202.5
. 3.
1233.1 1252.5
1240.5
1261.5 1184.3
(12+)
1193.1
1260.5
12 .5
1212.3
(1+)
12 .4
1240.4
(1+)
1251.
(1+)
1267.3
 
 
100 
101 
102 
   
 
 
 
 
  
    
Chapter III 
Modification of the novel modifying agent 
 
 
ABSTRACT 
Boronic acids and derivatives are sensitive compounds that entail certain handling requirements and, 
thus, though different methods are reported, modifications on their structure or their ground synthesis are 
difficult processes that often require different protection and deprotection steps. 
In this chapter, different attempts to obtain 2-carbonylbenzeneboronic acid derivatives will be 
presented leading to a strategy that started from the incorporation of a small linker, followed by a required 
triflation reaction to perform a Miyaura-borylation. Hydrolysis steps as deprotection procedures were also 
required to generate a modifiable boronated backbone that could be changed depending upon the 
intended application.  
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Chapter III.   
Modification of the novel modifying agent 
III.1. Introduction 
III.1.1. Chemical Properties of Boronic Acids 
Since the boronic acid moiety plays a major role in iminoboronate conjugation system and it has 
specific chemical properties that could drive the synthesis towards certain paths over others, boronic acid 
properties and chemical reactivity will be explained in detail. 
 
This chemical group presents a weak electron-withdrawing inductive effect due to the electronegative 
differences between boron and carbon (B = 2.05 and C = 2.55) and also a electron-withdrawing resonance 
effect due to the electronic deficiency of boron. Moreover, either aldehydes or ketones are 
electron-withdrawing groups and moderately deactivating groups, which means that these groups present 
an synergic effect with boronic acids, deactivating the aromatic ring.233 
In terms of handling, most compounds bearing boronic acids can be handled in air, at room 
temperature and often these compounds present long shelf-stability. However, since these reagents are 
prone to atmospheric oxidation and autoxidation, they should be stored under an inert atmosphere. When 
dehydrated, either with a water trapping agent or through co-evaporation or high vacuum, boronic acids 
tend to form cyclic and linear oligomeric anhydrides such as trimeric boroxines (Figure 28). Usually this 
is not an issue when used as synthetic intermediates (as they commonly are), however, for the desired 
synthetic routes of this project this property assumes a crucial relevance. 233 
Furthermore, upon exposure to air, dry species may decompose rapidly, and boronic anhydrides are 
considered to be initiators of the autoxidation process. For this reason, for long-term preservation it is 
advised to store these species under a slightly moist environment, as it happens for commercial samples. 
As an alternative, boronic ester are common surrogates of boronic acids that avoid anhydride 
generation.233 
 
Therefore, relevant for the synthetic routes to be described one should highlight that 
2-carbonylbenzeneboronic acids might present a slightly deactivated ring and should be handled under 
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inert and slightly moist atmosphere to avoid oxidation processes. Furthermore, dried samples can not  be 
left under ambient air with no special precautions, since they readily form the corresponding alcohols 
through a process of atmospheric oxidation (Figure 28).  
 
III.1.2. Chemical Stability of Boronic Acids 
The already mentioned oxidation processes only take into account boronic acids’ inherent properties 
and not their chemical stability towards external agents and conditions. Three processes that these 
species suffer from should be highlighted: ligand exchange and disproportionation, chemical oxidation 
and protolytic deboronation.233 
Regarding the first two processes that can occur while handling boronic acids, it is noteworthy that the 
substitution of the carbon-containing group of these species with other substituents is a slow process and 
thermodynamically unfavoured, which makes it very rare to find the disproportionation products 
(trialkylborane, borinic acid or boric acid) that are represented in Figure 28. Moreover, concerning the 
second process involving boronic acid chemical oxidation, the oxidative cleavage of the C-B bond of 
boronic acid derivatives with water (under a wide pH range) or oxygen is a kinetically slow process. 
Nevertheless, under specific conditions and potent oxidizing agents, boronic acids and derivatives are 
readily oxidized (Figure 28).233 
 
 
Figure 28 – Boronic Acids‘ Stability and degradation patterns 
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Finally, regarding the protolytic deboronation of boronic acids in aqueous media, the C-B bond is 
known for being highly protolytic resistant under neutral aqueous solutions, even at high temperatures. 
However, under highly acidic or basic aqueous conditions arylboronic acids can be promptly deboronated. 
Moreover, ortho-substituted and especially electron-poor arylboronic acids are recognized for their 
tendency to protodeboronate under basic aqueous conditions. The motif under study, 
2-carbonylbenzeneboronic acids, is precisely a good example of such structure. In the case of 
electron-rich arylboronic acids, they tend to deboronate faster in strongly acidic aqueous media.233 
Generally, arylboronic acids or esters tend to be very resistant to non-aqueous acids, but can be 
protodeboronated by means of metal-promoted C-B bond cleavage. In this regard, an order of 
effectiveness among metals that can perform aqueous protodeboronation was established: Cu (II) > Pb 
(II) > Ag (I) > Cd (II) > Zn (II) > Co (II) > Mg (II) > Ni (II), though other metals may promote the same 
transmetallation-protodeboronation, like Hg (II), Rh (II) or even Pd (0). 233 
Thus, to summarize, ortho-substituted and electron-poor arylboronic acids (such as 
2-carbonylbenzeneboronic acids) have a competitive protolytic deboronation which is exacerbated by the 
basic conditions and the use of transition metals.  
 
III.1.3. Synthesis of Boronic Acids 
With the objective of delineating a synthetic strategy to derivatize 2-ABBA/2-FBBA, a useful alternative 
to produce different 2-carbonylbenzeneboronic acid species could arise from modifications of aboronated 
species with the incorporation of the boronic acid in a final stage of the synthesis. For that reason, 
borylation methods will be discussed below. 
Many different methods have been reported to introduce the boronic acid functionality, though the 
most used ones involve the electrophilic trapping of arylmetal intermediates with borates from aryl halides 
or from directed ortho-metallation; the transmetallation of arylsilanes and arylstannanes; the transition 
metal-catalyzed coupling between aryl halides/triflates and diboronyl reagents or the direct boronylation 
by transition metal-catalyzed aromatic C-H functionalization.233 
Since the older borylation methods were based on hard organometallic species or generated from 
hard boron halides which required rigorously anhydrous conditions to be performed, the transition metal-
catalyzed coupling between aryl halides/triflates and diboronyl reagents seemed to be the most promising 
methodology to obtain the sought compounds. Thus, since diboronyl esters, such as 
bis(pinacolato)diboron (B2pin2), have been described as agents to perform a smooth palladium catalysed 
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cross-coulping reaction with aryl groups bearing good leaving agents, this protocol seemed to be a valid 
choice to pursue the strategy that started from aboronated species. Moreover, the scope of halo or 
triflatearene substrates in these reactions is very broad, even having described methods for ortho-
carbonylaryl derivatives, which would be unsuitable for any procedure using organolithium or 
organomagnesium intermediates without resorting to protection steps. Standard conditions for this 
coupling reaction involve, apart from the already mentioned diboronyl esters, PdCl2(dppf) as catalyst, 
potassium acetate as base and a polar aprotic solvent as the reaction medium.233 
 
III.2. Goals 
Hence, in this chapter, different strategies to obtain 2-carbonylbenzeneboronic acid derivatives will be 
presented, starting from modifications to 2-FBBA core and 2-ABBA core, in an attempt of having hydroxyl 
or amine derivates without performing any borylation methods and using the compounds already available 
in our inventory. 
Since this methodology proved to be inefficient, different strategies based on borylation methods were 
developed, though, in all cases, the borylation step proved to be the most crucial synthetic step of the 
strategies developed. In this chapter, all limitations that arose while developing borylation methods will be 
commented as well as all the solutions to overcome those problems. 
In the end, it will be presented a backbone featuring an acid function that could be early modified 
through amidations or esterifications, depending upon the purpose and the starting molecule. These last 
reactions will only be presented in Chapter IV.  
 
 
III.3. Strategies to achieve a modifiable backbone  
III.3.1. Modification of 2-carbonylbenzeneboronic acid 
Modification of 2-carbonylbenzeneboronic acids was attempted as a strategy to avoid borylation 
methods and to take advantage of commercially available reagents that bear this motif. First, an attempt 
to modify the 2-ABBA core was experimented, through an aromatic nitration of this unprotected structure 
and then, a methylation of a boronate ester derivative of 2-FBBA was also endeavoured to take advantage 
of all the ortho-formylbenzeneboronic acids available in the laboratory.  
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Nitration of some boronic acids has been reported and, based on one of those procedure, nitration of 
2-ABBA was attempted first. The retrosynthetic route outlined started from this reaction, which was the 
most crucial step of this strategy, and then move on (with our without protecting the carbonyl group) into 
a well-known reduction of the nitro group to afford amines. And, in the end, the last step would be based 
on the functionalization of this amine-derivative of 2-ABBA using halogen derivatives to perform SN2 
displacement of the halogens to afford secondary amines, under basic conditions (Scheme 35). 
 
 
 
 
 
 
 
 
103  104  105  88 
Scheme 35 – Retrosynthesis of amino-derivatives of 2-ABBA 
 
The first attempt on performing a nitration of 2-ABBA was based on a procedure that started from 
meta-amidederivatives of benzeneboronic acid, which seemed as a good starting point to nitrate 2-ABBA. 
As a first result, though a species with only three aromatics protons was isolated (as expected from 
compound 105), it did not present any alkylic proton signals (Scheme 36).  
 
 
HNO3, H2SO4 
 
-98 ºC, 40 min, Ar 
 
88  105 
Scheme 36 – Nitration attempt of 2-acetylbenzeneboronic acid (88) 
 
In another attempt at the same reaction, complete conversion of 2-ABBA was again detected by TLC, 
though, in this case, a different species was obtained with three other aromatic proton signals. 
Nevertheless, the major isolated products were unreacted 2-ABBA or a compound with four protons that 
could be the result of a protolytic deboronation. 
In the end, this strategy was dismissed due to results on infrared spectroscopy and mass spectrometry 
that, in any case, demonstrated none of the expected bands or masses for compound 105.  
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In a second attempt to obtain 2-ABBA derivatives, a strategy was outlined to take advantage of 
commercially available 2-FBBA. First, since organometallic agents were to be used in order to perform 
the methylation of the formyl group, a first protection of 2-FBBA was required to avoid any interference. 
Next, the most critical step of this strategy would be performed using methyllithium in THF at low 
temperatures, based on a reported procedure for aldehydes conjugated with alkenylboronic acids. Then, 
an oxidation would be performed using mild oxidizing agents selective towards secondary alcohols and 
lastly a simple deprotection step would be required to generate the envisioned 2-ABBA derivatives 
(Scheme 37). 
 
 
 
 
 
 
 
 
 
 
106  107  108  109  110 
Scheme 37 – Retrosynthesis of 2-ABBA derivatives from commercially available 2-FBBA 
 
Therefore, to follow the described retrosynthesis, the first protection step was performed with excellent 
yield. Then, different attempts on the methylation of the pinacolyl ester of 2-FBBA were attempted. 
However, no conversion was observed (Scheme 38), and thus, this strategy was rapidly discarded as a 
feasible possibility. 
 
 
Hexane, 3 h
 
 r.t., 95% 
  
1) DBU, THF,  
r.t., 10 min 
 
2) MeLi, THF, 
-78 ºC→0 ºC 
 
72 111 109 (R = H)  108 (R = H) 
Scheme 38 – Methylation attempt of 2-formylbenzeneboronic acid (72) 
 
Modifications of 2-carbonylbenzeneboronic acids proved to be very difficult to evaluate, since all 
available analytical techniques offered uncertain results impairing their interpretation. Boronic acids’ 
presence was a constant interrogation during these modification steps due to the possibility of protolytic 
deboronation, as explained in the introduction. Therefore, methods that introduce boronic acids further 
along the synthesis seemed to be a more attractive strategy. 
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III.3.2. Construction of 2-carbonylbenzeneboronic acid 
As mentioned in the previous topic, new synthetic methodologies that incorporated the boronic acid 
moiety in later steps of the synthetic path had to be developed. This strategy appeared to be more 
reasonable taking into account the difficulty found in working with boronic acid derivatives. Thus, the final 
goal was to find a core molecule that could be modified depending upon the intended biological 
application. To this end, three different strategies were studied aiming at the synthesis of these 
compounds.  
III.3.2.1. Strategy 1 
Based on the aforementioned the first retrosynthetic pathway considered for our target compound is 
depicted in Scheme 39, which started from 2’,4’-dihydroxyacetophenone (115) to ultimately generate 
5-hydroxy-2-ABBA (112). Compound 112 can then be further modified via phenol alkylation to yield 
different derivatives of 2-ABBA. Five consecutive steps would be required to obtain such molecules, 
starting from the selective protection of the para-hydroxyl group of 115, then, a triflation of the remaining 
hydroxyl group would yield a substrate (117) for the Miyaura-borylation. This was envisioned to be the 
crucial step of this synthetic pathway, since only deprotection procedures remained to be performed and 
they are believed to be simple steps (Scheme 39). 
 
 
 
 
 
112  113  114 
     
 
 
 
 
 
115  116  117 
Scheme 39 – Retrosynthesis of 5-hydroxyl-2-ABBA  
 
As expected, the first two steps were quite straightforward and reproducible (Scheme 40). In different 
attempts made, the protection with 3,4-dihydro-2H-pyran (118) gave excellent yields (from 93% to 97%) 
and the triflation with triflic anhydride (119) afforded compound 117 in good yields (from 75% to 80%). 
Then, the borylation reaction was studied.  
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DCM, PPTS, 5 h 
 
20 ºC, 97% 
 
 
DCM, 2 h 
-78 ºC, 80% 
 
 
 
115 118 116 119 117 
Scheme 40 – PTS protection and subsequent triflation of 2’,4’-dihydroxyacetophenone 
 
Protolytic deboronation was a major issue during this borylation process (Scheme 41), supposedly 
due to an interaction between the nearby oxygen from the acetyl group and the boron atom, making C-B 
bond more labile. Thus, after several unsuccessful attempts to perform the borylation with the standard 
conditions, product 114 was finally isolated but only in 6% yield. Then, we proceeded with the optimization 
of the reaction conditions. With this goal in mind, different palladium sources, ligands, bases and solvents 
were tested as shown in Table 11. In all cases, all reagents were dried and solvents distilled in order to 
have pure starting materials. Considering the results obtained with this screening, freshly distilled dioxane, 
sodium acetate, PdCl2(dppf) and bis(pinacolato)diboron (120) proved to be the most suitable system to 
perform this reaction. Despite this, even under the optimized reaction conditions, compound 114 was 
obtained in only 40% isolated yield, alongside with 43% isolated yield of 121. 
 
 
PdCl2dppf 
NaCH3COO, 
Dioxane, Ar, 
100 ºC
  
 
 
+ 
 
 
 
 
 
117 120 114  121 
Scheme 41 – Miyaura-borylation of compound 117 
 
Table 11 – Optimization attempts on Miyaura borylation. The best results are in bold. 
Solvent Palladium Ligand Base 
Toluene 
Dioxane 
MDE 
Pd (II) chloride 
Pd (II) acetate 
Pd (II) acetylacetonate 
Pd (II) trifluoroacetate 
PdCl2(dppf) 
Tris(dibenzylideneacetone)dipalladium 
(0) 
Triphenylphosphine 
(R)-BINAP 
(R)-DIOP 
Tributylphosphine 
2,2’-bipyridin 
KCH3COO 
NatOBu 
KtOBu (sublimed or not) 
TEA 
K2CO3 
NaCH3COO 
NH4CH3COO 
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Despite many attempts, this proportion of 1:1 between the borylation product (114) and the protolytic 
deboronation product (121) was never overcome. Despite those unsettling results, the remaining 
retrosynthetic path was still attempted. 
Based on reported procedures for the deprotection of THP or pinacolyl esters, different chemical 
deprotection strategies were attempted. These included the use of strong acids, oxidizing agents and 
specific protocols to selectively deprotect the pinacolyl ester or the THP independently (Scheme 42). 
 
 
Different 
Conditions 
 
a) - d) 
 
Different 
Conditions 
 
a) - d) 
 
114  113  112 
a) HCl 5% in THF, r.t., or equimolar solution of CH3COOH:dioxane, r.t.; 
b) NaIO4, 0.1 M HCl in a solution of THF and H2O, r.t.; 
c) KHF2 in MeOH followed by TMSCl/H2O in CH3CN, r.t., or 
diethanolamine in ether followed by HCl 0.1 M, r.t.; 
d) 10 mol% pyridinium p-toluenesulfonate in EtOH, 55 ºC 
Scheme 42 – Deprotection steps of compound 114  
 
The use of strong acids, generally, deprotected THP ether and originated 121 in considerable yields. 
The methodology using oxidizing agents such as NaIO4 gave a mixture of polar products that proved to 
be impossible to separate and the compound 121 as the major product.  
The first methodology to specifically deprotect pinacolyl boronate ester with the 2 step procedure was 
very effective, though the THP ether remained unaffected and a considerable amount of the protolytic 
deboronation product (121) was fomed. The second methodology with diethanolamine afforded a large 
number of products that were not isolated.  
The final methodology to deprotect THP ether selectively was very effectively achieved using an acidic 
catalysis in ethanol and afforded compound 113 in good isolated yields (80-85%). Unfortunately, 
subsequent pinacolyl boronate ester deprotection always afforded the protolytic deboronation compound 
(121) as a major product. 
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III.3.2.2. Strategy 2 
Taking into consideration the difficulties encountered in the above mentioned strategy, an alternative 
protocol was designated to prepare our target compounds. 
The envisioned retrosynthesis is shown in Scheme 43 and starts from alkylation of 
2’,4’-dihydroxyacetophenone to install an alkenyl and alkynyl function, then it follows the same steps 
described previously. Installing an alkenyl and a terminal alkynyl function permits different options to 
perform the functionalization of the scaffolds based on very efficient click reactions such as TEC or 
CuAAC, or other selective reactions, like Grubbs-metathesis. First, all results regarding the alkenyl moiety 
will be presented, followed by the results with alkynyl moiety. 
 
 
 
 
 
 
 
 
 
 
122  123  124  125  115 
Scheme 43 – Retrosynthesis of clickable-2-ABBA, R bears an alkenyl or alkynyl group 
 
When using 3-bromo-1-propene (126) as the alkylating agent, the first two steps of the synthesis were 
quite simple and reproducible (Scheme 44). In different attempts made, the reaction with the allyl bromide 
afforded very good yields of the alkylated product 125a (from 80 to 90%) and the triflation reaction with 
N-phenylbis(trifluoromethanesulfonimide) yielded the expected compound 124a in excellent yields (from 
90 to 93%).  
 
K2CO3, 
acetone reflux
 
20 h, 90% 
 
 
 
 
TEA, DCM 
1 h, 25 ºC, 93%
 
 
 
115 126 125a 127 124a 
Scheme 44 – Alkylation with 3-bromo-1-propene and subsequent triflation of 2’,4’-dihydroxyacetophenone 
 
Once again, the Miyaura-borylation step proved to be considerably more difficult and despite several 
attempts the boronated species was never isolated. Typically this reaction afforded three major products: 
protolytic deboronation compound (129), a dealkylated triflate and a hypothetic Claisen rearrangement 
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product (131, Scheme 45). From the crude 1H-NMR after 4 h of reaction it was possible to confirm the 
protolytic deboronation product was the major product. 
 
 
PdCl2dppf 
NaCH3COO, 
Dioxane, Ar, 
100 ºC
 
 
 
 
Δ 
 
 
 
 
 
Isomers. 
 
 
 
124a 128 129  130  131 
Scheme 45 – Miyaura-borylation of compound 124a and hypothetic Claisen rearrangement 
 
Then, the same reaction was attempted but using 4-bromo-1-butene instead of 3-bromo-1-propene, 
which would generate a thermodynamically unfavourable seven-member ring intermediary that would not 
proceed to the Claisen rearrangement. Furthermore, this length increase of the alkylated chain would also 
avoid allyl ether cleavage promoted by transition-metals, like palladium. 
 
Under the same conditions used in the previous example, the optimized alkylation step with 4-bromo-
1-butene proved to be much less efficient and reproducible affording the product 125b in low to moderate 
yields (from 20 to 44%). The triflation step with N-phenylbis(trifluoromethanesulfonimide) went smoothly 
yielding the product 124b in excellent yields (from 88 to 91%). Very gratifyingly, the Miyaura-borylation 
was performed successfully yielding the expected product 123b in 25% isolated yield (Scheme 46). No 
dealkylated product was ever detected and the protolytic deboronation was the only secondary product 
identified in the reaction mixture. A kinetic 1H-NMR study over 5 h of reaction proved that the protolytic 
deboronation product was formed at the same time as the boronated species (Figure 29). Thus, the 
improvement of this reaction proved to be very difficult, affording the product in only 20-30% yield.  
 
 
NaI, K2CO3,  
acetone 
reflux 
 
20 h, 44% 
 
 
TEA, DCM 
1 h, 25 ºC, 
91% 
 
 
 
PdCl2dppf, 
NaCH3COO, 
Dioxane, Ar 
 
6 h, 100 ºC, 
25% 
 
 
115 132 125b 127 124b 120 123b 
Scheme 46 – Alkylation with 4-bromo-1-butene and subsequent triflation of 2’,4’-dihydroxyacetophenone 
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Figure 29 – Kinetic 1H-NMR study of Miyaura-borylation from the alkene, A – Triflate compound 124b; 
B – Protolytic deboronation compound (alkylated 4-hydroxyacetophenone); C – Boronated compound 123b  
 
Hence, modifications of the borylated alkene were attempted. Instead of using thiol-ene click chemistry 
that produces reactive thiyl radicals and may reverse the iminoboronate modification (if performed on the 
conjugated biomolecule), a known selective reaction for alkenes was attempted to further functionalize 
this product. Grubbs cross-metathesis was selected as a feasible reaction to be performed with this core 
structure. First, different simple models were experimented in order to outline the optimal conditions for 
this reaction and to test its feasibility while using boronate derivatives. Following a described procedure, 
depicted in Scheme 47, methylvinylketone and vinyl acrylate were tested as models for the cross 
metathesis with compound 123b, affording the expected products in good yields (65 and 68%, 
respectively). However, when more complex compounds were used, this reaction proved to be 
unreproducible.  
 
 
acrylate/ketone (3 equiv) 
Grubbs-2 (2 mol %) 
CuI (3 mol %) 
 
Et2O (0.1 M) 
40 ºC, 3 h, Ar  
123b  133 
Scheme 47 – Grubbs cross-metathesis with compound 123b 
 
Considering the difficulties encountered in the previous synthesis, the installation of an alkyne function 
was attempted aiming to use this functionality in bioorthogonal reactions, such copper catalysed azide- 
A B C A A B C C 
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alkyne cycloaddition. Therefore, the alkylation of 2’,4’-dihydroxyacetophenone was performed with 
propragyl bromide (134) under the same conditions, to afford 66-68% of product 125c. Triflation of the 
monoalkylated species was the next step and, as before, afforded excellent yields of the expected 
compound 124c (from 94 to 96%). Miyaura-borylation of this substrate was the problematic step of this 
methodology, never affording the expected boronated compound 123c (Scheme 48). The only isolatable 
product was the dealkylated triflate species. Consumption of the starting material was quickly detected by 
TLC, but no product was ever detected. 
 
 
 
K2CO3,  
acetone 
reflux 
 
20 h, 68% 
 
 
 
TEA, DCM,  
1 h, 25 ºC, 
96% 
 
 
 
PdCl2dppf, 
NaCH3COO, 
Dioxane, Ar, 
100 ºC 
 
 
 
 
115  134 125c 127 124c 120 123c 
Scheme 48 – Alkylation, triflation and borylation starting from propragyl bromide and 2’,4’-dihydroxyacetophenone 
 
Consequently, since the dealkylation promoted by the palladium under such conditions could be the 
leading side reaction of this Miyaura-borylation, as before, an increase of length of the alkylic chain was 
used to test such hypothesis. Thus, another alkylation of 2’,4’-dihydroxyacetophenone was performed, 
though this time with 5-chloro-1-pentyne (135) and sodium iodide which afforded the expected product 
125d in 62% yield. From this point, N-phenylbis(trifluoromethanesulfonimide) was again used to introduce 
the triflate moiety generating the product 124d in very good yields (from 80 to 90%). Finally, the Miyaura-
borylation was performed on this substrate, and despite several attempts, only the starting material was 
ever isolated. Based on the 1H-NMR, the reaction after 2 h generated a very complex mixture, as shown 
by the spectra in Figure 30. Thus, different strategies were designed to solve this situation. 
 
 
 
NaI, K2CO3,  
acetone 
reflux 
 
28 h, 62% 
 
 
TEA, DCM,  
1 h, 25 ºC, 
90% 
 
 
 
PdCl2dppf, 
NaCH3COO, 
Dioxane, Ar, 
100 ºC 
 
 
  
 
115  135 125d 127 124d 120  123d 
Scheme 49 – Alkylation, triflation and borylation starting from 5-chloro-1-pentyne and 
2’,4’-dihydroxyacetophenone 
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Figure 30 – Kinetic 1H-NMR study of Miyaura-borylation from the alkyne 124d 
 
Based on these results we envisioned that the alkyne could be a possible source of complications via 
interactions with the catalyst. Therefore, two strategies were outlined to test this hypothesis: one, being 
the CuAAC performed in the triflate followed by the Miyaura-borylation and the second involving the use 
of a protected terminal alkyne. 
As depicted in Scheme 50, the first strategy was tested using tri(ethylene glycol)azide (136) which was 
reacted via CuAAC with compound 123d. This reaction afforded the product 137 in 98% yield, which was 
submitted to the Miyaura-borylation to generate 46% isolated yield of a mixture of compound 138 and the 
resulting protolytic deboronation compound (in a 1:1 ratio). Thus, a proof of concept was established, 
highlighting that the unprotected terminal alkyne plays a crucial role in inactivating the triflate for the 
Miyaura-borylation. Nevertheless, this strategy was not further pursued since performing a different 
Miyaura-borylation in individual substrates designed for a specific application would not be a feasible 
methodology.  
 
 
CuI (0.02 eq) 
DIPEA (0.04 eq) 
HOAc (0.04 eq) 
 
DCM, Ar, 
r.t., 5 h, 98% 
 
 
 
PdCl2dppf, 
NaCH3COO, 
Dioxane, Ar, 
100 ºC, 46%, 
8 h 
 
 
120 
  
124d 136 137  138 
Scheme 50 – CuAAC and subsequent Miyaura-borylation starting from compound 123d 
2,0 h 
0,0 h 
Chapter III. Modification of the novel modifying agent 
 
   
91 
 
Based on this, we tested the possibility to use protected alkyne functions, as depicted in Scheme 51. 
Therefore, (5-chloro-1-pentynyl)trimethylsilane was used to alkylate 2’,4’-dihydroxyacetophenone.This 
reaction afforded the product 125e in moderate yields (40-48%). Then, a triflation of this compound 
generated the product 124e in 82% yield. The borylation of this protected alkyne-triflate derivative was 
followed by 1H-NMR over 6 h. This study showed that the desired product was formed, though the 
protolytic deboronation product was also generated (Figure 31). In the course of the study, the borylated 
product 123e was isolated in 48% yield, and this species was used to test the trimethylsilane deprotection. 
Unfortunately, this deprotection did not go as well as planned and apart from the unreacted starting 
material, the only isolated product without the trimethylsilane group did not have pinacol boronate ester.  
 
 
 
 
 
NaI, K2CO3, 
acetone reflux 
 
40 h, 39% 
 
 
 
 
TEA, DCM,  
1 h, 25 ºC, 
82% 
 
 
 
 
PdCl2dppf,  
NaCH3COO, 
Dioxane, Ar, 
100 ºC, 6 h,  
48% 
 
 
 
 
 
115  139 125e 127 124e 120 123e 
Scheme 51 – Alkylation, triflation and borylation starting from (5-chloro-1-pentynyl)trimethylsilane and 
2’,4’-dihydroxyacetophenone 
 
 
 
Figure 31 – Kinetic 1H-NMR study of Miyaura-borylation from the protected alkyne; A – Triflate compound 124e; 
B – Protolytic deboronation compound (alkylated 4-hydroxyacetophenone); C – Boronated compound 123e  
A B C A B C C A 
2,0 h 
0,0 h 
4,0 h 
6,0 h 
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In the end, these studies aiming to prepare boronated compounds with biorthogonal handles that could 
be readily modified under native conditions did not afford the expected results. Furthermore, a likely 
insertion of palladium to generate organopalladium species with the alkene or the alkyne proved to be 
difficult to overcome.  
 
III.3.2.3. Strategy 3 
Since the previous delineated strategies proved to be impractical to prepare a core structure that may 
be further functionalized by means of simple chemical procedures, a different strategy was outlined as 
shown in Scheme 52. In this case, the goal was to synthesize the boronated compound with a small linker 
featuring a carboxylic acid to undergo modifications with amines or alcohols. To achieve this, the 
procedure follows similar sequential steps as described before: alkylation, triflation and Miyaura-
borylation. The borylation step is sensitive to the presence of an acid functionality, therefore this step will 
be performed with an ester instead of a carboxylic acid. For this reason, the last step will require a 
hydrolysis to generate the intended boronated carboxylic acid-derivative (Scheme 52). 
 
 
 
 
 
 
140  141  142 
     
 
 
 
 
 
115  143  144 
Scheme 52 – Retrosynthesis of 2-ABBA acid derivative 
 
As depicted in Scheme 53, 2’,4’-dihydroxyacetophenone was selectively alkylated with ethyl 
4-bromobutyrate (145) several times, under different conditions, with yields ranging from 50 to 87%. This 
wide variation was justified with the optimization of such step by decreasing the number of equivalents of 
sodium iodide from 2 to 1. This reagent was performing a competitive reaction that inhibited the desired 
alkylation of the hydroxylated ketone. After this, a triflation with N-phenylbis(trifluoromethanesulfonimide) 
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afforded 144 in very good yields (from 87 to 92%). Very gratifyingly, the Miyaura-borylation afforded the 
product 142 in the first attempt and after several attempts of optimization (mainly changing the time of the 
reaction from 4 to 30 h) in 64% of isolated product. 
 
     
 
NaI, K2CO3, 
acetone 
reflux,  
20 h, 87% 
 
 
 
TEA, DCM, 
1 h, 25 ºC,  
90% 
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CH3CN:HCl  
(1 M) (9:1),  
Ar, 20 h,  
r.t., 8%
 
 
 
TFA/H2O 
 
Ar, 90 ºC,  
3 h, 77% 
 
 
 
140 146 141  142 
Scheme 53 – Total synthesis of compound 141 
 
Once the boronated compound was synthesized, the remaining steps to obtain a modifiable core 
structure were deprotection steps. The hydrolysis of the linear alkylic ester, after optimization, led to a 
reproducible reaction that afforded the product 141 in good yields (70-77%). Then, the second step also 
afforded the expected product through a transesterification procedure with a phenylboronic acid resin 
(146). Despite this, compound 140 was found to be difficult to isolate and exhibit a poor stability. Therefore 
the pinacol removal was only performed after the amidation or esterification of the carboxylic acid, 
immediately prior to its use in bioconjugation reactions. 
 
NaCH3COO 
PdCl2dppf, 
Dioxane, Ar, 
95 ºC, 4 h,  
64% 
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III.4. Conclusion  
In this chapter, different attempts to obtain 2-carbonylbenzeneboronic acid derivatives were presented, 
leading to a strategy that started from the incorporation of a small linker, a required triflation reaction to 
perform a Miyaura-borylation and a final hydrolysis step to form a functionalizable carboxylic acid. 
The Miyaura-borylation proved to be the most difficult step of all the strategies, often leading to the 
undesired protolytic deboronation product as a side product. Despite different attempts on optimization 
and all the purifications performed on the starting materials, different kinetic 1H-NMR studies proved that 
2-acetylbenzeneboronate pinacolyl ester generation and its deboronation occurred in parallel, probably 
due to a B-O interaction that weakens the newly formed C-B bond.  
Nevertheless, in the end, a modifiable boronated backbone was obtained and used to further 
modification depending upon the intended application, as it will be discussed in Chapter IV.  
 
    
Chapter IV 
Applications 
 
 
 
ABSTRACT 
After the discovery and synthetic optimization to achieve the core molecule presented in Chapter III.  
different strategies to achieve different applications will be presented in this chapter. 
Several compounds with different properties were synthesized and important biological studies were 
performed. Namely, an artificial glycosylation of a protein based on a click procedure (CuAAC), the 
installation of a fluorescent probe in a protein through another click procedure (SPAAC), the direct 
functionalization of a protein with two different fluorescent probes, several PEGylations of different 
biomolecules and, finally, the attachement of a cytotoxic drug to a vitamin. 
From these bioconjugations, some led to important conclusions of the biological properties of the 
conjugates. Particularly, the fluorescent conjugations that led to the conclusion that iminoboronates are 
stable enough to go through cellular internalization, the sugar-dependent reversible PEGylation of insulin 
and the cytotoxic conjugate that accumulated preferentially in cancer cells vs healthy cells, in opposite to 
the free drug. 
Currently, the study of intracellular reversibility of the conjugate is in progress through the development 
of an "ON-OFF" probe that is specific for this type of conjugation. 
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Chapter IV.   
Applications 
IV.1. Introduction 
As mentioned briefly in Chapter I. protein chemical modification enables a wide range of applications 
in different biological areas, mainly due to the large number of functions that these biomolecules can 
perform. These applications are most evident in the field of medicinal chemistry and led to the production 
of several new biomolecule-based drugs approved by different regulatory authorities. Nevertheless, 
before leading to such remarkable compounds, these applications started from mimicking nature’s protein 
post-translational modifications, evolving then to the artificial enhancement of biomolecules.  
 
IV.1.1. Post-Translational Modification mimetics 
As mentioned in Chapter I. different post-translational modifications are crucial for the day-to-day 
operations of a living organism. These modifications have such a pivotal role in these organisms, that 
they can be used as criteria to distinguish some species over others, since the sites and regularity of 
PTMs on a given biomolecule can vary depending upon the living organism. Methylations, acetylations, 
phosphorylations, ubiquitinations and glycosylations were given as examples of PTMs, all of which can 
be artificially introduced by means of chemical modification of proteins.6  
Artificial glycosylation is a particularly important protein modification that allowed the emergence of 
one of the most interesting applications of chemical modifications of proteins, which is the development 
of vaccine candidates. Artificial glycosylation of proteins can be used for several biological purposes, 
among which the development of synthetic glycoprotein vaccines candidates for different pathologies, 
since polysaccharide antigens can interact directly with B cells, inducing a boost of the immune 
response.265 This strategy usually involves a carbohydrate antigen that is conjugated to an immunogenic 
carrier (e.g. BSA or keyhole limpet hemocyanin – KLH) via non-site-selective modification. There are still 
few examples of homogeneous glycovaccines,266 though, due to the potential of this application, the 
obtained heterogeneous mixtures were already administrered to living organisms, which led to interesting 
vaccine candidates against alkaloid drug addiction and anti-cancer therapy.14,267–272 These results attest 
the potential of this strategy and highlight the importance in developing new therapeutic approaches. 
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IV.1.2. Biomolecules’ enhancement 
Apart from the modifications made to mimic nature, more recently, addition of artificial agents to ease 
biomolecule purification, to modify its pharmacokinetics or even to confer previously absent therapeutic 
or imaging properties centred the attention of chemical modification of proteins. This enhancement allows 
the development of several applications that will help to solve some biological uncertainties. For instance, 
by performing certain modifications on specific proteins, the study of the protein’s function and distribution 
in vivo is possible, as well as the development of effective drug-delivery systems, such as ADCs.10,273 
IV.1.2.1. Bioimaging 
Bioimaging is another common application of bioconjugation procedures. This technique allows an 
evaluation of the protein’s function, interactions and distribution in biological assays and, ultimately, this 
system can be used as a diagnostic tool for certain pathologies.30  
Several biomolecules were already labeled and applied as diagnostic tools, either by nuclear or by 
optical bioimaging methods. The difference between these two imaging approaches lies on the used 
imaging agent, which can be directly or indirectly incorporated through conjugation. Usually, the indirect 
incorporation of these molecules rely on the conjugation of chelating agents that can trap different 
radioisotopes with imaging properties (99mTc, 18F, 111In, 123I, 68Ga). After chelation, a nuclear imaging 
method can be established, either by application of a positron emission tomography (PET), as much as a 
single photon emission computed tomography (SPECT). For optical fluorescence imaging, usually, 
molecules with imaging properties (like organic near-infrared fluorophores or quantum dots) are directly 
linked to the biomolecule.151 
In terms of medical imaging, although nuclear imaging is still the first-line technique, optical imaging is 
expanding as a valuable alternative due to the similar sensitivity and greater spatial and temporal 
resolution, without resorting to radioactive metals.50 
IV.1.2.2. Medicinal Chemistry 
Chemical modification of biomolecules also allows the improvement of therapeutic biomolecules or 
organic molecules. By modifying therapeutic biomolecules, enhancement of their pharmacokinetic 
properties or efficacy on given pathologies can be achieved. Through modification of therapeutic organic 
molecules with biomolecules it is conceivable that one might introduce targeting moieties that would allow 
the development of drug-delivery systems. PEGylation of biomolecules and construction of drug 
conjugates with targeting biomolecules emerge as the most valuable and commonly used applications. In 
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this field, such strategies recently led to FDA-approved drugs, such as PEGylated forms of hormones and 
antibody-drug conjugates for anti-cancer therapy.274 
Generally, PEGylation of therapeutic biomolecules increases in vivo stability, half-life, solubility, 
reduces toxicity, immunogenicity, antigenicity, kidney clearance and proteolysis. With such properties, 
this chemical modification of biomolecules improves pharmacokinetic parameters, such as the absorption 
rate and volume of distribution. This procedure has proven its utility in a large spectra of therapeutic 
applications, namely, different cancer types, acromegaly, hepatitis, gout or severe rheumatoid arthritis.274 
In order to highlight the relevance of the topic, BAY94-9027 (Figure 32) can be mentioned as a PEGylated 
form of rFVIII that is currently on clinical trials to extend the circulating half-life of this transcript factor, 
while preserving its biological activity.275 
 
 
Figure 32 – Structure of BAY94-9027. Adapted from a poster of a conference from the European Directorate for 
the Quality of Medicines 
 
Antibody-drug conjugates (ADCs) are one of the most promising biotech drugs, since that due to the 
unique targeting ability of antibodies, their attachment to therapeutic organic molecules, can lead to an 
effective therapy that spares healthy tissues by releasing its cargo only upon specific antigen recognition. 
However, despite ADCs’ conceptual simplicity, their individual components must have precise properties 
to cause a therapeutic benefit. The antibody should have high affinity and specificity for a defined and 
abundant antigen and its pharmacokinetic properties should be unaffected upon conjugation with the drug. 
The therapeutic organic molecule should be highly potent, thereby minimizing the number of payload 
molecules necessary to induce a therapeutic effect. Finally, the conjugation strategy must permit chemical 
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installation of the drug onto the antibody at a pre-determined site(s), and ensure stability of the conjugate 
whilst in circulation in vivo (Figure 33).  
 
 
Figure 33 – ADC’s general strutcture and features 
 
Efforts in this field have led to the recent commercialization approval of two ADCs: Adcetris® 
(brentuximab vedotin), for the treatment of refractory Hodgkin lymphoma and anaplastic large-cell 
lymphoma, and Kadcyla® (ado-trastuzumab emtansine), for the treatment of metastatic Her2+ breast 
cancer (Figure 34).276 Though anti-cancer therapy has been the most widely application for ADCs, it is 
foreseeable that other pathologies can be valid targets to be pursued in a near future.  
 
 
Figure 34 – Examples of recent FDA-approved ADCs: (A) Bretuximab vedotin – Adcetris® (assembled by means 
of maleimide conjugation); (B) Ado-trastuzumab emtansine – Kadcyla® (assembled by means of NHS conjugation). 
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Moreover, the targeting ability of antibodies is not exclusive of these biomolecules, once theoretically, 
any biomolecule that is selectively recognized by a receptor of a cell is a possible targeting moiety for a 
specific pathology. For instance, the vitamin folic acid (FA) displays high affinity towards a membrane 
protein (the folate receptor), that captures its ligands from the extracellular milieu and transports them 
inside the cell through an endocytic process. Since the expression of these receptors is largely absent 
from normal tissues, they are considered to be tumor antigens/biomarkers (Figure 35).40 Therefore, folate-
conjugates are being used as alternatives to ADCs for anti-cancer therapeutics. Furthermore, as an 
additional information (though a little off-topic, since this methodology does not rely on any bioconjugation 
procedures), small organic molecules have also been, recently, identified as molecules capable of binding 
to certain biomolecules, therefore exhibiting a possibility of designing conjugates for therapeutic 
applications.277,278 
 
 
Figure 35 – Illustration of overexpression of folate receptors in cancer cells 
 
IV.2. Goals  
In this chapter, the development of 2-ABBA derivatives to functionalize biomolecules for a diverse set 
of applications will be presented.  
These derivatives were prepared to perform an artificial glycosylation of proteins and a series of 
fluorescent 2-ABBA derivatives were also prepared and conjugated with different biomolecules, namely, 
with folate derivatives to study the potentially selective uptake by cancer cells. 
Finally, 2-ABBA derivatives were modified for therapeutic applications, namely to PEGylate peptides 
and proteins and to synthesize a folate-paclitaxel conjugate. The first method was used to study a sugar-
dependent reversible PEGylation of insulin. The folate-paclitaxel conjugate was compared with the 
unconjugated cytotoxic drug in terms of toxicity and selectivity of internalization. 
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IV.3. Applications of modified 2-ABBA 
In order to use this new bioconjugation methodology based on iminoboronate formation, it was 
necessary to functionalize the novel modifying agent presented in Chapter III. Therefore, compound 141 
is always used as the starting point for all reported applications. Usually, in each application a convergent 
synthetic strategy was applied, in which the amidation/esterification reaction was the convergence point.  
 
IV.3.1. Glycosylation 
Having as a goal the incorporation of α-D-glucose into the structure of the novel modifying agent (141), 
first, a Steglish esterification was attempted, based on literature precedents that gave the primary alcohol 
of glucose as the best nucleophile of all the alcohols present in its structure (Scheme 54).279 We used 
compound 141 (pinacolyl boronate ester) instead of compound 140 (boronic acid) to avoid interactions 
between the sugar molecule and the boronic acid moiety. Unfortunately, no product was obtained and 
only derivatives of glucose without aromatic protons NMR signals were isolated. 
 
 
 
1. DMAP, DCC,  
DCM, 0 ºC, 0,5 h 
 
2. DCM, 0 ºC→r.t. 
 
 
141 147 148 
Scheme 54 – First attempt of constructing a glycosyl derivative of 2-ABBA 
 
From this point, we have studied the hypothesis of having a poor activation of the carboxylic acid for 
the intended reaction by experimenting a different described protocol with a specific group to activate the 
carboxylic acid to perform sugar chemistry without protecting groups. In this case, a 
N-acylthiazolidine-2-thione intermediary (152) was isolated and this compound was reacted with 
unprotected α-D-glucose in order to obtain compound 148. However, in this last step, the reaction afforded 
products with inconclusive characterization, that included possible dimerization products. 
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Scheme 55 – Second attempt of constructing a glycosyl derivative of 2-ABBA 
 
Since this glycosylation was proving to be hard to obtain with unprotected saccharide molecules, we 
started to wonder if indirect coupling with a protected sugar molecule would not be a better strategy to 
afford the sought glycosyl derivative of 2-ABBA. Therefore, we outlined a synthetic route, in which there 
would be an indirect coupling through a click chemistry procedure (a CuAAC), after incorporating a 
bioorthogonal handle on compound 141. Thus, a terminal alkyne derivative of 2-ABBA was synthesized 
(154) and tested as a modifying agent of lysine residues from lysozyme. From this point, a protected 
azidesugar (155) was used to perform a CuAAC on the protein’s surface yielding the expected construct 
in ammonium acetate buffer (50 mM, pH 7.0) at room temperature as confirmed by ESI-FTICR-MS 
(Scheme 56, m/z values of the lysozyme conjugates are described in Chapter VI.).  
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141 
1. DMAP, EDC, DCM, 0 ºC, 1 h;  
2. DCM, 0 ºC→r.t., 17 h 
153 
Overall Yield 74% 
 
3. CH3CN:HCl (1 M) (9:1), Ar, 
20 h, rt, 61% 
146 
 
154 
  
 
Scheme 56 – Third attempt of constructing a glycosyl derivative of 2-ABBA – Synthesis of the alkyne derivative of 
2-ABBA (154) and reaction of lysozyme (10 μM) with compound 154 (1 mM) in ammonium acetate buffer (50 mM, 
pH 7) at room temperature. CuAAC between azidesugar (155) and the terminal alkyne on the protein’s surface. 
 
Therefore, this application demonstrated the feasibility of using this iminoboronate methodology and 
combine it with the first bioorthogonal reaction. Moreover, from this specific reaction, finally, the first 
glycosyl derivative conjugate was obtained, which means that an artificial glysocylation of lysozyme was 
completed. 
 
IV.3.2. Bioimaging 
Led by the success of the previous application, once the click chemistry was applied to indirectly attach 
a glycosyl derivative to the core molecule of the modifying agent, a new strategy was envisioned where 
another click chemistry procedure (SPAAC) would be used to attach a fluorescent molecule. Based on 
those premises, a different derivative of 2-ABBA bearing a bioorthogonal handle (an azide) was 
synthesized (157) and readily tested as a modifying agent of lysine residues from lysozyme. From that 
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154/DMSO  
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NH4CH3COO  
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CuSO4 (200 μM) 
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NH4CH3COO  
(50 mM, pH 7) 
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point, having the azide moiety indirectly installed in a protein a SPAAC with a cyclooctyne-fluorescein 
derivative (158) was performed on the protein’s surface yielding the expected constructs in ammonium 
acetate buffer (50 mM, pH 7.0) at room temperature as confirmed by ESI-FTICR-MS (Scheme 57, m/z 
values of the lysozyme conjugates are described in Chapter VI.).  
 
 
141 
1. DMAP, EDC, DCM, 0 ºC, 1 h;  
2. DCM, 0 ºC→r.t., 17 h 
156 
Overall Yield 75% 
 
3. CH3CN:HCl (1 M) (9:1), Ar,  
20 h, rt, 68% 
146 
 
157 
 
 
 
 
Scheme 57 – Synthesis of the azide derivative of 2-ABBA (157) and reaction of lysozyme (10 μM) with compound 
157 (1 mM) in ammonium acetate buffer (50 mM, pH 7) at room temperature. SPAAC between cyclooctyne-
fluorescein derivative (158) and the azide on the protein’s surface. 
 
Therefore, this application demonstrated the feasibility of using this iminoboronate methodology and 
combine it with another bioorthogonal reaction. Moreover, from this specific reaction, the first conjugate 
bearing a fluorescent probe was synthesized. 
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To test the possibility of using iminoboronate methodology in biological assays, a demonstration that 
the N-B interaction could endure cellular internalization had to be done. Thus, we next evaluated the 
possibility of designing a cancer cell targeting conjugate, in which, a fluorescent motif was linked to a 
targeting molecule through an iminoboronate conjugation. This was achieved by synthesizing fluorescent 
2-ABBA derivatives and conjugate them with N-(2-aminoethyl) folic acid (EDA-FA), which, in turn 
generated conjugates that were selectively recognized and internalized by cancer cells. 
Dansyl and nitrobenzofurazan fluorescent motifs were modified with ethylenediamine and 
ethanolamine, respectively, and each subsequently reacted with 141 (Scheme 58). Thus, two fluorescent 
derivatives of 2-ABBA were synthesized, though a deprotection step (removal of pinacolyl group) would 
still be required before performing the conjugation. 
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161  150 
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164 165 
Scheme 58 – Synthetic routes to obtain two fluorescent derivatives of 2-ABBA 
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As it was mentioned in the introduction, folate receptors are over-expressed in cancer cell lines due to 
their fast cell division and growth. Therefore, folic acid has been extensively used as a recognition moiety 
in several conjugates. Bearing that in mind, another key compound to advance with this strategy is the 
synthesis of a folic acid derivative, since it requires an available alkylic primary amine to form the intended 
iminoboronate conjugates. Thus, based on reported literature to synthesize N-(2-aminoethyl) folic acid 
(170, EDA-FA), this derivative was synthesized and stored. 
 
 
 
 
166   
 
168 
 DCM, 0 ºC→r.t.,  
24 h, Ar, 90% 
 
161 
 
 
169    
TFA, 2 h, r.t., 92%  
  
 
 
170    
Scheme 59 – Synthesis of N-(2-aminoethyl) folic acid (170, EDA-FA) 
 
Next, in order to be able to generate iminoboronates, removal of the pinacolyl protecting group was 
essential. A transesterification method that uses a boronic acid resin (146) under acidic conditions was 
used as the deprotecting procedure that afforded the final fluorescent compounds 171 and 173 (Scheme 
60 and Scheme 61). Once prepared, compounds 171 and 173 were immediately tested for their ability to 
conjugate with lysozyme. Gratifyingly, both compounds retained their ability to functionalize the protein, 
167 
1.DCC, NHS-OH, 
DMSO, 16 h, r.t. 
2. 167, TEA, 
DMSO, 24 h, r.t. 
Overall Yield - 69% 
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yielding the expected constructs in ammonium acetate buffer (50 mM, pH 7.0) at room temperature as 
confirmed by ESI-FTICR-MS (m/z values of the lysozyme conjugates are described in Chapter VI.). 
Encouraged by these results, we next evaluated the possibility of designing a cancer cell targeting 
conjugate, in which, the fluorescent motif is linked to the targeting molecule by a N-B bond. 
 
164 
146
CH3CN:HCl (1 M) 
(9:1), Ar, 20 h, r.t., 
27% 
 
 
 
171 
  
 
172 
ESI-MS: m/z [M+H-H2O]+calculated = 989.39022, m/z [M+H-H2O]+real = 989.39107 
Scheme 60 – Deprotection of pinacolyl boronate ester to generate 171. Reaction of lysozyme (10 μM) with 
compound 171 (200 μM) in ammonium acetate buffer (50 mM, pH 7) at room temperature. Reaction of EDA-FA 
(100 μM) with compound 171 (100 μM) in the same buffer to obtain 172 confirmed by HRMS.  
 
Therefore, the conjugation of 171 and 173 with EDA-FA was evaluated. As expected, upon the addition 
of 100 μM of 171 or 173 in DMSO to EDA-FA in ammonium acetate buffer (50 mM, pH 7.0) at room 
temperature, their corresponding iminoboronates were readily formed, as characterized by high resolution 
mass spectrometry – HRMS (Scheme 60 and Scheme 61). Following this, the conjugates’ ability to 
differentiate cancer and non-cancer cell lines was then studied.  
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165 
146
 CH3CN:HCl (1 M) 
(9:1), Ar, 22 h, r.t., 
53% 
 
173 
 
 
 
174 
ESI-MS: m/z [M+H]+calculated = 938.33545, m/z [M+H]+real = 938.33917 
Scheme 61 – Deprotection of pinacolyl boronate ester to generate 173. Reaction of lysozyme (10 μM) with 
compound 173 (200 μM) in ammonium acetate buffer (50 mM, pH 7) at room temperature. Reaction of EDA-FA 
(100 μM) with compound 173 (100 μM) in the same buffer to obtain 174 confirmed by HRMS.   
 
To study the internalization of fluorescent conjugates 172 and 174, conjugate 172 was generated prior 
to exposure to cells and tested against human non-small lung cancer cells (NCI-H460) and non-cancer 
human kidney embryonic cells (HEK 293). Interestingly, laser scanning confocal images of the HEK 293 
and NCI-H460 treated with 172, revealed that only the cancer cell line that over-expressed the FA receptor 
up took fluorescence, which suggests selective folate-receptor mediated internalization (Figure 36). 
To further elucidate this mechanism, the cancer cell line NCI-H460 was treated with 173 without 
EDA-FA. In agreement with a folate-receptor mediated internalization mechanism, without the recognition 
moiety, no fluorescence was detected inside the cells (Figure 37C). In contrast, when the same compound 
(173) was allowed to form the conjugate with EDA-FA, the previously generated N-B construct 174 
smoothly underwent internalization as shown in Figure 37D. Finally, the NCI-H460 cells were treated with 
EDA-FA prior to the addition of the conjugate 174. In this case, the internalization of the conjugate 174 
was considerably impaired due to the initial exposure to folic acid that reduced the cell’s need for this 
vitamin (Figure 37E). These results clearly stress the importance of the folate moiety to mediate the 
internalization process.  
Lysozyme  
(10 μM) 
173/DMSO  
(200 μM) 
 
NH4CH3COO  
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(100 μM) 
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(100 μM) 
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Figure 36 – HEK (A) and NCI-H460 (B) cells were incubated with compound 172 at 20 μM for 4 h. Images are an 
overlay of the emission of compound 172 in the 460-580 nm region upon excitation at 458 nm (green), and the 
emission of the membrane marker in the 650-700 nm region upon excitation at 514 nm (red).  
 
 
Figure 37 – NCI-H460 (C) was incubated with compound 173, NCI-H460 without (D) and with pre-treatment with 
EDA-FA (E), were incubated with compound 174. Incubation and imaging conditions are the same as described in 
Figure 36. 
 
Finally, to determine the contribution of the N-B bond to the formation and stability of these conjugates, 
the fluorescent compound 179, featuring no boronic acid was prepared via alkylation of 
4-hydroxyacetophenone with ethyl 4-bromobutyrate, followed by hydrolysis and N,N-dimethylpyridin-4-
amine (DMAP) catalysed esterification with 4-ethanolamine-7-nitrobenzofurazan (163). Once prepared, 
compound 179 was solubilised in DMSO and combined with EDA-FA in ammonium acetate buffer solution 
(50 mM, pH 7.0) at room temperature to form conjugate 180, as confirmed by HRMS. A mixture containing 
the conjugate was then used to treat the NCI-H460 cancer cells. This resulted in no fluorescence being 
detected inside the cells, presumably due to the poor stability of conjugate 180 under these conditions.  
Therefore, we studied the ability of compound 179 to modify lysozyme. The compound lacking the 
boronic acid functionality hardly formed the expected constructs with the protein after 30 min in ammonium 
acetate buffer (50 mM, pH 7.0). Even the ones that did form, seemed to hydrolyse in only 2 h under these 
A B 
C D E 
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reaction conditions. In stark contrast, in the same conditions, boronated compound 173 readily afforded 
the constructs with lysozyme within 30 min and the modifications were persistent after 2 h in ammonium 
acetate buffer (50 mM, pH 7.0) at room temperature. These results clearly highlight the contribution of a 
boronic acid to imine stabilization and internalization of the conjugates. 
 
 
 
 
K2CO3, NaI, 
acetone, reflux,  
20 h, 59%
 
 
TFA, H2O,  
90 ºC, 3 h
 
89% 
 
175 176 177  178 
    
 
 
 
 
 
179 
  
  
180 
ESI-MS: m/z [M+H]+calculated = 894.32796, m/z [M+H]+real = 894.32778 
Scheme 62 – Synthetic route to obtain the aboronated species (179). Reaction of lysozyme (10 μM) with 179 
(200 μM) in ammonium acetate buffer (50 mM, pH 7) at room temperature. Reaction of EDA-FA (100 μM) with 
compound 179 (100 μM) in ammonium acetate buffer (50 mM, pH 7) to obtain 180 confirmed by HRMS.   
 
 
Figure 38 – Image F shows NCI-H460 treated with compound 180. Incubation and imaging conditions are the same 
as described in Figure 36. 
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Therefore, this work showed for the first time that the N-B bond may be used to synthetize conjugates 
that selectively target cancer cells. Fluorescent 2-ABBA derivatives were successfully prepared and 
conjugated via a N-B linkage with lysozyme and N-(2-aminoethyl) folic acid, generating conjugates that 
were selectively recognized and internalized by NCI-H460 cancer cells, which over-express folic acid 
receptors. The ability of these iminoboronates to undergo a receptor mediated internalization and their 
efficiency to promote the selective and reversible functionalization of proteins, highlights these constructs 
to have a promising future in the design of conjugates that selectively target cancer cells. 
Though the internalization of conjugates bearing a N-B interaction was proven by the previous study, 
the possibility of releasing its cargo intracellularly was still unproven. Therefore, a strategy to develop an 
“ON-OFF” probe was envisioned for iminoboronates, where a coumarin would act as the fluorescent probe 
that would only be fluorescent if not conjugated to 2-carbonylbenzeneboronic acids (Scheme 63). 
 
Turn-ON  
72 
 
Intracellular Medium 
 Turn-OFF 
181  182 
Scheme 63 – Envisioned “ON-OFF” probe and its interaction with 2-carbonylbenzeneboronic acids 
 
Based on fact that the fluorescence of 7-hydroxycoumarin dyes can be decreased by disguising the 
7-phenolic hydroxyl group,280 we rationally designed compound 181 to complex with 
2-carbonylbenzeneboronic acid derivatives in order to have a turn-OFF probe whenever the 
iminoboronate is formed. This is an on-going study and so far only preliminary data can be reported. First, 
the synthesis of 181 is being optimized (Scheme 64), though the complexation with iminoboronates is not 
well characterize yet. After a proper study of the fluorescent properties of such probe and its complexation 
product is finished, biological in vitro assays will be conducted in order to determine whether or not the 
cargo is released inside the cell. 
 
 
+ NH4CH3COO 
sieves,  
NaBH3CN 
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r.t., 15 h, 30%  
183  184  181 
Scheme 64 – Synthesis of the fluorescent probe 181 
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Though the bioimaging results of this project are not fully complete yet, this iminoboronate 
bioconjugation has proven its value at being stable enough to be internalized by cancer cells. Therefore, 
is plausible to assume that such bioconjugation methodology can be used to develop therapeutic 
applications that can endure biological assays. 
 
IV.3.3. Therapeutics  
Once the applicability of iminoboronate methodology in therapeutic applications was proved to be a 
possible development of such bioconjugation procedure, two strategies with therapeutical potential were 
envisioned. One based on the enhancement of pharmacokinetic properties of biomolecules and another 
that intends to improve the efficacy/selectivity of a certain drug through targeted delivery. 
Starting from the bioconjugation methodology that could enhance the characteristics of a biomolecule 
through a PEGylation procedure, we have started by synthesizing a PEG derivative of 2-ABBA. To do so, 
compound 141 was modified through a Steglish esterification with a commercially available polyethylene 
glycol (185), affording the product in 70% yield. Next, the pinacolyl deprotection step affored compound 
186 in 50% yield (Scheme 65). Once prepared, this compound was immediately tested for its ability to 
conjugate with lysozyme and, pleasantly, it was able to functionalize the protein, yielding the expected 
constructs in ammonium acetate buffer (50 mM, pH 7.0) at room temperature as confirmed by 
ESI-FTICR-MS (Figure 39). 
 
141 
1. DMAP, EDC, DCM, 0 ºC, 1 h;  
2. DCM, 0 ºC→r.t., 24 h 
 
185 
Overall Yield 70% 
3. CH3CN:HCl (1 M) (9:1), Ar,  
11 h, r.t., 50% 
146 
 
186 
Scheme 65 – Synthesis of a 2-ABBA PEG derivative 
 
When this molecule was fully characterized and its ability to modify primary amines tested, the 
following step was to modify therapeutic peptides in order to have a possibility of enhancing their 
pharmacokinetic properties. Peptide/protein hormones can be therapeutic entities with suboptimal 
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pharmacokinetic properties and, therefore, they are usual targets of several bioconjugation strategies. 
Somatostatin, lanreotide (a pharmacophore of somatostatin)281 and insulin282 are examples of these 
biomolecules with different therapetutic indications. Though the biological assays to prove the advantage 
of having PEGylated therapeutic peptides using iminoboronate methodolgy were not performed, 
successful PEGylation of somatostatin, lanreotide and insulin were achieved (Figure 39).  
 
 
Figure 39 – Protein and Peptide Modifications with the PEG derivative of 2-ABBA (186) 
 
Furthermore, taking into consideration that there is still a demand for improved insulin formulations 
that mimic the physiological profile after endogenous insulin secretion, insulin-conjugates have been 
widely tested to improve insulin’s pharmacokinetics.282 Since, unlike pathological situations, the 
186 
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physiological levels of insulin are elevated when in presence of high blood sugar levels, a strategy that 
stabilizes insulin in circulation and releases its active form when the concentration of saccharide 
molecules is high is quite interesting.  
Due to the potential reversibility of iminoboronate methodology with saccharide molecules, the ability 
of fructose to release this insulin’s PEGylation was evaluated by mass spectrometry. This procedure was 
based on the construction of insulin-iminoboronate conjugates in ammonium acetate buffer (50 mM, pH 
7.0) at room temperature, followed, by the addition of fructose and direct evaluation of the reaction 
mixture, through ESI-FTICR-MS (Table 12). By mass spectra analysis, it was concluded that the presence 
of high concentrations of fructose disrupts the N-B interaction causing the release of free insulin. 
Therefore, this iminoboronate methodology can be interesting to improve insulin’s properties. 
 
Table 12 – Reversibility of Insulin’s PEGylation through addition of Fructose 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Insulin 5804.66358 [M+H]
+
 100.0 - 
Insulin + 186 6198.84587 [M+H]+ 40.6 6198.85059 
Insulin + 2x186 6593.01857 [M+H]+ 23.7 6593.03029 
Insulin + 3x186 6987.18817 [M+H]+ 10.2 6987.20999 
Insulin + 186 + Fructose 6198.854375 [M+H]+ 15.1 6198.851333 
Insulin + 2x186 + Fructose 6593.023645 [M+H]+ 9.8 6593.031036 
Insulin + 3x186 + Fructose 6987.194475 [M+H]+ 5.1 6987.210739 
 
The second therapeutic application envisioned for iminoboronate methodology was based on a 
targeted drug-delivery system based on folate-conjugates. For this a derivatization of 2-ABBA core 
molecule was performed to introduce a cytotoxic drug. Paclitaxel (PTX, 187) is an antimitotic agent that 
stabilizes altered microtubule strutures, thus disabling its normal degradation during cell division. This 
taxoid is especially cytotoxic to cancer cells, since these divide faster than other cells, though intestinal, 
hair follicles and myeloid cells can also be destroyed during this process, resulting on the known side 
effects of chemotherapy, like nausea, hair loss and myelosuppression.39 Therefore, finding new and safer 
avenues to deliver this potent cytotoxic drug is of crucial importance and that is the main objective of this 
second therapeutic application. 
 
Chapter IV. Applications 
 
116 
 
Figure 40 – Paclitaxel’s structure 
 
Folate-iminoboronate conjugates were chosen as the constructs able to carry PTX to cancer cells. A 
synthetic pathway to generate a 2-ABBA PTX derivative is depicted in Scheme 66. Starting from the acid 
derivative of the novel modifying agent (141), a Steglish esterification was performed, affording the 
product in 81% yield, followed by the already mentioned pinacolyl deprotection step that affored 
compound 188 in 67% yield. Once this compound was synthesized, its ability to conjugate with primary 
amines was evaluated by HRMS, either with 1-butylamine or with the same derivative of folic acid used 
during the bioimaging studies (EDA-FA). 
 
141 
1. DMAP, EDC, DCM, 0 ºC, 1 h;  
2. DCM, 0 ºC→r.t., 24 h 
PTX, 187 
   Overall Yield 81% 
          
3. CH3CN:HCl (1 M) (9:1), Ar, 
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146  
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189 
ESI-MS: m/z [M+H]+calculated = 1567.62499,  
m/z [M+H]+real = 1567.62473 
 
Scheme 66 – Synthesis of a 2-ABBA PTX derivative and reaction of EDA-FA (100 μM) with compound 188 (100 
μM) in ammonium acetate buffer (50 mM, pH 7) to obtain 189 confirmed by HRMS.   
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Once the ability of this 2-ABBA derivative to conjugate with primary amines was shown to be 
unaffected by the large size of PTX, the targeted delivery of compound 189 was tested in cancer cell lines. 
Unfortunately, the IC50 obtained for this bioconjugate was higher than PTX alone (21 nM for the conjugate 
versus 6 nM for PTX), meaning that this conjugate has proven to be less potent.  
The prepared bioconjugates and compounds were incubated with NCI-H460 cell line and the anti-
proliferative assays performed. As depicted in Figure 41, conjugate 189 was evaluated based on three 
control assays, which were made with: a) PTX (187) alone, b) PTX 2-ABBA derivative (188) alone and c) 
the same compound (188) conjugated with 1-butylamine (as a model iminoboronate that does not possess 
a targeting moiety). Based on the IC50 values determined, it was concluded that the conjugate under 
evaluation (189) has a better anti-proliferative effect than the PTX 2-ABBA derivative and the 1-butylamine 
iminoboronate conjugate, however conjugate 189 was less potent than PTX (187).  
 
Paclitaxel
0.0 0.5 1.0 1.5
0.20
0.25
0.30
0.35
0.40
LOG10 Conc (nM)
V
ia
b
il
it
y
 
ABBA
1.0 1.2 1.4 1.6 1.8 2.0
0.0
0.2
0.4
0.6
0.8
1.0
LOG10 Conc (nM)
V
ia
b
il
it
y
 
Determined IC50: 5.67±1.16 nM Determined IC50: 32.53±1.01 nM 
ABBA + FA-NH2
1.0 1.2 1.4 1.6 1.8 2.0
0.0
0.2
0.4
0.6
0.8
1.0
LOG10 Conc (nM)
V
ia
b
il
it
y
 
ABBA +BUTA
1.0 1.2 1.4 1.6 1.8 2.0
0.0
0.2
0.4
0.6
0.8
1.0
LOG10 Conc (nM)
V
ia
b
il
it
y
 
Determined IC50: 20.70±1.04 nM Determined IC50: 29.12±11.43 nM 
Figure 41 - Toxicity curves obtained for the NCI-H460 cell model and the determined IC50 – 48 hs of incubation 
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These results highlight that the targeted therapy is advantageous for any of the PTX derivatives 
synthesized (either bearing a ketone or an iminoboronate moiety), though the unmodified PTX appears 
to be more active. The fact that the conjugate bears no linker between the core molecule and the cytotoxic 
drug may affect its biological activity and that would justify the unexpected difference between the 
untargeted and unmodified treatment against the targeted iminoboronate methodology. 
 
Conjugate 189 Compound 188 
  
Figure 42 – Viability assay for CRL-1502 (Human Skin Normal Fibroblast) cell model - 24 hs of incubation 
 
Although the conjugate 189 was less potent than PTX alone, the penalty in activity could be well 
compensated by the increase in safety. Therefore, in an attempt to grant therapeutic value to this 
approach, the possibility of enhancing the selectivity of internalization towards cancerous cells was 
evaluated through a viability study with a non-cancerous cell line, determining if the cells were more viable 
with PTX alone or with the conjugate 189. 
Unfortunately, the viability assay for PTX alone couldn’t be done in due time. However, by comparing 
the conjugate 189 with the ABBA PTX derivative (188), the non-cancerous cell line appears to have a 
higher tolerability for the iminoboronate conjugate than for the unconjugated compound. Having in 
consideration a report that studied the viability of another human skin fibroblasts cell line (1043SK - 
proliferating human skin fibroblasts) against PTX, which detected a concentration between 10 and 50 nM 
to significantly decrease the viability of these cells,283 we envision that between the evaluated range 
(10-30 nM), much like the ABBA PTX derivative alone (188), isolated PTX will also be more cytotoxic than 
the conjugate 189. 
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IV.4. Conclusions  
In this chapter, the synthesis of several compounds with different chemical properties was presented, 
as well as the resulting biological applications. 
Apart from different protein conjugations, interesting applications were obtained. Namely, an artificial 
glycosylation of lysozyme, three new fluorescent probes for biomolecule conjugation, PEGylation of 
several biomolecules and a cytotoxic conjugate with a possible therapeutic application. 
The PEGylation of insulin with its reversibility dependence upon fructose concentration is an interesting 
method for a pharmaceutical application and the biological studies using a vitamin derivative (folic acid) 
as partner of conjugation are particularly interesting, as well. 
The cell internalization study resulted in an important conclusion, which was that iminoboronates are 
stable enough to go through cellular internalization. Furthermore, the toxicity assessment of paclitaxel 
versus paclitaxel conjugated to a folate derivative towards cangerigenous and non-cancerous cell lines 
was important to assess the possibility of having a greater level of selectivity.  
Currently, a study of intracellular reversibility of the conjugate is in progress through the development 
of an "ON-OFF" probe that is specific for this type of conjugation.  
Although, regardless of its outcome, during the process of finding biological applications for 
iminoboronate methodology, excess of reversibility under certain conditions was observed as the major 
issue of this bioconjugation system. Therefore, in Chapter V. a novel idea currently under study will be 
discussed. 
 
 
  
 
  
     
Chapter V 
Searching for pH Switchable Irreversibility  
 
 
 
ABSTRACT 
Based on the applications developed for 2-carbonylbenzeneboronic acids, it was clear that the 
applications were limited due to an excessive reversibility that also hampered the ability to separate the 
conjugated species from the starting materials. 
Hence, in this chapter, an ongoing study is presented, where an optimization to improve this 
bioconjugation system is envisioned and the synthesis of a compound with a possible pH switchable 
irreversibility is disclosed. 
So far the conjugation attempts did not proved to be a successful system, though molecule 
optimizations are being performed in order to achieve a pH controlled conjugation with iminoboronates as 
its foundation. 
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Chapter V.   
Searching for pH Switchable Irreversibility 
V.1. Introduction 
Considering the last set of applications mentioned in Chapter IV. (therapeutic applications of 
bioconjugates), the stability of such molecules is a crucial factor in the design of the constructs, since it 
significantly affects their potency, selectivity and pharmacokinetics.123 For instance, antibody-drug 
conjugates, which are therapeutic bioconjugates with given proofs of effectiveness, require stable linkers 
and conjugation systems to endure systemic circulation. However, upon cellular internalization and a 
given activation pathway, those ADCs must be able to release their cytotoxic cargos.284 Since the stability 
of conjugation systems was already discussed in Chapter I. the different strategies to design such linkers 
will be briefly commented, since one of these approaches inspired us to develop pH switchable irreversible 
derivatives of 2-carbonylbenzeneboronic acids. 
Hence, three different types of ADC linkers with different cleavage systems can be mentioned. Which 
are acid-labile linkers, that hydrolyse at mildly acidic environments exploiting the differences in pH 
between the bloodstream (pH 7.3 – 7.5) and intracellular media (endosomes pH 5.0 - 6.5; lysosomes pH 
4.5-5.0); enzyme-labile linkers, that have recognizable peptidic sequences for enzyme degradation 
mediated by lysosomal proteases; and disulfide-containing linkers, that are cleaved in the presence of an 
intracellular thiol, like gluthathione.123,285 
Of all the mentioned linker strategies, acid-labile hydrazone linkers were the first to be used in the 
construction of ADCs,286 and until today, still represent one of the most applied strategies for cleavable 
linkers. However, these linkers have shown non-specific release of the drug in clinical studies, have lower 
specificity in vitro and higher levels of toxicity in vivo when compared to highly stable linkers.287 One of 
those stabler linkers is based on a fairly recent concept of developing noncleavable (irreversible) linkers 
designed not to influence the cytotoxicity of the ADC.286 
Nevertheless, the utility of reversible versus irreversible linkers has been a topic of discussion during 
the last years, since ADC linkers are considered to be the crucial structure that limits higher efficacy and 
tolerability levels. Therefore, different strategies to design novel bioconjugates have to be developed in 
order to cover the gaps in the present state of the art. 
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V.2. Goals 
Considering the facts mentioned in the introduction and on the results from biological applications 
presented in Chapter IV. the main objective outlined for this chapter was to improve the iminoboronate 
bioconjugation.  
This goal was focused in a way as to avoid extra linkers and for the conjugation system itself to serve 
as a cleavable moiety triggered by an intercellular activation pathway (mildly acidic pH from endosomes 
and lysosomes). 
The preliminary results presented herein are a part of an ongoing project that requires improvement 
and lead us to the future perspectives of this study. 
 
V.3. pH Controlled Irreversibility 
Driven by the biological limitations that the iminoboronate conjugates presented, taking into 
consideration the difficulties to separate the conjugates from the unreacted compound and the inability of 
using the boronic acid in subsequent reactions (due to its importance in stabilizing the imine), other 
strategies to turn this reversible strategy into an irreversible one were envisioned.  
V.3.1. Concept to be developed 
To turn the iminoboronate methodology into an irreversible conjugation method, apart from ideas that 
were based on reducing strategies (either by adding a second reagent or by synthesizing a compound 
bearing reducing moieties), the one selected for further development was based on an intramolecular 
cyclization that could lead to a pH controlled reversibility. Thus, a 3-carboxy-2-formylbenzeneboronic acid 
was proposed as a 2-FBBA derivative presenting a functional group that could shift between an open and 
a cyclic form depending upon its protonation state (Scheme 67). 
 
 
 
 
 
87  
 
pH controlled 
 
190  191  192 
Scheme 67 – Target molecule (190) to obtain a pH controlled cyclization 
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As depicted in Scheme 67, upon reaction with a model primary amine, compound 190 is expected to 
react through the same mechanism as for 2-FBBA to generate the iminoboronate 191, at near neutral pH. 
The major difference of this methodology is the anticipated cyclization through acid or base-promoted 
catalysis that would bring extra stability to transport a given conjugate. However, once formed, acid 
catalysis can also promote the cleavage of the conjugate as depicted in Scheme 68. Therefore, this 
strategy is based on the introduction of a carboxylic acid that will act as a pH “lock” for iminoboronates. 
 
 
H+ 
 
 
 
H2O 
 
 
 
 
 
 
192  193  194  195 
Scheme 68 – Predicted Mechanism of the conjugate’s degradation under acidic pH 
 
V.3.2. Synthetic Pathway towards an Irreversible Molecule 
Hence, a few retrosynthetic pathways leading to compound 190 were outlined. Scheme 69 represents 
the strategy that afforded the best results. In such proposal, regardless of the deprotecting steps required 
after installing all functionalities into the core molecule (acid, aldehyde and boronic acid), the crucial steps 
would be: a Miyaura borylation, a triflation and a Duff reaction or hexamine aromatic formylation (from 
198 to 197). 
 
 
 
 
 
 
 
 
 
190  196  197  198 
Scheme 69 – Retrosynthetic pathway to synthesize the intended molecule 
 
Based on Scheme 69, the first chemical reaction (hexamine aromatic formylation) smoothly afforded 
three different isomers of formylated 198, in which the major isolated product was 197. The following step 
(triflation) did not afford the expected product 196 as the major product and, thus, a carbonyl protecting 
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step was introduced to avoid any cross-reactions. For that, an acid-catalysed protection with trimethyl 
orthoformate gave compound 201 in 94% yield. In contrast with the unprotected species, this protected 
aldehyde, under the same conditions afforded the triflate product in excellent yields. Once again, the 
Miyaura borylation was the rate-limiting step in the synthesis of ortho-carbonylbenzeneboronic acids 
affording the boronate ester 204 in only 20% yield. However, at this stage, the molecule already had all 
the organic functionalities required for the envisioned strategy and all the remaining steps would only be 
deproctection steps (from two esters to acids and an acetal to an aldehyde).  
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Scheme 70 – Synthetic route to target molecule (190) to obtain a pH controllable cyclization 
 
Since acid-catalysed hydrolysis is known to deprotect all the functionalities present in 204, a reported 
procedure of ester hydrolysis was followed, in which a major product (203) precipitated from the reaction 
mixture. Longer reaction times were attempted in an effort to also hydrolyze the boronate ester and, thus, 
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generate 206 (a tautomer from the intended molecule) in a single step, but this was not possible and a 
subsequent deprotection step was required to complete this synthesis. Compound 190 was not isolated, 
though its presence in solution was verified by reacting compound 206 with primary amines to test its 
ability of generating imines or the cyclized ƴ-lactone depicted in Scheme 67. 
 
V.3.3. Preliminary Results 
Starting from the evaluation of 206 as being able to generate the aldehyde in solution, the most simple 
reaction of imine formation was performed. For that, this compound was dissolved in aqueous media 
(D2O) and a primary amine (1-butylamine) was added to this solution and left reacting at room 
temperature. After 18 h, the reaction mixture was evaluated by performing 1H-NMR, which led to the 
following conclusions: no aldehyde proton was detected (as in all reactions between 1-butylamine and 
2-carbonylbenzeneboronic acid), and the conversion to the cyclized form (192) was also unobserved. In 
this spectrum, the only species present were the reagent (206) and the imine in 35% conversion (191). 
In order to promote the cyclization, a disruption of the interaction between boron and nitrogen was 
attempted by adding a single equivalent of fructose to the reaction mixture and register another 1H-NMR 
to report any differences. From this second study, it is concluded that the imine hydrolysed completely, 
though through this experiment it seems that the cyclized ƴ-lactone observed is the one from the starting 
material instead of the one from the expected product (192). Nevertheless, driven by these promising 
results of imine formation, a study at different pHs was undertaken to evaluate its influence on imine 
generation and cyclization. 
Based on previous assays for 2-carbonylbenzeneboronic acid, four reactions between compound 206 
with 1-butylamine were performed under naturing conditions (ammonium acetate buffer with different pHs 
at 25 ºC). From this study, the cyclized form remained undetected and imine formation was observed to 
be more favourable with increasing pHs (Figure 43). As a control of this reaction, 2-carboxybenzaldehyde 
reacted under the exact same conditions, only to afford no imine or ƴ-lactone at any of the studied pHs. 
From this study, it was concluded that possibly there is too much ring restrainment to form the ƴ-lactone 
and, therefore, a new set of compounds were envisioned to add an extra atom to the carboxy moiety for 
generating a six-membered ring, instead of the five-membered ring depicted in Scheme 67. 
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Figure 43 – Conversion of Imine Formation with 206 in percentage 
 
V.3.4. Molecule’s Modification to Promote Cyclization 
In order to improve the conjugation based on the carboxylic acid derivative of 2-FBBA and promote 
the cyclization pathway mentioned above, a plan was developed to generate a six-membered ring on the 
cyclized form instead of the ƴ-lactone. This suggestion was made since the interaction between N-B to 
enhance imine formation can hamper the cyclization due to an expected thermodynamically disfavoured 
intermediary with a cluster-like conformation, as depicted in Figure 44. 
 
 
Figure 44 – Optimized geometry (PBE0/6-31G**) of the expected intermediary between the imine (191) and the 
final product (ƴ-lactone, 192) 
 
Therefore and based on the fact that compound 206 was already synthesized, a path to take 
advantage of this compound was envisioned, in which the cyclization pathway could be favoured (without 
26%
29%
31%
33%
pH 6 pH 7 pH 8 pH 9
Conversion (%)
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changing the properties intended for this strategy). This pathway was based on the synthesis of a 
hydroxamic acid instead of the carboxylic acid as demonstrated by Scheme 71. 
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207  208  209 
Scheme 71 – Improved intended molecule (207) to obtain a pH controlled cyclization 
 
The synthesis and optimization of reaction conditions to obtain compound 207 are under development 
and no crucial information can yet arise from discussing the results obtained this far. 
 
V.4. Conclusions 
In this chapter, an acknowledgement of the limitations of iminoboronate bioconjugation system is 
presented and as a possible solution, an ongoing work based on a potentially pH controllable reversibility 
was discussed. 
So far, an acidic derivative of 2-formylbenzeneboronic acid was already synthesized, though it did not 
work as well as envisioned. Currently, modifications of this derivative are being developed to decrease 
the expected ring tension of the intermediaries required to form the cyclized amine. 
Therefore, we began to improve this bioconjugation method in order to have a broader number of 
biological applications that could be applied for this interesting selective conjugation of primary amines of 
biomolecules. 
 
  
 
 
 
General Conclusions 
Taking into account the main goal of this project, i.e. the development of several new reagents to 
modify non-recombinant proteins, it can be stated that the goal was successfully achieved. 
Manipulation of non-recombinant proteins was completed through a selective and rather controllable 
modification of lysine residues (and the N-terminal motif). Iminoboronate bioconjugation method was 
considered a valuable tool to modify lysine residues and it is considered to be very selective towards 
primary amines. 
From this proven methodology, different synthetic procedures were investigated so that chemical 
entities could be incorporated into structures that also presented 2-carbonylbenzeneboronic acids. From 
these chemical derivatives of formyl/acetyl boronic acids, different biological applications were pursued 
and interesting results were achieved. Namely, one that proved the level of stabilization of iminoboronate 
modification through a cell internalization procedure and another that compared a conjugated and 
unconjugated cytotoxic drug to a vitamin derivative in order to confirm if a greater level of selectivity could 
be attained. 
Finally, recognizing the lack of stability of our bioconjugation method under certain conditions, 
chemical improvements for this methodology were and are being pursued so that a pH switchable lock 
could be obtained. This envisioned irreversible linkage in the conjugate could be controlled upon specific 
pH conditions.  
Currently, two projects are moving in parallel, one that will allow the conformation of iminoboronate 
conjugate release after cell internalization, through the development of an “ON-OFF” probe for this 
technology and another based on optimizing the 2-carbonylbenzeneboronic acid core to achieve a more 
controllable conjugation. 
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Chapter VI.   
Materials and Methods 
VI.1. General Remarks 
All chemicals and solvents were of analytical reagent grade and were purchased from Alfa Aesar or 
Sigma-Aldrich. Tetrahydrofuran was distilled from sodium-benzophenone system prior to use. 
Dichloromethane and diethyl ether were distilled over CaH2 prior to use. Dioxane was distilled over 
metallic sodium prior to use. All reactions were performed in oven-dried glassware or in sterilized 1.5-2 
mL eppendorf tubes and, generally, performed under inert atmosphere. 
Thin layer chromatography was performed using Merck silica gel 60F254 aluminium plates and 
visualized by UV light, iodine, potassium permanganate dip, p-anisaldehyde dip, ninhydrin dip and 
dinitrophenylhydrazine dip. Flash column chromatography was performed using Merck silica gel 60 
(230-400 mesh ASTM) eluting with various solvent mixtures and using an air aquarium pump to apply 
pressure.  
NMR spectra were obtained on a Bruker 400 Ultra-Shield (400 MHz), a Bruker Avance 500 (500 MHz) 
and a Bruker Avance III 600 Cryo (600 MHz) using deuterated chloroform, acetone, methanol or 
dimethylsulfoxide as solvents and (CH3)4Si (1H) as internal standard; chemical shifts, δ, are expressed in 
ppm, and coupling constants, J, are expressed in Hz. Multiplicities are given as: s (singlet), d (doublet), 
dd (double doublet), dt (double triplet), t (triplet), td (triple triplet), tt (triple triplet), q (quartet), quint 
(quintuplet) and m (multiplet).  
The infrared spectra were collected on a FTIR Shimadzu IRAffinity-1 infrared spectrophotometer. The 
spectra were determined using in KBr disks or thin films between NaCl plates. Only the most significant 
absorption bands are reported.  
The UV-visible spectra were recorded on a Shimadzu UV-1603 UV-visible spectrometer with a 
temperature controlled (25 ºC) cell holder. 
Low resolution ESI mass spectra were carried on a linear trap mass analyser (ThermoFinnigan LTQ) 
equipped with an orthogonal electrospray interface. The linear trap mass spectrometer was operated in 
the negative mode with the ion source voltage set to 5 kV, capillary voltage -49 V, tube lens offset -250 
V, capillary temperature 350 ºC, sheath gas flow rate 20 (arbitrary units), auxiliary gas flow rate 10 
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(arbitrary units) and sweep gas flow rate 5 (arbitrary units). Mass spectra were acquired over the scan 
range m/z 200 to 1000. 
Precursor ions were selected with an isolation width of 2 m/z units and activated for 30 ms. Collision-
induced dissociation (CID) experiments used helium as the collision gas and normalised collision energy 
settings were in the range 30-80%, depending on the compound. Data were processed using Xcalibur 1.3 
software (ThermoFinnigan, now ThermoScientific). 
High resolution mass spectrometry was performed on an equipment with the following specifications: 
FTICR-MS Bruker Daltonics Apex Qe, Apollo II combi source, 7 Tesla Magnet. Native mass spectrometry 
was performed, thus maintaining secondary and tertiary structures of the protein during the process of 
ionization, which was operated in positive mode. Data Analysis was used as the deconvolution software. 
 
VI.2. Experimental Section of Chapter II 
VI.2.1. Experimental Details of Experimental Results and Optimization 
 
VI.2.1.1. Reactions with aboronated compounds 
 + 
 
Aqueous Media 
 
25 ºC 
 
87 
 
77 (R1 = -H, R2 = -H) 
78 (R1 = -H, R2 = -COOH) 
79 (R1 = -H, R2 = -OH) 
80 (R1 = -CH3, R2 = -H) 
 
210 
Scheme 72 – Reactions with aboronated compounds 
 
Formaldehyde (77), 2-carboxybenzaldehyde (78), salicylaldehyde (79) and acetophenone (80) (0.33 
mmol) were added to a 10 mL round bottom flask and then dissolved in 2 mL of water (0.165 M). 
Afterwards, 1 eq of 1-butylamine (87) was added to the same flask and these compounds reacted for 18 
h at 25 ºC. At that pre-determined times, one drop of the reaction mixture was taken from the media and 
diluted in D2O in order to collect a 1H-NMR spectrum and evaluate the product’s conversion. These 
conversions were calculated using the following formula: integration of α-protons from the imine divided 
by the sum of α-protons from the imine and from the amine. 
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VI.2.1.2. Preliminary reaction with 2-formylbenzeneboronic acid and 
optimization results 
 + 
 
Aqueous Media 
 
25 ºC 
 
87  72  211 
Scheme 73 – Reaction between 2-FBBA and 1-butylamine 
 
2-Formylbenzeneboronic acid (72, 50 mg, 0.33 mmol) was added to a 10 mL round bottom flask and 
then dissolved in 2 mL of solvent (water or phosphate buffer solution [50 mM, pH 8.02]). Afterwards, 
1-butylamine (87, 33 μL, 0.33 mmol) was added to the same flask and these compounds reacted for 18 
h at 25 ºC (Scheme 73). At that time, one drop of the reaction mixture was taken from the media and 
diluted in D2O in order to collect a 1H-NMR spectrum and evaluate the product’s conversion based on the 
comparison of the signal from α-protons of 1-butylamine and the same protons from imine, which differ 
from ~2.5 ppm to ~3.6 ppm, respectively. The conversion in neat water was 49% and in the phosphate 
buffer 52%. 
 
From an equivalent reaction performed on an organic solvent (dichloromethane), it was possible to 
isolate the imine by evaporating the solvent and performing a 1H-NMR in CDCl3. Due to a quantitative 
reaction it was possible to characterize product 211:  
1H-NMR (400 MHz, CDCl3) δ 8.38 (s, 1H, ArCHNCH2-), 7.61 (d, J=7.1 Hz, 
1H, CHarom), 7.49 (d, J=7.5 Hz, 1H, CHarom), 7.31 (t, J=7.3 Hz, 1H, CHarom), 
7.19 – 7.13 (m, 1H, CHarom), 3.59 (t, J=7.3 Hz, 2H, =NCH2CH2-), 1.71 – 1.61 
(m, 2H, -CH2CH2CH2CH3), 1.27 (dd, J=15.1, 7.5 Hz, 2H, -CH2CH2CH3), 0.79 (t, , J=7.4 Hz, 
3H, -CH2CH2CH3). 
13C NMR (100 MHz, CDCl3) δ 165.14 (s, ArCHNCH2-), 138.53 (s, Carom), 133.03 (s, Carom), 131.58 (s, 
Carom), 130.92 (s, Carom), 127.66 (s, Carom), 125.73 (s, Carom), 52.81 (s, =NCH2CH2-), 31.44 
(s, -CH2CH2CH2-), 20.34 (s, -CH2CH2CH3), 13.77 (s, -CH2CH2CH3). 
IR (film): 1639.49 cm-1 (N=C) 
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VI.2.1.2.1. Reactions with formylbenzeneboronic acids 
 
  
 
 
81 82 83 84 85 
0% 0% 18% 53% 0% 
Figure 45 – Compounds 81 to 85 and respective imine conversion from reacting with 1-butylamine in KPi 
buffer (50.0 mM; pH 8.02), for 18 h at 25 ºC 
 
3-Fluoro-2-formylphenylboronic acid (83), 2-formyl-4,5-methylenedioxyphenylboronic acid (84), 
3-formyl-2-thienylboronic acid (85) and 4-formylphenylboronic acid (81) were purchased from 
Sigma-Aldrich and used without further purification. Compound 82 - potassium 
2-formylphenyltrifluoroborate - was synthesized according to a procedure described in the literature 
(Molander, G.A. and Figueroa, R. Journal of Organic Chemistry 2006, 71(16), 6135). 
A formylboronic acid (0.33 mmol) was added to a 10 mL round bottom flask and then dissolved in 2 
mL of KPi buffer (50.0 mM, pH 8.02). Afterwards, 1-butylamine (87, 33 μL, 1eq) was added to the same 
flask and these compounds reacted for 18 h at 25 ºC (Figure 45). Then, a drop of the reaction mixture 
was taken from the media and diluted in D2O in order to collecta 1H-NMR spectrum and evaluate the 
product’s conversion. Results are resumed in Figure 45. 
 
Characterization of the imine obtained from reaction with compound 83: 
1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H, ArCHNCH2-), 7.47 – 7.33 (m, 2H, 
2xCHarom), 6.96 – 6.81 (m, 1H, CHarom), 3.76 (dd, J = 17.8, 10.2 Hz, 2H, 
=NCH2CH2-), 1.85 – 1.73 (m, 2H, -CH2CH2CH2CH3), 1.43 (dt, J = 15.0, 7.4 
Hz, 2H, -CH2CH2CH3), 0.94 (t, J = 7.4 Hz, 3H, -CH2CH2CH3). 
13C NMR (100 MHz, CDCl3) δ 159.26 (s, ArCHNCH2-), 133.75 (s, Carom), 133.68 (s, Carom), 126.05 (s, 
Carom), 125.13 (s, Carom), 125.05 (s, Carom), 114.50(s, CaromF), 114.30 (s, CaromF), 52.87 (s, =NCH2CH2-), 
31.41 (s, -CH2CH2CH2-), 20.33 (s, -CH2CH2CH3), 13.81 (s, -CH2CH2CH3). 
IR (film): 1641.42 cm-1 (CN) 
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Characterization of the imine obtained from reaction with compound 84: 
1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H, ArCHNCH2-), 7.09 (d, J = 9.6 
Hz, 2H, 2xCHarom), 5.94 (s, 2H, -OCH2O-), 3.61 (t, J = 7.2 Hz, 2H, 
=NCH2CH2-), 1.72 (dt, J = 15.0, 7.5 Hz, 2H, -CH2CH2CH2CH3), 1.34 (dt, J 
= 14.7, 7.4 Hz, 2H, -CH2CH2CH3), 0.88 (t, J = 7.4 Hz, 3H, -CH2CH2CH3). 
13C NMR (100 MHz, CDCl3) δ 164.25 (s, ArCHNCH2-), 152.40 (s, Carom), 147.40 (s, Carom), 132.44 (s, 
Carom), 111.10 (s, Carom), 106.04 (s, Carom), 101.06 (s, Carom), 52.64 (s, =NCH2CH2-), 31.52 
(s, -CH2CH2CH2-), 20.31 (s, -CH2CH2CH3), 13.74 (s, -CH2CH2CH3). 
 IR (film): 1641.42 cm-1 (CN) 
 
VI.2.1.2.1. Reagents stoichiometry 
Reactions of 18 h were performed according to the procedure for 2-formylbenzeneboronic acid (72), 
using KPi buffer (12.5 mM; pH 8.02) and changing equivalents of 2-formylbenzeneboronic acid (72) from 
1 eq to 20 eq (Scheme 73). Conversions are resumed in Table 13. 
 
Table 13 - Reagents stoichiometry from 1H-NMR in D2O 
Quantity of 2-FBBA (72) Conversions 
1 equivalent 58% 
5 equivalents 71% 
10 equivalents 69% 
20 equivalents 68% 
 
VI.2.1.2.2. Buffer concentration 
Reactions of 18 h were performed according to the same procedure, using 1 equivalent of 
2-formylbenzeneboronic acid (72), at different concentrations of KPi buffer pH 8.02 (Scheme 73). 
Conversions are resumed in Table 14. 
 
Table 14 - Buffer concentration conversions from 1H-NMR in D2O 
Buffer Concentration Conversions 
0.00 mM KPi 53% 
12.5 mM KPi 58% 
25.0 mM KPi 50% 
37.5 mM KPi 41% 
50.0 mM KPi 52% 
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VI.2.1.2.3. Reaction time 
Reactions were performed according to the general procedure, using 1 eq of 2-formylbenzeneboronic 
acid (72); KPi buffer (12.5 mM; pH 8.02) as solvent and different reaction times (6, 18, 24 and 48 h) 
(Scheme 73). Conversions are resumed in Table 15.  
Table 15 - Reaction time conversions from 1H-NMR in D2O 
Reaction Time Conversions 
6 h 56% 
18 h 58% 
24 h 50% 
48 h 53% 
 
VI.2.1.2.4. Vicinal diols 
 + 
 
+ 
 
Aqueous Media 
 
25 ºC 
 
87  72  212  213 
Scheme 74 – Reaction between 2-FBBA and 1-butylamine and vicinal diols 
 
2-Formylbenzeneboronic acid (72, 25.0 mg, 0.17 mmol) was added to 10 mL round bottom flasks and 
then dissolved in 2 mL of water. Afterwards, 1 equivalent of cathecol (18.4 mg), p-nitrocathecol (26.0 mg) 
and D-glucose (33.0 mg) were added to these flasks, separately. Then, 1 equivalent of 1-butylamine (87, 
33 μL) was also added and these compounds reacted for 18 h at 25 ºC. At that time, one drop of reaction 
mixture was taken from the media and diluted in D2O to collect a 1H-NMR spectrum and evaluate the 
product’s conversion. No significant imine formation was detected in any of such reactions.  
 
VI.2.1.2.5. Tautomerism of 2-formylbenzeneboronic acid 
During the scope of the reaction with 2-formylbenzeneboronic acid (72), a tautomerism (enhanced by 
increasing pHs) was detected. This cyclization, between the aldehyde and boronic acid, led to a peak 
vanishing, related with the formyl proton, and the appearance of a new one at ~6.0 ppm, associated with 
the proton in the tertiary carbon – compound 86 (Scheme 31, p.47). Also, worth mentioning, a shift of the 
α-protons of 1-butylamine (87) was detected whenever the amine was unprotonated or protonated, which 
differed from ~2.6 to ~2.9 ppm, respectively. This was proven by performing 1H-NMR of reagents 
1-butylamine (87) and 2-formylbenzeneboronic acid (72) at different conditions: 
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 1-Butylamine (87):  
1H-NMR (400 MHz, CDCl3) δ 2.52 (t, J = 7.3 Hz, 2H, NH2CH2CH2-), 1.26-1.17 (m, 4H, 
NH2CH2CH2CH2), 0.88 (s, 2H, NH2CH2-), 0.75 (t, J = 7.0 Hz, 3H -CH2CH2CH3). 
1H-NMR (400 MHz, D2O) δ 2.58 (t, J = 7.0 Hz, 2H, NH2CH2CH2-), 1.41-1.20 (m, 4H, NH2CH2CH2CH2), 
0.84 (t, J = 7.3 Hz, 3H -CH2CH2CH3).  
At acidic conditions (5% HCl solution) 
1H-NMR (400 MHz, D2O) δ 2.88 (t, J = 7.0 Hz, 2H, NH2CH2CH2-), 1.57-1.51 (m, 2H, 
NH2CH2CH2CH2),1.36-1.30 (m, 2H, NH2CH2CH2CH2-), 0.87 (t, J = 7.3 Hz, 3H -CH2CH2CH3). 
 2-Formylbenzeneboronic acid (72): 
1H-NMR (400 MHz, CDCl3) δ 9.93 (s, 1H, ArCHO), 8.32 (dd, J = 5.6, 3.2 Hz, 1H, CHarom), 7.99 – 7.88 
(m, 1H, CHarom), 7.76 – 7.70 (m, 2H, 2xCHarom). 
1H-NMR (400 MHz, D2O) δ 9.90 (s, 1H, ArCHO), 7.92 (d, J = 7.6 Hz, 1H, CHarom), 7.68 (dd, J = 10.6, 
4.1 Hz, 1H, CHarom), 7.58 (dd, J = 10.9, 4.1 Hz, 2H, 2xCHarom) 
At basic conditions (5% NaOH solution): 
1H-NMR (400 MHz, D2O) δ 7.43 (d, J = 5.7 Hz, 1H, CHarom), 7.27 (d, J = 8.1 Hz, 3H, 3xCHarom), 6.04 
(s, 1H, -BOCH(OH)-). 
 
VI.2.1.1. Preliminary reaction with 2-acetylbenzeneboronic acid and 
optimization results 
2-Acetylbenzeneboronic acid (88, 55.0 mg, 0.33 mmol) was added to a 10 mL round bottom flask and 
then dissolved in 2 mL of water or KPi buffer pH 8.02 (50.0 mM). Afterwards, 1 equivalent of 1-butylamine 
(87, 33 μL) was added to the same flask and these compounds reacted for 18 h at 25 ºC (Scheme 32, 
p.47). At that time, one drop of each reaction mixture was taken from the media and diluted in D2O in 
order to collect a 1H-NMR spectrum and evaluate the product’s conversion based on the comparison of 
the signal from α-protons of 1-butylamine or the same protons from imine (89), which differ from ~2.5 ppm 
to ~3.6 ppm, respectively. Conversions are resumed in Table 16. 
Table 16 - First Reactions conversions from 1H-NMR in D2O 
Solvent Conversions 
Water 88% 
KPi buffer pH 8.02 (50.0 mM) 88% 
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 Characterization of compound 89: 
1H NMR (400 MHz, D2O) δ 7.61 (d, J = 7.6 Hz, 1H, CHarom), 7.50 – 7.42 (m, 
2H, 2xCHarom), 7.35 – 7.28 (m, 1H, CHarom), 3.60 – 3.49 (m, 2H, =NCH2CH2-),  
2.42 (s, 3H, -CNCH3), 1.69 – 1.57 (m, 2H, -CH2CH2CH2CH3), 1.40 – 1.30 (m, 
2H, -CH2CH2CH3), 0.88 (t, J = 7.4 Hz, 3H-CH2CH2CH3). 
13C NMR (100 MHz, D2O) δ 176.72 (s, ArCHNCH2-), 139.06 (s, Carom), 132.41 (s, Carom), 128.19 (s, 
Carom), 127.52 (s, Carom), 123.98 (s, Carom), 44.43 (s, =NCH2CH2-), 30.92 (s, -CH2CH2CH2-), 20.09 
(s, -CH2CH2CH3), 19.12 (s, ArCNCH3), 12.98 (s, -CH2CH2CH3). 
 IR (film): 1647.21 cm-1 (CN) 
 
 
90 
0% 
Figure 46 - Compound 90 and conversion from reacting it with butylamine in water, for 18 h at 25 ºC 
 
Using the same protocol, 4-acetylbenzeneboronic acid (90, 0.33 mmol) was reacted with 1 equivalent 
of 1-butylamine (87) in water, only to find that no imine was detected by 1H-NMR after 18 h of reaction at 
room temperature (Figure 46).  
 
VI.2.1.1.1. Kinetic study 
2-Acetylbenzeneboronic acid (88, 11.0 mg, 0.067 mmol) was added to a NMR tube and then dissolved 
in 0.4 mL of D2O. Afterwards, at room temperature, 1 equivalent of 1-butylamine (87, 7 μL) was added to 
the same tube and several 1H-NMR were performed to study the reaction’s kinetics (Scheme 32, p.47). 
Results are shown in Table 17. 
 
Table 17 – Kinetic study conversions from 1H-NMR in D2O 
Time Conversions 
15 minutes 81% 
90 minutes 83% 
180 minutes 84% 
480 minutes 84% 
1440 minutes 84% 
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VI.2.1.1.2. Influence of pH 
2-Acetylbenzeneboronic acid (88, 55.0 mg, 0.33 mmol) was added to a 10 mL round bottom flask and 
then dissolved in 2 mL of KPi buffer (50.0 mM) at different pH’s. Afterwards, 1 equivalent of 1-butylamine 
(87, 33 μL) was added and these compounds reacted for 24 h at 25 ºC (Scheme 32, p.47). At that time, 
one drop of reaction mixture was taken from the media and diluted in D2O to collect a 1H-NMR spectrum 
and evaluate the product’s conversion. Also, 1 week later, the same tube was re-submitted to collect more 
information regarding the stability of the formed imine (89). Conversions are resumed in Table 8 (p.49). 
 
VI.2.1.2. Reactions of 2-carbonylbenzeneboronic acids and biomolecules 
VI.2.1.2.1. Protected lysine 
 Synthesis of Boc-Lys-OCH3 
Boc-β-Lys(Z)-OH (214) was purchased from Sigma-Aldrich, and two reactions were made to 
synthesize Boc-Lys-OCH3. First, C-terminal was protected with iodomethane according to an existing 
procedure, obtaining compound 215 in 86% yield (Scheme 75, Liu, R. et al. Angewandte Chemie 2010, 
122, 3279), and afterwards performed a hydrogenation catalyzed by Pd/C 20% (m/m) in MeOH, obtaining 
compound 91 in 81% yield (Scheme 76, Climie,I.J.; Evans,D.A. Tetrahedron; 1982, 38, 697). NMR 
characterization of both compounds in accordance with the ones described in literature. 
 
Step 1 – C-terminal protection of Boc-Lys(Z)-OH 
 
CH3I,  
K2PO4, DMF, 30 h 
 
r.t., N2, 86% 
 
214  215 
Scheme 75 – C-terminal protection of Boc-Lys(Z)-OH 
 
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.21 (m, 5H, CHarom Cbz), 5.09 (m, 2H, -CH2- Cbz), 4.24 (dd, J = 
13.0, 8.0 Hz, 1H, -CH2CH(COOCH3)NH-), 3.68 (s, 3H, -OCH3), 3.14 (dd, J = 12.9, 6.5 Hz, 2H, 
NHCH2CH2), 1.74 (d, J = 5.6 Hz, 1H, -NHCH2CH2aCH2-), 1.61 (td, J = 14.4, 8.0 Hz, 1H, -NHCH2CH2bCH2), 
1.55 – 1.44 (m, 2H, - CH2CH2CH2-), 1.40 (s, 9H, -CH3 -tBu), 1.34 (d, J = 6.8 Hz, 2H, -CH2CH2CH-). 
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Step 2 - Cbz Deprotection of Boc-Lys(Z)-OCH3 
 
20% (m/m) Pd(C) 
MeOH, 4 h 
 
r.t., H2, 81% 
 
216  91 
Scheme 76 – Cbz Deprotection of Boc-Lys(Z)-OCH3 
 
1H NMR (400 MHz, D2O) δ 4.09 (m, J = 9.0, 5.1 Hz, 1H, -CH2CH(COOCH3)NH-), 3.72 (s, 3H, -OCH3),  
2.72 (t, J = 7.3 Hz, 2H, -NHCH2CH2CH2-), 1.78-1.46 (m, 4H, -NHCH2CH2CH2-), 1.45-1.32 (m, 
12H, -CH2CH2CH- and -tBu).  
 
 Reaction between Boc-Lys-OCH3 and 2-carbonylbenzeneboronic acids 
Boc-Lys-OCH3 (40.0 mg, 0.15 mmol) was added to an eppendorf and dissolved in 0.92 mL of D2O. 
Afterwards, 1 equivalent of boronic acid was added and left to react for 16 h at 25 ºC (Scheme 33, p.49). 
At the end, 0.4 mL of the reaction mixture were removed and a 1H-NMR spectrum was collected and the 
conversions determined. Conversions are based on the comparison of the signal from α-protons of 
Boc-Lys-OCH3 or the same protons from imine, which differ from ~2.7 ppm to ~3.6 ppm, respectively. 
Results are resumed in Table 9 (p.49). 
 
VI.2.1.2.2. Somatostatin 
Somatostatin was purchased from Sigma-Aldrich and used without further purification. 
 
 General procedure for reactions with Somatostatin 
2-Formylbenzeneboronic and 2-acetylbenzeneboronic acids (50.0 mM) were reacted with 10 μM of 
somatostatin in NH4HCO3 buffer (10.0 mM, pH 7.8) at room temperature (Scheme 34, p.50) After 5 
minutes of reaction the solutions were evaluated by performing an ESI-MS and the conjugated species 
were detected. Low resolution ESI-MS results and performed fragmentations are resumed in Table 18 for 
2-formylbenzeneboronic acid (72, 2-FBBA) and in Table 19 for 2-acetylbenzeneboronic acids (88, 
2-ABBA). 
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Table 18 – Low resolution ESI-MS results of conjugation between SST and 2-FBBA (72) 
m/z Intensity Interpretation 
Fragmentations 
(MS/MS) 
Interpretation 
1635.72 22% SST - - 
1731.83 38% SST + 2-FBBA – 2xH2O - - 
1750.70 65% SST + 2-FBBA – 1xH2O - - 
1845.77 23% SST + 2x(2-FBBA) – 3xH2O - - 
1863.78 100% SST + 2x(2-FBBA) – 2xH2O 1827 (- 2(H2O) 
1882.71 50% SST + 2x(2-FBBA) – 1xH2O - - 
1977.77 43% SST + 3x(2-FBBA) – 3xH2O - - 
1996.78 58% SST + 3x2-FBBA – 2xH2O 
1978 - 1xH2O 
1960 - 2xH2O 
1942 - 3xH2O 
1828 - 1x2-FBBA -2xH2O 
 
Table 19 – Low resolution ESI-MS results of conjugation between SST and 2-ABBA (88) 
m/z Intensity Interpretation 
Fragmentations 
(MS/MS) 
Interpretation 
1635.67 12% SST - - 
1763.78 28 % SST + 2-ABBA – 1xH2O - - 
1781.85 48 % SST + 2-ABBA - - 
1910.87 88 % SST + 2x(2-ABBA) – 1xH2O 
1874.75 - 2xH2O 
1856.81 - 3xH2O 
1927.84 100 % SST + 2x(2-ABBA) - - 
 
VI.2.1.2.3. Proteins 
Lysozyme, from chicken egg white; cytochrome c and myoglobin, from equine heart and ribonuclease 
A, from bovine pancreas, were purchased from Sigma-Aldrich and used without further purification. 
 
 General Procedure for reactions with Lysozyme 
2-Formylbenzeneboronic and 2-acetylbenzeneboronic acids (10 and 20 mM, respectively) reacted 
with 10 μM of lysozyme in NH4CH3CO2 buffer (20.0 mM, pH 7.0) at room temperature. After 30 minutes 
of reaction the solutions were evaluated by performing an ESI-FTICR-MS and the conjugated species 
were detected, up to 6 modifications. Results of reaction with 2-FBBA and 2-ABBA are shown in Figure 
47 and Figure 6 (p.51), respectively. 
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Figure 47 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified Lyz; Black – Reaction between Lyz 
(10.0 µM) and 10.0 mM of 2-FBBA (72) in ammonium acetate buffer (20.0 mM, pH 7.0) 
 
 Reactions with Different Solvents 
2-Formylbenzeneboronic and 2-acetylbenzeneboronic acids (10.0 mM) reacted with 10 μM of 
lysozyme in NH4CH3CO2 buffer (20.0 mM, pH 5.0) or water at room temperature. After 5 minutes of 
reaction the solutions were evaluated by performing an ESI-FTICR-MS and the conjugated species were 
detected. Results are shown in Figure 48 and Figure 49. 
 
 
Figure 48 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified Lyz; Black – Reaction between Lyz 
(10.0 µM) and 10.0 mM of 2-ABBA (88) in ammonium acetate buffer (20.0 mM, pH 5.0) 
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Figure 49 – Overlaid deconvoluted ESI-FTICR-MS spectra. Grey - unmodified Lyz; Black – Reaction between Lyz 
(10.0 µM) and 10.0 mM of 2-FBBA (72) in neat water 
 
 Reactions with different aldehydes 
3-fluoro-2-formylphenylboronic acid (83), 2-Formyl-4,5-methylenedioxyphenylboronic acid (84), and 
3-formyl-2-thienylboronic acid (85) (10.0 mM) reacted with 10.0 μM of lysozyme in NH4CH3CO2 buffer 
(20.0 mM, pH 7.0) at 25 ºC. After 5 minutes of reaction the solutions were evaluated by performing an 
ESI-FTICR-MS and the conjugated species were detected. Results are shown in Figure 7 (p.52). 
 
 Reactions with different proteins 
2-Formylbenzeneboronic acid (10.0 mM) reacted with 10.0 μM of cytochrome c, ribonuclease A or 
myoglobin in NH4CH3CO2 buffer (20.0 mM, pH 7.0) at 25 ºC. After 5 minutes of reaction the solutions were 
evaluated by performing an ESI-FTICR-MS and the conjugated species were detected. Results of reaction 
of 2-FBBA with cytochrome c, ribonuclease A or myoglobin are shown in Figure 8 (p.53), Figure 9 (p.54) 
and Figure 10 (p.54), respectively. 
 
 Stability of Conjugates 
2-Formylbenzeneboronic and 2-acetylbenzeneboronic acids (10.0 mM) reacted with 10.0 μM of 
lysozyme in NH4CH3CO2 buffer (20.0 mM, pH 7.0) at  25 ºC. After determined times of reaction (0, 1, 2, 3 
and 4 h) an aliquot was removed from the media and evaluated by performing an ESI-FTICR-MS. Results 
of reaction with 2-ABBA and 2-FBBA are shown in Figure 50 and Figure 51, respectively.  
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Figure 50 – Deconvoluted ESI-FTICR-MS spectra of reaction between Lyz (10.0 µM) and 10.0 mM of 2-ABBA (88) 
in ammonium acetate buffer (20.0 mM, pH 7.0) after 0, 1, 2, 3 and 4 h 
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Figure 51 – Deconvoluted ESI-FTICR-MS spectra of reaction between Lyz (10.0 µM) and 10.0 mM of 2-FBBA (72) 
in ammonium acetate buffer (20.0 mM, pH 7.0) after 0, 1, 2, 3 and 4 h 
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VI.2.2. Experimental Details of Computational Studies 
All calculations were performed using the Gaussian 03 software package,289 and the PBE0 functional, 
without symmetry constraints. That functional uses a hybrid generalized gradient approximation (GGA), 
including 25 % mixture of Hartree-Fock290 exchange with DFT291 exchange-correlation, given by Perdew, 
Burke and Ernzerhof functional (PBE).292,293 The optimized geometries were obtained with a standard 
6-31G(d,p) basis set.294–298  Transition state optimizations were performed with the Synchronous Transit-
Guided Quasi-Newton Method (STQN) developed by Schlegel et al.,299,300 after a thorough search of the 
Potential Energy Surfaces (PES). Frequency calculations were performed to confirm the nature of the 
stationary points, yielding one imaginary frequency for the transition states and none for the minima. Each 
transition state was further confirmed by following its vibrational mode downhill on both sides, and 
obtaining the minima presented on the energy profiles. A Natural Population Analysis (NPA)301–308 and 
the resulting Wiberg indices309–317 were used to study the electronic structure and bonding of the optimized 
species.  
The influence of basis set size and solvent on the calculated reaction mechanism was tested by means 
of single point energy calculations using a 6-311++G(d,p) basis set and the geometries optimized at the 
PBE0/6-31G(d,p) level. Solvent effects (water) were considered using the Polarizable Continuum Model 
(PCM) initially devised by Tomasi and coworkers as implemented on Gaussian 03. The molecular cavity 
was based on the united atom topological model applied on UAHF radii, optimized for the HF/6-31G(d) 
level. The free energy values calculated with the better basis set and including solvent effects are similar 
to the electronic energy values obtained with the smaller basis set in the gas phase, and, hence, these 
latter are the ones presented in the energy profile. For example, the activation free energy for the 
formation of 89 from 88 and 1-butylamine is 9 kcal/mol at the PBE0/6-311++G(d,p) 
(PCM)//PBE0/6-31G(d,p) level, comparing to 12 kcal/mol, the energy barrier calculated at the 
PBE0/6-31G(d,p) level (cf. Figure 24). Similarly, the overall energy balance for the reaction is –7 and –10 
kcal/mol, by the same order. The same happens when there is no B-atom involved in the reaction, i.e., 
the reagent is acetophenone (Figure 13), with a maximum difference of 2 kcal/mol for the relevant energy 
values calculated at the two levels of theory. 
 
Atomic Coordinates for the Optimized Species are given on the following pages. 
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Acetophenone and 1-butylamine 
 
Z-Isomer 
A 
6        0.904045      0.234520      1.529644 
6        1.061171      0.246452      0.038543 
8        0.202838      0.758626     -0.675786 
6        2.242005     -0.402257     -0.598998 
6        2.408264     -0.257024     -1.981783 
6        3.485676     -0.847315     -2.626018 
6        4.404506     -1.601410     -1.896764 
6        3.168363     -1.160292      0.124982 
6        4.241959     -1.761214     -0.523419 
1        1.853905      0.229866      2.066191 
1        0.315713     -0.659018      1.799934 
1        0.311895      1.101471      1.829188 
1        1.674163      0.328077     -2.526301 
1        3.611741     -0.724165     -3.697661 
1        5.247245     -2.066174     -2.400640 
1        3.046729     -1.298292      1.194382 
1        4.952927     -2.354222      0.043994 
7       -1.769096     -1.661716      1.547371 
6       -1.995374     -2.340487      0.279145 
6       -3.616197     -3.015710     -1.577137 
6       -3.432417     -2.305277     -0.240394 
6       -5.049957     -2.970272     -2.090080 
1       -2.062279     -0.687174      1.449249 
1       -2.354573     -2.077130      2.266163 
1       -1.336051     -1.880031     -0.468465 
1       -1.664838     -3.383958      0.372832 
1       -3.295128     -4.061525     -1.477831 
1       -2.945152     -2.564856     -2.320718 
1       -3.741630     -1.254224     -0.331491 
1       -4.099528     -2.755623      0.509672 
1       -5.151889     -3.484563     -3.050872 
1       -5.387207     -1.937025     -2.228629 
1       -5.737888     -3.447150     -1.383155 
8       -2.194218      1.216501      0.691216 
1       -1.384087      1.161236      0.149742 
1       -2.896339      1.411119      0.065312 
 
TSA-B 
6        0.792943      0.512633      1.736147 
6        0.385207      0.066997      0.325506 
8       -0.055431      1.076949     -0.436714 
6        1.480811     -0.749615     -0.352645 
6        1.938844     -0.342581     -1.604154 
6        2.945990     -1.052128     -2.252597 
6        3.501910     -2.181463     -1.658656 
6        2.046635     -1.881626      0.240918 
6        3.047892     -2.596799     -0.408810 
1        1.636767      1.198353      1.635513 
1        1.099591     -0.313456      2.387385 
1       -0.038290      1.053251      2.197968 
1        1.484992      0.541490     -2.039683 
1        3.298134     -0.721604     -3.225961 
1        4.287528     -2.735958     -2.164070 
1        1.712721     -2.213699      1.222326 
1        3.478325     -3.475615      0.063287 
7       -0.865622     -0.879314      0.556956 
6       -1.334652     -1.562965     -0.659263 
6       -3.233553     -2.844707     -1.732708 
6       -2.716602     -2.167467     -0.467005 
6       -4.617035     -3.455316     -1.552056 
1       -1.621997     -0.075040      0.812320 
1       -0.709380     -1.536158      1.318850 
1       -1.340539     -0.792119     -1.436343 
1       -0.604437     -2.324104     -0.952136 
1       -2.523875     -3.622673     -2.043330 
1       -3.256333     -2.111678     -2.549394 
1       -3.415992     -1.380083     -0.155895 
1       -2.692390     -2.899955      0.352763 
1       -4.965345     -3.933236     -2.472298 
1       -5.352953     -2.693225     -1.273851 
1       -4.614770     -4.215257     -0.763100 
8       -2.096515      1.274031      0.777442 
1       -1.107897      1.388812      0.112293 
1       -2.865384      1.425086      0.220412 
 
B 
6        0.791023      0.464546      1.669688 
6        0.348820     -0.036669      0.292790 
8       -0.005962      1.039158     -0.528733 
6        1.489598     -0.785594     -0.393412 
6        2.064858     -0.299203     -1.566674 
6        3.113616     -0.983577     -2.176553 
6        3.600233     -2.163401     -1.623490 
6        1.984268     -1.972256      0.155430 
6        3.030135     -2.657807     -0.452654 
1        1.648396      1.129603      1.547534 
1        1.086653     -0.356600      2.330595 
1       -0.025812      1.020496      2.139863 
1        1.679227      0.620780     -1.990695 
1        3.551877     -0.590720     -3.089922 
1        4.418194     -2.696398     -2.099653 
1        1.550347     -2.371812      1.070115 
1        3.401016     -3.578664     -0.011254 
7       -0.855314     -0.877371      0.490789 
6       -1.340272     -1.552489     -0.712114 
6       -3.256622     -2.885060     -1.710914 
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6       -2.705507     -2.180926     -0.475351 
6       -4.624636     -3.512500     -1.477016 
1       -2.029362      0.482687      0.944383 
1       -0.678211     -1.558158      1.224330 
1       -1.403007     -0.790492     -1.496448 
1       -0.632803     -2.315996     -1.071130 
1       -2.546852     -3.657897     -2.033984 
1       -3.317069     -2.166425     -2.538945 
1       -3.409841     -1.404986     -0.145007 
1       -2.640497     -2.901669      0.353115 
1       -4.996416     -4.010827     -2.377330 
1       -5.362794     -2.756781     -1.186738 
1       -4.586050     -4.258937     -0.676059 
8       -2.303889      1.431711      0.962333 
1       -0.759201      1.479464     -0.085206 
1       -3.078850      1.484532      0.395734 
 
C 
6        0.776923      0.485624      1.612394 
6        0.344658     -0.023207      0.236080 
8       -0.001563      1.134788     -0.572737 
6        1.471274     -0.810356     -0.429858 
6        2.102096     -0.366214     -1.590210 
6        3.154521     -1.090551     -2.147736 
6        3.582671     -2.271869     -1.553550 
6        1.897239     -2.008017      0.152868 
6        2.944680     -2.732404     -0.402865 
7       -0.812898     -0.844953      0.396081 
6       -1.416788     -1.365687     -0.825273 
6       -3.287712     -2.829269     -1.721365 
6       -2.630886     -2.218443     -0.488562 
6       -4.517350     -3.664108     -1.387373 
1        1.656850      1.132044      1.530090 
1        1.027158     -0.346639      2.272708 
1       -0.046978      1.054230      2.054443 
1        0.741399      1.748860     -0.545801 
1        1.748259      0.535262     -2.079863 
1        3.633033     -0.731742     -3.054714 
1        4.401994     -2.837515     -1.987771 
1        1.379223     -2.376549      1.033553 
1        3.262148     -3.662618      0.060037 
1       -1.508563     -0.314177      0.918396 
1       -1.711003     -0.565284     -1.523033 
1       -0.668915     -1.977432     -1.344019 
1       -2.554326     -3.450876     -2.252398 
1       -3.566648     -2.027898     -2.418557 
1       -3.367008     -1.601048      0.045950 
1       -2.325868     -3.010203      0.207869 
1       -4.970732     -4.091175     -2.287344 
1       -5.280273     -3.058880     -0.885497 
1       -4.262813     -4.493030     -0.717763 
8       -2.366162      1.711700      0.860865 
1       -1.617699      1.728839      0.239748 
1       -2.249299      2.488630      1.413547 
 
TSC-D 
6        0.723270      0.392256      1.748695 
6        0.362313     -0.324493      0.481510 
8       -0.003502      1.521980     -0.587057 
6        1.478572     -0.932090     -0.304076 
6        1.863592     -0.449659     -1.556034 
6        2.909226     -1.062026     -2.240901 
6        3.572590     -2.154441     -1.689044 
6        2.146606     -2.029123      0.250801 
6        3.187867     -2.638535     -0.441815 
7       -0.858754     -0.787173      0.386572 
6       -1.318249     -1.545360     -0.769076 
6       -3.255483     -2.887754     -1.694681 
6       -2.699886     -2.121423     -0.499826 
6       -4.637527     -3.471439     -1.431590 
1        1.586916      1.040607      1.598069 
1        0.985110     -0.348935      2.513826 
1       -0.130331      0.971776      2.103443 
1        0.544130      2.252316     -0.282191 
1        1.330096      0.407863     -1.952280 
1        3.206747     -0.680583     -3.213573 
1        4.387885     -2.627855     -2.228500 
1        1.845597     -2.413176      1.222086 
1        3.698835     -3.491594     -0.004895 
1       -1.583313     -0.000763      0.708143 
1       -1.354300     -0.879328     -1.642072 
1       -0.599917     -2.341141     -0.995445 
1       -2.561256     -3.694362     -1.967059 
1       -3.298762     -2.218519     -2.564090 
1       -3.376127     -1.297028     -0.238939 
1       -2.651958     -2.780133      0.377526 
1       -5.017811     -4.011148     -2.304225 
1       -5.357978     -2.683529     -1.186987 
1       -4.617219     -4.172215     -0.589728 
8       -2.126815      1.327661      0.509910 
1       -1.063570      1.589731     -0.062007 
1       -2.277951      1.879472      1.281852 
 
D 
6        0.607898      0.347122      1.722736 
6        0.162058     -0.472329      0.548302 
8        0.620598      2.687734     -0.452461 
6        1.256492     -1.148982     -0.213624 
6        2.142607     -0.361344     -0.956322 
6        3.182395     -0.962417     -1.658746 
Chapter VI. Materials and Methods 
 
 
151 
6        3.354022     -2.344072     -1.616192 
6        1.429587     -2.534845     -0.174665 
6        2.476980     -3.129038     -0.872789 
7       -1.080921     -0.510268      0.254219 
6       -1.569964     -1.248369     -0.894548 
6       -3.181360     -3.070452     -1.629442 
6       -2.527085     -2.352221     -0.454346 
6       -4.129681     -4.179109     -1.191264 
1        1.204029      1.194540      1.366438 
1        1.238337     -0.250653      2.388889 
1       -0.253853      0.723999      2.276682 
1        0.559820      3.090271     -1.322228 
1        1.989517      0.716007     -0.982019 
1        3.863871     -0.348218     -2.240634 
1        4.170502     -2.808823     -2.161399 
1        0.746170     -3.146420      0.408845 
1        2.607689     -4.206759     -0.834987 
1       -1.843125      1.118922      0.444247 
1       -2.120916     -0.533489     -1.520980 
1       -0.763592     -1.670240     -1.509183 
1       -2.402157     -3.488299     -2.280662 
1       -3.727415     -2.339736     -2.240885 
1       -3.296297     -1.916015      0.195562 
1       -1.978444     -3.076250      0.163644 
1       -4.588496     -4.677981     -2.050343 
1       -4.937233     -3.783365     -0.565756 
1       -3.603771     -4.941343     -0.605913 
8       -1.990401      2.086178      0.316219 
1       -0.311482      2.535817     -0.193142 
1       -2.189736      2.430286      1.191089 
 
E-Isomer 
C’ 
6        1.864655     -0.248751      1.210404 
6        0.882296      0.040790      0.075469 
8        0.262675      1.330711      0.325362 
6        1.654328      0.228100     -1.229684 
6        1.946151     -0.874066     -2.035841 
6        2.693986     -0.720034     -3.199641 
6        3.159619      0.537629     -3.572906 
6        2.130089      1.487367     -1.605601 
6        2.874442      1.640144     -2.772110 
7       -0.067250     -1.021273     -0.092206 
6       -0.761774     -1.583420      1.051649 
6       -2.573311     -1.437198      2.830954 
6       -1.693488     -0.663999      1.853801 
6       -3.483375     -0.540930      3.660692 
1        2.615396      0.543025      1.246703 
1        2.368098     -1.204301      1.044392 
1        1.359503     -0.287052      2.182018 
1       -0.166378      1.277409      1.186165 
1        1.565416     -1.846698     -1.741192 
1        2.909857     -1.586534     -3.818547 
1        3.740563      0.658394     -4.482838 
1        1.904781      2.345670     -0.981652 
1        3.232271      2.626066     -3.055750 
1       -0.725697     -0.741070     -0.818822 
1       -1.363048     -2.415333      0.663862 
1       -0.030733     -2.042741      1.728537 
1       -1.936703     -2.035122      3.497245 
1       -3.180888     -2.157481      2.267211 
1       -2.322314     -0.092076      1.158344 
1       -1.107125      0.069174      2.431082 
1       -4.109842     -1.125803      4.341000 
1       -4.148184      0.048005      3.019705 
1       -2.902606      0.162271      4.267942 
8       -1.537042      0.957323     -1.830070 
1       -0.941687      1.005416     -2.584592 
1       -1.016985      1.354001     -1.110630 
 
TSC’-D’ 
6        1.821599     -0.080853      1.290200 
6        1.012982     -0.205619      0.032111 
8        0.088134      1.663712      0.087151 
6        1.718063      0.104823     -1.249427 
6        1.756220     -0.869805     -2.250848 
6        2.462030     -0.644905     -3.429723 
6        3.142054      0.553559     -3.616352 
6        2.404972      1.308417     -1.444853 
6        3.108979      1.529401     -2.620958 
7       -0.011950     -1.031382     -0.068635 
6       -0.664491     -1.617572      1.088109 
6       -2.513152     -1.435887      2.816525 
6       -1.685187     -0.701684      1.768063 
6       -3.520094     -0.532540      3.516899 
1        2.456784      0.802871      1.241261 
1        2.471242     -0.959236      1.385403 
1        1.194112     -0.018030      2.180831 
1       -0.350115      1.751263      0.941050 
1        1.236277     -1.808480     -2.088099 
1        2.484460     -1.411680     -4.198754 
1        3.695138      0.730225     -4.534493 
1        2.325783      2.084417     -0.691874 
1        3.626409      2.473024     -2.768176 
1       -0.742857     -0.563066     -0.837432 
1       -1.184443     -2.515355      0.732534 
1        0.082820     -1.963041      1.813199 
1       -1.844849     -1.889503      3.561533 
1       -3.041265     -2.270352      2.336120 
1       -2.337080     -0.272137      0.997444 
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1       -1.166787      0.142212      2.244299 
1       -4.107743     -1.084773      4.256578 
1       -4.218333     -0.090203      2.798457 
1       -3.019293      0.290467      4.038628 
8       -1.483903      0.491406     -1.301208 
1       -1.343587      0.653854     -2.238993 
1       -0.733232      1.230063     -0.640115 
 
D’ 
6        1.998909     -0.252335      1.373583 
6        1.269567     -0.660371      0.123479 
8       -0.158767      2.114325      0.509441 
6        1.827357     -0.178055     -1.170899 
6        1.648612     -0.940408     -2.332223 
6        2.141037     -0.494911     -3.553278 
6        2.813416      0.723626     -3.632722 
6        2.509383      1.040471     -1.259009 
6        2.991069      1.490195     -2.484378 
7        0.179119     -1.329727      0.056891 
6       -0.496012     -1.818437      1.239420 
6       -2.402271     -1.366158      2.859755 
6       -1.660342     -0.898606      1.612761 
6       -3.572373     -0.460278      3.221582 
1        3.074349     -0.181038      1.198187 
1        1.823791     -0.938420      2.203270 
1        1.623095      0.736525      1.663543 
1       -0.861641      2.649180      0.886970 
1        1.122684     -1.887042     -2.253878 
1        2.006139     -1.101758     -4.444207 
1        3.197767      1.073195     -4.586675 
1        2.620789      1.661197     -0.376140 
1        3.502116      2.446812     -2.542441 
1       -0.912616     -0.301924     -1.119598 
1       -0.887872     -2.816459      1.004817 
1        0.168238     -1.932407      2.107946 
1       -1.702147     -1.416258      3.704672 
1       -2.765487     -2.391435      2.706082 
1       -2.355770     -0.843857      0.765243 
1       -1.271344      0.118206      1.751056 
1       -4.091049     -0.812294      4.118624 
1       -4.304138     -0.417587      2.407769 
1       -3.233209      0.563592      3.413147 
8       -1.312712      0.513280     -1.490429 
1       -0.790592      0.681909     -2.281240 
1       -0.595397      1.626865     -0.218667 
 
4-Acetylbenzeneboronic acid and 
1-Butylamine 
 
Z-Isomer 
E 
6        1.358824       1.453834       1.940854  
6        1.507769       1.405888       0.449182  
8        0.665772       1.927457      -0.278102  
6        2.658462       0.689369      -0.170357  
6        2.833814       0.791295      -1.556095  
6        3.885686       0.137291      -2.178114  
6        4.785907      -0.647301      -1.441688  
6        3.549962      -0.090639       0.574528  
6        4.594624      -0.752863      -0.058301  
5        5.971917      -1.386760      -2.146457  
7       -1.419602      -0.296510       2.042876  
6       -1.669751      -1.006107       0.796370 
6       -3.306683      -1.662651      -1.052256  
6       -3.098669      -0.916022       0.260968  
6       -4.731105      -1.560992      -1.582897  
8        6.097566      -1.241164      -3.500630 
8        6.811215      -2.133351      -1.365617  
1        2.310334       1.417927       2.473059  
1        0.726216       0.603076       2.246028  
1        0.814686       2.360825       2.211947  
1        2.128306       1.394133      -2.118975  
1        4.020410       0.226997      -3.252360 
1        3.421385      -0.196719       1.646983  
1        5.278647      -1.36293 0      0.524671  
1       -2.032355      -0.65522 0      2.769389  
1       -0.981553      -0.605535       0.040457  
1       -1.393764      -2.061186       0.928652  
1       -3.041729      -2.719608      -0.913059  
1       -2.605808      -1.273798      -1.803238  
1       -3.352538       0.14561 0      0.130226  
1       -3.794745      -1.305131       1.019002  
1       -4.850583      -2.103057      -2.526275  
1       -5.012353      -0.517163      -1.761354  
1       -5.449937      -1.976052      -0.867713  
1        6.836215      -1.709519      -3.896963  
1        7.525677      -2.571214      -1.834508  
1       -1.6596 00      0.68814 0      1.908190 
8       -1.697916       2.563938       1.070176  
1       -2.38844 0      2.75538 0      0.430511  
1       -0.889971       2.441734       0.535917  
 
TSE-F 
6        1.280312      1.794370      2.175564 
6        0.867322      1.349395      0.766036 
8        0.422009      2.358820      0.006416 
6        1.960287      0.531420      0.086317 
6        2.427822      0.941879     -1.160735 
6        3.431056      0.225783     -1.804948 
6        3.990840     -0.922233     -1.229800 
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6        2.514848     -0.609639      0.675396 
6        3.510619     -1.326564      0.023900 
5        5.114523     -1.725043     -1.956207 
7       -0.381261      0.400255      1.001787 
6       -0.852716     -0.282443     -0.214133 
6       -2.752243     -1.566075     -1.283875 
6       -2.233471     -0.888677     -0.019022 
6       -4.133634     -2.180452     -1.099987 
8        5.546631     -1.270103     -3.174021 
8        5.608372     -2.844306     -1.337464 
1        2.122677      2.481418      2.071580 
1        1.591405      0.967923      2.824094 
1        0.450193      2.333608      2.641109 
1        1.983730      1.831503     -1.595167 
1        3.791539      0.557729     -2.775067 
1        2.174218     -0.945048      1.653706 
1        3.931511     -2.213114      0.490791 
1       -0.220030     -0.257561      1.761769 
1       -0.860852      0.489367     -0.990229 
1       -0.122178     -1.042443     -0.508985 
1       -2.041372     -2.341898     -1.597063 
1       -2.779044     -0.832426     -2.099871 
1       -2.933231     -0.102378      0.294079 
1       -2.206370     -1.621619      0.800268 
1       -4.483543     -2.658122     -2.019796 
1       -4.870684     -1.420625     -0.818531 
1       -4.127033     -2.941382     -0.311983 
1        6.240446     -1.793989     -3.581391 
1        6.300382     -3.302619     -1.820127 
1       -1.136705      1.200955      1.261142 
8       -1.615372      2.553880      1.228249 
1       -2.384418      2.702768      0.670861 
1       -0.628297      2.669087      0.560365 
 
F 
6        1.290296      1.731695      2.092698 
6        0.828437      1.235309      0.720284 
8        0.469467      2.314201     -0.095139 
6        1.956495      0.479303      0.022508 
6        2.530512      0.964163     -1.152454 
6        3.567159      0.269159     -1.767361 
6        4.061987     -0.927308     -1.235099 
6        2.442434     -0.715567      0.563483 
6        3.475793     -1.406199     -0.055052 
5        5.224672     -1.702908     -1.927392 
7       -0.377783      0.400446      0.931534 
6       -0.879655     -0.270231     -0.267013 
6       -2.812804     -1.594196     -1.244697 
6       -2.243558     -0.895368     -0.014383 
6       -4.178627     -2.220087     -0.994399 
8        5.755239     -1.178902     -3.077007 
8        5.654226     -2.869293     -1.348832 
1        2.149633      2.392428      1.961072 
1        1.589823      0.907489      2.747877 
1        0.482120      2.291168      2.573742 
1        2.152813      1.889722     -1.571766 
1        4.005683      0.659798     -2.681897 
1        2.009911     -1.114837      1.479244 
1        3.840360     -2.333362      0.379097 
1       -0.193719     -0.283362      1.660557 
1       -0.949749      0.493786     -1.048768 
1       -0.178918     -1.034987     -0.636276 
1       -2.108871     -2.367133     -1.580020 
1       -2.883167     -0.872621     -2.069394 
1       -2.941377     -0.118610      0.327766 
1       -2.169590     -1.618973      0.810848 
1       -4.563521     -2.714771     -1.891249 
1       -4.911494     -1.464155     -0.691493 
1       -4.130428     -2.969310     -0.196543 
1        6.468250     -1.691184     -3.465540 
1        6.372746     -3.309541     -1.808996 
1       -1.536998      1.762542      1.402254 
8       -1.813903      2.711224      1.425481 
1       -2.588705      2.763648      0.858570 
1       -0.274901      2.758224      0.358779 
 
G 
6        1.578734      0.298672      0.742606 
6        0.796473     -0.081543     -0.517938 
6        1.621837      0.207047     -1.768689 
6        2.806775     -0.505823     -1.983833 
6        3.601717     -0.234334     -3.088286 
6        3.244337      0.754445     -4.017084 
6        1.247969      1.180843     -2.693822 
6        2.050658      1.450173     -3.798948 
7        0.460915     -1.465709     -0.440309 
6       -0.212878     -2.109172     -1.558247 
6       -2.332084     -2.621568     -2.859956 
6       -1.693414     -1.778388     -1.761911 
6       -3.809233     -2.312637     -3.068537 
5        4.142544      1.059813     -5.256003 
8        3.731977      2.038211     -6.123289 
8        5.294106      0.333465     -5.409443 
1        1.838788      1.362560      0.730791 
1        2.504779     -0.275037      0.807272 
1        0.968577      0.091257      1.627334 
1        3.084574     -1.288978     -1.284002 
1        4.518369     -0.797143     -3.242930 
1        0.312105      1.713680     -2.559543 
1        1.744966      2.211195     -4.511966 
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1        0.345583     -1.877864     -2.472511 
1       -0.112484     -3.192810     -1.408129 
1       -2.209949     -3.686856     -2.620123 
1       -1.787968     -2.460800     -3.800546 
1       -1.801336     -0.712984     -1.993962 
1       -2.226205     -1.942787     -0.814005 
1       -4.243069     -2.929378     -3.861905 
1       -3.957501     -1.262808     -3.344284 
1       -4.383985     -2.496172     -2.153765 
1        4.316231      2.189482     -6.870035 
1        5.814524      0.554352     -6.185505 
8       -0.420493      0.724355     -0.528492 
1       -0.167248      1.639792     -0.358398 
1       -0.037792     -1.634374      0.430797 
8       -1.592381     -0.574789      1.671763 
1       -2.478441     -0.902989      1.497504 
1       -1.386392     -0.003918      0.910625 
 
TSG-H 
6        1.576764      0.255351      0.872218 
6        1.030198     -0.347349     -0.386982 
6        1.722520      0.005262     -1.661894 
6        2.962245     -0.591259     -1.922415 
6        3.653982     -0.278474     -3.085759 
6        3.135526      0.634438     -4.013390 
6        1.189565      0.917774     -2.574247 
6        1.895051      1.221517     -3.733612 
7        0.321713     -1.441334     -0.281274 
6       -0.201606     -2.169783     -1.425620 
6       -2.166940     -2.512419     -2.983982 
6       -1.634740     -1.765132     -1.766692 
6       -3.604529     -2.138365     -3.321598 
5        3.917927      0.985086     -5.319328 
8        3.353802      1.887029     -6.180778 
8        5.123441      0.369601     -5.527974 
1        1.775604      1.318086      0.731920 
1        2.532158     -0.236144      1.098487 
1        0.887873      0.099810      1.704320 
1        3.379302     -1.304456     -1.215698 
1        4.613988     -0.747473     -3.283016 
1        0.227876      1.362492     -2.340645 
1        1.476357      1.931165     -4.442114 
1        0.453425     -2.008688     -2.287388 
1       -0.163104     -3.238753     -1.182005 
1       -2.100528     -3.595463     -2.810585 
1       -1.521061     -2.303333     -3.847382 
1       -1.664598     -0.681365     -1.927132 
1       -2.278282     -1.960191     -0.899238 
1       -3.963404     -2.678144     -4.203330 
1       -3.694219     -1.066200     -3.525748 
1       -4.279059     -2.372209     -2.490689 
1        3.866729      2.074497     -6.970480 
1        5.570312      0.613686     -6.341991 
8       -0.719820      1.018306     -0.362417 
1       -0.541987      1.892069      0.001209 
1       -0.357814     -1.359714      0.582381 
8       -1.301489     -0.518645      1.390828 
1       -2.217345     -0.809051      1.375090 
1       -1.128145      0.336254      0.539248 
 
H 
6        1.658999      0.176358      0.824701 
6        1.252911     -0.598590     -0.392650 
6        1.943598     -0.211548     -1.662900 
6        3.128721     -0.837231     -2.058787 
6        3.766178     -0.442482     -3.229198 
6        3.243923      0.583610     -4.027600 
6        1.409325      0.819742     -2.442952 
6        2.057685      1.203424     -3.611552 
7        0.330259     -1.476532     -0.297139 
6       -0.148166     -2.182980     -1.471082 
6       -2.154254     -2.534758     -2.985885 
6       -1.604407     -1.820237     -1.756505 
6       -3.611381     -2.191136     -3.267121 
5        3.965058      1.024748     -5.340071 
8        3.399918      2.031780     -6.076742 
8        5.124496      0.380289     -5.683486 
1        1.310338      1.208137      0.702480 
1        2.748724      0.202659      0.924317 
1        1.208731     -0.243435      1.726051 
1        3.546050     -1.636179     -1.450767 
1        4.685535     -0.934356     -3.535082 
1        0.492632      1.304894     -2.113564 
1        1.640089      2.002071     -4.218841 
1        0.462740     -1.983498     -2.361676 
1       -0.080327     -3.258700     -1.259818 
1       -2.050434     -3.620589     -2.854995 
1       -1.540733     -2.274209     -3.858312 
1       -1.681991     -0.732742     -1.881912 
1       -2.217103     -2.073242     -0.880231 
1       -3.981104     -2.708068     -4.158024 
1       -3.737884     -1.115249     -3.428255 
1       -4.254647     -2.475932     -2.427080 
1        3.877245      2.269602     -6.875185 
1        5.533391      0.685393     -6.496883 
8       -1.194020      1.548104     -0.395424 
1       -1.407303      2.390808      0.012477 
1       -0.849366     -1.025669      0.985255 
8       -1.490396     -0.471874      1.497236 
1       -2.331854     -0.930490      1.422718 
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1       -1.369488      0.884585      0.302782 
 
E-Isomer 
G’ 
6        1.788428     -0.226097      1.002696 
6        0.802978      0.184370     -0.091552 
6        1.562236      0.402261     -1.398995 
6        1.776215     -0.666259     -2.273033 
6        2.512752     -0.484576     -3.437879 
6        3.058275      0.762935     -3.767988 
6        2.106191      1.651799     -1.711919 
6        2.838646      1.824921     -2.880954 
7       -0.209785     -0.810537     -0.297125 
6       -0.911931     -1.399364      0.827905 
6       -2.673866     -1.260532      2.656362 
6       -1.775457     -0.479462      1.702695 
6       -3.515522     -0.367809      3.558852 
5        3.881885      0.961347     -5.078437 
8        4.386276      2.208429     -5.340003 
8        4.057104     -0.122863     -5.898054 
1        2.584634      0.517952      1.068433 
1        2.231679     -1.197535      0.770518 
1        1.299137     -0.292484      1.980864 
1        1.344116     -1.631362     -2.028255 
1        2.668600     -1.323506     -4.110871 
1        1.942675      2.484336     -1.035816 
1        3.251007      2.802708     -3.115605 
1       -1.565931     -2.173841      0.407579 
1       -0.194325     -1.935947      1.461156 
1       -2.055628     -1.928656      3.271403 
1       -3.331494     -1.914350      2.068269 
1       -2.387788      0.163049      1.055750 
1       -1.138251      0.188287      2.304906 
1       -4.156021     -0.957736      4.221563 
1       -4.163051      0.290717      2.969881 
1       -2.884027      0.268318      4.188937 
1        4.886120      2.281299     -6.156546 
1        4.570032      0.046537     -6.691825 
8        0.263359      1.490877      0.244622 
1       -0.152082      1.411902      1.110063 
1       -0.864303     -0.452966     -0.992580 
8       -1.572731      1.344590     -1.906501 
1       -0.976559      1.392686     -2.660512 
1       -1.026374      1.670555     -1.171223 
TSG’-H’ 
6        1.755361     -0.023325      1.112943 
6        0.927387     -0.070770     -0.137819 
6        1.631666      0.257312     -1.415347 
6        1.617884     -0.679607     -2.453523 
6        2.324439     -0.439373     -3.626888 
6        3.068382      0.733593     -3.796191 
6        2.371304      1.435340     -1.573115 
6        3.073819      1.664704     -2.746697 
7       -0.131563     -0.850616     -0.254415 
6       -0.797605     -1.446815      0.889207 
6       -2.616179     -1.242756      2.647170 
6       -1.766147     -0.509879      1.615491 
6       -3.572066     -0.319766      3.392143 
5        3.865665      0.998942     -5.113059 
8        4.572583      2.167862     -5.210060 
8        3.814403      0.047374     -6.096899 
1        2.420578      0.839056      1.087995 
1        2.374893     -0.926718      1.164968 
1        1.142173      0.026543      2.014281 
1        1.058175     -1.600205     -2.321388 
1        2.306808     -1.175834     -4.425594 
1        2.334785      2.185917     -0.791396 
1        3.634668      2.587693     -2.864802 
1       -1.363973     -2.305412      0.508576 
1       -0.059435     -1.853810      1.591420 
1       -1.961700     -1.753637      3.366957 
1       -3.187877     -2.033822      2.143783 
1       -2.405674     -0.022281      0.869404 
1       -1.203456      0.290412      2.116093 
1       -4.177622     -0.870781      4.118211 
1       -4.255792      0.181073      2.698610 
1       -3.027583      0.459017      3.937468 
1        5.045266      2.291041     -6.036695 
1        4.318261      0.252409     -6.888103 
8        0.077316      1.828918     -0.003639 
1       -0.350901      1.895383      0.857206 
1       -0.849371     -0.328131     -0.998937 
8       -1.551630      0.772499     -1.419779 
1       -1.407008      0.960366     -2.352206 
1       -0.765014      1.456076     -0.738591 
 
H’ 
6        1.922625     -0.223567      1.258531 
6        1.204784     -0.586394     -0.012028 
6        1.822833     -0.133965     -1.289332 
6        1.621627     -0.875604     -2.461348 
6        2.174104     -0.455567     -3.663450 
6        2.938598      0.718134     -3.739934 
6        2.589508      1.035183     -1.353105 
6        3.129388      1.453851     -2.563326 
7        0.080626     -1.193989     -0.108885 
6       -0.647421     -1.652355      1.053792 
6       -2.549716     -1.108104      2.647785 
6       -1.758202     -0.666356      1.422459 
6       -3.665908     -0.136214      3.009230 
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5        3.558885      1.188514     -5.094353 
8        4.300575      2.339400     -5.094149 
8        3.324385      0.423167     -6.205488 
1        3.004803     -0.216169      1.112857 
1        1.683976     -0.898114      2.081891 
1        1.598707      0.785738      1.540343 
1        1.032318     -1.785804     -2.403241 
1        2.020501     -1.045442     -4.563101 
1        2.724149      1.641535     -0.463288 
1        3.708244      2.372368     -2.603513 
1       -1.097994     -2.619803      0.797283 
1       -0.007658     -1.822119      1.931706 
1       -1.868717     -1.218650      3.502555 
1       -2.974634     -2.105075      2.468278 
1       -2.433232     -0.554749      0.563995 
1       -1.309325      0.321853      1.584307 
1       -4.221901     -0.471211      3.890369 
1       -4.379206     -0.030608      2.184719 
1       -3.265362      0.859879      3.227087 
1        4.660804      2.593196     -5.947225 
1        3.724650      0.746995     -7.015961 
8       -0.105737      2.254685      0.360053 
1       -0.796932      2.821324      0.711825 
1       -0.923923     -0.110382     -1.313033 
8       -1.265846      0.726126     -1.694310 
1       -0.705697      0.866962     -2.464413 
1       -0.535458      1.793323     -0.388796 
 
2-Acetylbenzeneboronic acid and 
1-Butylamine 
 
Hypothetic Mechanism 1 
Z-Isomer 
I 
6        0.854547     -1.945101     -1.003922 
6        1.269959     -1.477102      0.349058 
8        0.731053     -1.914872      1.367853 
6        2.293517     -0.418412      0.520219 
7       -1.246787      0.546246     -1.240847 
6       -0.743351      1.913531     -1.265647 
6        2.482318      0.009713      1.845675 
6        3.953076      1.138222     -0.272620 
6        3.017303      0.144188     -0.534165 
6       -1.706411      2.979761     -0.744953 
6       -1.122982      4.388638     -0.770494 
6       -2.089323      5.447255     -0.254348 
6        3.428260      1.006794      2.084749 
5        1.620464     -0.640238      3.008539 
6        4.159295      1.565752      1.037114 
8        2.113338     -1.596428      3.860739 
8        0.486264      0.028446      3.425675 
1        1.700669     -2.063483     -1.684998 
1        0.175746     -1.169005     -1.409571 
1        0.309990     -2.885903     -0.913649 
1       -1.341941     -1.248237      1.475046 
1       -2.103530      0.492804     -1.784736 
1        0.180487      1.941293     -0.672557 
1       -0.448089      2.161053     -2.294815 
1        4.519257      1.580279     -1.086906 
1        2.848891     -0.184205     -1.555101 
1       -2.002836      2.719185      0.280551 
1       -2.628813      2.954517     -1.344203 
1       -0.819803      4.637432     -1.796870 
1       -0.202565      4.408243     -0.171339 
1       -1.644808      6.447204     -0.280480 
1       -2.384095      5.240809      0.780324 
1       -3.004160      5.474258     -0.856670 
1        3.594849      1.363337      3.098264 
1        4.889777      2.343552      1.242299 
1        2.910449     -2.011761      3.525136 
1        0.127729     -0.406235      4.207761 
8       -1.716560     -0.370531      1.615572 
1       -1.044248      0.034123      2.185534 
1       -1.499593      0.297473     -0.279536 
 
TSI-J 
6        0.786343     -2.089774     -1.043142 
6        1.093575     -1.270367      0.164994 
8        0.589955     -1.566080      1.267874 
6        2.157901     -0.256886      0.213497 
7       -0.694119      0.491333     -0.669536 
6       -0.329427      1.888800     -0.479667 
6        2.347100      0.193141      1.526439 
6        3.897761      1.167390     -0.606321 
6        2.917107      0.214726     -0.857202 
6       -1.491702      2.878255     -0.550223 
6       -1.062775      4.325474     -0.331705 
6       -2.221818      5.310917     -0.412040 
6        3.332362      1.151747      1.753873 
5        1.388215     -0.522827      2.593434 
6        4.101255      1.633366      0.694288 
8        1.908368     -1.441323      3.506573 
8        0.320817      0.234205      3.118165 
1        1.505638     -2.917669     -1.087539 
1        0.869476     -1.504657     -1.958194 
1       -0.215311     -2.512328     -0.961419 
1       -1.721228     -1.333196      1.641041 
1       -1.186359      0.382542     -1.552251 
1        0.161525      1.972315      0.497810 
1        0.431757      2.159395     -1.224600 
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1        4.504084      1.551947     -1.421097 
1        2.748641     -0.146223     -1.867992 
1       -2.243523      2.596445      0.199697 
1       -1.986089      2.787437     -1.529210 
1       -0.299675      4.593914     -1.075164 
1       -0.573220      4.411463      0.647442 
1       -1.888040      6.340650     -0.249988 
1       -2.983903      5.085587      0.341903 
1       -2.708347      5.269465     -1.392912 
1        3.506553      1.529347      2.758403 
1        4.867922      2.381201      0.879327 
1        2.732978     -1.827593      3.206536 
1        0.108492     -0.127792      3.985487 
8       -2.060817     -0.443175      1.786761 
1       -1.316515     -0.036984      2.269068 
1       -1.337612      0.204406      0.075272 
 
J 
6        0.651167     -1.757932     -1.121987 
6        0.755712     -0.695201     -0.042149 
8        0.466717     -1.195810      1.181592 
6        2.081013      0.030640      0.052578 
7       -0.405057      0.358956     -0.379743 
6       -0.150449      1.805705     -0.160460 
6        2.395828      0.214130      1.400949 
6        4.102118      1.095201     -0.653230 
6        2.906018      0.458764     -0.982924 
6       -1.407371      2.615719     -0.438967 
6       -1.189125      4.104965     -0.186608 
6       -2.434664      4.936105     -0.464521 
6        3.594335      0.858418      1.705810 
5        1.192605     -0.423156      2.301857 
6        4.442077      1.292096      0.685760 
8        1.529348     -1.254450      3.408641 
8        0.228476      0.599576      2.784831 
1        1.395220     -2.528512     -0.913010 
1        0.842435     -1.356471     -2.122848 
1       -0.337666     -2.227542     -1.101463 
1       -2.026240     -1.033309      1.794926 
1       -0.737392      0.214454     -1.332427 
1        0.162728      1.907847      0.882619 
1        0.681651      2.112092     -0.799760 
1        4.773755      1.430134     -1.438899 
1        2.645575      0.297705     -2.027790 
1       -2.222310      2.246715      0.196662 
1       -1.726506      2.467843     -1.481914 
1       -0.358703      4.462974     -0.809290 
1       -0.873890      4.248392      0.854446 
1       -2.255663      5.997551     -0.269959 
1       -3.270537      4.617939      0.167412 
1       -2.752961      4.838735     -1.508283 
1        3.880398      1.016642      2.743931 
1        5.380502      1.783644      0.930668 
1        2.263045     -1.828436      3.181173 
1        0.324928      0.640286      3.740722 
8       -2.078491     -0.075438      1.696291 
1       -1.296263      0.218886      2.244762 
1       -1.175015      0.088739      0.304282 
 
TSJ-K 
6        0.634530     -1.624081     -1.180672 
6        0.692558     -0.610051     -0.048408 
8        0.462491     -1.248745      1.159819 
6        2.033159      0.091791      0.095054 
7       -0.452609      0.388114     -0.269174 
6       -0.165380      1.834373     -0.241742 
6        2.396981      0.128750      1.443112 
6        4.048485      1.211712     -0.548040 
6        2.837403      0.622080     -0.908977 
6       -1.441344      2.632094     -0.471455 
6       -1.199763      4.137726     -0.424295 
6       -2.466163      4.946252     -0.673999 
6        3.607393      0.729919      1.784261 
5        1.241434     -0.631024      2.281070 
6        4.429489      1.266434      0.792906 
8        1.580865     -1.541351      3.323684 
8        0.287022      0.369862      2.968374 
1        1.402788     -2.381895     -1.017660 
1        0.805187     -1.157817     -2.156700 
1       -0.340180     -2.123983     -1.187405 
1       -1.946351     -0.863482      1.885140 
1       -0.918672      0.167573     -1.146445 
1        0.259738      2.066064      0.740210 
1        0.594490      2.098844     -0.986498 
1        4.700320      1.623291     -1.313913 
1        2.546951      0.574596     -1.957019 
1       -2.188167      2.351356      0.282139 
1       -1.870193      2.365921     -1.449576 
1       -0.437148      4.407595     -1.166721 
1       -0.778827      4.403419      0.553810 
1       -2.268759      6.021382     -0.629377 
1       -3.234634      4.717604      0.072184 
1       -2.888493      4.726671     -1.660773 
1        3.922835      0.772232      2.825011 
1        5.378155      1.724838      1.061049 
1        2.290548     -2.120724      3.041172 
1        0.318725      0.165529      3.909686 
8       -1.801550      0.088926      1.817174 
1       -0.849148      0.240781      2.470496 
1       -1.266819      0.186017      0.790178 
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K 
6        0.654656     -1.671355     -1.154619 
6        0.684746     -0.577446     -0.096417 
8        0.426245     -1.168949      1.155635 
6        2.046350      0.087016      0.055094 
7       -0.409446      0.391590     -0.399757 
6       -0.154402      1.827102     -0.244635 
6        2.413351      0.130446      1.402647 
6        4.078458      1.179857     -0.584917 
6        2.860197      0.605687     -0.946670 
6       -1.426466      2.623291     -0.503132 
6       -1.218908      4.126475     -0.349135 
6       -2.485200      4.929273     -0.617811 
6        3.631192      0.713479      1.747582 
5        1.253115     -0.617403      2.215670 
6        4.461427      1.234907      0.755428 
8        1.523434     -1.471584      3.319652 
8        0.278871      0.476579      2.964782 
1        1.383043     -2.442720     -0.898712 
1        0.893668     -1.279481     -2.148653 
1       -0.338502     -2.131918     -1.182144 
1       -2.040061     -0.865634      1.937127 
1       -0.765757      0.219306     -1.334531 
1        0.192609      2.003230      0.779598 
1        0.650972      2.180712     -0.905227 
1        4.735050      1.582855     -1.351358 
1        2.567764      0.563057     -1.993997 
1       -2.213998      2.284311      0.182121 
1       -1.789579      2.411451     -1.520396 
1       -0.421811      4.456130     -1.028647 
1       -0.857895      4.337473      0.665928 
1       -2.312627      6.002922     -0.496172 
1       -3.288447      4.641262      0.068982 
1       -2.849456      4.764780     -1.637933 
1        3.944371      0.757693      2.788980 
1        5.414962      1.683245      1.022373 
1        2.306027     -1.999054      3.152002 
1        0.289768      0.207256      3.892708 
8       -1.949941      0.087142      1.814978 
1       -0.675006      0.353411      2.586532 
1       -1.509424      0.138198      0.908723 
 
TSK-L 
6        0.672685     -1.694840     -1.176854 
6        0.693186     -0.574188     -0.146398 
8        0.407986     -1.156117      1.122479 
6        2.067663      0.060119      0.017252 
7       -0.374495      0.385539     -0.475463 
6       -0.146214      1.813838     -0.240121 
6        2.474472      0.023429      1.353549 
6        4.095695      1.165249     -0.611932 
6        2.863451      0.624154     -0.974252 
6       -1.422159      2.603433     -0.498850 
6       -1.239432      4.100695     -0.273491 
6       -2.509807      4.898106     -0.538983 
6        3.706525      0.573495      1.701409 
5        1.322768     -0.751637      2.106373 
6        4.514662      1.142623      0.718998 
8        1.427895     -1.539319      3.242625 
8        0.216500      0.740861      2.939881 
1        1.381090     -2.471916     -0.884993 
1        0.945291     -1.327363     -2.171352 
1       -0.327989     -2.136470     -1.220114 
1       -2.026401     -0.887179      1.922820 
1       -0.681575      0.244043     -1.431744 
1        0.165965      1.942737      0.801509 
1        0.671540      2.212164     -0.860039 
1        4.735775      1.606849     -1.370791 
1        2.542343      0.645171     -2.013526 
1       -2.221382      2.224376      0.150328 
1       -1.755516      2.432060     -1.533923 
1       -0.430088      4.471087     -0.916845 
1       -0.907743      4.270146      0.759124 
1       -2.355828      5.967519     -0.365542 
1       -3.325555      4.568936      0.113651 
1       -2.846282      4.774462     -1.574373 
1        4.049678      0.563675      2.734526 
1        5.477421      1.569909      0.985780 
1        2.285362     -1.422942      3.656321 
1        0.190834      0.418673      3.847241 
8       -2.068388      0.053294      1.715689 
1       -0.688791      0.551032      2.568689 
1       -1.597790      0.088891      0.843024 
 
L 
6        0.685790     -1.801225     -1.031972 
6        0.790343     -0.554478     -0.167303 
8        0.496824     -0.928730      1.189311 
6        2.207413      0.003524     -0.104375 
7       -0.231864      0.394749     -0.578106 
6       -0.097341      1.772731     -0.097341 
6        2.678671      0.034287      1.212209 
6        4.259206      0.948714     -0.887140 
6        2.984229      0.459411     -1.163095 
6       -1.324658      2.591785     -0.469098 
6       -1.269239      4.001270      0.111590 
6       -2.485271      4.840525     -0.257741 
6        3.956957      0.526592      1.475126 
5        1.506144     -0.566633      2.043318 
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6        4.744605      0.982595      0.422197 
8        1.336628     -0.785390      3.377128 
8       -0.906451      1.356397      3.085560 
1        1.368658     -2.568566     -0.662315 
1        0.945835     -1.580317     -2.071818 
1       -0.336958     -2.185889     -0.995153 
1       -1.925940     -1.083757      1.642738 
1       -0.332550      0.374685     -1.587687 
1       -0.020262      1.737387      0.995506 
1        0.811640      2.259743     -0.483995 
1        4.884209      1.309332     -1.699312 
1        2.614377      0.441737     -2.185652 
1       -2.222080      2.081134     -0.098304 
1       -1.424078      2.646152     -1.564223 
1       -0.355566      4.504372     -0.233303 
1       -1.186670      3.924745      1.202927 
1       -2.426387      5.843551      0.175865 
1       -3.408516      4.375930      0.104843 
1       -2.576778      4.952586     -1.344135 
1        4.347396      0.558990      2.490107 
1        5.741537      1.368040      0.614814 
1        2.090473     -0.490841      3.893512 
1       -0.390435      0.664254      3.512539 
8       -2.334506     -0.300133      1.259931 
1       -1.528635      0.859456      2.520265 
1       -1.729397     -0.108122      0.512262 
 
M 
6        0.731939     -1.771278     -1.041925 
6        0.859929     -0.481767     -0.245891 
8        0.541006     -0.834070      1.158248 
6        2.286613      0.025805     -0.159325 
7       -0.031728      0.499424     -0.757327 
6       -0.060622      1.789629     -0.065739 
6        2.771751      0.006558      1.152144 
6        4.365088      0.898252     -0.948124 
6        3.065876      0.475875     -1.218163 
6       -1.267861      2.600835     -0.507807 
6       -1.345514      3.950199      0.199132 
6       -2.568570      4.761973     -0.206704 
6        4.075256      0.434684      1.408207 
5        1.576185     -0.515329      1.999335 
6        4.869910      0.875544      0.354868 
8        1.399245     -0.679929      3.342378 
1        1.389920     -2.540340     -0.631890 
1        0.992972     -1.593195     -2.087231 
1       -0.299615     -2.135099     -0.995917 
1       -0.971236      0.112193     -0.786983 
1       -0.099890      1.678224      1.028046 
1        0.861385      2.332023     -0.309087 
1        4.994150      1.254473     -1.759155 
1        2.665979      0.509409     -2.227653 
1       -2.178228      2.027119     -0.281954 
1       -1.241141      2.740412     -1.597031 
1       -0.434855      4.525713     -0.015610 
1       -1.352628      3.780756      1.283367 
1       -2.602029      5.724175      0.313693 
1       -3.493809      4.225043      0.029662 
1       -2.571711      4.965543     -1.283507 
1        4.477751      0.431110      2.419052 
1        5.886026      1.210165      0.542571 
1        2.171758     -0.412687      3.846417 
8       -0.915608      1.397776      3.335593 
1       -0.283303      0.729893      3.623741 
1       -1.525439      0.897520      2.768552 
8       -2.165605     -0.402832      1.477495 
1       -2.660581     -1.104538      1.909376 
1       -1.244893     -0.720185      1.433352 
 
TSM-N 
6        0.544730     -1.682670     -1.154996 
6        0.782186     -0.326844     -0.583583 
8        0.609137     -1.390588      1.740237 
6        2.180841      0.091395     -0.304585 
7       -0.227139      0.431283     -0.320286 
6       -0.145170      1.791569      0.199568 
6        2.586687      0.017332      1.047154 
6        4.362097      0.848184     -0.988150 
6        3.054563      0.493115     -1.312329 
6       -1.261429      2.645924     -0.387864 
6       -1.298139      4.031885      0.247392 
6       -2.412232      4.906599     -0.311951 
6        3.907000      0.376470      1.331960 
5        1.525013     -0.513840      2.127023 
6        4.789266      0.786602      0.334175 
8        1.569996     -0.013329      3.421670 
1        1.143777     -2.417155     -0.615914 
1        0.858653     -1.681491     -2.206552 
1       -0.511032     -1.953521     -1.099926 
1       -1.112240     -0.133291      0.089105 
1       -0.280714      1.739048      1.291353 
1        0.839505      2.212958     -0.022563 
1        5.044701      1.167980     -1.769866 
1        2.716916      0.541815     -2.344508 
1       -2.220326      2.141200     -0.211338 
1       -1.141984      2.727677     -1.476585 
1       -0.329930      4.528580      0.096878 
1       -1.421064      3.916720      1.331418 
1       -2.419037      5.893839      0.159615 
1       -3.393760      4.451232     -0.141612 
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1       -2.299077      5.054417     -1.391787 
1        4.264731      0.314040      2.358431 
1        5.811915      1.052436      0.586423 
1        2.220814      0.687408      3.516112 
8       -1.177831      1.173283      3.165635 
1       -0.398390      0.751319      3.551256 
1       -1.570691      0.463828      2.624032 
8       -1.650850     -0.796954      1.241718 
1       -2.288831     -1.510491      1.158280 
1       -0.512788     -1.200886      1.621164 
 
N 
6        0.641713     -1.661333     -1.386884 
6        0.802848     -0.320544     -0.737454 
8        0.830478     -1.564489      1.814170 
6        2.205974      0.069899     -0.376114 
7       -0.235233      0.375018     -0.472144 
6       -0.129510      1.694891      0.131373 
6        2.607336      0.007155      0.975549 
6        4.402301      0.855452     -1.014929 
6        3.104537      0.485196     -1.358688 
6       -1.219311      2.611487     -0.411543 
6       -1.261667      3.948587      0.319798 
6       -2.347149      4.878491     -0.206138 
6        3.914807      0.389664      1.294674 
5        1.577931     -0.465660      2.070894 
6        4.810813      0.806287      0.313867 
8        1.405871      0.225947      3.248384 
1        0.965704     -2.440848     -0.689927 
1        1.272490     -1.735906     -2.279789 
1       -0.401501     -1.824902     -1.663838 
1       -1.455237     -0.523568      0.631123 
1       -0.291775      1.599724      1.215283 
1        0.861401      2.146658     -0.018804 
1        5.093223      1.182387     -1.786746 
1        2.784650      0.532058     -2.396660 
1       -2.185722      2.102163     -0.302699 
1       -1.071117      2.766982     -1.488781 
1       -0.283882      4.442696      0.234436 
1       -1.418206      3.755886      1.388863 
1       -2.359951      5.828316      0.337389 
1       -3.338900      4.424638     -0.102587 
1       -2.197805      5.104626     -1.267974 
1        4.247675      0.342136      2.330103 
1        5.824065      1.088906      0.584223 
1        1.922398      1.037204      3.258627 
8       -1.384973      1.349364      3.239187 
1       -0.549377      0.992936      3.563839 
1       -1.723062      0.624772      2.686955 
8       -1.847386     -0.845978      1.474537 
1       -2.745248     -1.116049      1.264944 
1       -0.017330     -1.605171      2.277684 
 
E-Isomer 
M’  
6        1.811138     -2.261035     -1.113255 
6        1.506106     -0.853818     -0.617818 
8        0.505847     -1.020623      0.470672 
6        2.692296     -0.227641      0.092565 
7        1.042879      0.009159     -1.642786 
6        2.463517     -0.071340      1.462834 
6        4.872575      0.720542      0.318604 
6        3.884960      0.173628     -0.496762 
6        3.461139      0.481718      2.268164 
5        1.004802     -0.570659      1.660172 
6        4.666870      0.870429      1.693110 
8        0.189171     -0.575980      2.760519 
6       -0.085907     -0.433009     -2.449591 
6       -0.539504      0.692513     -3.368995 
6       -1.710456      0.296174     -4.260568 
6       -2.163054      1.424679     -5.178424 
1        0.895609     -2.761645     -1.436223 
1        2.256489     -2.849428     -0.308138 
1        2.510515     -2.218994     -1.952089 
1        0.830604      0.923557     -1.233426 
1        5.814028      1.041528     -0.118657 
1        4.031232      0.076897     -1.568411 
1        3.309117      0.616146      3.337555 
1        5.451102      1.300332      2.309607 
1        0.643040     -0.263426      3.546690 
1        0.218183     -1.293427     -3.059021 
1       -0.942687     -0.768725     -1.838238 
1        0.313049      1.006757     -3.985113 
1       -0.816098      1.562207     -2.757836 
1       -2.552236     -0.025909     -3.633191 
1       -1.430194     -0.577739     -4.864604 
1       -3.003155      1.118071     -5.809355 
1       -1.350370      1.746259     -5.839037 
1       -2.481830      2.298571     -4.600134 
8       -0.110476      2.320441     -0.145824 
1        0.434433      2.652611      0.572066 
1       -0.814038      1.793211      0.286253 
8       -1.876057      0.468169      0.922841 
1       -1.679001      0.305443      1.853520 
1       -1.353834     -0.227722      0.494130 
 
TSM’-N’ 
6        2.160586     -1.996120     -1.715764 
6        1.858114     -0.685183     -1.058330 
8        0.096147     -1.049949      1.244741 
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6        2.810090     -0.222076     -0.014003 
7        0.813843      0.002773     -1.343897 
6        2.400250      0.029050      1.311300 
6        5.106329      0.327022      0.531298 
6        4.151745     -0.082535     -0.390674 
6        3.394689      0.418879      2.218196 
5        0.872970     -0.119669      1.765214 
6        4.727129      0.567622      1.848373 
8        0.402001      0.838142      2.667482 
6       -0.258755     -0.400349     -2.243696 
6       -0.565899      0.705892     -3.247120 
6       -1.775232      0.366411     -4.111959 
6       -2.100654      1.460394     -5.120359 
1        1.564967     -2.758407     -1.198379 
1        3.210478     -2.258910     -1.588622 
1        1.903292     -2.018536     -2.776555 
1        0.454788      0.892190     -0.730203 
1        6.140759      0.447714      0.224016 
1        4.449475     -0.273050     -1.419118 
1        3.119105      0.589234      3.257825 
1        5.468960      0.865394      2.584070 
1        1.094106      1.456716      2.916066 
1       -0.018455     -1.337905     -2.749959 
1       -1.130059     -0.574734     -1.596111 
1        0.312599      0.880991     -3.882858 
1       -0.750584      1.635038     -2.694813 
1       -2.641566      0.193623     -3.460988 
1       -1.596445     -0.579860     -4.640888 
1       -2.974346      1.199027     -5.724885 
1       -1.262351      1.632763     -5.804423 
1       -2.315641      2.408415     -4.616167 
8       -0.440737      1.777476     -0.095769 
1       -0.108617      2.055547      0.765449 
1       -1.228148      1.013765      0.178092 
8       -1.928614     -0.050226      0.456803 
1       -2.595979      0.139881      1.121681 
1       -0.950538     -0.668525      0.988740 
 
N’(1) 
6        2.182197     -1.984048     -1.882835 
6        1.860090     -0.716984     -1.120774 
8        0.169602     -1.032769      1.487651 
6        2.853362     -0.290885     -0.091147 
7        0.802913     -0.018640     -1.283625 
6        2.458661      0.062676      1.214325 
6        5.170404      0.187442      0.457332 
6        4.204646     -0.232606     -0.449906 
6        3.453527      0.474339      2.111682 
5        0.956383      0.030407      1.698934 
6        4.795418      0.536063      1.750430 
8        0.475745      1.141783      2.388829 
6       -0.215326     -0.415475     -2.238036 
6       -0.474559      0.703132     -3.244574 
6       -1.606124      0.372726     -4.211952 
6       -1.862276      1.485018     -5.220543 
1        1.471150     -2.767469     -1.599079 
1        3.180943     -2.347825     -1.641473 
1        2.110580     -1.846203     -2.965758 
1       -0.228198      1.301181     -0.444987 
1        6.212113      0.239880      0.154298 
1        4.503839     -0.495185     -1.461486 
1        3.173305      0.730658      3.132518 
1        5.543301      0.850148      2.472888 
1        1.168691      1.803886      2.473569 
1        0.016093     -1.347367     -2.769531 
1       -1.132331     -0.600190     -1.660879 
1        0.449317      0.899708     -3.805378 
1       -0.709869      1.625324     -2.699290 
1       -2.522733      0.176161     -3.640371 
1       -1.374390     -0.559893     -4.744346 
1       -2.679271      1.228191     -5.901724 
1       -0.971833      1.681510     -5.827849 
1       -2.129910      2.419675     -4.716243 
8       -0.962119      1.795662     -0.012915 
1       -0.589662      1.999979      0.855640 
1       -1.995371      0.530240      0.654215 
8       -2.348731     -0.218195      1.191287 
1       -2.774030      0.199600      1.945452 
1       -0.795742     -0.843729      1.581459 
 
TSN’-O 
6        2.419365     -2.166576     -1.900507 
6        2.138719     -0.874744     -1.170173 
8       -0.146517     -0.518936      1.110974 
6        2.950424     -0.593333      0.046183 
7        1.243728     -0.035307     -1.536533 
6        2.371517     -0.032776      1.200953 
6        5.127288     -0.613451      1.127480 
6        4.320405     -0.880759      0.027571 
6        3.205396      0.222863      2.298034 
5        0.846210      0.351872      1.321866 
6        4.566308     -0.066116      2.275807 
8        0.568390      1.646544      1.777525 
6        0.463411     -0.373089     -2.716622 
6       -0.644652      0.629476     -2.994943 
6       -1.422852      0.305956     -4.265823 
6       -2.550045      1.293712     -4.538092 
1        3.197446     -2.755400     -1.415681 
1        2.707249     -1.984375     -2.942419 
1        1.508313     -2.775421     -1.927544 
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1       -0.267452      2.145013     -0.995385 
1        6.190102     -0.833682      1.085842 
1        4.770616     -1.297015     -0.869692 
1        2.772147      0.638762      3.206457 
1        5.182926      0.132859      3.147691 
1        1.390259      2.132326      1.899110 
1        1.123888     -0.433243     -3.597320 
1        0.014744     -1.373535     -2.610624 
1       -0.210071      1.635389     -3.083483 
1       -1.334971      0.644807     -2.142634 
1       -1.835738     -0.708819     -4.187355 
1       -0.732890      0.287395     -5.120559 
1       -3.093771      1.039697     -5.453136 
1       -2.164277      2.312649     -4.651370 
1       -3.270248      1.304968     -3.713252 
8       -0.818968      2.646349     -0.380160 
1       -0.335902      2.543365      0.458830 
1       -2.031305      1.487485      0.159690 
8       -2.469419      0.727847      0.608236 
1       -2.943366      1.113808      1.350108 
1       -1.048608     -0.118637      1.068754 
 
O 
6        2.800885     -1.793727     -2.357151 
6        2.303231     -1.022075     -1.181013 
8       -0.104734     -0.468433      1.173679 
6        3.154970     -0.756241     -0.010832 
7        1.118115     -0.538541     -1.030913 
6        2.428602     -0.095091      0.992878 
6        5.132369     -0.792042      1.335085 
6        4.494385     -1.112000      0.139916 
6        3.089771      0.216502      2.175672 
5        0.917790      0.200613      0.495346 
6        4.431750     -0.132876      2.345572 
8        0.648674      1.621214      0.239111 
6        0.001622     -0.701418     -1.937621 
6       -0.275086      0.561613     -2.751474 
6       -1.584138      0.456179     -3.526195 
6       -1.883274      1.701428     -4.350603 
1        3.741947     -1.358881     -2.707590 
1        2.096318     -1.809508     -3.188309 
1        3.017371     -2.824960     -2.057770 
1       -1.755083      3.196584     -0.735087 
1        6.175267     -1.057440      1.481781 
1        5.037395     -1.628595     -0.647845 
1        2.559910      0.723756      2.978271 
1        4.939277      0.106809      3.276534 
1        1.466344      2.113397      0.140651 
1        0.149657     -1.561931     -2.600002 
1       -0.869573     -0.915335     -1.308766 
1        0.562559      0.752721     -3.436957 
1       -0.316121      1.408041     -2.057861 
1       -2.395981      0.276533     -2.810409 
1       -1.552565     -0.420955     -4.187129 
1       -2.828148      1.605044     -4.893828 
1       -1.094315      1.893998     -5.086155 
1       -1.959758      2.589403     -3.712496 
8       -1.762910      2.754775      0.118322 
1       -0.837061      2.433901      0.246386 
1       -2.433507      1.185592      0.004054 
8       -2.600103      0.213243     -0.024256 
1       -3.293622      0.056593      0.622437 
1       -0.986428     -0.239960      0.828369 
 
Hypothetic Mechanism 2 
Z-Isomer 
P 
6        0.748629     -1.662019     -1.033026 
6        1.168646     -1.045013      0.259097 
8        0.367694     -0.956675      1.194201 
6        2.513694     -0.455884      0.458456 
7       -1.265135      0.750338     -1.772604 
6       -0.744385      1.967521     -1.157377 
6        2.667101      0.318833      1.624670 
6        4.817782     -0.077889     -0.150936 
6        3.579930     -0.647002     -0.425091 
6       -1.793929      2.913202     -0.576001 
6       -1.180732      4.127311      0.114278 
6       -2.220943      5.062178      0.718509 
6        3.918998      0.879940      1.877636 
5        1.433879      0.560606      2.596057 
6        4.986134      0.684618      1.001750 
8        1.311054     -0.069264      3.809730 
8        0.635630      1.643245      2.350604 
1        1.575173     -2.040917     -1.634328 
1        0.210223     -0.875917     -1.600611 
1        0.034729     -2.464347     -0.834924 
1       -1.477033     -0.801373      0.949598 
1       -1.879389      0.996589     -2.543622 
1       -0.060754      1.675543     -0.350852 
1       -0.134226      2.500580     -1.899108 
1        5.648794     -0.228747     -0.833307 
1        3.454020     -1.243298     -1.323084 
1       -2.407331      2.350310      0.141231 
1       -2.475503      3.243177     -1.374758 
1       -0.564172      4.682307     -0.606346 
1       -0.492992      3.777833      0.895260 
1       -1.754765      5.920224      1.213540 
1       -2.833702      4.541402      1.462890 
1       -2.899825      5.450457     -0.049136 
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1        4.066988      1.489137      2.766006 
1        5.952169      1.133023      1.217204 
1        1.894731     -0.826942      3.886546 
1       -0.059331      1.704332      3.014311 
8       -2.396612     -0.644017      0.673451 
1       -1.839928      0.262666     -1.081155 
1       -2.765967     -1.523478      0.558924 
 
TSP-Q 
6        0.522179     -1.954917     -0.802181 
6        0.870979     -0.909874      0.218048 
8        0.361513     -1.001275      1.372820 
6        2.150884     -0.162153      0.183932 
7       -0.403796      0.594310     -0.724154 
6       -0.261595      1.917785     -0.123650 
6        2.463966      0.356458      1.445998 
6        4.157412      0.740432     -0.766928 
6        2.979558      0.018010     -0.923052 
6       -1.364841      2.899160     -0.508672 
6       -1.176599      4.270660      0.132826 
6       -2.284229      5.252722     -0.226024 
6        3.649185      1.080623      1.577824 
5        1.390902      0.016305      2.590627 
6        4.488883      1.270308      0.481517 
8        1.685652     -0.905685      3.600180 
8        0.559895      1.063698      2.987072 
1        1.069593     -2.869977     -0.547458 
1        0.796845     -1.662860     -1.816962 
1       -0.547107     -2.168421     -0.752998 
1       -1.477431     -1.073716      1.264878 
1       -0.350972      0.644656     -1.737690 
1       -0.236018      1.783131      0.963873 
1        0.718426      2.315619     -0.413268 
1        4.819455      0.891695     -1.614741 
1        2.717557     -0.393709     -1.894573 
1       -2.335573      2.481875     -0.206930 
1       -1.401252      3.008145     -1.603105 
1       -0.205305      4.682217     -0.172340 
1       -1.124629      4.151535      1.222509 
1       -2.126410      6.226466      0.247801 
1       -3.262212      4.880169      0.097782 
1       -2.335889      5.414608     -1.308563 
1        3.922957      1.501442      2.542307 
1        5.410667      1.834821      0.595862 
1        2.318176     -1.563607      3.306264 
1        0.111993      0.810073      3.799848 
8       -2.337023     -0.952558      0.818871 
1       -1.299035      0.171162     -0.465312 
1       -2.755417     -1.816738      0.835445 
 
Q 
6        0.522403     -1.794922     -0.783026 
6        0.722359     -0.546508      0.066325 
8        0.311445     -0.723008      1.343498 
6        2.128945      0.007094      0.085455 
7       -0.243464      0.532599     -0.577460 
6       -0.158355      1.902368     -0.003395 
6        2.498142      0.317091      1.394080 
6        4.242825      0.722800     -0.776155 
6        2.973172      0.199003     -1.006430 
6       -1.345986      2.743143     -0.441114 
6       -1.272476      4.157508      0.128248 
6       -2.464268      5.014820     -0.276159 
6        3.775146      0.842197      1.599365 
5        1.291173     -0.004620      2.433796 
6        4.639883      1.040622      0.524561 
8        1.504285     -0.930438      3.495250 
8        0.660575      1.185848      2.923433 
1        1.141883     -2.589525     -0.363613 
1        0.816869     -1.649080     -1.827874 
1       -0.523175     -2.116715     -0.744424 
1       -1.439631     -0.706027      1.336403 
1       -0.107881      0.562535     -1.587732 
1       -0.119093      1.784495      1.087438 
1        0.791419      2.335598     -0.327853 
1        4.926036      0.877823     -1.606654 
1        2.669000     -0.058426     -2.020394 
1       -2.271945      2.259433     -0.102599 
1       -1.397284      2.796159     -1.539320 
1       -0.342150      4.635045     -0.205555 
1       -1.208594      4.097982      1.221483 
1       -2.390317      6.021876      0.144378 
1       -3.404394      4.576141      0.075209 
1       -2.532035      5.113904     -1.365274 
1        4.098517      1.096928      2.606054 
1        5.634676      1.445372      0.694140 
1        1.882412     -1.743643      3.155866 
1        0.236561      0.959753      3.756487 
8       -2.284982     -0.531330      0.854969 
1       -1.193200      0.152469     -0.369010 
1       -2.745154     -1.373768      0.815284 
 
TSQ-R 
6        0.546786     -1.764494     -0.830572 
6        0.671809     -0.521401      0.041703 
8        0.320569     -0.820848      1.361072 
6        2.069600      0.053313      0.099756 
7       -0.355957      0.477016     -0.473029 
6       -0.197890      1.878885     -0.025348 
6        2.476696      0.314157      1.408551 
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6        4.154245      0.839477     -0.785218 
6        2.885119      0.309412     -1.000795 
6       -1.409244      2.700664     -0.437024 
6       -1.284642      4.159148     -0.007089 
6       -2.493678      4.995634     -0.404537 
6        3.753925      0.844984      1.600972 
5        1.353117     -0.031571      2.510751 
6        4.587318      1.103104      0.514977 
8        1.600360     -0.984883      3.521154 
8        0.658374      1.103049      2.993330 
1        1.202530     -2.539148     -0.430136 
1        0.836039     -1.571362     -1.868681 
1       -0.481620     -2.140690     -0.815657 
1       -0.888180     -0.739991      1.421056 
1       -0.388598      0.437272     -1.489472 
1       -0.090190      1.856118      1.065282 
1        0.725338      2.295945     -0.442444 
1        4.808194      1.042598     -1.628746 
1        2.551675      0.099881     -2.015766 
1       -2.310354      2.260130      0.009135 
1       -1.543285      2.655623     -1.528887 
1       -0.375683      4.590885     -0.446064 
1       -1.145852      4.200347      1.080369 
1       -2.382067      6.035550     -0.083683 
1       -3.411011      4.604682      0.048798 
1       -2.636583      4.996812     -1.490918 
1        4.100874      1.059152      2.609207 
1        5.581009      1.513227      0.676224 
1        2.097274     -1.727726      3.173850 
1        0.226599      0.862489      3.818400 
8       -1.997561     -0.445754      1.066672 
1       -1.388894      0.031679      0.101399 
1       -2.506812     -1.232772      0.849091 
 
R 
6        0.544823     -1.745872     -0.829877 
6        0.631953     -0.483216      0.026636 
8        0.207347     -0.781529      1.333719 
6        2.061174      0.027521      0.171555 
7       -0.287777      0.514378     -0.557554 
6       -0.207203      1.869044      0.001314 
6        2.530053      0.362142      1.449930 
6        4.168989      0.693386     -0.812665 
6        2.875977      0.200611     -0.948780 
6       -1.394160      2.705141     -0.454648 
6       -1.349766      4.130357      0.086726 
6       -2.542684      4.968796     -0.353587 
6        3.837714      0.852160      1.564634 
5        1.629039      0.209936      2.747318 
6        4.654860      1.017021      0.451192 
8        1.786819     -0.820426      3.646887 
8        0.927295      1.307852      3.181724 
1        1.170275     -2.525664     -0.391368 
1        0.872007     -1.579386     -1.860610 
1       -0.491572     -2.096651     -0.848935 
1       -0.774126     -0.841675      1.338787 
1       -0.135546      0.550533     -1.561609 
1       -0.205696      1.778071      1.092210 
1        0.735908      2.365512     -0.272321 
1        4.796050      0.821376     -1.690601 
1        2.506118     -0.049505     -1.940748 
1       -2.321549      2.214203     -0.131292 
1       -1.426711      2.736857     -1.554448 
1       -0.418839      4.613886     -0.237669 
1       -1.305914      4.095982      1.182839 
1       -2.489727      5.984744      0.049530 
1       -3.484622      4.524752     -0.013431 
1       -2.591183      5.046998     -1.445519 
1        4.221910      1.116380      2.547484 
1        5.665179      1.399727      0.566227 
1        2.256039     -1.558681      3.252720 
1        0.507128      1.107434      4.024692 
8       -2.433084     -0.557747      0.725367 
1       -1.885531     -0.123835      0.022859 
1       -2.883619     -1.292021      0.298994 
 
S 
6       -0.408850     -3.405021     -2.478250 
6       -0.444552     -2.026270     -1.809720 
8        1.406787     -1.729515      2.497190 
6        0.959841     -1.621046     -1.334671 
7       -0.951590     -1.083203     -2.742144 
6       -1.018557      0.333571     -2.418229 
6        1.417911     -1.494395     -0.001646 
6        3.199280     -1.140991     -2.179853 
6        1.860689     -1.431006     -2.392989 
6       -2.100381      0.779473     -1.430589 
6       -2.255780      2.296417     -1.393252 
6       -3.309472      2.763493     -0.397298 
6        2.791131     -1.218548      0.176584 
5        0.640020     -1.492261      1.385342 
6        3.674598     -1.044916     -0.877237 
8       -0.671102     -1.200120      1.602698 
8       -1.390376     -2.169426     -0.690885 
1       -0.035504     -4.162987     -1.781271 
1        0.247737     -3.398402     -3.349041 
1       -1.422633     -3.671711     -2.793642 
1        0.861612     -1.633199      3.284652 
1       -1.821998     -1.417074     -3.144990 
1       -0.032009      0.648263     -2.059123 
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1       -1.177362      0.860970     -3.368202 
1        3.863488     -0.994019     -3.026997 
1        1.478646     -1.495382     -3.407388 
1       -1.856320      0.422888     -0.422624 
1       -3.053899      0.309218     -1.706191 
1       -2.512948      2.658759     -2.397981 
1       -1.288446      2.754416     -1.145636 
1       -3.403338      3.853925     -0.391679 
1       -3.058619      2.445844      0.620623 
1       -4.292917      2.345848     -0.639509 
1        3.159417     -1.131654      1.193491 
1        4.721084     -0.828071     -0.682657 
1       -1.151015     -1.193682      0.757313 
1       -1.165613     -2.981486     -0.217843 
8       -3.659615     -2.302307     -2.386117 
1       -4.463106     -2.758980     -2.125384 
1       -3.092936     -2.283423     -1.598548 
 
TSS-M’’ 
6       -0.448297     -3.176849     -3.047232 
6       -0.202634     -1.935468     -2.241594 
8        0.668356      0.519540      1.373790 
6        1.131894     -1.737351     -1.626347 
7       -1.062647     -0.968292     -2.419302 
6       -1.004367      0.427749     -2.008053 
6        1.358778     -1.103843     -0.381732 
6        3.524275     -2.035188     -1.955117 
6        2.215863     -2.204574     -2.386483 
6       -2.224894      0.832736     -1.189660 
6       -2.119269      2.280169     -0.720523 
6       -3.342462      2.724997      0.070774 
6        2.692999     -0.950153      0.020152 
5        0.266321     -0.613606      0.680820 
6        3.764920     -1.401862     -0.742002 
8       -0.894128     -1.196189      0.940932 
8       -1.455352     -2.975859     -0.565809 
1        0.006363     -4.043219     -2.570734 
1       -0.012582     -3.046382     -4.046177 
1       -1.521676     -3.331548     -3.154591 
1       -0.005932      0.705271      2.036331 
1       -1.989518     -1.291463     -2.737456 
1       -0.080240      0.604473     -1.456314 
1       -0.953834      1.029971     -2.925609 
1        4.346084     -2.396255     -2.566313 
1        2.039516     -2.689436     -3.341273 
1       -2.301733      0.163884     -0.326622 
1       -3.132111      0.691283     -1.791178 
1       -1.977776      2.944934     -1.584224 
1       -1.219408      2.383868     -0.100087 
1       -3.244591      3.760422      0.411096 
1       -3.488231      2.093684      0.953500 
1       -4.252299      2.657434     -0.535582 
1        2.880277     -0.453574      0.967394 
1        4.782846     -1.261179     -0.389123 
1       -1.166159     -2.060894      0.297595 
1       -1.296625     -3.841626     -0.178825 
8       -3.396539     -2.302205     -2.104707 
1       -3.958056     -3.024351     -2.394966 
1       -2.775831     -2.675058     -1.398442 
 
M’’ 
6       -0.162540     -3.411492     -2.102398 
6       -0.048962     -1.962318     -1.642965 
8        0.420892     -1.713250      1.999463 
6        1.394434     -1.509794     -1.523997 
7       -0.835730     -1.147712     -2.475397 
6       -0.919242      0.283405     -2.250711 
6        1.808199     -1.378192     -0.195562 
6        3.572945     -0.902710     -2.291798 
6        2.261921     -1.270921     -2.583816 
6       -1.965018      0.739986     -1.229565 
6       -2.086398      2.257915     -1.151788 
6       -3.130916      2.723119     -0.145218 
6        3.124635     -1.010536      0.084342 
5        0.545609     -1.695081      0.647852 
6        4.004287     -0.776178     -0.967968 
8       -0.501683     -1.970112     -0.203906 
8       -3.200381     -2.269074      0.250888 
1        0.381945     -4.071524     -1.424192 
1        0.249082     -3.514256     -3.108979 
1       -1.216775     -3.702955     -2.123610 
1       -0.464364     -1.970021      2.276214 
1       -1.744460     -1.569036     -2.672853 
1        0.072235      0.647746     -1.957436 
1       -1.146428      0.760528     -3.213883 
1        4.269766     -0.707899     -3.102537 
1        1.918493     -1.358911     -3.610858 
1       -1.706228      0.340514     -0.240861 
1       -2.936490      0.306307     -1.507283 
1       -2.334401      2.651940     -2.146519 
1       -1.109269      2.686826     -0.891865 
1       -3.199378      3.814725     -0.109756 
1       -2.889396      2.374507      0.865283 
1       -4.124254      2.337059     -0.400083 
1        3.459146     -0.903984      1.112747 
1        5.031795     -0.487918     -0.764599 
1       -2.232236     -2.196905      0.125716 
1       -3.484749     -1.364703      0.415625 
8       -3.555992     -2.367881     -2.460079 
1       -3.890377     -3.205797     -2.788821 
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1       -3.570416     -2.441425     -1.482523 
 
Hypothetic Mechanism 3 
Z-Isomer 
T 
6       -0.433283     -3.417174     -2.105133 
6       -0.415253     -1.952373     -1.678346 
8        0.429775     -3.628394      1.285193 
6        1.002355     -1.527792     -1.315253 
7       -0.969353     -1.154865     -2.729084 
6       -1.075348      0.290816     -2.596908 
6        1.458642     -1.683550      0.003154 
6        3.174003     -0.706684     -1.998580 
6        1.864416     -1.058033     -2.308077 
6       -2.072199      0.855444     -1.572868 
6       -2.374887      2.330983     -1.818427 
6       -3.317618      2.930464     -0.783356 
6        2.779533     -1.314872      0.293845 
5        0.554145     -2.275516      1.156544 
6        3.633427     -0.827772     -0.690435 
8        0.072761     -1.485157      2.178155 
8       -1.224221     -1.943130     -0.457523 
1       -0.085285     -4.042244     -1.280252 
1        0.215050     -3.558298     -2.971561 
1       -1.455820     -3.704611     -2.370444 
1       -0.096879     -3.842502      2.062236 
1       -1.862781     -1.553827     -3.005329 
1       -0.077930      0.699769     -2.399854 
1       -1.365051      0.667187     -3.586463 
1        3.833777     -0.336865     -2.778579 
1        1.491086     -0.969400     -3.324445 
1       -1.670602      0.766940     -0.549543 
1       -3.001546      0.271674     -1.603300 
1       -2.810221      2.440226     -2.820590 
1       -1.434107      2.897861     -1.833759 
1       -3.526027      3.984011     -0.993082 
1       -2.890305      2.871641      0.223919 
1       -4.274492      2.397829     -0.766513 
1        3.152773     -1.424845      1.310212 
1        4.654148     -0.552114     -0.440436 
1        0.317881     -0.565083      2.055110 
1       -1.335017     -1.021839     -0.192263 
8       -3.645265     -2.309326     -1.845058 
1       -4.129677     -3.128114     -1.710931 
1       -2.939302     -2.316472     -1.175674 
 
TST-U 
6       -0.435373     -3.433460     -2.115772 
6       -0.297662     -1.949619     -1.977758 
8        0.339714     -3.635449      0.987740 
6        1.008996     -1.439221     -1.489168 
7       -1.112171     -1.200169     -2.695721 
6       -1.147259      0.256359     -2.729100 
6        1.307255     -1.616286     -0.129919 
6        3.193288     -0.536032     -1.947619 
6        1.934057     -0.914453     -2.398918 
6       -2.032927      0.865637     -1.643559 
6       -2.305132      2.345758     -1.892877 
6       -3.141719      2.982273     -0.790742 
6        2.582451     -1.225118      0.284880 
5        0.117537     -2.223031      0.817239 
6        3.515023     -0.690912     -0.600571 
8       -0.153211     -1.466386      2.021716 
8       -1.160549     -1.993910     -0.031928 
1       -0.092770     -3.916862     -1.195991 
1        0.213434     -3.746618     -2.942279 
1       -1.467456     -3.715894     -2.333677 
1       -0.301747     -3.947469      1.633848 
1       -1.995014     -1.656023     -2.922107 
1       -0.125136      0.630391     -2.646404 
1       -1.522761      0.540456     -3.718770 
1        3.919779     -0.127957     -2.644266 
1        1.680877     -0.822626     -3.453238 
1       -1.535172      0.753076     -0.671948 
1       -2.977191      0.308862     -1.588474 
1       -2.816092      2.461413     -2.858228 
1       -1.351119      2.881606     -1.986164 
1       -3.331367      4.040114     -0.995068 
1       -2.635357      2.915606      0.177929 
1       -4.111056      2.482168     -0.691946 
1        2.858055     -1.339786      1.331761 
1        4.498338     -0.394952     -0.244038 
1        0.633265     -1.440695      2.570896 
1       -1.430049     -1.102048      0.222318 
8       -3.407763     -2.390094     -1.551396 
1       -4.029902     -3.096044     -1.359451 
1       -2.728809     -2.434611     -0.846929 
 
U 
6       -0.450320     -3.499244     -2.170726 
6       -0.220525     -2.040272     -2.229913 
8        0.168196     -3.573719      0.757901 
6        1.039728     -1.499741     -1.687413 
7       -1.139959     -1.268830     -2.720268 
6       -1.134507      0.189477     -2.768852 
6        1.179546     -1.522947     -0.284454 
6        3.188434     -0.462189     -2.014315 
6        2.014354     -0.979390     -2.546579 
6       -2.100357      0.784580     -1.750333 
6       -2.124749      2.307327     -1.821471 
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6       -3.081472      2.918571     -0.805793 
6        2.363539     -0.954321      0.201601 
5        0.056765     -2.108332      0.784258 
6        3.355523     -0.445701     -0.631401 
8        0.248778     -1.556350      2.117502 
8       -1.326612     -1.666876      0.367449 
1       -0.286802     -3.811075     -1.120442 
1        0.327176     -3.990750     -2.765947 
1       -1.443501     -3.784475     -2.519734 
1       -0.543737     -3.916149      1.308554 
1       -2.059730     -1.714253     -2.819391 
1       -0.114115      0.530107     -2.585570 
1       -1.412390      0.481015     -3.788864 
1        3.958645     -0.069810     -2.671798 
1        1.859391     -0.991831     -3.623584 
1       -1.790856      0.440898     -0.757443 
1       -3.106662      0.380343     -1.917607 
1       -2.409290      2.626605     -2.833671 
1       -1.112239      2.696244     -1.651110 
1       -3.083960      4.010893     -0.866574 
1       -2.799168      2.641350      0.215164 
1       -4.107363      2.572208     -0.970962 
1        2.484532     -0.905969      1.280379 
1        4.263560     -0.028615     -0.203091 
1        0.786490     -2.176647      2.614101 
1       -1.665968     -1.225518      1.152929 
8       -3.269229     -2.277171     -1.399580 
1       -3.742991     -3.074582     -1.152274 
1       -2.604851     -2.122867     -0.678378 
 
V 
6       -0.463943     -3.351891     -2.600847 
6       -0.247080     -1.962989     -2.120693 
8       -0.655018     -2.978002      0.387196 
6        1.101071     -1.550368     -1.692938 
7       -1.249337     -1.157850     -2.017389 
6       -1.212227      0.229633     -1.553757 
6        1.342518     -1.504800     -0.302711 
6        3.357467     -0.910336     -2.242410 
6        2.084962     -1.287740     -2.651869 
6       -2.481380      0.951037     -1.977824 
6       -2.492795      2.398581     -1.497510 
6       -3.763231      3.139527     -1.892605 
6        2.646650     -1.132210      0.055182 
5        0.240589     -1.867445      0.891972 
6        3.633037     -0.830549     -0.879377 
8        0.925584     -2.294843      2.102056 
8       -0.598059     -0.719985      1.228888 
1       -0.230167     -4.006332     -1.755103 
1        0.241843     -3.569517     -3.408554 
1       -1.488434     -3.528934     -2.932449 
1       -0.839130     -3.458393      1.202095 
1       -2.179823     -1.605126     -2.025572 
1       -1.100052      0.201877     -0.457608 
1       -0.317040      0.697177     -1.975086 
1        4.124097     -0.686531     -2.978274 
1        1.851206     -1.359393     -3.712220 
1       -3.347592      0.421127     -1.558839 
1       -2.588017      0.923732     -3.071321 
1       -1.618043      2.923469     -1.903841 
1       -2.378262      2.413993     -0.406460 
1       -3.748502      4.173444     -1.535403 
1       -4.650108      2.654548     -1.471006 
1       -3.886206      3.165549     -2.980932 
1        2.880749     -1.088666      1.116666 
1        4.626595     -0.541190     -0.545917 
1        1.614815     -2.925540      1.880787 
1       -0.187225     -0.284383      1.979858 
8       -3.080736     -2.601662     -0.778660 
1       -3.489480     -3.469994     -0.795126 
1       -2.259998     -2.701021     -0.226100 
 
TSV-W 
6       -0.495013     -3.343744     -2.599848 
6       -0.268847     -1.958032     -2.120419 
8       -0.394295     -3.262344      0.346885 
6        1.084460     -1.539366     -1.712960 
7       -1.268140     -1.152238     -1.984202 
6       -1.213585      0.242513     -1.545897 
6        1.340989     -1.532138     -0.323886 
6        3.314974     -0.822128     -2.264104 
6        2.047835     -1.219188     -2.673685 
6       -2.465470      0.976974     -1.999061 
6       -2.452568      2.436897     -1.557681 
6       -3.706940      3.190272     -1.979777 
6        2.635286     -1.131927      0.033738 
5        0.269001     -2.014510      0.850402 
6        3.602332     -0.774605     -0.902223 
8        0.932696     -2.246372      2.122632 
8       -0.773801     -1.001092      1.084753 
1       -0.255509     -3.995571     -1.751769 
1        0.203958     -3.560343     -3.413772 
1       -1.521405     -3.515232     -2.931464 
1       -0.634266     -3.734364      1.151251 
1       -2.198462     -1.592126     -1.935499 
1       -1.118459      0.223861     -0.450320 
1       -0.305981      0.687218     -1.963820 
1        4.067584     -0.554729     -2.999943 
1        1.803008     -1.260596     -3.733064 
1       -3.346341      0.476206     -1.574584 
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1       -2.563162      0.922658     -3.092229 
1       -1.566011      2.934206     -1.972777 
1       -2.343298      2.480510     -0.466746 
1       -3.674806      4.232897     -1.650160 
1       -4.605148      2.733265     -1.550924 
1       -3.823318      3.189572     -3.069098 
1        2.874160     -1.105965      1.094432 
1        4.590241     -0.464722     -0.570384 
1        1.627144     -2.899765      2.011805 
1       -0.709004     -0.747635      2.009347 
8       -3.060033     -2.466066     -0.482463 
1       -3.223965     -3.411136     -0.544375 
1       -2.248541     -2.413117      0.066190 
 
W 
6       -0.507649     -3.350263     -2.685845 
6       -0.292343     -1.979730     -2.159760 
8       -0.398686     -3.368604      0.269238 
6        1.053420     -1.553511     -1.737592 
7       -1.298310     -1.190825     -1.975837 
6       -1.236245      0.201560     -1.532335 
6        1.279738     -1.557950     -0.341567 
6        3.281935     -0.792811     -2.233454 
6        2.030880     -1.208234     -2.673867 
6       -2.466784      0.954204     -2.015938 
6       -2.444101      2.414550     -1.576002 
6       -3.675767      3.185439     -2.032067 
6        2.558649     -1.137301      0.046422 
5        0.209178     -2.106347      0.809941 
6        3.538244     -0.751643     -0.865573 
8        0.872604     -2.352508      2.077363 
8       -0.868896     -1.126573      1.094904 
1       -0.226793     -4.041605     -1.884204 
1        0.166993     -3.513560     -3.532956 
1       -1.540426     -3.527597     -2.993941 
1       -0.584231     -3.891183      1.056942 
1       -2.223048     -1.638693     -1.852161 
1       -1.163165      0.186488     -0.436465 
1       -0.315154      0.636947     -1.928689 
1        4.045456     -0.505192     -2.950071 
1        1.808109     -1.242327     -3.738197 
1       -3.368231      0.468012     -1.618171 
1       -2.536065      0.898423     -3.110757 
1       -1.539768      2.897706     -1.968691 
1       -2.362344      2.459771     -0.482541 
1       -3.636861      4.227925     -1.702947 
1       -4.591952      2.742608     -1.627021 
1       -3.762945      3.184641     -3.124010 
1        2.778268     -1.117603      1.111406 
1        4.512231     -0.425641     -0.509184 
1        1.618843     -2.942595      1.949901 
1       -0.737749     -0.853859      2.007472 
8       -2.951101     -2.413643     -0.288914 
1       -2.190611     -3.024054     -0.182670 
1       -2.640024     -1.746426      0.350140 
 
TSW-N’ 
6       -0.505049     -3.305858     -2.602514 
6       -0.333952     -1.914830     -2.082671 
8       -0.686082     -3.044778      0.444391 
6        1.035018     -1.495712     -1.704763 
7       -1.375890     -1.192486     -1.870647 
6       -1.310295      0.199743     -1.439017 
6        1.336308     -1.508469     -0.324825 
6        3.274950     -0.825482     -2.300948 
6        1.986407     -1.183602     -2.678986 
6       -2.494136      0.971828     -2.006159 
6       -2.481977      2.435287     -1.577931 
6       -3.665588      3.222169     -2.125425 
6        2.651370     -1.151951      0.006736 
5        0.323407     -1.881382      0.915430 
6        3.604214     -0.809496     -0.948834 
8        1.005060     -2.466515      2.047835 
8       -0.446899     -0.743404      1.318736 
1       -0.171258     -4.011895     -1.836845 
1        0.137627     -3.440308     -3.479269 
1       -1.539425     -3.514146     -2.884583 
1       -0.703335     -3.595396      1.236049 
1       -2.321775     -1.850758     -1.373502 
1       -1.312940      0.212849     -0.341697 
1       -0.360511      0.640098     -1.761558 
1        4.012772     -0.564820     -3.054184 
1        1.712334     -1.203729     -3.731610 
1       -3.426020      0.497786     -1.669717 
1       -2.489304      0.905672     -3.102676 
1       -1.544773      2.902365     -1.908516 
1       -2.476016      2.489632     -0.481722 
1       -3.634771      4.267556     -1.803596 
1       -4.615386      2.796814     -1.783205 
1       -3.675856      3.211955     -3.220977 
1        2.924198     -1.141632      1.059533 
1        4.608576     -0.532728     -0.638663 
1        1.727866     -3.026837      1.757327 
1       -0.619992     -0.818790      2.261148 
8       -2.853850     -2.506073     -0.477963 
1       -3.263724     -3.305318     -0.823269 
1       -1.850003     -2.781360      0.059386 
 
N’(3) 
6       -0.546407     -3.179416     -2.361125 
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6       -0.471318     -1.766087     -1.862692 
8       -0.782459     -4.624005      0.525993 
6        0.916479     -1.263650     -1.582091 
7       -1.553319     -1.115632     -1.675332 
6       -1.535184      0.260697     -1.220139 
6        1.458705     -1.338297     -0.282121 
6        3.017215     -0.407485     -2.435106 
6        1.702550     -0.812919     -2.644187 
6       -2.341058      1.136612     -2.174256 
6       -2.465522      2.576198     -1.687562 
6       -3.258268      3.459471     -2.642391 
6        2.793811     -0.949097     -0.104818 
5        0.645414     -1.833424      0.971863 
6        3.568075     -0.477452     -1.160039 
8        1.175082     -2.730331      1.870945 
8       -0.586587     -1.324631      1.216872 
1       -0.302210     -3.875057     -1.546735 
1        0.172649     -3.340052     -3.171290 
1       -1.555190     -3.395873     -2.719273 
1       -0.270490     -4.287269      1.268084 
1       -2.592231     -2.242156     -0.556061 
1       -1.996484      0.279148     -0.225564 
1       -0.517829      0.660564     -1.105137 
1        3.610977     -0.044879     -3.269328 
1        1.277355     -0.776864     -3.644128 
1       -3.337881      0.696026     -2.304150 
1       -1.867600      1.120136     -3.165348 
1       -1.462814      2.999805     -1.541676 
1       -2.942331      2.582468     -0.698211 
1       -3.337630      4.485253     -2.269328 
1       -4.275111      3.076653     -2.782570 
1       -2.783932      3.500433     -3.629126 
1        3.232346     -0.996399      0.890543 
1        4.595041     -0.168323     -0.988648 
1        2.009886     -3.093983      1.562416 
1       -1.040852     -1.754463      1.948808 
8       -2.923777     -2.834777      0.151864 
1       -3.665036     -3.303016     -0.242266 
1       -1.558766     -4.033930      0.469611 
 
E-Isomer 
T’ 
6        0.544823     -1.745872     -0.829877 
6        0.631953     -0.483216      0.026636 
8        0.207347     -0.781529      1.333719 
6        2.061174      0.027521      0.171555 
7       -0.287777      0.514378     -0.557554 
6       -0.207203      1.869044      0.001314 
6        2.530053      0.362142      1.449930 
6        4.168989      0.693386     -0.812665 
6        2.875977      0.200611     -0.948780 
6       -1.394160      2.705141     -0.454648 
6       -1.349766      4.130357      0.086726 
6       -2.542684      4.968796     -0.353587 
6        3.837714      0.852160      1.564634 
5        1.629039      0.209936      2.747318 
6        4.654860      1.017021      0.451192 
8        1.786819     -0.820426      3.646887 
8        0.927295      1.307852      3.181724 
1        1.170275     -2.525664     -0.391368 
1        0.872007     -1.579386     -1.860610 
1       -0.491572     -2.096651     -0.848935 
1       -0.774126     -0.841675      1.338787 
1       -0.135546      0.550533     -1.561609 
1       -0.205696      1.778071      1.092210 
1        0.735908      2.365512     -0.272321 
1        4.796050      0.821376     -1.690601 
1        2.506118     -0.049505     -1.940748 
1       -2.321549      2.214203     -0.131292 
1       -1.426711      2.736857     -1.554448 
1       -0.418839      4.613886     -0.237669 
1       -1.305914      4.095982      1.182839 
1       -2.489727      5.984744      0.049530 
1       -3.484622      4.524752     -0.013431 
1       -2.591183      5.046998     -1.445519 
1        4.221910      1.116380      2.547484 
1        5.665179      1.399727      0.566227 
1        2.256039     -1.558681      3.252720 
1        0.507128      1.107434      4.024692 
8       -2.433084     -0.557747      0.725367 
1       -1.885531     -0.123835      0.022859 
1       -2.883619     -1.292021      0.298994 
 
TST’-U’ 
6        0.592728     -2.355065     -1.461956 
6        0.007194     -1.019297     -1.142911 
8       -0.625287     -1.756059      0.899845 
6        0.858855      0.009692     -0.478900 
7       -1.084830     -0.598943     -1.715207 
6        0.616569      0.333306      0.863023 
6        2.662530      1.597563     -0.625988 
6        1.868572      0.624961     -1.225442 
6        1.437457      1.309975      1.433980 
5       -0.576619     -0.460614      1.645003 
6        2.445537      1.939382      0.707813 
8       -0.371641     -0.588124      3.068053 
8       -1.895358      0.211740      1.482646 
6       -5.136958     -0.547657     -4.614441 
6       -4.122105     -1.401609     -3.865573 
6       -3.055993     -0.566615     -3.165061 
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6       -2.038451     -1.429973     -2.433704 
1        1.273269     -2.645420     -0.664205 
1        1.158791     -2.276817     -2.399672 
1       -0.169634     -3.126467     -1.577487 
1       -1.529785     -2.078818      0.976430 
1       -1.425763      0.353246     -1.419809 
1        3.447973      2.083253     -1.198009 
1        2.032825      0.355544     -2.266836 
1        1.279741      1.561462      2.480790 
1        3.070265      2.694022      1.179222 
1        0.403897     -1.127440      3.234239 
1       -2.174891      0.475784      2.363804 
1       -5.896267     -1.166259     -5.101610 
1       -4.651345      0.055823     -5.388674 
1       -5.651459      0.139509     -3.934693 
1       -3.640939     -2.099568     -4.564079 
1       -4.640979     -2.022962     -3.123569 
1       -3.524798      0.121717     -2.451082 
1       -2.532204      0.060504     -3.898051 
1       -2.546120     -2.088190     -1.713810 
1       -1.505570     -2.071405     -3.144113 
8       -2.039343      1.687907     -0.639436 
1       -1.320774      2.322092     -0.550117 
1       -2.063593      1.221434      0.249343 
 
U’ 
6        0.756431     -2.242357     -1.729119 
6        0.160002     -0.920299     -1.410876 
8       -0.700939     -1.829646      0.928791 
6        0.951148      0.039318     -0.608794 
7       -1.022894     -0.560489     -1.779759 
6        0.547279      0.312008      0.712972 
6        2.827296      1.546791     -0.464914 
6        2.087122      0.619559     -1.186691 
6        1.337320      1.236060      1.409862 
5       -0.690093     -0.466957      1.482821 
6        2.444575      1.856812      0.839269 
8       -0.535749     -0.416788      2.928778 
8       -2.004128      0.210724      1.227291 
6       -5.246885     -0.605496     -4.429695 
6       -4.221324     -1.424388     -3.656786 
6       -3.067885     -0.575188     -3.133974 
6       -2.053288     -1.405249     -2.361108 
1        0.610416     -2.835415     -0.817966 
1        1.830969     -2.133594     -1.889934 
1        0.297029     -2.754522     -2.575805 
1       -1.477833     -2.264741      1.293351 
1       -1.359632      0.394328     -1.451508 
1        3.697344      2.017403     -0.913485 
1        2.376687      0.367083     -2.205006 
1        1.066329      1.439886      2.443254 
1        3.025830      2.572241      1.415929 
1        0.146853     -1.040084      3.186211 
1       -2.329719      0.472842      2.093672 
1       -6.067081     -1.232396     -4.791478 
1       -4.791372     -0.118519     -5.298611 
1       -5.678590      0.179397     -3.800027 
1       -3.827972     -2.223740     -4.299465 
1       -4.712077     -1.926227     -2.812403 
1       -3.449970      0.221440     -2.484284 
1       -2.563371     -0.075883     -3.971424 
1       -2.532982     -1.929983     -1.523896 
1       -1.600545     -2.162473     -3.007824 
8       -1.989446      1.728940     -0.805007 
1       -1.273273      2.357646     -0.669314 
1       -2.072087      1.245568      0.082705 
 
TSU’-V’ 
6        0.667927     -2.270803     -1.640800 
6        0.091837     -0.915025     -1.404148 
8       -0.828780     -1.758451      1.044908 
6        0.910699      0.030588     -0.590786 
7       -1.053440     -0.518034     -1.823868 
6        0.587573      0.284319      0.756727 
6        2.806539      1.530332     -0.509886 
6        2.013025      0.629349     -1.210795 
6        1.419284      1.189201      1.430563 
5       -0.649012     -0.423763      1.567694 
6        2.504696      1.811092      0.819824 
8       -0.517204     -0.323291      3.008175 
8       -1.956579      0.391041      1.338419 
6       -5.294076     -0.665361     -4.454838 
6       -4.138765     -1.458162     -3.857661 
6       -3.131685     -0.576986     -3.127874 
6       -1.982193     -1.380998     -2.536968 
1        0.493936     -2.819303     -0.706885 
1        1.747659     -2.203238     -1.792225 
1        0.206652     -2.813693     -2.467266 
1       -1.553756     -2.163785      1.529997 
1       -1.501238      0.607961     -1.348508 
1        3.653874      2.003823     -0.997723 
1        2.242515      0.400878     -2.249919 
1        1.197084      1.388305      2.476651 
1        3.122452      2.507392      1.381484 
1        0.203656     -0.885845      3.298363 
1       -2.103968      0.892724      2.147213 
1       -6.003767     -1.319179     -4.970468 
1       -4.934569      0.073199     -5.179474 
1       -5.843657     -0.123562     -3.677768 
1       -3.626590     -2.017306     -4.652635 
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1       -4.531700     -2.212218     -3.162364 
1       -3.632708     -0.017576     -2.328459 
1       -2.725712      0.174229     -3.818212 
1       -2.365225     -2.127506     -1.827150 
1       -1.467584     -1.930617     -3.335950 
8       -1.929061      1.540364     -0.757057 
1       -1.226849      2.200212     -0.738199 
1       -1.975784      1.051302      0.321620 
 
V’ 
6        0.600263     -2.322159     -1.576527 
6        0.035744     -0.946451     -1.395032 
8       -0.838430     -1.794379      1.134841 
6        0.869338      0.002396     -0.589005 
7       -1.079401     -0.518640     -1.850223 
6        0.609417      0.233498      0.776991 
6        2.726079      1.559653     -0.568204 
6        1.920881      0.649531     -1.245416 
6        1.443440      1.153930      1.427043 
5       -0.569112     -0.488549      1.631510 
6        2.483850      1.813296      0.778018 
8       -0.453796     -0.348017      3.064186 
8       -1.933974      0.400668      1.453339 
6       -5.278461     -0.678130     -4.541188 
6       -4.117033     -1.467909     -3.951641 
6       -3.133247     -0.593867     -3.182999 
6       -1.973109     -1.387294     -2.598955 
1        0.453405     -2.839737     -0.621675 
1        1.676004     -2.269351     -1.764999 
1        0.115774     -2.893415     -2.370172 
1       -1.480290     -2.213185      1.715813 
1       -1.601132      0.910536     -1.251882 
1        3.534931      2.064068     -1.089535 
1        2.102355      0.447007     -2.299014 
1        1.261002      1.343956      2.482590 
1        3.107258      2.518996      1.321055 
1        0.312643     -0.833630      3.375301 
1       -1.980562      0.946645      2.247541 
1       -5.971137     -1.327936     -5.084647 
1       -4.922268      0.086989     -5.239499 
1       -5.846798     -0.167484     -3.756351 
1       -3.585571     -1.995159     -4.755794 
1       -4.505736     -2.249299     -3.284481 
1       -3.653885     -0.069823     -2.371190 
1       -2.733610      0.187414     -3.843109 
1       -2.356188     -2.167412     -1.925097 
1       -1.439729     -1.904356     -3.410090 
8       -1.887604      1.707278     -0.682656 
1       -1.114417      2.282383     -0.676601 
1       -1.941389      0.999547      0.605507 
W’ 
6        0.362026     -2.398018     -1.345925 
6       -0.110995     -0.977583     -1.299637 
8       -0.241930     -2.093791      1.675447 
6        0.771161     -0.017518     -0.555747 
7       -1.162520     -0.501475     -1.848808 
6        0.754853      0.101608      0.850212 
6        2.522103      1.653126     -0.740557 
6        1.637320      0.757407     -1.333073 
6        1.668659      1.003933      1.410894 
5       -0.234631     -0.701990      1.838808 
6        2.543577      1.769094      0.644017 
8       -0.299139     -0.294238      3.196453 
8       -1.870470     -0.182359      1.280043 
6       -5.159655     -0.495641     -4.829737 
6       -4.113683     -1.339510     -4.112584 
6       -3.116260     -0.501961     -3.320855 
6       -2.069330     -1.347456     -2.609712 
1        0.301352     -2.792338     -0.324402 
1        1.414520     -2.428316     -1.645238 
1       -0.225598     -3.027236     -2.015824 
1       -0.605586     -2.503050      2.465553 
1       -1.659396      0.995778     -1.178807 
1        3.190344      2.247642     -1.357075 
1        1.614415      0.653458     -2.415239 
1        1.714690      1.096835      2.494314 
1        3.238245      2.451265      1.126580 
1       -0.122902      0.643337      3.297541 
1       -2.304867      0.062515      2.104672 
1       -5.861479     -1.118437     -5.392690 
1       -4.690290      0.198724     -5.535027 
1       -5.740399      0.101274     -4.118302 
1       -3.572904     -1.954560     -4.844923 
1       -4.612552     -2.045983     -3.435425 
1       -3.646218      0.107966     -2.577717 
1       -2.607841      0.204786     -3.989824 
1       -2.565763     -2.054563     -1.929689 
1       -1.522395     -1.951788     -3.348109 
8       -1.902654      1.693170     -0.498744 
1       -1.103783      2.225286     -0.417439 
1       -1.902521      0.614208      0.658331 
 
TSW’-N’’ 
6        0.437900     -2.366138     -1.512557 
6       -0.122564     -0.993933     -1.272130 
8       -0.033295     -2.197492      1.568932 
6        0.801058     -0.023457     -0.591540 
7       -1.266555     -0.537233     -1.597265 
6        0.927672      0.042190      0.810991 
6        2.383610      1.797367     -0.856808 
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6        1.520249      0.854267     -1.405980 
6        1.804924      1.004863      1.334276 
5        0.150525     -0.875735      1.836102 
6        2.532149      1.870320      0.523626 
8       -0.154511     -0.414299      3.097847 
8       -2.478398     -0.383662      1.354311 
6       -4.834972     -0.493348     -5.068309 
6       -4.157430     -1.281589     -3.954753 
6       -2.982769     -0.535483     -3.332139 
6       -2.299810     -1.330841     -2.224847 
1        0.517008     -2.876513     -0.547715 
1        1.448468     -2.281193     -1.924494 
1       -0.171600     -2.970979     -2.184990 
1       -0.584571     -2.606175      2.243757 
1       -1.748142      1.038889     -0.903057 
1        2.934846      2.471542     -1.506100 
1        1.390482      0.801234     -2.483833 
1        1.942676      1.064667      2.412846 
1        3.208508      2.595758      0.966394 
1       -0.009689      0.531932      3.174545 
1       -2.430220     -0.148149      2.284634 
1       -5.676190     -1.046306     -5.497314 
1       -4.132804     -0.272989     -5.879863 
1       -5.219122      0.462773     -4.696934 
1       -3.811375     -2.247566     -4.347182 
1       -4.890575     -1.517810     -3.172108 
1       -3.322347      0.422879     -2.919361 
1       -2.243789     -0.293238     -4.107837 
1       -3.029569     -1.561694     -1.436591 
1       -1.941710     -2.291145     -2.621302 
8       -2.016094      1.772826     -0.293116 
1       -1.177873      2.180415     -0.054581 
1       -2.408598      0.466648      0.872202 
 
N’’ 
6        0.752756     -2.063695     -2.183818 
6        0.209126     -0.847248     -1.466642 
8       -0.694467     -1.272068      1.484831 
6        1.207135     -0.001379     -0.747252 
7       -1.024933     -0.520963     -1.418633 
6        1.008254      0.403258      0.587540 
6        3.307908      1.214683     -0.825180 
6        2.358410      0.401539     -1.432957 
6        1.985418      1.215493      1.179114 
5       -0.262338     -0.005363      1.430750 
6        3.126043      1.619274      0.492963 
8       -0.912169      0.995988      2.149481 
8       -3.342423     -1.276268      1.770305 
6       -4.838882     -0.485191     -4.633757 
6       -4.007439     -1.308479     -3.658610 
6       -2.875122     -0.506926     -3.025593 
6       -2.039568     -1.338914     -2.055481 
1        0.407689     -2.969175     -1.673017 
1        1.842597     -2.076742     -2.169503 
1        0.414666     -2.118700     -3.222858 
1       -1.625818     -1.365016      1.801670 
1       -2.208728      0.547991     -0.442480 
1        4.187330      1.528740     -1.379926 
1        2.503104      0.095510     -2.466032 
1        1.863109      1.520463      2.217567 
1        3.869204      2.241134      0.983767 
1       -0.464658      1.838361      2.023515 
1       -3.696260     -0.892615      2.577720 
1       -5.643613     -1.080145     -5.076352 
1       -4.221295     -0.099185     -5.452257 
1       -5.296652      0.374614     -4.133028 
1       -3.592252     -2.183393     -4.177341 
1       -4.655537     -1.704962     -2.865961 
1       -3.285637      0.359017     -2.492069 
1       -2.218325     -0.107526     -3.810244 
1       -2.688384     -1.715686     -1.251990 
1       -1.636904     -2.218840     -2.573519 
8       -2.952021      0.861838      0.122797 
1       -2.489553      1.292220      0.854515 
1       -3.366267     -0.542041      1.111724 
 
X 
6        2.250005     -2.144490     -1.764721 
6        2.018326     -0.796795     -1.125263 
8       -0.171559     -0.634978      1.085959 
6        2.854085     -0.487330      0.073067 
7        1.164337      0.049972     -1.561840 
6        2.308009     -0.046600      1.294636 
6        5.092406     -0.398055      1.018760 
6        4.238599     -0.662205     -0.045092 
6        3.191979      0.199598      2.355688 
5        0.768132      0.214214      1.520730 
6        4.565885      0.025697      2.234213 
8        0.406735      1.375621      2.199152 
6        0.387683     -0.319977     -2.739200 
6       -0.740732      0.655326     -3.041450 
6       -1.461100      0.308137     -4.339785 
6       -2.615854      1.253935     -4.643933 
1        3.079165     -2.678665     -1.301367 
1        2.433101     -2.058115     -2.841093 
1        1.348605     -2.756832     -1.641040 
1        0.413643      1.642525     -0.856061 
1        6.164004     -0.528508      0.898882 
1        4.657147     -0.991974     -0.992666 
1        2.788884      0.511525      3.318460 
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1        5.219731      0.215749      3.080447 
1        1.189176      1.864747      2.471596 
1        1.060690     -0.372154     -3.610625 
1       -0.034858     -1.329339     -2.621931 
1       -0.339841      1.674866     -3.099339 
1       -1.457439      0.649358     -2.212040 
1       -1.837801     -0.722454     -4.283680 
1       -0.743532      0.323120     -5.171972 
1       -3.118454      0.987507     -5.578882 
1       -2.265205      2.287569     -4.735828 
1       -3.362748      1.230552     -3.843481 
8       -0.163626      2.347069     -0.479783 
1        0.137693      2.426493      0.434233 
1       -1.614419      1.462333     -0.018977 
8       -2.271062      0.849216      0.391155 
1       -2.695530      1.368779      1.079745 
1       -1.064461     -0.217510      1.015129 
 
TSX-O 
6        2.419365     -2.166576     -1.900507 
6        2.138719     -0.874744     -1.170173 
8       -0.146517     -0.518936      1.110974 
6        2.950424     -0.593333      0.046183 
7        1.243728     -0.035307     -1.536533 
6        2.371517     -0.032776      1.200953 
6        5.127288     -0.613451      1.127480 
6        4.320405     -0.880759      0.027571 
6        3.205396      0.222863      2.298034 
5        0.846210      0.351872      1.321866 
6        4.566308     -0.066116      2.275807 
8        0.568390      1.646544      1.777525 
6        0.463411     -0.373089     -2.716622 
6       -0.644652      0.629476     -2.994943 
6       -1.422852      0.305956     -4.265823 
6       -2.550045      1.293712     -4.538092 
1        3.197446     -2.755400     -1.415681 
1        2.707249     -1.984375     -2.942419 
1        1.508313     -2.775421     -1.927544 
1       -0.267452      2.145013     -0.995385 
1        6.190102     -0.833682      1.085842 
1        4.770616     -1.297015     -0.869692 
1        2.772147      0.638762      3.206457 
1        5.182926      0.132859      3.147691 
1        1.390259      2.132326      1.899110 
1        1.123888     -0.433243     -3.597320 
1        0.014744     -1.373535     -2.610624 
1       -0.210071      1.635389     -3.083483 
1       -1.334971      0.644807     -2.142634 
1       -1.835738     -0.708819     -4.187355 
1       -0.732890      0.287395     -5.120559 
1       -3.093771      1.039697     -5.453136 
1       -2.164277      2.312649     -4.651370 
1       -3.270248      1.304968     -3.713252 
8       -0.818968      2.646349     -0.380160 
1       -0.335902      2.543365      0.458830 
1       -2.031305      1.487485      0.159690 
8       -2.469419      0.727847      0.608236 
1       -2.943366      1.113808      1.350108 
1       -1.048608     -0.118637      1.068754 
 
Wiberg Index Structure 
O (89) 
6        1.788312      0.514803     -0.783557 
6        2.432810     -0.720470     -0.677200 
6        1.806341     -1.803646     -0.060360 
6        0.522710     -1.660612      0.459243 
6       -0.101429     -0.419958      0.344320 
6        0.507757      0.686423     -0.269331 
6       -1.443514     -0.065875      0.833155 
6       -2.306098     -1.043849      1.556955 
5       -0.495477      1.967755     -0.257321 
8       -0.981883      2.408860     -1.535225 
8       -0.155446      3.067252      0.580455 
6       -6.222725      2.727751     -1.001697 
6       -5.199426      2.703520      0.126490 
6       -3.967045      1.873539     -0.214141 
6       -2.950206      1.856904      0.926258 
7       -1.740730      1.156959      0.560852 
1        2.299610      1.345515     -1.264785 
1        3.436843     -0.842669     -1.075814 
1        2.320370     -2.757354      0.015517 
1        0.030691     -2.502275      0.940983 
1       -3.275778     -0.633360      1.837811 
1       -1.792847     -1.391313      2.459586 
1       -2.469902     -1.922669      0.924908 
1       -0.854769      1.733130     -2.203813 
1       -0.229089      3.860515      0.043634 
1       -7.094752      3.334301     -0.739095 
1       -5.789075      3.144957     -1.916639 
1       -6.578309      1.718306     -1.236033 
1       -5.667583      2.310531      1.039572 
1       -4.888189      3.729471      0.362752 
1       -3.467131      2.269229     -1.104926 
1       -4.266414      0.842026     -0.447420 
1       -3.394434      1.434355      1.835536 
1       -2.630656      2.878567      1.160879 
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VI.2.3. Experimental Details of Reversibility 
VI.2.3.1. Preliminary 1H-NMR reversibility study 
2-Acetylbenzeneboronic acid (88, 8,0 mg, 0.05 mmol) was added to an eppendorf tube and then 
dissolved in 0.3 mL of D2O. Afterwards, 1 equivalent of 1-butylamine (87, 5 μL) was added to the same 
tube and these compounds reacted for 18 h at 25 ºC. Subsequently, a 1H-NMR spectrum was collected 
to evaluate the conjugation rate. Then, 0.1 mL of D2O containing 1 eq of different molecules (described 
in Table 20 and Table 21) were added to the tube. From that moment on, several 1H-NMR spectra were 
collected in order to study the reaction’s reversibility. Results are shown in Figure 26 (p.72) and resumed 
in Table 20 and Table 21. 
 
Table 20 - Reversibility Study, imine conversions (%) from 1H-NMR in D2O (1) 
t (min) D-Glucose D-Fructose 
D-Glutathione 
Reduced 
D-Lactose D-Sucrose 
0 94 87 81 87 89 
45 82 44 16 84 87 
120 81 41 11 84 87 
1440 81 44 7 84 87 
 
Table 21 - Reversibility Study, imine conversions (%)  from 1H-NMR in D2O (2) 
t (min) Adenine Cytosine Thymine Ephedrine 
Dopamine 
Hydrochloride 
0 82 93 90 86 86 
45 82 91 85 84 50 
120 82 91 86 84 24 
1440 81 91 86 84 21 
 
 
VI.2.3.2. Reversibility study with Lysozyme 
To study reversibility of the link formed, equal quantities of reduced glutathione, dopamine 
hydrochloride and D-fructose (10.0 mM) were added to the modified lysozyme with 
2-formylbenzeneboronic acid and the results were evaluated through ESI-FTICR-MS, detecting absence 
of conjugates or the decrease in their number, thus proving its reversibility. Results are shown in Figure 
27 (p.73). 
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VI.3. Experimental Section of Chapter III 
VI.3.1. Experimental Details of strategies to achiveve a modifiable backbone 
 
VI.3.1.1. Modification of 2-carbonylbenzeneboronic acid 
VI.3.1.1.1. Nitration of 2-acetylbenzeneboronic acids 
 Synthesis of 2-acetyl-X-nitrobenzeneboronic acid 
Literature basis - Keana, J. F. W.; Cai, X. S. Bioconjugate Chemistry 1991, 2, 317. 
 
 General nitration procedure 
A solution of fuming nitric acid was prepared at -50 ºC by adding dropwise 0.63 mL of sulphuric acid 
(12.2 mmol, 4 eq) into 0.51 mL of nitric acid (12.2 mmol, 4 eq). Seperately, 2-acetylbenzeneboronic acid 
(88, 0.5 g, 3.0 mmol) was added to a 25 mL round bottom flask and then dissolved in 1 mL of sulphuric 
acid (18.3 mmol, 6 eq) at -98 ºC. Then the solution of fuming nitric acid was slowly added to the solution 
containing compound 88 and left reacting for 40 min at -98 ºC (Scheme 36, p.81). After that time, the 
reaction mixture was poured into ice-water and left for 10 min. Since no crystals were detected (as it had 
happened in the reported work from literature basis), a multiple extraction using ethyl acetate was 
performed. Several recrystallization attemps and column cromatographies never afforded the expected 
product. 
 
Species with three aromatic proton signals, but without alkylic proton signals: 
1H NMR (400 MHz, D2O) δ 8.82 (d, J = 1.9 Hz, 1H, CHarom), 8.46 (dd, J = 8.1, 2.1 Hz, 1H, CHarom), 
7.72 (d, J = 8.1 Hz, 1H, CHarom). 
1H NMR (400 MHz, D2O) δ 8.23 (d, J = 7.0 Hz, 2H, 2xCHarom), 7.62 (d, J = 8.2 Hz, 1H, CHarom). 
 
Species bearing four aromatic proton signals: 
1H NMR (400 MHz, D2O) δ 8.09 (d, J = 7.7 Hz, 1H, CHarom), 7.70 (t, J = 7.3 Hz, 1H, CHarom), 7.57 (t, J 
= 9.0 Hz, 2H, 2xCHarom), 2.70 (s, 3H, CaromCOCH3). 
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VI.3.1.1.2. Methylation of 2-formylbenzeneboronic acids 
 Synthesis of 2-formylbenzeneboronic acid derivatives 
Step 1 - Pinacol protection of 2-formylbenzeneboronic acid – Synthesis of compound 109 (R = H) 
Literature basis - Lautens, M.; Mancuso, J. Journal of Organic Chemistry 2004, 69 (10), 3478 and 
Vogels, C.M.; Nikolcheva, L.G.; Norman, D.W.; Spinney, H.A.; Decken, A.; Baerlocher, M.O.; Westcott, 
S.A. Canadian Journal of Chemistry 2001, 79 (7), 1115. 
2-Formylbenzeneboronic acid (72, 0.20 g, 1.33 mmol) was added to a 10 mL round bottom flask and 
then dissolved in 5.3 mL of previously distilled hexane. Afterwards, 1 equivalent of pinacol (111, 0.16 g) 
and 20% (m/m) of molecular sieves were added and these compound left reacting for 3 h at 25 ºC (first 
reaction of Scheme 38, p.82). At that time, an extra step of dehydration was performed using dried 
magnesium sulphate and, then, a vaccum filtration performed. Evaporation of the solvents affored the 
product (109 (R = H)) in 95 % yield. The product’s characterization was in accordance to what is described 
on the literature. 
1H NMR (400 MHz, CDCl3) δ 10.53 (s, 1H, CaromCOH), 7.94 (dd, J = 7.3, 1.4 Hz, 1H, 
CHarom), 7.87 – 7.82 (m, 1H, CHarom), 7.56 (pd, J = 7.4, 1.5 Hz, 2H, 2xCHarom), 1.38 
(s, 12H, C(CH3)2). 
 
Step 2 – Methylation of pinacolylboronate ester 109 (R=H) 
Literature basis - Vaultier, M.; Rasset-Deloge, C. Bulletin de la Société Chimique de France 1994, 131, 
915. 
Compound 109 (R=H, 0.3 g, 1.28 mmol) was then added to a 10 mL round bottom flask and dissolved 
in 3.8 mL of freshly distilled tetrahydrofuran. Afterwards, 1 equivalent of DBU (0.2 mL) was added to the 
solution and these compounds reacted for 10 minutes at room temperature. Then, the reaction mixture 
was cooled down to -78 ºC and once it reached this temperature, 1.1 equivalents methyl lithium (37 μL) 
was slowly added to the flask. These compounds were left reacting until the reaction warmed to 0 ºC 
(second reaction of Scheme 38, p.82). At that time, the reaction mixture was acidified until it reached pH 
2~4 and a multiple extraction with ether (3x10 mL) was performed. Evaporation of the solvents and a 
subsequent 1H-NMR evaluation of the crude reaction only showed unreacted compound 109. After three 
attemps on making this reaction, the same conclusion was always obtained. 
1H NMR (400 MHz, CDCl3) δ 10.51 (s, 1H, CaromCOH), 7.93 – 7.86 (m, 1H, CHarom), 7.81 (d, J = 7.1 
Hz, 1H, CHarom), 7.55 – 7.44 (m, 2H, 2xCHarom), 1.33 (s, 12H, C(CH3)2). 
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VI.3.1.2. Construction of 2-carbonylbenzeneboronic acid 
VI.3.1.2.1. Strategy 1 
 Synthesis of compound 116 
Literature basis - Fillaut, J.-L.; Andriès, J.; Marwaha, R. D.; Lanoë, P.-H.; Lohio, O.; Toupet, L.; Gareth 
Williams, J. a. Journal of Organometallic Chemistry 2008, 693(2), 228. 
In a round bottom flask, 2’,4’-dihydroxyacetophenone (115, 1.0 g, 6.6 mmol) and 0.2 equivalents of 
pyridinium p-toluenesulfonate (PPTS, 0.33 g) were dissolved in 20 mL of freshly distilled dichloromethane 
(DCM). Afterwards a 5 mL solution of freshly distilled dichloromethane with 3 equivalents of 
3,4-dihydro--pyran (118, 1.8 mL, 20 mM) was added to the reaction mixture and left reacting at 20 ºC 
for 5 h (first reaction of Scheme 40, p.84). After that time, the solvent was evaporated and a 
recrystallization with hot hexane was performed. The product 116 was obtained in 97% yield. 
1H NMR (400 MHz, CDCl3) δ 11.86 (d, J = 1.5 Hz, 1H, ArOH), 7.36 (d, J = 2.4 
Hz, 1H, CHarom), 7.19 (dd, J = 9.0, 2.6 Hz, 1H, CHarom), 6.85 (dd, J = 9.0, 2.2 
Hz, 1H, CHarom), 5.26 (s, 1H, -OCH(CH2)O-), 3.88 (t, J = 10.3 Hz, 
1H, -OCH2aCH2-), 3.58 (m, 1H, -OCH2bCH2-), 2.56 (s, 3H, CaromCOCH3), 1.97 – 1.59 (m, 6H, 3xCH2). 
 
 Synthesis of compound 117 
Literature basis - Penhoat, M.; Levacher, V.; Dupas, G. The Journal of Organic Chemistry 2003, 68, 
9517 and Patent: Anacor Pharmaceuticals, Inc.; GlaxoSmithKline; US2010/256092; (2010); (A1) English. 
In a round bottom flask, compound 116 (1.4 g, 5.9 mmol) and 3 equivalents of freshly distilled 
triethylamine (TEA, 2.5 mL, 17.6 mmol) were dissolved in 17 mL freshly distilled dichloromethane (DCM) 
and cooled down to -78 ºC. Afterwards, 1.6 equivalents of triflic anhydride (119, 1.8 mL, 20 mM) were 
slowly added to the reaction mixture and left reacting at -78 ºC for 2 h (second reaction of Scheme 40, 
p.84). After that time, the reaction mixture was diluted with water and a multiple extraction with 
dichloromethane (4x10 mL) and brine (4x10 mL) was performed. Then a recrystallization with hot hexane 
was done to obtain product 117 in 80% yield. 
1H NMR (400 MHz, CDCl3) δ 7.44 (dd, J = 2.4, 0.9 Hz, 1H, CHarom), 7.23 
(m, 2H, CHarom), 5.46 (t, J = 3.0 Hz, 1H, -OCH(CH2)O-), 3.92 – 3.76 (m, 1H, 
-OCH2aCH2-), 3.64 (m, 1H, -OCH2bCH2-), 2.61 (s, 3H, CaromCOCH3), 2.05 – 
1.86 (m, 3H, 3xCH2a), 1.77 – 1.60 (m, 3H, 3xCH2b). 
Chapter VI. Materials and Methods  
 
178 
 Synthesis of compound 114 
Literature basis - Anacor Pharmaceuticals, Inc.; GlaxoSmithKline US2010/256092 2010. 
In a flame dried round bottom flask, under inert atmosphere, compound 117 (0.1 g, 0.27 mmol), 
bis(pinacolato)diboron (120, 0.14 g, 0.42 mmol), [1,1’-bis(diphenylphosphino)ferrocene]palladium (II) 
chloride (PdCl2dppf, 0.022 g, 0.027 mmol) and sodium acetate (NaCH3COO, 0.066 g, 0.81 mmol) were 
flushed 3 times with Argon. Then, 2 mL of previously distilled dioxane were added and the reaction mixture 
was heated at 100 ºC for 4 h (Scheme 41, p.84), after which the solvent was concentrated in vacuo and 
the crude purified by preparative chromatography (silica gel, ethyl acetate:hexane [1:4]) to give compound 
114 in 40% yield and the side-product (121) in 43% yield. 
 
Optimization attempts on Miyaura-borylation: 
Literature basis - Ishiyama, T.; Murata, M.; Miyaura, N. Journal of Organic Chemistry 1995, 60, 7508 
and Ishiyama, T.; Itoh, Y.; Kitano, T.; Miyaura, N. Tetrahedron Letters, 1997, 38(19), 3447. 
In a flame dried round bottom flask, under inert atmosphere, compound 117 (0.05 g, 0.14 mmol), 
bis(pinacolato)diboron (120, 0.07 g, 0.27 mmol), catalyst (6.8 μmol), ligand (13.6 μmol) and base (0.41 
mmol) were flushed 3 times with Argon. Then, 2 mL of previously distilled solvent were added and the 
reaction mixture was heated at 100 ºC. The reactions were monitored by TLC throughout 8 h. Results 
and reagents are described in Table 11 (p.84). 
 
Boronated product (114): 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 2.0 Hz, 1H, CHarom), 7.42 (d, J = 
8.1 Hz, 1H, CHarom), 7.22 (dd, J = 8.1, 2.2 Hz, 1H, CHarom), 5.46 (s, 
1H, -OCH(CH2)O-), 3.87 – 3.78 (m, 1H, -OCH2aCH2-), 3.63 – 3.54 (m, 1H, 
-OCH2bCH2-), 2.57 (s, 3H, CaromCOCH3), 2.14 – 1.98 (m, 3H, 3xCH2a), 1.70 
– 1.56 (m, 3H, 3xCH2b), 1.40 (s, 12H, C(CH3)2). 
 
Protolytic deboronation product (121): 
1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H, CHarom), 7.58 (d, J = 7.6 Hz, 1H, 
CHarom), 7.37 (t, J = 7.9 Hz, 1H, CHarom), 7.28 (d, J = 2.0 Hz, 1H, CHarom), 5.49 
(d, J = 2.8 Hz, 1H, -OCH(CH2)O-), 3.95 – 3.82 (m, 1H, -OCH2aCH2-), 3.70 – 
3.57 (m, 1H, -OCH2bCH2-), 2.60 (s, 3H, CaromCOCH3), 2.08 – 1.86 (m, 3H, 3xCH2a), 1.79 – 1.53 (m, 3H, 
3xCH2b). 
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 Synthesis of compounds 113 and 112 (Procedures for deprotection steps) 
 
a) Strong acids 
a1 – Hydrochloric acid (HCl) 
Literature basis - Martin, R.; Jones, J. B. Tetrahedron Letters 1995, 36, 8399. 
In a flame dried round bottom flask, under inert atmosphere, compound 114 (0.04 g, 0.11 mmol) was 
dissolved in 1 mL of tetrahydrofuran (THF). After complete dissolution, 1 mL of HCl 5 % was added to the 
solution and left reacting at 25 ºC for 20 h. Then, the solvents were evaporated under vaccum and a 
preparative chromatography (silica gel, ethyl acetate:hexane [1:1]) was performed. This procedure 
afforded vestigial ammounts of compound 113 and the protolytic deboronation product 
(4-hydroxyacetophenone). 
 
a2 –Acetic acid (CH3COOH) 
Literature basis - Protective Groups In Organic Synthesis; Greene, T. W.; Wuts, P. G. M.; Third Ed.; 
Wiley-VCH, 1999; Vol. 23. 
In a flame dried round bottom flask, under inert atmosphere, compound 114 (0.05 g, 0.14 mmol) was 
dissolved in 1 mL of dioxane. After complete dissolution, 1 mL of CH3COOH was added to the solution 
and left reacting at 25 ºC for 20 h. Then, a multiple extraction with diethyl ether (3x5 mL) and brine (3x5 
mL) was performed and the solvents evaporated under vaccum. This procedure afforded vestigial 
ammounts of compound 113. 
 
b) Oxidizing agents  
Literature basis - Coutts, S. J.; Adams, J.; Krolikowski, D.; Snow, R. J. Tetrahedron Letters 1994, 35, 
5109. 
In a flame dried round bottom flask, under inert atmosphere, compound 113 (0.05 g, 0.19 mmol) was 
dissolved in 1.5 mL of THF. After complete dissolution, 1.3 equivalents of NaIO4 (0.05 mg, 0.25 mmol) 
were added, followed by dilution with 0.2 mL of water. The reaction mixture was left reacting at 25 ºC for 
0.5 h. Then, 0.15 mL of 0.1 M HCl was added to this mixture and reacted for 20 h at 25 ºC. Afterwards, a 
multiple extraction with diethyl ether (3x5 mL) and brine (3x5 mL) was performed and the solvents 
evaporated under vaccum. The 1H-NMR evaluation of this oil in vestigial ammounts showed a large 
mixture of unidentified compounds. 
Chapter VI. Materials and Methods  
 
180 
c) Methods for Pinacolyl deprotection 
c1 – Through trifluoroborate formation  
Literature basis – Yuen, A.K.L.; Hutton, C.A.; Tetrahedron Letters 2005, 46, 7899 
In a flame dried round bottom flask, under inert atmosphere, compound 114 (0.07 g, 0.21 mmol) was 
dissolved in 0.7 mL of methanol. After complete dissolution, a solution of 0.3 mL of water with 5.6 
equivalents of potassium hydrogen fluoride (KHF2, 0.09 mg, 1.16 mmol) was added to the previous 
solution and left reacting at 25 ºC for 2 h. Then, the solvents were evaporated under vaccum to afford an 
oil that was dissolved in hot acetone. The solid that did not dissolve was separated with a hot gravity 
filtration. The solvent was, once again, evaporated under vaccum and a recrystallization with hot acetone 
and ether afforded the trifluoroborate derivative of compound 114.  
This derivative was then used to perform the last deprotecting step. This compound (42 mg, 0.16 
mmol) was dissolved in 1.5 mL of acetonitrile and 3 equivalents of water (9 μL, 0.48 mmol) and, then, 3 
equivalents of trimethylsilyl chloride (TMSCl, 61 μL, 0.48 mmol) were added dropwise and left reacting at 
25 ºC for 1 h. After which, multiple extraction with 3x1 mL of sodium bicarbonate was performed. Finally, 
several column chromatographies were performed and compounds 113, 112 and the protolytic 
deboronation product were isolated in insignificant yields (lower than 5 %). 
 
c2 – Through complexation with diethylamine  
Literature basis – Sun, J.; Perfetti, M.T.; Santos, W.L. Journal of Organic Chemistry 2011; 76(9), 3571 
In a flame dried round bottom flask, under inert atmosphere, compound 113 (0.05 g, 0.19 mmol) was 
dissolved in 1.5 mL of diethyl ether. After complete dissolution, 1.1 equivalents of diethylamine (20 μL, 
0.21 mmol) were added and left reacting at 25 ºC for 22 h. At that time, a multiple extaction with brine 
(3x2 mL) and dichloromethane (3x2 mL) was performed and HCl 0.1 M was added to the aqueous phase 
to cleave the complexation between diethylamine and the boronic acid. Evaluation of this phase did not 
afford any separable compound, supposably due to a known complexation with 
2-carbonylbenzeneboronic acids (Klis, T.; Serwatowski, J. Tetrahedron Letters 2007, 48, 5223). 
 
d) Methods for THP deprotection 
Literature basis – Miyashita, M.; Yoshikoshi, A.; Grieco P.A. Journal of Organic Chemistry, 1977, 42(23), 
3772 
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In a flame dried round bottom flask, under inert atmosphere, compound 114 (0.24 g, 0.7 mmol) was 
dissolved in 5 mL of ethanol. After complete dissolution, 0.1 equivalents of PPTS (18 mg, 0.07 mmol) 
were added and left reacting at 55 ºC for 4 h. At that time, the solvent was evaporated and a flash column 
chromatography (silica gel, ethyl acetate:hexane [1:4 - 3:7]) was performed, affording compound 113 in 
82% yield. 
 
 Compound 113: 
1H NMR (400 MHz, CDCl3) δ 7.23 (d, J = 4.4 Hz, 1H, CHarom), 7.08 (s, 1H, 
CHarom), 6.83 (d, J = 7.9 Hz, 1H, CHarom), 2.41 (s, 3H, CaromCOCH3), 1.37 (s, 
12H, C(CH3)2). 
 
 Compound 112: 
1H NMR (400 MHz, D2O) δ 7.47 (s, 1H, CHarom), 7.37 (d, J = 8.0 Hz, 1H, CHarom), 
7.14 (d, J = 7.9 Hz, 1H, CHarom), 2.61 (s, 3H, CaromCOCH3). 
 
 
 Protolytic deboronation product: 
1H NMR (400 MHz, D2O) δ 7.40 (d, J = 8.5 Hz, 2H, 2xCHarom), 7.13 (d, J = 8.5 Hz, 
2H, 2xCHarom), 2.61 (d, J = 10.2 Hz, 3H, CaromCOCH3). 
 
 
VI.3.1.2.2. Strategy 2 
 General Procedures 
Step 1 – Alkylation Procedure 
Literature basis - Al-Smadi, M.; Hanold, N.; Kalbitz, H.; Meier, H.; Synthesis, 2009, 15, 2539 
 
+  
(NaI), K2CO3, 
acetone 
 
reflux, ~h, 
~% 
 
115 
 
217 
X = Br or Cl 
125x 
Scheme 77 – General alkylation procedure of compound 115 
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In a round bottom flask (A), 2’,4’-dihydroxyacetophenone (115, 1 equivalent) and potassium carbonate 
(1 equivalent) were heated in acetone to reflux for 2 h. In a separate round bottom flask (B), haloalkyl 
derivatives (217x, 1 equivalent) and sodium iodide (1.1 equivalents) were stirred in acetone at room 
temperature for 2 h. Then, flask B was transferred to flask A and refluxed for 20 h (Scheme 77). After that, 
acetone was evaporated to dryness and water was added to the reaction mixture. Then, the compound 
was extracted with diethyl ether. The solution was dried (Na2SO4), concentrated and purified by column 
chromatography (silica gel, hexane:diethyl ether) to give different compounds (125x) with variable yields. 
 
Step 2 – Triflation Procedure 
Literature basis - Luker, T.; Bonnert, R.; Paine, S.W.; Schmidt, J.; Sargent, C.; Cook, A.R.; Cook, A.; 
Gardiner, P.; Hill, S.; Weyman-Jones, C.; Patel, A.; Thom, S.; Thorne, P.; Journal of Medicinal Chemistry 
2011 ,  54 (6), 1779 
 
 
+ 
 
TEA, DCM 
 
1 h, 25 ºC,  
~% 
 
125x  127  124x 
Scheme 78 – General Triflation of compound 125x 
 
In a round bottom flask, N-Phenyltrifluoromethanesulfonimide (127, 1.2 equivalents) was added 
portion wise to a solution of  the alkylated compound (125x, 1 equivalent) with triethylamine (1.5 
equivalents) in DMF (0.5 M) and the reaction stirred for 1 h at 25 ºC (Scheme 78). Water was added and 
the mixture extracted with diethyl ether. The organic layer was washed with water, LiCl (aq), brine, dried 
(Na2SO4), concentrated and purified by column chromatography (silica gel, hexane:diethyl ether) to give 
different compounds (124x) with variable yields. 
 
Step 3 – Miyaura-Borylation Procedure 
Literature basis - Patent: Anacor Pharmaceuticals, Inc.; GlaxoSmithKline; US2010/256092; (2010); 
(A1) English 
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+ 
 
NaCH3COO,  
PdCl2dppf 
 
Dioxane, Ar, 
100 ºC, ~h, ~% 
 
124x  120  123x 
Scheme 79 – General Miyaura-borylation of compound 124x 
 
In a flame dried round bottom flask, under inert atmosphere, the triflate derivative (124x, 1 equivalent), 
bis(pinacolato)diboron (120, 2 equivalents), [1,1’-bis(diphenylphosphino)ferrocene]palladium (II) chloride 
(PdCl2dppf, 0.1 equivalents) and sodium acetate (NaCH3COO, 3 equivalents) were flushed 3 times with 
Argon. Then, previously distilled dioxane (0.15 M) was added and the reaction mixture was heated at 100 
ºC for 4 h (Scheme 79), after which it was concentrated in vacuo and the crude purified by flash column 
cromatography (silica gel, ethyl acetate:hexane) to give different compounds (123x) with variable yields. 
For the kinetic 1H-NMR evaluations, at pre-determined times, 0.1 mL of the reaction mixture were 
transferred to a NMR tube and diluted with 0.3 mL of deuterated DMSO. At this point, a 1H-NMR spectrum 
was collected for each sample. 
 
 Reactions starting with 3’-bromopropen (Scheme 44 and Scheme 45, p.87) 
Step 1 – Alkylation – Synthesis of compound 125a 
Following the general alkylation procedure (without sodium iodide) and using 3’-bromopropen (126, 
0.013 mol) as the mentioned haloalkyl derivative, compound 125a was obtained as a white solid in 90% 
yield (2.34g). 
1H NMR (600 MHz, CDCl3) δ 12.71 (s, 1H, CaromOH), 7.60 (d, J = 8.9 Hz, 1H, 
CHarom), 6.43 (ddd, J = 8.9, 2.3, 1.2 Hz, 1H, CHarom), 6.38 (d, J = 1.4 Hz, 1H, 
CHarom), 6.04 – 5.97 (m, 1H, CH2CHCH2O-), 5.40 (d, J = 17.3 Hz, 1H, 
CH2aCHCH2O-), 5.30 (d, J = 10.5 Hz, 1H, CH2bCHCH2O-), 4.54 – 4.52 (m, 2H, CH2CHCH2O-), 2.54 – 
2.52 (m, 3H, CaromCOCH3). 
13C NMR (151 MHz, CDCl3) δ 202.72 (s, CaromCOCH3), 165.22 (s, CHCaromOHC), 165.12 (s, 
CaromOCH2-), 132.45 (s, CHarom), 132.29 (s, CH2CHCH2O-), 118.48 (s, CH2CHCH2O-), 114.07 (s, 
CHCaromCOCH3), 108.09 (s, CHarom), 101.75 (s, CHarom), 69.05 (s, CH2CHCH2O-), 26.33 (s, CaromCOCH3). 
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Step 2 – Triflation – Synthesis of compound 124a 
Following the general triflation procedure and using compound 125a as the starting material (0.012 
mol), compound 124a was obtained as a white solid in 93% yield (3.64g). 
1H NMR (600 MHz, CDCl3) δ 7.83 (d, J = 8.8 Hz, 1H, CHarom), 6.96 (dd, J = 
8.8, 2.4 Hz, 1H, CHarom), 6.83 (d, J = 2.3 Hz, 1H, CHarom), 6.07 – 5.96 (m, 1H, 
CH2CHCH2O-), 5.43 (dd, J = 17.3, 1.1 Hz, 1H, CH2aCHCH2O-), 5.36 (dd, J = 
10.5, 1.2 Hz, 1H, CH2bCHCH2O-), 4.65 – 4.58 (m, 2H, CH2CHCH2O-), 2.59 
(s, 3H, CaromCOCH3). 
13C NMR (151 MHz, CDCl3) δ 195.21 (s, CaromCOCH3), 162.72 (s, (CH)2CaromOCH2), 148.57 (s, 
CaromOTf), 132.87 (s, CHarom), 131.66 (s, CH2CHCH2O-), 124.10 (s, CHCaromCOCH3), 119.06 (s, 
CH2CHCH2O-), 118.72 (q, J = 320,1 Hz, -SO2CF3), 114.12 (s, CHarom), 109.77 (s, CHarom), 69.70 (s, 
CH2CHCH2O-), 29.13 (s, CaromCOCH3). 
 
Step 3 – Miyaura-Borylation – Synthesis of compound 123a (Unsuccessful) 
Based on general borylation procedure, several attempts were developed to synthesize compound 
123a, however, all proved to be unsuitable. Among those attempts, experiences with diferent number of 
equivalents of the starting materials, different temperatures and times, different concentrations and 
diferent purifications of the starting materials were performed.  
 
 Reactions starting with 4-bromo-1-butene (Scheme 46, p.87) 
Step 1 – Alkylation – Synthesis of compound 125b 
Following the general alkylation procedure and using 4-bromo-1-butene (132, 0.013 mol) as the 
mentioned haloalkyl derivative, compound 125b was obtained as a white solid in 44% yield (1.2g). 
1H NMR (600 MHz, CDCl3) δ 12.73 (s, 1H, CaromOH), 7.59 (dd, J = 8.9, 1.2 
Hz, 1H, CHarom), 6.44 – 6.37 (m, 2H, 2xCHarom), 5.90 – 5.82 (m, 1H, 
CH2CHCH2-), 5.16 (d, J = 17.2 Hz, 1H, CH2aCHCH2-), 5.11 (d, J = 10.3 Hz, 
1H, CH2bCHCH2-), 4.01 (td, J = 6.7, 1.1 Hz, 2H, -CHCH2CH2O-), 2.55 – 2.51 (m, 5H, -CHCH2CH2O- and 
CaromCOCH3). 
13C NMR (126 MHz, CDCl3) δ 202.59 (s, CaromCOCH3), 165.49 (s, CHCaromOHC), 165.26 (s, 
CaromOCH2-), 133.92 (s, CH2CHCH2-), 132.36 (s, CHarom), 117.48 (s, CH2CHCH2-), 113.93 (s, 
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CHCaromCOCH3), 107.97 (s, CHarom), 101.42 (s, CHarom), 67.52 (s, -CHCH2CH2O-), 33.34 
(s, -CHCH2CH2O-), 26.23 (s, CaromCOCH3). 
 
Step 2 – Triflation – Synthesis of compound 124b 
Following the general triflation procedure and using compound 125b as the starting material (0.01 
mol), compound 124b was obtained as a white solid in 91% yield (3.08g). 
1H NMR (600 MHz, CDCl3) δ 7.82 (d, J = 8.7 Hz, 1H, CHarom), 6.94 (d, J 
= 8.6 Hz, 1H, CHarom), 6.78 (s, 1H, CHarom), 5.92 – 5.77 (m, 1H, 
CH2CHCH2-), 5.14 (dd, J = 29.6, 13.3 Hz, 2H, CH2CHCH2-), 4.06 (t, J = 
4.7 Hz, 2H, -CHCH2CH2O-), 2.56 (s, 5H, -CHCH2CH2O- and 
CaromCOCH3). 
13C NMR (151 MHz, CDCl3) δ 195.17 (s, CaromCOCH3), 163.07 (s, CaromOCH2-), 148.55 (s, CaromOTf), 
133.53 (s, CH2CHCH2-), 132.90 (s, CHarom), 123.83 (s, CHCaromCOCH3), 118,69 (q, J = 320,9 
Hz, -SO2CF3), 117.81 (s, CH2CHCH2-), 113.73 (s, CHarom), 109.53 (s, CHarom),  68.21 (s, -CHCH2CH2O-), 
33.23 (s, -CHCH2CH2O-), 29.01 (s, CaromCOCH3). 
 
Step 3 – Miyaura-Borylation – Synthesis of compound 123b 
Following the general borylation procedure and using compound 124b as the starting material (0.3 
mmol), compound 123b was obtained as a yellow solid in 25% yield (0.024g). This reaction was monitored 
by a 1H-NMR kinetic study following the mentioned general procedure (Figure 29, p.88). 
1H NMR (600 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 1H, CHarom), 6.96 (d, 
J = 2.3 Hz, 1H, CHarom), 6.85 (dd, J = 8.6, 2.4 Hz, 1H, CHarom), 5.93 – 
5.84 (m, 1H, CH2CHCH2-), 5.16 (d, J = 17.2 Hz, 1H, CH2aCHCH2-), 5.11 
(d, J = 10.2 Hz, 1H, CH2bCHCH2-), 4.07 (t, J = 6.6 Hz, 
2H, -CHCH2CH2O-),  2.56 – 2.52 (m, 5H, -CHCH2CH2O- and CaromCOCH3), 1.43 (s, 12H, 2xC(CH3)2). 
13C NMR (151 MHz, CDCl3) δ 198.61 (s, CaromCOCH3), 162.74 (s, CaromOCH2-), 134.18 (s, 
CH2CHCH2-), 133.51 (s, CHCaromCOCH3), 130.86 (s, CHarom), 118.04 (s, CHarom), 117.43 (s, CH2CHCH2-), 
114.16 (s, CHarom), 83.71 (s, C(CH3)2), 67.40 (s, -CHCH2CH2O-), 33.58 (s, -CHCH2CH2O-), 25,05 (s, 
C(CH3)2), 24.92 (s, CaromCOCH3). 
13C-HMBC 138.5 (s, CaromB) 
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 General procedure of Cross-Metathesis (Scheme 47, p.88) 
Literature Basis – Voigtritter, K.; Ghorai, S.; Lipshutz, B.H. Journal of Organic Chemistry 2011, 76, 
4697 
In a flame dried round bottom flask, under inert atmosphere, compound 123b (1 equivalent), 
acrylate/ketone (3 equivalents), Hoveyda-Grubbs 2nd generation catalyst (0.03 equivalents) and copper 
iodide (0.02 equivalents) were placed under an Argon. Freshly distilled diethyl ether (0.1 M) was added 
and a reflux condenser was placed on the vial. The reaction mixture was heated at 40 ºC for 3 h (Scheme 
47, p.88), after which it was concentrated in vacuo and the crude purified by flash column cromatography 
(silica gel, diethyl ether:hexane) to give different compounds (133x) with variable yields. 
 
Synthesis of compound 133a 
Following the general procedure of cross-methathesis and using methyl vinyl ketone as the starting 
material (0.35 mmol), compound 133a was obtained as a yellow solid in 65% yield (0.027g). 
1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 8.6 Hz, 1H, CHarom), 6.96 
(s, 1H, CHarom), 6.90 – 6.81 (m, 2H, CHarom, CHCO), 6.19 (d, J = 
16.0 Hz, 1H, CH2CHCH), 4.16 (t, J = 6.3 Hz, 2H, OCH2CH2), 2.72 
(q, J = 6.3 Hz, 2H, CH2CH2CH), 2.55 (s, 3H, CHCOCH3), 2.27 (s, 
3H, CaromCOCH3), 1.43 (s, 12H, CCH3). 
13C NMR (101 MHz, CDCl3) δ 198.60 (s, COCH3), 162.32 (s, CaromOCH2), 143.33 (s, CHCHCO), 
133.88 (s, CHCCO), 133.35 (s, CH2CHCH), 130.88 (s, CHarom), 117.96 (s, CHarom), 114.19 (s, CHarom),  
83.80 (s, C(CH3)2), 66.16 (s, OCH2CH2), 32.29 (s,CH2CH2CH), 27.15 (s, CHCOCH3), 25.08 (s, C(CH3)2), 
24.99 (s, CaromCOCH3). 
13C-HMBC 138.7 (s, CaromB) 
 
Synthesis of compound 133b 
Following the general procedure of cross-methathesis and using methyl acrylate as the starting 
material (0.11 mmol), compound 133b was obtained as a yellowish solid in 68% yield (0.081 g). 
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1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 1H, CHarom), 
7.06 – 6.91 (m, 2H, CHarom, CHCO), 6.83 (d, J = 8.6 Hz, 1H, 
CHarom), 5.95 (d, J = 16.0 Hz, 1H, CH2CHCH), 4.12 (t, J = 6.3 
Hz, 2H, OCH2), 3.72 (s, 3H, OCH3), 2.68 (q, J = 6.3 Hz, 2H, 
CH2CH), 2.53 (s, 3H, COCH3), 1.42 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 198.50 (s, CaromCOCH3), 166.70 (s, CHCOOCH3), 162.26 (s, 
CaromOCH2), 144.53 (s, CHCHCO), 133.73 (s, CH3COCarom), 130.81 (s, CHarom), 123.31 (s, CH2CHCH), 
117.87 (s, CHarom), 114.12 (s, CHarom), 83.68 (s, C(CH3)2), 66.03 (s, OCH2CH2), 51.62 (s, COOCH3), 31.93 
(s, CH2CH2CH), 25.00 (s, C(CH3)2), 24.90 (s, CH3COCarom) 
13C-HMBC 138.7 (s, CaromB) 
 
Synthesis of compound 133c (Unsuccessful) 
Following the general procedure of cross-methathesis and using a synthesized dansyl derivative 
(N-[(5-N,N-Dimethylaminonaphthylsulfonylamino)ethyl]-2-methacrylamide, Literature Basis – Sun, W.; 
Bandmann, H.; Schrader, T. Chemistry – A European Journal 2007, 13, 7701), three attempts were made 
to produce compound 133c though all proved to be unsuccessful. 
 
Synthesis of compound 133d 
Triethylene glycol monomethyl ether acrylate was synthesized according to a procedure described in 
the literature (Ryu, J.-H.; Roy, R.; Ventura, J.; Thayumanavan, S. Langmuir, 2010, 26(10), 7086) and 
applied to the mentioned general procedure of cross-methathesis. This reaction afforded compound 133d 
was obtained as a colorless liquid in 60% yield (0.165 g trans isomer and 0.008 g of cis isomer). 
1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 
8.6 Hz, 1H, CHarom), 7.03 (d, J = 15.7 Hz, 
1H, CHCO), 6.95 (d, J = 1.9 Hz, 1H, 
CHarom), 6.85 (dd, J = 8.6, 1.9 Hz, 1H, 
CHarom), 5.99 (d, J = 15.7 Hz, 1H, CH2CHCH), 4.32 – 4.28 (m, 2H, OCH2), 4.14 (t, J = 6.3 Hz, 2H, OCH2), 
3.75 – 3.71 (m, 2H, OCH2), 3.69 – 3.62 (m, 6H, OCH2), 3.56 – 3.52 (m, 2H, OCH2), 3.37 (s, 3H, OCH3), 
2.71 (t, J = 6.4 Hz, 2H, 2H, CH2CH), 2.55 (s, 3H, COCH3), 1.43 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 198.60 (s, CaromCOCH3), 166.29 (s, CHCOOCH3), 162.34 (s, 
CaromOCH2), 144.81 (s, CHCHCO), 133.82 (s, CH3COCarom), 130.88 (s, CHarom), 123.47 (s, CH2CHCH), 
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117.90 (s, CHarom), 114.26 (s, CHarom), 83.78 (s, C(CH3)2), 72.04 (s, OCH2), 70.74 (s, OCH2), 70.70 (s, 
OCH2), 69.31 (s, OCH2), 66.08 (s, OCH2), 66.00 (s, OCH2), 63.71 (s, OCH2), 59.19 (s, OCH3), 32.04 (s, 
CH2CH2CH), 25.08 (s, C(CH3)2), 24.99 (s, CaromCOCH3). 
13C-HMBC 138.4 (s, CaromB) 
 
 Reactions starting with propargyl bromide (Scheme 48, p.89) 
Step 1 – Alkylation – Synthesis of compound 125c 
Following the general alkylation procedure and using propargyl bromide (134, 6.6 mmol) as the 
mentioned haloalkyl derivative, compound 125c was obtained as a white solid in 68% yield (0.85 g). 
1H NMR (500 MHz, CDCl3) δ 11.89 (s, 1H, CaromOH), 7.32 (d, J = 3.0 Hz, 1H, 
CHarom), 7.18 (dd, J = 9.1, 3.0 Hz, 1H, CHarom), 6.94 (d, J = 9.1 Hz, 1H, CHarom), 
4.68 (d, J = 2.4 Hz, 2H, CHCCH2O-), 2.62 (s, 3H, CaromCOCH3), 2.54 (t, J = 
2.4 Hz, 1H, CHCCH2O-). 
 
Step 2 – Triflation – Synthesis of compound 124c 
Following the general triflation procedure and using compound 125c as the starting material (0.42 
mmol), compound 124c was obtained as a white solid in 94% yield (0.12 g). 
1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 3.1 Hz, 1H, CHarom), 7.29 – 7.25 
(m, 1H, CHarom), 7.15 (dd, J = 9.0, 3.1 Hz, 1H, CHarom), 4.75 (d, J = 2.4 Hz, 
2H, CHCCH2O-), 2.61 (s, J = 9.9 Hz, 3H, CaromCOCH3), 2.58 (s, J = 2.4 Hz, 
1H, CHCCH2O-). 
 
Step 3 – Miyaura-Borylation – Synthesis of compound 123c (Unsuccessful) 
Based on general borylation procedure, two attempts were made to synthesize compound 123c, 
however, after a few minutes of reaction the starting material 124c was fully consumed without forming 
any new relevant spot on the TLC.  
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 Reactions starting with 5-chloro-1-pentyne (Scheme 49, p.89) 
Step 1 – Alkylation – Synthesis of compound 125d 
Following the general alkylation procedure and using 5-chloro-1-pentyne (135, 6.6 mmol) as the 
mentioned haloalkyl derivative, after 28 h, compound 125d was obtained as a white solid in 62% yield 
(0.9 g). 
1H NMR (500 MHz, CDCl3) δ 12.72 (s, 1H, CaromOH), 7.62 (d, J = 8.7 Hz, 
1H, CHarom), 6.46 – 6.39 (m, 2H, 2xCHarom), 4.10 (t, J = 6.1 Hz, 
2H, -CH2CH2CH2O-), 2.55 (s, 3H, CaromCOCH3), 2.40 (td, J = 6.9, 2.6 Hz, 
2H, -CH2CH2CH2-), 2.05 – 1.97 (m, 3H, CHCCH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 202.70 (s, CaromCOCH3), 165.51 (s, CaromOCH2-), 165.31 (s, 
CHCaromOHC), 132.43 (s, CHarom), 114.01 (s, -CHCaromCOCH3), 108.02 (s, CHarom), 101.47 (s, CHarom), 
83.14 (s, CHCCH2CH2-), 69.31 (s, CHCCH2CH2-), 66.54 (s, -CH2CH2CH2O-), 27.91 (s, CHCCH2CH2-), 
26.36 (s, CaromCOCH3), 15.20 (s, -CH2CH2CH2-). 
 
Step 2 – Triflation – Synthesis of compound 124d 
Following the general triflation procedure and using compound 125d as the starting material (0.42 
mmol), compound 124d was obtained as a white solid in 90% yield (1.2 g). 
1H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 8.8 Hz, 1H, CHarom), 6.96 
(dd, J = 8.8, 2.4 Hz, 1H, CHarom), 6.82 (d, J = 2.2 Hz, 1H, CHarom), 4.15 
(t, J = 6.1 Hz, 2H, -CH2CH2CH2O-), 2.59 (s, 3H, CaromCOCH3), 2.42 
(td, J = 6.8, 2.7 Hz, 2H, -CH2CH2CH2-), 2.13 – 1.91 (m, 3H, 
CHCCH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 195.20 (s, CaromCOCH3), 163.05 (s, CaromOCH2-), 148.62 (s, CaromOTf), 
132.89 (s, CHarom), 124.10 (s, CaromCOCH3), 118.73 (q, J = 320.7 Hz, - SO2CF3), 113.79 (s, CHarom), 
109.51 (s, CHarom), 82.83 (s, CHCCH2CH2-), 69.53 (s, CHCCH2CH2-), 67.17 (s, -CH2CH2CH2O-), 29.23 
(s, CHCCH2CH2-), 27.75 (s, CaromCOCH3), 15.11 (s, -CH2CH2CH2-). 
 
Step 3 – Miyaura-Borylation – Synthesis of compound 123d (Unsuccessful) 
Based on general borylation procedure, two attempts were made to synthesize compound 123d, 
however, after a few minutes of reaction the starting material 124c was also fully consumed without 
forming any new relevant spot on the TLC. This decomposition was later demonstrated by performing a 
1H-NMR of the crude reaction after 2 h (Figure 30, p.90). 
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 Alternative substrate for Miyaura-Borylation starting with 5-chloro-1-pentyne (Scheme 
50, p.90) 
Step 1 – Synthesis of compound 137 
Literature Basis – Shao, C.; Wang, X.; Zhang, Q.; Luo, S.; Zhao, J.; Hu, Y. Journal of Organic 
Chemistry 2011, 76, 6832 
In a flame dried round bottom flask, under inert atmosphere, compound 124d (65 mg, 0.2 mmol), 
copper iodide (0.4 mg, 1.8 μmol), N,N-Diisopropylethylamine (DIPEA, 0.7 μL, 3.7 μmol) and acetic acid 
(HOAc, 0.2 μL, 3.7 μmol) were mixed in 1 mL of freshly distilled dichloromethane. Then, compound 136 
(37 mg, 0.2 mmol) was added at room temperature and left reacting for 5 h (first reaction of Scheme 50, 
p.90). The reaction mixture was concentrated and purified through a flash chromatography column (silica 
gel, dichloromethane) to afford 98 mg of compound 137 as a greenish oil (98%). 
1H NMR (600 MHz, CDCl3) δ 7.82 (d, J = 8.8 
Hz, 1H, CHarom), 7.54 (s, 1H, -NCHC-), 6.94 
(d, J = 8.8 Hz, 1H, CHarom), 6.80 (s, 1H, 
CHarom), 4.51 (t, J = 4.9 Hz, 2H, -OCH2CH2N-), 
4.10 (t, J = 6.1 Hz, 2H, -CH2CH2CH2O-), 3.85 
(t, J = 4.9 Hz, 2H, -OCH2CH2N-), 3.60 (dd, J = 6.6, 3.8 Hz, 6H, -OCH2-), 3.53 (dd, J = 5.1, 3.7 Hz, 
2H, -OCH2-), 3.36 (s, 3H, -OCH3), 2.91 (t, J = 7.4 Hz, 2H, -CCH2CH2-), 2.58 (s, 3H, CaromCOCH3), 2.26 – 
2.19 (m, 2H, -CH2CH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 195.18 (s, CaromCOCH3), 163.16 (s, CaromOCH2-), 148.60 (s, CaromOTf), 
146.64 (s, -NCHCCH2-), 132.91 (s, CHarom), 123.98 (s, CaromCOCH3), 122.39 (s, -NCHC-), 118.72 (q, J = 
320.7 Hz, -SO2CF3), 113.68 (s, CHarom), 109.62 (s, CHarom), 72.00 (s, -OCH2-), 70.61 (s, -OCH2-), 70.57 
(s, -OCH2-), 69.63 (s, -OCH2CH2N-), 68.08 (s, -CH2CH2CH2O-), 59.15 (s, -OCH3), 50.26 (s, -OCH2CH2N-), 
29.22 (s, CaromCOCH3), 28.66 (s, -CH2CH2CH2-), 22.02 (s, -CCH2CH2-). 
 
Step 2 – Miyaura-Borylation with compound 137 (resulting from CuAAC) 
Literature basis – Patent: Anacor Pharmaceuticals, Inc.; GlaxoSmithKline; US2010/256092; (2010); 
(A1) English 
In a flame dried round bottom flask, under inert atmosphere, compound 137 (93 mg, 0.17 mmol), 
bis(pinacolato)diboron (120, 88 mg, 0.35 mmol), [1,1’-bis(diphenylphosphino)ferrocene]palladium (II) 
chloride (14 mg; 0.017 mmol) and sodium acetate (42 mg, 0.52 mmol) were flushed 3 times with Argon. 
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Then, 2 mL of previously distilled dioxane were added and degassed for 10 minutes with bubbling Argon. 
The reaction mixture was heated at 100 ºC for 8 h (second reaction of Scheme 50, p.90), after which the 
solvent was concentrated in vacuum and the crude residue purified by flash column chromatography 
(silica gel, dichloromethane:methanol (1:0 – 9.5:0.5)) to give a light yellow oil (42 mg). This oil was a 
mixture of compound 138 (44%) and the protolytic deboronation compound (56%). 
 
 
Signals from the protolytic deboronation compound are marked with (*) 
1H NMR (600 MHz, CDCl3) δ 7.89 (d, J = 8.2 Hz, 1.28H, 2xCHarom*), 7.74 (d, J = 8.6 Hz, 1H, CHarom), 
7.51 (s, 0.59H, -NCHC-*), 7.49 (s, 1H, -NCHC-), 6.93 (d, J = 1.6 Hz, 1H, CHarom), 6.89 (d, J = 8.4 Hz, 
1.28H, CHarom*), 6.83 (dd, J = 8.4, 2.1 Hz, 1H, CHarom), 4.48 (t, J = 5.0 Hz, 3.42H, -OCH2CH2N- 
and -OCH2CH2N-*), 4.06 (q, J = 5.7 Hz, 3.38H, -CH2CH2CH2O- and , -CH2CH2CH2O-*), 3.82 (t, J = 4.9 
Hz, 3.37H, -OCH2CH2N- and -OCH2CH2N-*), 3.61 – 3.53 (m, 10.12H, , -OCH2- and , -OCH2-*), 3.50 (dd, 
J = 5.0, 3.8 Hz, 3.29H, , -OCH2- and , -OCH2-*), 3.34 (d, J = 0.7 Hz, 5.11H, , -OCH3 and -OCH3*), 2.89 
(dd, J = 13.0, 6.7 Hz, 3.47H, , -CCH2CH2- and , -CCH2CH2-*), 2.52 (s, 4.86H, CaromCOCH3 and  
CaromCOCH3*), 2.18 (dd, J = 13.5, 6.6 Hz, 3.45H, -CH2CH2CH2- and -CH2CH2CH2-*), 1.41 (s, 12H, 
2xC(CH3)2). 
13C NMR (151 MHz, CDCl3) δ 198.51 (s, CaromCOCH3), 196.88 (s, CaromCOCH3*), 162.97 (s, 
CaromOCH2-), 162.76 (s, CaromOCH2-*), 146.84 (s, -NCHCCH2-), 146.83 (s, -NCHCCH2-*),  133.42 (s, 
CaromCOCH3), 130.85 (s, CHarom), 130.65 (s, CHarom*), 130.26 (s, CaromCOCH3*), 122.31 (s, -NCHC-), 
122.29 (s, -NCHC-*), 118.00 (s, CHarom), 114.19 (s, CHarom), 113.99 (s, CHarom*), 83.65 (s, C(CH3)2), 71.95 
(s, -OCH2-), 70.56 (s, -OCH2-), 70.53 (s, -OCH2-), 69.60 (s, -OCH2CH2N-), 67.19 (s, -CH2CH2CH2O-), 
67.04 (s, -CH2CH2CH2O-*), 59.11 (s, -OCH3), 50.16 (s, -OCH2CH2N-), 28.83 (s, -CH2CH2CH2-), 28.81 (s, 
-CH2CH2CH2-*), 26.43 (s, CaromCOCH3*), 25.01 (s, C(CH3)2), 24.89 (s, CaromCOCH3), 22.11 
(s, -CCH2CH2-), 22.06 (s, -CCH2CH2-*). 
13C-HMBC 138.5 (s, CaromB) 
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 Reactions starting with (5-chloro-1-pentynyl)trimethylsilane (Scheme 51, p.91) 
Step 1 – Alkylation – Synthesis of compound 125e 
Following the general alkylation procedure and using (5-chloro-1-pentynyl)trimethylsilane (139, 6.6 
mmol) as the mentioned haloalkyl derivative, after 40 h, compound 125e was obtained as a white solid in 
39% yield (0.7 g). 
1H NMR (600 MHz, CDCl3) δ 12.72 (s, 1H, CaromOH), 7.60 (d, J = 8.8 
Hz, 1H, CHarom), 6.43 – 6.38 (m, 2H, 2xCHarom), 4.07 (t, J = 6.1 Hz, 
2H, -CH2CH2CH2O-), 2.53 (s, 3H, CaromCOCH3), 2.41 (t, J = 6.9 Hz, 
2H, -CH2CH2CH2-), 1.98 (p, J = 6.5 Hz, 2H, (CH3)3SiCCCH2CH2-), 
0.13 (s, 9H, (CH3)3SiCCCH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 202.64 (s, CaromCOCH3), 165.54 (s, CaromOCH2-), 165.31 (s, 
CHCaromOHC), 132.40 (s, CHarom), 113.95 (s, -CHCaromCOCH3), 108.01 (s, CHarom), 105.83 (s, 
(CH3)3SiCCCH2-), 101.44 (s, CHarom), 85.60 (s, (CH3)3SiCCCH2-), 66.69 (s, -CH2CH2CH2O-), 28.05 (s, 
(CH3)3SiCCCH2CH2-), 26.32 (s, CaromCOCH3), 16.60 (s, -CH2CH2CH2-), 0.21 (s, (CH3)3SiCCCH2CH2-). 
 
Step 2 – Triflation – Synthesis of compound 124e 
Following the general triflation procedure and using compound 125e as the starting material (2.6 
mmol), compound 124e was obtained as a white solid in 82% yield (0.9 g). 
1H NMR (600 MHz, CDCl3) δ 7.83 (d, J = 8.8 Hz, 1H, CHarom), 
6.95 (dd, J = 8.8, 2.3 Hz, 1H, CHarom), 6.80 (d, J = 2.2 Hz, 1H, 
CHarom), 4.13 (t, J = 6.1 Hz, 2H, -CH2CH2CH2O-), 2.58 (s, 3H, 
CaromCOCH3), 2.44 (t, J = 6.9 Hz, 2H, -CH2CH2CH2-), 2.01 (p, J 
= 6.5 Hz, 2H, (CH3)3SiCCCH2CH2-), 0.13 (s, 9H, (CH3)3SiCCCH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 195.16 (s, CaromCOCH3), 163.12 (s, CaromOCH2-), 148.64 (s, CaromOTf), 
132.88 (s, CHarom), 124.03 (s, -CHCaromCOCH3), 118.73 (q, J = 320.6 Hz, - SO2CF3), 113.79 (s, CHarom), 
109.47 (s, CHarom), 105.43 (s, (CH3)3SiCCCH2-), 85.92 (s, (CH3)3SiCCCH2-), 67.35 (s, -CH2CH2CH2O-), 
29.19 (s, (CH3)3SiCCCH2CH2-), 27.85 (s, CaromCOCH3), 16.51 (s, -CH2CH2CH2-), 0.14 (s, 
(CH3)3SiCCCH2CH2-). 
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Step 3 – Miyaura-Borylation – Synthesis of compound 123e 
Following the general borylation procedure and using compound 124e as the starting material (0.24 
mmol), compound 123e was obtained as a white solid in 48% yield (46 mg). This reaction was monitored 
by a 1H-NMR kinetic study following the mentioned general procedure (Figure 31, p.91). 
1H NMR (600 MHz, CDCl3) δ 7.77 (d, J = 8.6 Hz, 1H, CHarom), 6.96 
(d, J = 2.4 Hz, 1H, CHarom), 6.86 (dd, J = 8.6, 2.4 Hz, 1H, CHarom), 
4.11 (t, J = 6.1 Hz, 2H, -CH2CH2CH2O-), 2.55 (s, 3H, 
CaromCOCH3), 2.43 (t, J = 7.0 Hz, 2H, -CH2CH2CH2-), 1.99 (t, J = 
6.5 Hz, 2H, (CH3)3SiCCCH2CH2-), 1.43 (s, 12H, 2xC(CH3)2), 0.13 (s, 9H, (CH3)3SiCCCH2CH2-). 
13C NMR (151 MHz, CDCl3) δ 198.66 (s, CaromCOCH3), 162.77 (s, CaromOCH2-), 133.52 
(s, -CHCaromCOCH3), 130.89 (s, CHarom), 118.14 (s, CHarom), 114.01 (s, CHarom), 106.02 (s, 
(CH3)3SiCCCH2-), 85.51 (s, (CH3)3SiCCCH2-), 83.73 (s, C(CH3)2), 66.52 (s, -CH2CH2CH2O-), 28.23 (s, 
(CH3)3SiCCCH2CH2-), 25.05 (s, C(CH3)2), 24,92 (s, CaromCOCH3), 16.65 (s, -CH2CH2CH2-), 0.23 (s, 
(CH3)3SiCCCH2CH2-). 
13C-HMBC 138.6 (s, CaromB) 
 
Step 4 – Deprotection – Synthesis of compound 123e1 (Unsuccessful) 
Literature Basis – Cai, C.; Vasella, A. Helvetica Chimica Acta 1995, 78(3), 732 
In a flame dried round bottom flask, under inert atmosphere, compound 123e (30 mg, 0.075 mmol) 
was dissolved in 0.5 mL of THF at 0 ºC. Then a solution of 0.7 mL of THF (with 5% water) with 
tetrabutylammonium fluoride trihydrate (30 mg, 0.095 mmol) was added and stirred for 5 minutes. Then, 
1.2 mL hexane was added and it was left stirring for more 10 minutes. After that, the reaction mixture was 
concentrated under reduced pressure and a preparative chromatography was performed (silica gel, 
hexane:diethyl ether (3:2)) to afford the starting material as the minor product and a product without alkylic 
proton signals as the major product. No expected product was ever detected. 
 
VI.3.1.2.3. Strategy 3 
 Synthesis of compound 143 
Literature basis - Al-Smadi, M.; Hanold, N.; Kalbitz, H.; Meier, H.; Synthesis, 2009, 15, 2539 
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In a round bottom flask (A), 2’,4’-dihydroxyacetophenone (115, 5.0 g, 32.9 mmol) and potassium 
carbonate (4.5 g, 32.9 mmol) were heated in acetone to reflux for 2 h. In a separate round bottom flask 
(B), ethyl 4-bromobutyrate (145, 4.7 mL, 32.9 mmol) and sodium 
iodide (5.4 g, 36.1 mmol) were stirred in acetone at room 
temperature for 2 h. Then, flask B was transferred to flask A and 
refluxed for 20 h (first reaction of Scheme 53, p.93). After that, 
acetone was evaporated to dryness and 200 mL of water were added and extracted with diethyl ether 
(3*200 mL). The solution was dried (Na2SO4), concentrated and purified by column chromatography (silica 
gel, hexane:diethyl ether (9:1)) to give a viscous oil that solidified below 20 ºC; compound 143 (7.6 g, 
87%) 
1H NMR (400 MHz, CDCl3): δ 12.70 (s, 1H, CaromOH), 7.59 (d, J = 8.9 Hz, 1H, CHarom), 6.39 (d, J = 8.9 
Hz, 1H, CHarom), 6.36 (s, 1H, CHarom), 4.12 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.02 (t, J = 6.1 Hz, 2H, 
OCH2CH2), 2.52 (s, 3H, COCH3), 2.48 (t, J = 7.2 Hz, 2H, CH2CH2CO), 2.09 (p, J = 6.6 Hz, 2H, 
CH2CH2CH2), 1.24 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, CDCl3): δ 202.62 (s, CCOCH3), 173.01 (s, CH2COO), 165.37 (s, CHCaromOHC), 
165.21 (s, (CH)2CaromOCH2), 132.39 (s, CHarom), 113.95 (s, CHCaromCOCOH), 107.85 (s, CHarom), 101.42 
(s, CHarom), 67.15 (s, OCH2CH2), 60.59 (s, OCH2CH3), 30.68 (s, CH2CH2CO), 26.28 (s, COCH3), 24.39 
(s, CH2CH2CH2), 14.29 (s, CH2CH3). 
HRMS (ESI): m/z calculated [M+Na]+ = 289.10464, found [M+Na]+ = 289.10334. 
 
 Synthesis of compound 144 
Literature basis - Luker, T.; Bonnert, R.; Paine, S.W.; Schmidt, J.; Sargent, C.; Cook, A.R.; Cook, A.; 
Gardiner, P.; Hill, S.; Weyman-Jones, C.; Patel, A.; Thom, S.; Thorne, P.; Journal of Medicinal Chemistry 
2011 ,  54 (6), 17 
In a round bottom flask, N-Phenyltrifluoromethanesulfonimide (127, 3.05 g, 8.5 mmol) was added 
portion wise to a solution of compound 143 (3.0 g, 11.3 mmol) and triethylamine (TEA, 4.7 mL, 33.8 mmol) 
in DMF (27 mL) and the reaction stirred for 2 h at 25 ºC (second reaction of Scheme 53, p.93). After that, 
the mixture mixture was diluted in water and extracted with diethyl ether. The organic layer was washed 
with water, LiCl (aq), brine, dried (Na2SO4), concentrated and purified by column chromatography (silica 
gel, hexane:diethyl ether (4:1 – 1:1)) to give compound 144 as a white solid (3.9 g, 90%). 
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1H NMR (400 MHz, CDCl3): δ 7.82 (d, J = 8.8 Hz, 1H, CHarom), 
6.93 (d, J = 8.8 Hz, 1H, CHarom), 6.79 (s, 1H, CHarom), 4.14 (q, J 
= 7.1 Hz, 2H, OCH2CH3), 4.08 (t, J = 6.1 Hz, 2H, OCH2CH2), 2.57 
(s, 3H, COCH3), 2.50 (t, J = 7.1 Hz, 2H, CH2CH2CO), 2.13 (p, J 
= 6.6 Hz, 2H, CH2CH2CH2), 1.24 (t, J = 7.1 Hz, 3H, CH2CH3). 
13C NMR (101 MHz, CDCl3): δ 195.14 (s, CCOCH3), 172.93 (s, CH2COO), 162.96 (s, 
(CH)2CaromOCH2), 148.58 (s, CaromOTfC), 132.89 (s, CHarom), 124.05 (s, CaromCOCH3), 118.70 (q, J = 
320.6 Hz, -SO2CF3), 113.68 (s, CHarom), 109.53 (s, CHarom), 67.85 (s, OCH2CH2), 60.71 (s, OCH2CH3), 
30.49 (s, CH2CH2CO), 29.15 (s, COCH3), 24.27 (s, CH2CH2CH2), 14.28 (s, CH2CH3). 
HRMS (ESI): m/z calculated [M+K]+ = 437.027867, found [M+K]+ = 437.027219. 
 
 Synthesis of compound 142 
Literature basis - Patent: Anacor Pharmaceuticals, Inc.; GlaxoSmithKline; US2010/256092; (2010); 
(A1) English 
In a flame dried round bottom flask, under inert atmosphere, 144 (0.5 g, 1.25 mmol), 
bis(pinacolato)diboron (120, 0.6 g, 2.51 mmol), [1,1’-bis(diphenylphosphino)ferrocene]palladium (II) 
chloride (0.1 g; 0.125 mmol) and sodium acetate (0.3 g, 3.76 mmol) were flushed 3 times with Argon. 
Then, 8 mL of previously distilled dioxane were added and degassed for 10 minutes with bubbling Argon. 
The reaction mixture was heated at 95 ºC for 4 h (third reaction of Scheme 53, p.93), after which the 
solvent was concentrated in vacuum and the crude residue purified by flash column chromatography 
(silica gel, dichloromethane:diethyl ether (19:1 – 9:1)) to give 142 as a white solid (0.3 g, 64%). 
1H NMR (400 MHz, CDCl3): δ 7.74 (d, J = 8.6 Hz, 1H, CHarom), 
6.93 (s, 1H, CHarom), 6.82 (d, J = 8.6 Hz, 1H, CHarom), 4.11 (q, J 
= 7.1 Hz, 2H, OCH2CH3), 4.04 (t, J = 6.0 Hz, 2H, OCH2CH2), 
2.54 – 2.45 (m, 5H, COCH3, CH2CH2CO), 2.12 – 2.05 (m, 2H, 
CH2CH2CH2), 1.41 (s, 12H, 2xC(CH3)2), 1.23 (t, J = 7.1 Hz, 3H, OCH2CH3). 
13C NMR (101 MHz, CDCl3): δ 198.54 (s, CaromCOCH3), 173.16 (s, CH2COO), 162.57 (s, CaromOCH2), 
133.47 (s, CH3COCarom), 130.79 (s, CHarom), 117.94 (s, CHarom), 113.98 (s, CHarom), 83.63 (s, C(CH3)2), 
66.87 (s, OCH2CH2), 60.54 (s OCH2CH3), 30.60 (s, CH2CH2CO), 24,95 (s, C(CH3)2), 24.54 (s, 
CH3COCarom), 24.47 (s, CH2CH2CH2), 14.32 (s, OCH2CH3). 
13C-HMBC 138.5 (s, CaromB) 
HRMS (ESI): m/z calculated [M+H]+ = 377.213364, found [M+H]+ = 377.211988. 
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 Synthesis of compound 141 
Literature basis - Griffin, D.R.; Andrea M. Kasko, A.M.; Journal of the American Chemical Society 
2012, 134, 13103 
In a round bottom flask, under inert atmosphere, compound 142 (1.3 g, 3.4 mmol) was stirred in a 
solution of trifluoroacetic acid (1 mL) and water (9.5 mL) at 90 ºC for 3 h (fourth reaction of Scheme 53, 
p.93), after which the solvent was concentrated in vacuo. The product was purified by flash column 
chromatography (silica gel, dichloromethane:diethyl ether 9:1 – 1:1) and recrystallized in diethyl ether to 
afford 141 (0.9 g, 77%). 
1H NMR (400 MHz, CDCl3): δ 7.77 (d, J = 8.6 Hz, 1H, CHarom), 6.96 
(d, J = 2.3 Hz, 1H, CHarom), 6.85 (dd, J = 8.6, 2.3 Hz, 1H, CHarom), 
4.09 (t, J = 6.0 Hz, 2H, OCH2CH2), 2.58 (t, J = 7.1 Hz,2H, 
CH2CH2COOH), 2.55 (s, 3H, COCH3), 2.12 – 2.05 (m, 2H, 
CH2CH2CH2), 1.44 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3): δ 198.92 (s, CaromCOCH3), 178.49 (s, CH2COO), 162.64 (s, CaromOCH2), 
133.53 (s, CH3COCarom), 130.83 (s, CHarom), 117.86 (s, CHarom), 114.16 (s, CHarom), 83.73 (s, C(CH3)2), 
66.75 (s, OCH2CH2), 30.39 (s, CH2CH2CO), 24.99 (s, C(CH3)2), 24.77 (s, COCH3), 24.28 (s, CH2CH2CH2). 
13C-HMBC 138.7 (s, CaromB) 
HRMS (ESI): m/z calculated [M+H]+ = 349.182029, found [M+H]+ = 349.181109. 
 
 Synthesis of compound 140 
Literature basis - Pennington, T.E.; Kardiman, C.; Hutton, C.A.; Tetrahedron Letters 2004, 45, 6657 
Treatment of compound 141 with 5 equiv of polystyrene–boronic acid (146) in acetonitrile/1 M HCl 
(9:1) for 20 h at 25 ºC (fifth reaction of Scheme 53, p.93) gave 8% yield of compound 140, after 
evaporating solvents and performing a flash column chromatography (silica gel, acetone:methanol).  
1H NMR (400 MHz, D2O) δ 7.95 (d, J = 8.0 Hz, 1H, CHarom), 6.96 (s, 
2H, 2xCHarom), 4.13-4.09 (m, 2H, OCH2CH2), 2.55-2.47 (m, 5H, 
COCH3 and CH2CH2CH2), 2.03 (d, J = 7.0 Hz, 2H, -CH2CH2COOH). 
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VI.4. Experimental Section of Chapter IV 
VI.4.1. General Procedures 
VI.4.1.1. Esterification or amidation of compound 141 
 General Procedure for Amidation Reaction 
Literature basis - Park, S. Y.; Oh, K. T.; Oh, Y. T.; Oh, N. M.; Youn, Y. S.; Lee, E. S. Chemical 
Communication, 2012, 48, 2522 
 
1) DCC, NHS-OH,  
THF, 16 h, r.t. 
 
2) THF, 2 h,  
r.t., ~% 
  
141 218 219 
Scheme 80 – General Procedure for Amidation of compound 141 
 
In a round bottom flask, under inert atmosphere, compound 141 (1 equivalent), 
N,N’-dicyclohexylcarbodiimide (DCC, 2 equivalents) and N-hydroxysuccinimide (NHS-OH, 1 equivalent) 
were mixed at room temperature in previously distilled tetrahydrofuran (0.06 M) and stirred overnight. 
Then, DCU was filtered from the reaction and the amine derivative (218x, 1.2 equivalents) was added and 
the solution stirred for 2 h at room temperature (Scheme 80). After that, the solvent was concentrated 
under reduced pressure and redissolved in ethyl acetate, which was then washed with water and brine. 
The solvents were evaporated under reduced pressure and the crude products were further purified by 
flash column chromatography to afford different compounds with different yields (219x). 
 
 General Procedure for Esterification Reaction 
Literature basis - Liu, Z.; Hu, J.; Sun, J.; He, G.; Li, Y.; Zhang, G.; Journal of Polymer Science Part A: 
Polymer Chemistry 2010, 48 (16), 3573 
 
141 
1) DCC, DMAP,  
ACN, 0.5 h, 0 ºC 
 
2) ACN, 22h,  
0 ºC→r.t., ~% 
 
 
220 
 221  
Scheme 81 – General Procedure for Esterification of compound 141 
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In a round bottom flask, under inert atmosphere, compound 141 (1 equivalent), 
N,N’-dicyclohexylcarbodiimide (DCC, 3 equivalents) and 4-dimethylaminopyridine (DMAP, 0.1 equivalent) 
were mixed at 0 ºC in previously distilled acetonitrile (ACN, 0.11 M) and stirred for 30 minutes. A solution 
of the alcohol derivative (221x, 2 equivalents) in previously distilled acetonitrile (0.22 M) was added via a 
syringe and the solution was stirred for 22 h at room temperature (Scheme 81). The solvent was, then, 
concentrated in vacuo and the residues were purified by flash column chromatography to afford different 
compounds with different yields (220x). 
 
VI.4.1.2. Deprotection of pinacolyl boronate ester 
Literature basis - Pennington, T.E.; Kardiman, C.; Hutton, C.A.; Tetrahedron Letters 2004, 45, 6657 
 
 
CH3CN:HCl (1M) (9:1) 
20 h, r.t., Ar, ~% 
 
146 
 
 
219 (X = N) 
220 (X = O) 
 
222 
 
Scheme 82 – General procedure for deprotection of pinacolyl boronate ester of compounds 219x and 220x  
 
Treatment of compound 219x or 220x with 5 equiv of polystyrene–boronic acid in acetonitrile/1 M HCl 
(9:1) for 20 h at 25 ºC (Scheme 82), gave different yields of compounds 222x, after evaporating solvents 
and performing a flash column chromatography. These compounds were immediately used for 
conjugation after deprotection. 
 
VI.4.2. Experimental Details of Glycosilation 
VI.4.2.1. Direct insertion of glycosyl derivative 
 First Attempt to synthesize a glycosyl derivative 148 (Unsuccessful) 
Based on the general procedure for esterification of compound 141, using freshly distilled 
dichloromethane instead of THF and D-glucose (147) as the alcohol derivative (Scheme 54, p.102), an 
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attempt was made to synthesize compound 148 though after a preparative chromatography (silica gel, 
ethyl ether) no product with aromatic proton signals was ever detected. 
 
 Second Attempt to synthesize a glycosyl derivative 148  
Step 1 – Synthesis of compound 131 
Literature Basis - Chen, N.; Jia, W.; Xu, J. European Journal of Organic Chemistry 2009 (33), 5841 
In a round bottom flask, 2-ethanolamine (150, 0.6 mL, 0.01 mol) was dissolved in an aqueous solution 
of potassium hydroxide (50 mL of KOH (1 M)) and, then, carbon disulfide (149, 3.1 mL, 0.05 mol) was 
added. The reaction mixture was heated at reflux for 16 h (top reaction of Scheme 55, p.103). After cooling 
to room temperature, the reaction mixture was extracted with dichloromethane (3x20 mL), dried (Na2SO4), 
filtered and concentrated under reduced pressure to give the crude product, which was purified by 
recrystallization with ethyl acetate to afford the product 131 as colorless crystals (0.4 g, 35%). 
 
1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H, CH2NHCS), 3.99 (t, J = 7.6 Hz, 2H, -CH2CH2NH-), 
3.55 (t, J = 7.6 Hz, 2H, -SCH2CH2-). 
13C NMR (101 MHz, CDCl3) δ 201.84 (s, -SCSNH-), 51.46 (s, -CH2CH2NH-), 33.77 (s, -SCH2CH2-). 
 
Step 2 – Synthesis of compound 152 
Literature Basis - Baczko, K.; Plusquellec, D. Tetrahedron Letters 1991, 47(23), 3817 
In a round bottom flask, under inert atmosphere, compound 141 (0.1 g, 0.3 mmol) and 
N,N’-dicyclohexylcarbodiimide (DCC, 0.09 g, 0.43 mmol) were dissolved in 5 mL of distilled ethyl acetate. 
Then, compound 130 (34 mg, 0.3 mmol) was added and the compounds were left reacting for 40 h at 
room temperature (middle reaction from Scheme 55, p.103). After that, the reaction mixture was filtrated 
and the solution concentrated under reduced pressure. The crude product was further purified flash 
column chromatography (silica gel, dichloromethane:diethyl ether (1:0 – 1:1)) to afford compound 152 in 
31% yield (40 mg). 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 1H, CHarom), 
6.95 (d, J = 2.0 Hz, 1H, CHarom), 6.86 (dd, J = 8.6, 2.0 Hz, 1H, 
CHarom), 4.57 (t, J = 7.5 Hz, 2H, NCH2CH2S), 4.09 (t, J = 6.0 Hz, 
2H, OCH2CH2), 3.44 (t, J = 6.9 Hz, 2H, CH2CH2CON), 3.27 (t, J 
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= 7.5 Hz, 2H, NCH2CH2S), 2.54 (s, 3H, COCH3), 2.18 (p, J = 6.4 Hz, 2H, CH2CH2CH2), 1.43 (s, 12H, 
2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 201.74 (s, NCSS), 198.57 (s, CaromCOCH3), 174.11 (s, CH2CON), 
162.62, 133.54 (s, CH3COCarom), 130.87 (s, CHarom), 117.96 (s, CHarom), 114.19 (s, CHarom), 83.70 (s, 
C(CH3)2), 66.81 (s, OCH2CH2), 56.05 (s, CONCH2CH2), 35.12 (s, NCH2CH2S), 28.40 (s, CH2CH2CH2), 
25.04 (s, C(CH3)2), 24.93 (s, COCH3), 24.37 (s, CH2CH2CO). 
13C-HMBC 138.5 (s, CaromB)^ 
 
Step 3 – Glycosyl derivative selective esterification (Unsuccessful) 
Literature Basis - Baczko, K.; Plusquellec, D. Tetrahedron Letters 1991, 47(23), 3817 
In a round bottom flask, under inert atmosphere, compound 152 (40 mg, 0.09 mmol) was dissolved in 
0.5 mL of freshly distilled pyridine (over CaH2). Then, 4-dimethylaminopyridine (DMAP, 9 mg, 0.07 mmol) 
and sodium hydride (60%, 2 mg, 0.04 mmol) were added, followed by D-glucose (35 mg, 0.18 mmol). 
Compounds were left reacting at room temperature for 24 h (last reaction of Scheme 55, p.103), after 
which, acetic acid was added to the reaction mixture and the reaction mixture concentrated under reduced 
pressure. Multiple extractions between different aqueous and organic phases were made, though the 
evaluation of the crude product never indicated the presence of compound 148. 
 
VI.4.2.2. Indirect insertion of glycosyl derivative 
 Synthesis of pinacolyl boronate ester of compound 154 (222a) 
Following the general procedure for esterification of compound 141, using propargyl alcohol as the 
alcohol derivative (0.6 mmol), EDC instead of DCC and DCM instead of ACN, after 17 h, compound 222a 
was obtained as a white solid in 74% yield (0.1 g). 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 1H, CHarom), 
6.95 (d, J = 1.9 Hz, 1H, CHarom), 6.84 (dd, J = 8.6, 2.0 Hz, 1H, 
CHarom), 4.69 (d, J = 1.8 Hz, 2H, -OCH2CCH), 4.07 (t, J = 6.0 
Hz, 2H, -OCH2CH2-), 2.60 – 2.53 (m, 5H, -CH2CH2COO- and 
CaromCOCH3), 2.48 (s, 1H, -OCH2CCH), 2.17 – 2.10 (m, 2H, -CH2CH2CH2-), 1.43 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 198.59 (s, CaromCOCH3), 172.37 (s, -CH2COO-), 162.56 (s, CaromOCH2), 
133.64 (s, CaromCOCH3), 130.86 (s, CHarom), 117.94 (s, CHarom), 114.17 (s, CHarom), 83.79 (s, C(CH3)2), 
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77.69 (s, CH2CCH), 75.11 (s, -OCH2CCH), 66.74 (s, -OCH2CH2-), 52.13 (s, -OCH2CCH), 30.42 (s, 
CH2CH2CO), 25.07 (s, -C(CH3)2), 24.96 (s, CaromCOCH3), 24.45 (s, -CH2CH2CH2-). 
13C-HMBC 138.6 (s, CaromB) 
HRMS (ESI): m/z calculated [M+H]+ = 387.19773, found [M+H]+ = 387.19765. 
 
 Synthesis of compound 154 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound 222a 
as the starting material (64 mg, 0.2 mmol), after 25 h, compound 154 was obtained as a white solid in 
61% yield (34 mg). 
 
HRMS (ESI): m/z calculated [M+H]+ = 327.10132, found [M+H]+ = 327.10152. 
 
 Conjugation of compound 154 with Lysozyme 
Compound 154 dissolved in DMSO (1 mM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 22. 
 
Table 22 – Conjugation of compound 154 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.84832 [M+H]
+
 52.1 - 
Lysozyme + 154 14582.95071 [M+H]
+
 100.0 14582.94930 
Lysozyme + 2x154 14869.08390 [M+H]
+
 27.8 14869.05029 
Lysozyme + 3x154 15154.15850 [M+H]
+
 46.8 15155.15127 
Lysozyme + 4x154 15441.27006 [M+H]
+
 34.6 15441.252260 
Lysozyme + 5x154 15727.38332 [M+H]
+
 15.5 15727.353245 
Lysozyme + 6x154 16012.47857 [M+H]
+
 15.2 16012.44641  
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 CuAAC on Lysozyme’s surface 
Based on the procedure to conjugate compound 154 with lysozyme in NH4CH3CO2 buffer (50.0 mM, 
pH 7.0) at room temperature, an ESI-FTICR-MS and the conjugated species were detected. Afterwards, 
compound 155 dissolved in DMSO (5 mM) was added to the conjugated lyzosyme, alongside with copper 
sulfate (200 μM) and sodium ascorbate (5 mM) and this mixture was left reacting overnight at 37 ºC and 
1200 rpm. After that, an ESI-FTICR-MS was performed to detect the result of a click reaction. HRMS 
results of click product, as well as the deconvulted masses for unconjugated and conjugated species are 
shown in Table 23. 
 
Table 23 – CuAAC reaction between compound 154 and 155 on Lysozyme’s surface 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
154-155 696.20458 [M+H]
+
 - 696.20104 
Lysozyme 14297.82149 [M+H]
+
 100.0 - 
Lysozyme + 154-155 14953.08122 [M+H]+ 0.48 14953.02274 
Lysozyme + 154-155 14934.09105 [M+H-H2O]+ 1.11 14934.01218 
Lysozyme + 154-155 14918.22193 [M+H-2H2O]+ 0.15 14918.00161 
 
VI.4.3. Experimental Details of Bioimaging 
VI.4.3.1. Indirect attachment of a fluorescent probe 
 Synthesis of compound 156 
Literature basis – Wu, J.-C.;Wang, D.-X.;Huang, Z.-T.; Wang, M-X Journal of Organic Chemistry, 
2010, 75(24), 8604 
 +  
 
 
223  224  156 
Scheme 83 – Synthesis of compound 156 
 
In a round bottom flask, sodium azide (223, 1.0 g, 16.0 mmol) was slowly added to a solution of 
2-bromoethanol (224, 0.6 mL, 8.0 mmol) in 1 mL of water that was stirring over an ice bath. Then, the 
reactions were left stirring until they reach the room temperature. After 6 h, another equivalent of sodium 
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azide (223, 0.5 g, 8.0 mmol) was added and the reaction mixture heated at 80 ºC over 18 h (Scheme 83). 
After that time, the reaction was cooled down to room temperature and the residue was extracted with 
diethyl ether (10x10 mL), dried with MgSO4, filtered and the solvent evaporated to afford 2-azidoethanol 
(156) as a colorless oil (0.3 g, 41%). 
1H NMR (400 MHz, CDCl3) δ 3.68 (d, J = 3.0 Hz, 2H, CH2CH2OH), 3.34 (d, J = 2.0 Hz, 
2H, N3CH2CH2). 
13C NMR (101 MHz, CDCl3) δ 61.07 (s, CH2CH2OH), 53.23 (s, N3CH2CH2). 
NMR characterization in accordance with the one described in literature 
 
 Synthesis of pinacolyl boronate ester of 157 (222b) 
Following the general procedure for esterification of compound 141, using 2-azidoethanol (156) as the 
alcohol derivative (0.6 mmol), EDC instead of DCC and DCM instead of ACN, after 24 h, compound 222b 
was obtained as a white solid in 75% yield (0.09 g). 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 1H, CHarom), 
6.95 (d, J = 1.2 Hz, 1H, CHarom), 6.84 (dd, J = 8.6, 1.2 Hz,1H, 
CHarom), 4.28 – 4.23 (m, 2H, -OCH2CH2N3), 4.08 (t, J = 5.9 
Hz, 2H, -OCH2CH2CH2-), 3.49 – 3.43 (m, 2H, -OCH2CH2N3), 
2.61 – 2.52 (m, 5H, -CH2CH2COO- and CaromCOCH3), 2.13 (p, J = 6.5 Hz, 2H, -CH2CH2CH2-), 1.43 (s, 
12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 198.48 (s, CaromCOCH3), 172.79 (s, -CH2COO-), 162.55 (s, CaromOCH2), 
133.69 (s, CaromCOCH3), 130.83 (s, CHarom), 118.01 (s, CHarom), 114.12 (s, CHarom), 83.71 (s, C(CH3)2), 
66.82 (s, -OCH2CH2-), 63.13 (s, -OCH2CH2N3), 49.83 (s, -OCH2CH2N3), 30.50 (s, -CH2CH2CO-), 25.05 
(s, -C(CH3)2), 24.93 (s, CaromCOCH3), 24.46 (s, -CH2CH2CH2-). 
13C-HMBC 138.6 (s, CaromB) 
HRMS (ESI): m/z calculated [M+H]+ = 418.21476, found [M+H]+ = 418.21457. 
 
 Synthesis of compound 157 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound 222b 
as the starting material (68 mg, 0.2 mmol), after 20 h, compound 157 was obtained as a white solid in 
68% yield (37 mg).  
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HRMS (ESI): m/z calculated [M+Na]+ = 358.11835, found [M+Na]+ = 358.11896. 
 
 Conjugation of compound 157 with Lysozyme 
Compound 157 dissolved in DMSO (1 mM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 24. 
Table 24 – Conjugation of compound 157 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.81535 [M+H]
+
 51.7 - 
Lysozyme + 157 14614.03345 [M+H]
+
 100.0 14614.04070 
Lysozyme + 2x157 14931.15101 [M+H]
+
 86.7 14931.15926 
Lysozyme + 3x157 15248.30297 [M+H]
+
 42.9 15248.27783 
Lysozyme + 4x157 15565.40485 [M+H]
+
 50.3 15565.39639 
Lysozyme + 5x157 15881.52008 [M+H]
+
 37.5 15881.50740 
Lysozyme + 6x157 16198.65607 [M+H]
+
 14.2 16198.68338 
 
 
 SPAAC on Lysozyme’s surface 
Based on the procedure to conjugate compound 157 with lysozyme in NH4CH3CO2 buffer (50.0 mM, 
pH 7.0) at room temperature, an ESI-FTICR-MS and the conjugated species were detected. Afterwards, 
compound 158 dissolved in DMSO (5 mM) was added to the conjugated lyzosyme and, after 1 h, an ESI-
FTICR-MS was performed to detect the result of a click reaction. HRMS results of deconvulted masses 
for unconjugated and conjugated species are shown in Table 25. 
Table 25 - SPAAC reaction between compound 157 and 158 on Lysozyme’s surface 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14299.76846 [M+H]
+
 97.6 - 
Lysozyme + 157-158 15330.25383 [M+H]
+
 0.4 15330.22730 
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VI.4.3.2. Direct attachment of a fluorescent probe 
VI.4.3.2.1. Cell internalization study 
 Synthesis of 2-Dansylaminoethylamine (DNH(CH2)2NH2, 162) 
Literature basis - Sun, W.; Bandmann, H., Schrader, T.; Chemistry - A European Journal 2007, 13, 
7701 
In a round bottom flask, 1,2-ethylenediamine (161, 7.4 mL, 111 mmol) was diluted in dichloromethane 
previously distilled over CaH2 (25 mL) and cooled to 0 ºC, while stirring. A solution of dansyl chloride (159, 
1.0 g, 3.7 mmol) in dichloromethane 16 mL was added dropwise. The mixture was stirred while warming 
to room temperature (reaction on the left of Scheme 58, p.106). It was subsequently acidified with HCl (1 
M) and then extracted with dichloromethane (3x20 mL). The organic layer was dried (MgSO4) and 
concentrated to afford DNH(CH2)2NH2 as a light yellow solid (1.02 g, 94%). 
1H NMR (400 MHz, CDCl3) δ 8.53 (d, J = 8.5 Hz, 1H, CHarom), 8.31 (d, J 
= 8.5 Hz, 1H, CHarom), 8.24 (d, J = 7.5 Hz, 1H, CHarom), 7.57 – 7.49 (m, 
2H, 2xCHarom), 7.17 (d, J = 7.5 Hz, 1H, CHarom), 2.93 – 2.86 (m, 8H, 
CaromN(CH3)2 and -NHCH2CH2NH2), 2.69 (t, J = 5.7 Hz, 
2H, -NHCH2CH2NH2). 
13C NMR (101 MHz, CDCl3) δ 152.11 (s, CaromN(CH3)2), 134.88 (s, CaromSO2NH), 130.50 (s, CHarom), 
130.01 (s, CHarom), 129.73 (s, CNCaromCH), 129.68 (s, CHarom), 128.48 (s, CHCaromCSO2), 123.30 (s, 
CHarom), 118.86 (s, CHarom), 115.31 (s, CHarom), 45.62 (s, -NHCH2CH2NH2) 45.52 (s, CaromN(CH3)2), 40.99 
(s, -NHCH2CH2NH2). 
NMR characterization in accordance with the one described in literature 
 
 Synthesis of 4-(2-Hydroxyethylamino)-7-nitro-2,1,3-benzoxadiazole (NBD-NH(CH2)2OH, 163) 
Literature basis - Onoda, M.; Uchiyama, S., Santa, T., Imai, K.; Analytical Chemistry 2002, 74(16), 
4089 
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In a round bottom flask, under inert atmosphere, 4-Chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl, 160, 
100 mg, 0.50 mmol) was dissolved in acetonitrile (10 mL). After the addition of 2-ethanolamine (150, 200 
μL) in acetonitrile (5 mL), the solution was stirred at room temperature for 30 minutes (reaction on the 
right of Scheme 58, p.106). The reaction mixture was concentrated and the residue was purified by column 
chromatography (silica gel, dichloromethane-methanol (1:0 – 19:1)) to afford NBD-NH(CH2)2OH as an 
orange solid in 49% yield. This compound was immediately used after being synthesized.  
 
 Synthesis of N-(2-aminoethyl) folic acid (EDA-FA, 170, Scheme 59, p.107) 
Literature basis - Rutnakornpituk, M.; Puangsin, N.; Theamdee, P.; Rutnakornpituk, B.; Wichai, U.; 
Polymer, 2011, 52, 987 
The derivative of folic acid (N-(2-aminoethyl) folic acid (EDA-FA)) was synthesized according to an 
existing procedure obtaining 69% in the first step and 92% in the second one. 
HRMS (ESI): m/z calculated [M+H]+ = 484.20514, found [M+H]+ = 484.205640. 
 
 Synthesis of compound 164 
Following the general procedure for amidation of compound 141, using DNH(CH2)2NH2 (162) as the 
amine derivative (0.34 mmol), after 2 h, compound 164 was obtained as a light yellow solid in 23% yield 
(41 mg). 
1H NMR (400 MHz, CDCl3): δ 8.51 (d, J = 
8.5 Hz, 1H, CHarom), 8.25 (d, J = 8.6 Hz, 1H, 
CHarom), 8.18 (d, J = 7.2 Hz, 1H, CHarom), 
7.73 (d, J = 8.6 Hz, 1H, CHarom), 7.51 (dt, J 
= 19.6, 8.0 Hz, 2H, CHarom), 7.15 (d, J = 7.6 Hz, 1H, CHarom), 6.93 (d, J = 1.9 Hz, 1H, CHarom), 6.80 (dd, J 
= 8.6, 1.7 Hz, 1H, CHarom), 6.25 (s, 1H, CONHCH2), 6.00 (t, J = 5.6 Hz, 1H, CH2NHSO2), 3.96 (t, J = 5.8 
Hz, 2H, OCH2CH2), 3.25 (dd, J = 10.3, 5.3 Hz, 2H, CONHCH2), 2.96 (dd, J = 10.3, 5.3 Hz, 2H, 
CH2NHSO2), 2.85 (s, 6H, CaromN(CH3)2), 2.52 (s, 3H, COCH3), 2.17 (t, J = 7.2 Hz, 2H, CH2CH2CONH), 
2.00 – 1.96 (m, 2H, CH2CH2CH2), 1.42 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3): δ 198.68 (s, CaromCOCH3), 173.26 (s, CH2CONH), 162.66 (s, CaromOCH2), 
152.11 (s, CaromN(CH3)2), 134.45 (s, CHCaromSO2), 133.50 (s, CH3COCarom), 130.95 (s, CHarom), 130.66 
(s, CHarom), 129.95 (s, CNCaromCH), 129.67 (s, CHaromCSO2), 129.54 (s, CHCaromCSO2), 128.60 (s, 
CHarom), 123.31 (s, CHarom), 118.73 (s, CHarom), 118.17 (s, CHarom), 115.33 (s, CHaromCNCH3), 113.90 (s, 
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CHarom), 83.72 (s, C(CH3)2 ), 67.09 (s, OCH2CH2), 45.49 (s, CaromN(CH3)2), 43.25 (s, CH2NHSO2), 39.27 
(s, CONHCH2), 32.42 (s, CH2CH2CONH), 24,96 (s, C(CH3)2), 24,93 (s, CH2CH2CH2), 24,87 (s, COCH3). 
13C-HMBC 138.6 (s, CaromB) 
HRMS (ESI): m/z calculated [M+K]+ = 662.247383, found [M+K]+ = 662.247221. 
 
 
Figure 52 – UV spectrum of compound 164 
 
Applying the Beer–Lambert law: 
λmax = 290nm; Absorbance (Absmax)= 0.404; Molar absorption coefficient (ε)= 8080 M-1cm-1 
 
 
 Synthesis of compound 171 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound  164 
as the starting material (14 mg, 0.02 mmol), after 18 h, compound 171 was obtained as a light green solid 
in 27% yield (3 mg). 
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 Conjugation of compound 171 with Lysozyme 
Compound 171 dissolved in DMSO (200 µM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 26. 
 
Table 26 – Conjugation of compound 171 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.86852 [M+H]+ 100.0 - 
Lysozyme + 171 14803.04136 [M+H]+ 28.6 14803.02332 
 
 Conjugation of 171 with EDA-FA 
Compounds 171 was dissolved in DMSO, as well as EDA-FA. From these solutions compound 171 
(100 μM) reacted with 100 μM of EDA-FA in NH4CH3CO2 buffer (50.0 mM, pH 7.0) at room temperature. 
After 10 minutes, the reactions mixtures were evaluated by performing an ESI-FTICR-MS and the 
conjugated species were detected: 
 
HRMS (ESI): m/z calculated [M+H-H2O]+ = 989.39022, found [M+H-H2O]+ = 989.39107 
 
 Synthesis of compound 165 
Following the general procedure for esterification of compound 141, using NBD-NH(CH2)2OH (163) as 
the alcohol derivative (0.23 mmol), after 22 h, compound 165 was obtained as an orange solid in 88% 
yield (0.09 g). 
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1H NMR (400 MHz, CDCl3): δ 8.44 (d, J = 8.6 Hz, 
1H, CHCHCNO2), 7.71 (d, J = 8.6 Hz, 1H, 
CHarom), 6.90 (s, 1H, CHarom), 6.84 (s, 1H, 
CH2NHC), 6.78 (d, J = 8.6 Hz, 1H, CHarom), 6.19 
(d, J = 8.6 Hz, 1H, NHCCHCH), 4.45 (t, J = 5.0 Hz, 2H, OCH2CH2NH), 4.06 (t, J = 5.7 Hz, 2H, OCH2CH2), 
3.75 (d, J = 5.0 Hz, 2H, OCH2CH2NH), 2.58 (t, J = 7.1 Hz, 2H, CH2CH2COO), 2.53 (s, 3H, COCH3), 2.15 
– 2.07 (m, 2H, CH2CH2CH2), 1.42 (s, 12H, CCH3). 
13C NMR (101 MHz, CDCl3): δ 198.57 (s, CaromCOCH3), 173.50 (s, CH2COO), 162.40 (s, CaromOCH2), 
144.32 (s, 2xCNO), 143.88 (s, CCNO2CH), 143.67 (s, CCNHCH), 136.37 (s, CHCHCNO2), 133.71 (s, 
CH3COCarom), 130.83 (s, CHarom), 118.04 (s, CHarom), 113.91 (s, CHarom), 99.05 (s, NHCCHCH), 83.78 (s, 
C(CH3)2), 66.69 (s, OCH2CH2), 61.85 (s, OCH2CH2NH), 43.21 (s, OCH2CH2NH), 30.52 (s, CH2CH2CO), 
25.06 (s, C(CH3)2), 24.92 (s, COCH3), 24.41 (s, CH2CH2CH2). 
13C-HMBC 138.5 (s, CaromB) 
HRMS (ESI): m/z calculated [M+Na]+ = 577.208100, found [M+Na]+ = 577.207605. 
 
 
Figure 53 – UV spectrum of compound 165 
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Applying the Beer–Lambert law: 
λmax = 480 nm; Absorbance (Absmax)= 0.604; Molar absorption coefficient (ε)= 12080 M-1cm-1 
 
 Synthesis of compound 173 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound  165 
as the starting material (46 mg, 0.08 mmol), after 18 h, compound 173 was obtained as a orange solid in 
27% yield (11 mg). 
 
 
 Conjugation of compound 173 with Lysozyme 
Compound 173 dissolved in DMSO (200 µM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 27, Figure 54 and Figure 55. 
 
Table 27 – Conjugation of compound 173 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.84145 [M+H]+ 100.0 - 
Lysozyme + 173 14732.91497 [M+H]+ 15.1 14732.89023 
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Figure 54 – Lyzosyme (10.0 µM) with compound 173 dissolved in DMSO (200.0 µM) in ammonium acetate buffer 
(50.0 mM, pH 7.0) after 30 minutes – Positive Mode of ESI-FTICR-MS full spectrum 
 
Figure 55 – Lyzosyme (10.0 µM) with compound 173 dissolved in DMSO (200.0 µM) in ammonium acetate buffer 
(50.0 mM, pH 7.0) after 2 h – Positive Mode of ESI-FTICR-MS full spectrum 
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 Conjugation of 173 with EDA-FA 
Compounds 173 was dissolved in DMSO, as well as EDA-FA. From these solutions compounds 173 
(100 μM) reacted with 100 μM of EDA-FA in NH4CH3CO2 buffer (50.0 mM, pH 7.0) at room temperature. 
After 10 minutes, the reactions mixtures were evaluated by performing an ESI-FTICR-MS and the 
conjugated species were detected: 
 
HRMS (ESI): m/z calculated [M+H]+ = 938.33545, found [M+H]+ = 938.33917 
 
 Synthesis of compound 177 
Literature Basis – Al-Smadi, M.; Hanold, N.; Kalbitz, H.; Meier, H.; Synthesis, 2009, 15, 2539 
In a round bottom flask (A), 4’-hydroxyacetophenone (175, 0.5 g, 3.6 mmol) and potassium carbonate 
(0.5 g, 3.6 mmol) were heated in acetone to reflux for 3 h. In a separate round bottom flask (B), ethyl 4-
bromobutyrate (176, 0.8 mL, 5.5 mmol) and sodium iodide (0.8 g, 5.5 mmol) were stirred in acetone at 
room temperature for 2 h. Then, flask B was transferred to flask A and refluxed for 14 h (first reaction of 
Scheme 62, p.111). After that, acetone was evaporated and 200 mL of water were added and extracted 
with diethyl ether (3x200 mL). The solution was dried (Na2SO4), concentrated and purified by column 
chromatography (silica gel, hexane:diethyl ether (9:1)) to give a viscous oil that solidified below 20 ºC; 
compound 177 (0.54 g, 59%). 
1H NMR (400 MHz, CDCl3): δ 7.90 (d, J = 8.7 Hz, 2H, 2xCHarom), 
6.90 (d, J = 8.7 Hz, 2H, 2xCHarom), 4.13 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 4.06 (t, J = 6.1 Hz, 2H, OCH2CH2), 2.57 – 2.46 (m, 5H, 
COCH3, COCH2CH2), 2.12 (p, J = 6.6 Hz, 2H, CH2CH2CH2), 1.24 (t, 
J = 7.1 Hz, 3H, OCH2CH3). 
13C NMR (101 MHz, CDCl3): δ 196.84 (s, CaromCOCH3), 173.11 (s, OCOCH2), 162.85 (s, 
CHCaromOCH2), 130.67 (s, CHarom), 130.44 (s, CHCaromCOCH), 114.22 (s, CHarom), 67.07 (s, OCH2CH2), 
60.60 (s, OCH2CH3), 30.74 (s, COCH2CH2), 26.42 (s, COCH3), 24.56 (s, CH2CH2CH2), 14.32 (s, 
OCH2CH3). 
HRMS (ESI): m/z calculated [M+Na]+ = 273.109730, found [M+Na]+ = 273.108601. 
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 Synthesis of compound 178 
Literature Basis – Griffin, D.R.; Andrea M. Kasko, A.M.; Journal of the American Chemical Society 
2012, 134, 13103 
In a round bottom flask, 177 (0.3 g, 1.2 mmol) was stirred in a solution of trifluoroacetic acid (TFA, 
0.35 mL) and water (3.35 mL) at 90 ºC for 3 h (second reaction of Scheme 62, p.111). The product 
precipitates during the reaction and it was filtrated and washed with water and acetone to afford 178 as a 
white solid (0.24 g, 89%). 
1H NMR (400 MHz, DMSO): δ 7.79 (d, J = 8.5 Hz, 2H, 2xCHarom), 6.90 
(d, J = 8.5 Hz, 2H, 2xCHarom), 3.94 (t, J = 6.3 Hz, 2H, OCH2CH2), 2.38 
(s, 3H COCH3), 2.27 (t, J = 7.2 Hz, 2H, COCH2CH2), 1.86 – 1.81 (m, 
2H, CH2CH2CH2). 
13C NMR (101 MHz, DMSO): δ 196.47 (s, CaromCOCH3), 174.20 (s, OCOCH2), 162.48 (s, 
CHCaromOCH2), 130.61 (s, CHarom), 129.92 (s, CHCaromCOCH), 114.34 (s, CHarom), 67.08 (s, OCH2CH2), 
30.11 (s, COCH2CH2), 26.50 (s, COCH3), 24.18 (s, CH2CH2CH2). 
HRMS (ESI): m/z calculated [M+Na]+ = 245.078430, found [M+Na]+ = 245.077406. 
 
 Synthesis of compound 179 
Literature Basis – Liu, Z.; Hu, J.; Sun, J.; He, G.; Li, Y.; Zhang, G.; Journal of Polymer Science Part A: 
Polymer Chemistry 2010, 48 (16), 3573 
In a round bottom flask, under inert atmosphere, 178 (25 mg, 0.11 mmol), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDC, 65 mg, 0.34 mmol) and 4-dimethylaminopyridine (DMAP, 2 mg, 
0.01 mmol) were mixed at 0 ºC in 1 mL of previously distilled dichloromethane and stirred for 1 h. A 
solution of NBDNH(CH2)2OH (163, 50 mg, 0.23 mmol) in 0.5 mL of previously distilled acetone was added 
via a syringe and the solution was stirred for 5 h at room temperature (third reaction of Scheme 62, p.111). 
Then, the solvent was concentrated in vacuo and the residue was dissolved in dichloromethane and 
washed with a solution of 5% NaHCO3. The organic phases were dried (MgSO4) and concentrated to a 
residue that was further purified by column chromatography (silica gel, dichloromethane:ethyl acetate 1:0 
– 9:1) to afford 179 as an orange solid (34 mg, 71%). 
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1H NMR (400 MHz, DMSO): δ 9.44 (s, 1H, 
CNHCH2), 8.44 (d, J = 9.0 Hz, 1H, CHCHaromCNO2), 
7.78 (d, J = 8.6 Hz, 2H, CHarom), 6.85 (d, J = 8.6 Hz, 
2H, CHarom), 6.41 (d, J = 9.0 Hz, 1H, NHCCHaromCH), 
4.27 (t, J = 5.0 Hz, 2H, NHCH2CH2O), 3.95 (t, J = 6.3 Hz, 2H, OCH2CH2), 3.70 (s, 2H, NHCH2CH2O), 2.44 
(s, 3H, COCH3), 2.40 (t, J = 7.1 Hz, 2H, COCH2CH2), 1.92 – 1.87 (m, 2H, CH2CH2CH2). 
13C NMR (101 MHz, DMSO): δ 196.26 (s, CCOCH3), 172.56 (s, OCOCH2), 162.22 (s, CHCaromOCH2), 
145.21 (s, 2xCaromNO), 144,43 (s, CCaromNO2CH), 144,07 (s, CCaromNHCH2), 137.88 (s, CHCHaromCNO2), 
130.42 (s, CHarom), 129.82 (s, CHCaromCOCH), 114.10 (s, CHarom), 99.54 (s, NHCCHaromCH), 66.86 (s, 
OCH2CH2), 61.79 (s, NHCH2CH2O), 42.31 (s, NHCH2CH2O), 30.09 (s, COCH2CH2), 26.41 (s, COCH3), 
24.00 (s, CH2CH2CH2). 
HRMS (ESI): m/z calculated [M+Na]+ = 451.122420, found [M+Na]+ = 451.121982. 
 
 Conjugation of compound 179 with Lysozyme 
Compound 179 dissolved in DMSO (200 µM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 28, Figure 56 and Figure 57. 
 
Table 28 – Conjugation of compound 179 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.77072 [M+H]+ 100.0 - 
Lysozyme + 179 14687.05288 [M+H]+ 6.5 14687.01321 
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Figure 56 – Lyzosyme (10.0 µM) with compound 179 dissolved in DMSO (200.0 µM) in ammonium acetate buffer 
(50.0 mM, pH 7.0) after 30 minutes – Positive Mode of ESI-FTICR-MS full spectrum 
 
 
Figure 57 – Lyzosyme (10.0 µM) with compound 179 dissolved in DMSO (200.0 µM) in ammonium acetate buffer 
(50.0 mM, pH 7.0) after 2 h – Positive Mode of ESI-FTICR-MS full spectrum 
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 Bioimaging Cell Assays 
Cell staining procedure: Cell lines were culture in RPMI-1640 medium with phenol red supplemented 
with 10% fetal bovine serum and antibiotic antimycotic solution (100 units/ml penicillin, 0.1 mg/ml 
streptomycin and 0.25 mg/ml amphotericin B) at 37 ºC and under a 5% CO2 atmosphere.  
Cells were plated on a Slide 8 well plate and incubated for 2 days in the incubator. Prior to the addition 
of the cells the chambers were coated with poly-L-Lysine for one h and then each well washed with fresh 
cell culture medium. Samples to be tested were added at approximately 20 μM concentration in phenol-
red free RPMI-1640 medium for 4 h. When pre-treatment with FA-ethylenediamine was employed, the 
concentration used was 71.4 μM and the incubation time was 1 h. Cells were washed and their membrane 
stained with WGA-Alexa 594 dye for 15-20 minutes. After this staining treatment, the cells were washed 
and fresh phenol-red free RPMI-1640 medium was added. Cell imaging was carried on a Leica TCS-SP5 
Multiphoton/Confocal Fluorescence Microscope equipped with a continuous Ar ion laser (458, 476, 488, 
496 and 514 nm) and a Helium-Neon laser (633 nm). 
 
VI.4.3.2.2. Cell release study (preliminary results) 
 Synthesis of compound 181 
Literature basis – Denton, T.T; Zhang, X.; Cashman, J.R. Journal of Medicinal Chemistry, 2005, 48 
(1), 224 
In a round bottom flask, under inert atmosphere, compound 183 (50 mg, 0.25 mmol), ammonium 
acetate (184, 0.2 g, 2.45 mmol) and molecular sieves (30% (m/m)) were mixed at room temperature in 1 
mL of previously distilled methanol. Then, sodium cyanoborhydride (30 mg, 0.49 mmol) was added to the 
reaction mixture and the resultant solution was stirred at room temperature for 15 h (Scheme 64, p.112). 
Then, a filtration was performed to remove the molecular sieves and the solvent was concentrated in 
vacuo to be further purified through recryrstalization with acetone/diethyl ether and acetone/hexane. 
Compound 171 was obtained as a white greenish solid (17 mg, 30%). 
1H NMR (400 MHz, DMSO) δ 7.80 (d, J = 9.3 Hz, 1H, -CCHCHCO-), 7.27 (d, 
J = 8.6 Hz, 1H, CHarom), 6.44 (d, J = 8.6 Hz, 1H, CHarom), 5.94 (d, J = 9.3 Hz, 
1H, -CCHCHCO-), 4.71 (dd, J = 13.3, 6.6 Hz, 1H, -CCHNH2CH3), 1.38 (d, J = 
6.7 Hz, 3H, -CCHNH2CH3). 
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VI.4.4. Experimental Details of Therapeutics 
VI.4.4.1. PEGylation of biomolecules 
 Synthesis of pinacolyl boronate ester of 186 (222c) 
Following the general procedure for esterification of compound 141, using 
(triethyleneglycol)monomethyl ester (185) as the alcohol derivative (0.6 mmol) and DCM instead of ACN, 
after 24 h, compound 222c was obtained as a colorless oil in 70% yield (0.1 g). 
1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.6 
Hz, 1H, CHarom), 6.91 (s, 1H, CHarom), 6.81 
(dd, J = 8.6, 1.5 Hz, 1H, CHarom), 4.22 – 4.17 
(m, 2H, -OCH2-), 4.03 (t, J = 6.0 Hz, 2H, 
OCH2CH2), 3.67 – 3.63 (m, 2H, -OCH2-), 3.63 – 3.56 (m, 6H, -OCH2-), 3.50 (dd, J = 6.0, 3.0 Hz, 
2H, -OCH2-), 3.32 (d, J = 0.6 Hz, 3H, CH2OCH3), 2.54 – 2.48 (m, 5H, CH2CH2CH2 and COCH3), 2.11 – 
2.05 (m, 2H, CH2CH2COO), 1.39 (s, 12H, CCH3). 
13C NMR (101 MHz, CDCl3) δ 198.40 (s, CaromCOCH3), 173.00 (s, CH2COO), 162.49 (s, CaromOCH2),  
133.44 (s, CH3COCarom), 130.75 (s, CHarom), 117.87 (s, CHarom), 113.97 (s, CHarom), 83.56 (s, C(CH3)2), 
71.89 (s, -OCH2-), 70.57 (s, -OCH2-), 70,53 (s, -OCH2-), 69.06 (s, -OCH2-), 66.77 (s, OCH2CH2), 63.62 
(s, -OCH2-), 59.02 (s CH2OCH3), 30.42 (s, CH2CH2CH2), 24.94 (s, C(CH3)2), 24,82 (s, COCH3), 24.39 (s, 
CH2CH2CO). 
13C-HMBC 138.4 (s, CaromB) 
HRMS (ESI): m/z calculated [M+H]+ = 495.27644, found [M+H]+ = 495.27638. 
 
 Synthesis of compound 186 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound 222c 
as the starting material (90 mg, 0.2 mmol), after 11 h, compound 186 was obtained as a colorless oil in 
50% yield (39 mg). 
 
HRMS (ESI): m/z calculated [M+Na]+ = 435.18004, found [M+Na]+ = 435.18012 
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 Conjugation of 186 with EDA-FA 
Compounds 186 was dissolved in DMSO, as well as EDA-FA. From these solutions compound 186 
(100 μM) reacted with 100 μM of EDA-FA in NH4CH3CO2 buffer (50.0 mM, pH 7.0) at room temperature. 
After 10 minutes, the reactions mixtures were evaluated by performing an ESI-FTICR-MS and the 
conjugated species were detected. 
 
HRMS (ESI): m/z calculated [M+H]+ = 878.39833, found [M+H]+ = 878.39054 
 
 Conjugation (and reversibility) of compound 186 with Insulin 
Compound 186 dissolved in DMSO (200 µM) reacted with 10 µM of insulin in NH4CH3CO2 buffer (50.0 
mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by performing 
an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted masses for 
unconjugated and conjugated species are shown in Table 29, alongside with the relative abundances of 
the species. 
 
Table 29 – Conjugation of compound 186 with Insulin 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Insulin 5804.67089 [M+H]+ 100.0 - 
Insulin + 186 6198.84587 [M+H]+ 40.6 6198.85059 
Insulin + 2x186 6593.01857 [M+H]+ 23.7 6593.03029 
Insulin + 3x186 6987.18817 [M+H]+ 10.1 6987.20999 
 
The reversibility of the reaction was studied by removing 240 μL of the evaluated reaction and mixing 
it with 10 μL of an aqueous solution of D-fructose (0.2 M) to perform another ESI-FTICR-MS and detect 
the abundance of the conjugates. Table 30 depicts the decrease of both conjugated species in terms of 
relative abundance. 
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Table 30 – Conjugation of compound 186 with Insulin after adding 1 equivalent of D-fructose (8 mM) 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Insulin 5804.67089 [M+H]+ 100.0 - 
Insulin + 186 6198.86322 [M+H]+ 25.5 6198.871333 
Insulin + 2x186 6593.04273 [M+H]+ 21.7 6593.051036 
Insulin + 3x186 6987.194965 [M+H]+ 11.1 6987.230739 
 
Then, the conjugation system was further stressed by removing 100 μL of the previous evaluated 
reaction and mixed it with 40 μL of an aqueous solution of D-fructose (0.2 M) to perform another ESI-
FTICR-MS and detect the abundance of the conjugates. Table 31 depicts the decrease of both conjugated 
species in terms of relative abundance. 
 
Table 31 – Conjugation of compound 186 with Insulin after adding 10 equivalent of D-fructose (50 mM) 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Insulin 5804.67163 [M+H]+ 100.0 - 
Insulin + 186 6198.854375 [M+H]+ 15.1 6198.851333 
Insulin + 2x186 6593.023645 [M+H]+ 9.8 6593.031036 
Insulin + 3x186 6987.194475 [M+H]+ 5.1 6987.210739 
 
 Conjugation of 186 with Lysozyme 
Compound 186 dissolved in DMSO (200 µM) reacted with 10 µM of lysozyme in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 32. 
 
Table 32 – Conjugation of 186 with Lysozyme 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lysozyme 14296.77789 [M+H]
+
 100.0  
Lysozyme + 186 14690.96088 [M+H]
+
 11.4 14690.95759 
 
 Conjugation of 186 with Lanreotide 
Compound 186 dissolved in DMSO (200 µM) reacted with 10 µM of lanreotide in NH4CH3CO2 buffer 
(50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
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performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 33. 
Table 33 – Conjugation of compound 186 with Lanreotide 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Lanreotide 1096.48289 [M+H]
+
 100.0 - 
Lanreotide + 186 1508.68336 [M+H]
+
 8.7 1508.67316 
Lanreotide + 186 1491.67312 [M+H-H
2
O]
+
 8.4 1491.67042 
Lanreotide + 2x186 1919.87037 [M+H]
+
 5.6 1919.85615 
Lanreotide + 2x186 1901.85868 [M+H-H
2
O]
+
 1.5 1901.84613 
 
 Conjugation of 186 with Somatostatin 
Compound 186 dissolved in DMSO (200 µM) reacted with 10 µM of somatostatin in NH4CH3CO2 
buffer (50.0 mM, pH 7.0) at room temperature. After 10 minutes of reaction the solution was evaluated by 
performing an ESI-FTICR-MS and the conjugated species were detected. HRMS results of deconvulted 
masses for unconjugated and conjugated species are shown in Table 34. 
Table 34 – Conjugation of compound 186 with Somatostatin 
Reaction Deconvoluted Mass Molecule Abundance [%] Expected Mass 
Somatostatin 1637.79955 [M+H]
+
 91.2 - 
Somatostatin + 186 2031.01289 [M+H-H
2
O]
+
 3.8 2030.97980 
Somatostatin + 186 2014.00736 [M+H-2H
2
O]
+
 17.8 2013.96978 
Somatostatin + 2x186 2443.27939 [M+H-H
2
O]
+
 2.0 2443.16274 
Somatostatin + 2x186 2425.24118 [M+H-2H
2
O]
+
 2.9 2425.15273 
Somatostatin + 2x186 2407.21567 [M+H-3H
2
O]
+
 2.8 2407.14271 
 
VI.4.4.2. Study of the selectivity of internalization of iminoboronate 
conjugates 
 Synthesis of pinacolyl boronate ester of 188 (222d) 
Following the general procedure for esterification of compound 141, using paclitaxel (187) as the 
alcohol derivative (0.6 mmol), EDC instead of DCC and DCM instead of ACN, after 24 h, compound 222d 
was obtained as a white solid in 81% yield (56 mg). 
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Literature basis for NMR characterization of PTX – Chen, J.-Z.; Ranade, S.V.; Xie, X.-Q. International 
Journal of Pharmaceutics 2005, 305, 129 and Chmurny, G.N.; Hilton, B.D.; Brobst, S.; Look, S.A.; 
Witherup, K.M.; Beutler, J.A. Journal of Natural Products 1992, 55(4), 414 
1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 8.0 Hz, 
2H, 2xCHarom), 7.73 (dd, J = 13.6, 8.1 Hz, 3H, 
3xCHarom), 7.60 (t, J = 7.3 Hz, 1H, CHarom), 7.50 (dd, 
J = 14.6, 7.3 Hz, 3H, 3xCHarom), 7.41 – 7.30 (m, 7H, 
7xCHarom), 6.91 (dd, J = 17.2, 5.4 Hz, 2H, NH and 
CHarom), 6.81 (dd, J = 8.6, 1.8 Hz, 1H, CHarom), 6.37 
– 6.12 (m, 2H, -CH(OCOCH3)- and 
C(CH3)CH(OCO)CH2), 6.01 – 5.93 (m, 
1H, -NHCH(Ph)CH(OCO)-), 5.67 (d, J = 7.0 Hz, 1H, 
-C(OH)CH(OCOPh)CH-), 5.53 (d, J = 2.8 Hz, 1H, -CH(Ph)CH(OCO)COO-), 4.96 (d, J = 9.5 Hz, 
1H, -CH2CH(OCH2)C-), 4.44 (dd, J = 10.7, 6.7 Hz, 1H, -C(CH3)CH(OH)CH2-), 4.31 (d, J = 8.5 Hz, 1H, 
C(OCOCH3)CH2aOCH), 4.19 (d, J = 8.4 Hz, 1H, C(OCOCH3)CH2bOCH), 4.05 – 3.96 (m, 
2H, -OCH2CH2CH2-), 3.81 (d, J = 7.0 Hz, 1H, -CH(OCOPh)CHC(OCOCH3)-), 2.71 – 2.52 (m, 
6H, -CH2CH2COO- and -C(OH)CH2bC(OCH2)- and CaromCOCH3), 2.46 (s, 3H, -COCH3), 2.37 (dd, J = 
15.2, 9.3 Hz, 1H, -CH(OCO)CH2aC(OH)-), 2.21 (s, 3H, -COCH3), 2.18 – 2.02 (m, 
5H, -CH(OCO)CH2bC(OH)- and -CH2CH2CH2- and 2xC(OH)), 1.94 (s, 3H, -COCCH3CH(OH)-), 1.91 – 
1.83 (m, 1H, -C(OH)CH2aC(OCH2)-), 1.67 (s, 3H, C=CCH3), 1.43 (s, 12H, 2xOC(CH3)2), 1.22 (s, 3H, 
1xC(CH3)2), 1.12 (s, 3H, 1xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 203.90 (s, C(OCOCH3)COC(CH3)), 198.56 (s, CaromCOCH3), 172.21 
(s, -CH(OCO)COOCH-), 171.35 (s, -CHOCOCH3), 169.90 (s, -COCOCH3), 168.14 (s, -CH2COO-), 167.20 
(s, PhCOO-), 167.10 (s, PhCONH-), 162.40 (s, CaromOCH2), 142.81 (s, -CH(OCO)C(CH3)C-), 136.94 (s, 
CaromCONH), 133.78 (s, CHarom), 133.74 (s, CaromCHNH), 133.65 (s, CaromCOCH3), 132.88 
(s, -C(CH3)CC(CH3)2C(OCOCH3)-), 132.15 (s, CHarom), 130.86 (s, CHarom), 130.32 (s, CHarom), 129.26 (s, 
CaromCOOCH), 129.20 (s, CHarom), 128.86 (s, CHarom), 128.63 (s, CHarom), 127.15 (s, CHarom), 126.55 (s, 
CHarom), 118.10 (s, CHarom), 113.94 (s, CHarom), 84.53 (s, -CH2CH(OCH2)C-), 83.74 (s, C(CH3)2), 81.13 
(s, CH(OCOCH3), 79.21 (s, -CH2C(OH)CH(OCOPh)-), 76.52 (s, C(OCOCH3)CH2OCH), 75.68 (s, 
CH(OCOCH3), 75.17 (s, -C(OH)CH(OCOPh)CH-), 74.13 (s, -CH(Ph)CH(OCO)COO-), 72.22 (s., 
C(CH3)CH(OCO)CH2), 71.95 (s, -C(CH3)CH(OH)CH2-), 66.46 (s, -OCH2CH2-), 58.58 
(s, -COCCH3CH(OH)-), 52.81 (s, -NHCH(Ph)CH(OCO)-), 45.66 (s, -CH(OCOPh)CHC(OCOCH3)-), 43.26 
(s, Csp2C(CH3)2C(OH)-), 35.66 (s, -C(OH)CH2C(OCH2)-), 35.62 (s, -CH(OCO)CH2C(OH)-), 30.22 
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(s, -CH2CH2CO-), 26.89 (s, -C(CH3)2), 25.05 (s, -OC(CH3)2), 24.93 (s, CaromCOCH3), 24.34 
(s, -CH2CH2CH2-), 22.82 (s, -OCOCH3), 22.24 (s, -C(CH3)2), 20.94 (s, -OCOCH3), 14.95 (s, C(CH3)), 
9.70 (s, C=CCH3). 
13C-HMBC 138.2 (s, CaromB) 
HRMS (ESI): m/z calculated [M+K]+ = 1222.45903, found [M+K]+ = 1222.46159 
 
 Synthesis of compound 188 
Following the general procedure of deprotection of pinacolyl boronate ester and using compound 222d 
as the starting material (56 mg, 0.05 mmol), after 6 h, compound 188 was obtained as a white solid in 
67% yield (34 mg). 
 
 
HRMS (ESI): m/z calculated [M+Na]+ = 1124.40676, found [M+Na]+ = 1124.40796 
 
 Conjugation of 188 with EDA-FA 
Compounds 188 was dissolved in DMSO, as well as EDA-FA. From these solutions compound 188 
(100 μM) reacted with 100 μM of EDA-FA in NH4CH3CO2 buffer (50.0 mM, pH 7.0) at room temperature. 
After 10 minutes, the reactions mixtures were evaluated by performing an ESI-FTICR-MS and the 
conjugated species were detected: 
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HRMS (ESI): m/z calculated [M+H]+ = 1567.62499, found [M+H]+ = 1567.62473 
 
 Conjugation of 188 with 1-butylamine 
Compounds 188 was dissolved in DMSO, as well as 1-butylamine. From these solutions compound 
188 (100 μM) reacted with 100 μM of 1-butylamine in NH4CH3CO2 buffer (50.0 mM, pH 7.0) at room 
temperature. After 10 minutes, the reactions mixtures were evaluated by performing an ESI-FTICR-MS 
and the conjugated species were detected: 
 
HRMS (ESI): m/z calculated [M+H]+ = 1157.50346, found [M+H]+ = 1157.50685 
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 Toxicity and Viability Cell Assays 
Cell Culture. Human normal skin fibroblasts (CRL-1502), colon adenocarcinoma (CACO-2) and lung 
cancer (NCI-H460) cell lines were purchased from ATCC and cultivated in media RPMI-1640 with 
L- glutamine and supplemented with 10% fetal bovine serum (FBS), antibiotic and antimycotic solution 
and kept in a humidified atmosphere with 5% CO2 and at 37 ºC.  
Anti-proliferative assay. NCI-H460 cells were plated in 96-well plates at a density of 5x104 cells/mL. 
Plates were incubated overnight and treated next day with the samples to be tested. Samples comprised 
compound 188 (ABBA PTX derivative), compound 170 (EDA-FA), conjugate 189 (between ABBA PTX 
derivative and EDA-FA) and conjugate between compound 188 and 1-butylamine. These last conjugates 
were obtained by mixing equal micromolar amounts of compound 188 with either compound 170 or 
1-butylamine and leaving mixtures at room temperature for approximately 1 h. These samples were then 
diluted with the cell culture media with only 0.5% FBS (after dilution, the percentage of organic solvent is 
<<1% (v/v)). Cells were incubated for 48 h with several concentrations of the samples to be tested. After 
incubation, media was removed and cells washed with Hank´s balanced salt solution (HBSS). 0.5% FBS 
fresh cell culture media containing 50 g/ml neutral red was added to the plate and left for 3 h. Cells were 
then washed with PBS and the amount of neutral red retained by the cells extracted and dissolved with 
an organic solution (19.96 ml distilled water, 20 ml ethanol and 400 l glacial acetic acid). Plate was gently 
shake and read at 540 nm in a plate reader. Viability was determined by the ratio of absorbance of treated 
cells and non-treated cells (control). For each experimental condition, 4 repliques were done. IC50 were 
determined using GraphPad Prism software. 
Toxicity Assays. CRL-1502 cells were plated in 96-well plates and grown until forming a monolayer. 
Samples were prepared as described previously. In this case, incubation was carried on for 24 h and 
viability was determined likewise as explained before. Results are shown in Figure 42 (p.118) and Figure 
58. 
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Figure 58 – Viability assay for CRL-1502 (Human Skin Normal Fibroblast) cell model - 24 h of incubation 
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VI.5. Experimental Section of Chapter V 
VI.5.1. Experimental Details of pH Controlled Irreversibility 
VI.5.1.1. Synthesis of irreversible molecule 
 Synthesis of compound 197 
Literature basis – Gleye, C.; Lewin, G.; Laurens, A.; Jullian, J.-C.; Loiseau, P.; Bories, C.; 
Hocquemiller, R. Journal of Natural Products 2003, 66(5), 690 and Sato, M.; Kuwahara, Y.; Matsuyama, 
S.; Suzuki, T.; Bioscience, Biotechnology and Biochemistry 1993, 57(8), 1299 
In a round bottom flask, compound 198 (0.5 g, 3.6 mmol) and hexamethylenetetramine (0.54 g, 3.6 
mmol) were mixed in 10 mL of trifluoroacetic acid was heated at reflux for 6 h (first reaction of Scheme 
70, p.126). The reaction mixture was diluted with water and extracted with diethyl ether, dried over 
Na2SO4, and filtered and solvent was evaporated under reduced pressure. The crude product was then 
purified by flash column chromatography (silica gel, petroleum ether:dichloromethane:ether 3:1:1) to 
afford 197 as a white solid (0.3 g, 50%). 
1H NMR (600 MHz, CDCl3) δ 12.19 (s, 1H, CaromOH), 10.62 (s, 1H, CaromCOH), 7.54 – 
7.50 (m, 1H, CHarom), 7.46 (dd, J = 7.5, 1.1 Hz, 1H, CHarom), 7.15 (d, J = 8.4 Hz, 1H, 
CHarom), 3.94 (s, 3H, CaromCOOCH3). 
13C NMR (151 MHz, CDCl3) δ 197.56 (s, CaromCOH), 166.38 (s, CaromCOOCH3), 163.21 (s, CaromOH), 
135.99 (s, CHarom), 133.58 (s, CaromCOOCH3), 122.65 (s, CHarom), 122.36 (s, CHarom), 118.37 (s, 
CaromCOH), 52.95 (s, CaromCOOCH3). 
NMR characterization in accordance with the one described in literature 
 
 Synthesis of compound 201 
Literature basis – Patwardhan, S. A.; Dev, S. Synthesis 1974, 348; Sato, M.; Kuwahara, Y.; 
Matsuyama, S.; Suzuki, T.; Bioscience, Biotechnology and Biochemistry 1993, 57(8), 1299 and Taylor, 
E.C.; Chiang, C.-S. Synthesis 1977 (07), 467 
In a round bottom flask, compound 197 (1 g, 5.5 mmol) and Amberlyst® 15 (25% (m/m)) were mixed 
with trimethyl orthoformate (200, 3 mL, 11 mmol) at room temperature for 30 h (second reaction of 
Scheme 70, p.126). The reaction mixture was then filterend, using dichloromethane to clean the resin and 
the resulting solution was cleaned with sodium bicarbonate (2x10 mL) and brine (2x 10 mL). This solution 
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was dried over MgSO4 and filtered under vaccum. In the end, the solvent was evaporated under reduced 
pressure to afford 201 as a colorless oil (1.2 g, 94%). 
1H NMR (600 MHz, CDCl3) δ 8.89 (s, 1H, CaromOH), 7.31 (dd, J = 7.6, 1.2 Hz, 1H, 
CHarom), 7.25 (t, J = 7.9 Hz, 1H, CHarom), 7.02 (dd, J = 8.2, 1.2 Hz, 1H, CHarom), 6.30 
(s, 1H, CaromCH(OCH3)2), 3.87 (s, 3H, CaromCOOCH3), 3.44 (s, 6H, CaromCH(OCH3)2). 
13C NMR (151 MHz, CDCl3) δ 168.10 (s, CaromCOOCH3), 157.18 (s, CaromOH), 131.16 
(s, CaromCOOCH3), 129.92 (s, CHarom), 121.73 (s, CHarom), 121.42 (s, CHarom), 120.84 (s, CaromCH(OCH3)2), 
103.77 (s, CaromCH(OCH3)2), 54.63 (s, CaromCH(OCH3)2), 52.42 (s, CaromCOOCH3). 
NMR characterization in accordance with the one described in literature 
 
 Synthesis of compound 205 
Literature basis - Luker, T.; Bonnert, R.; Paine, S.W.; Schmidt, J.; Sargent, C.; Cook, A.R.; Cook, A.; 
Gardiner, P.; Hill, S.; Weyman-Jones, C.; Patel, A.; Thom, S.; Thorne, P.; Journal of Medicinal Chemistry 
2011 ,  54 (6), 1779 
In a round bottom flask, N-Phenyltrifluoromethanesulfonimide (202        ., 3.0 g, 8.4 mmol) was added 
portion wise to a solution of compound 201 (1.2 g, 5.3 mmol) and triethylamine (2.2 mL, 15.0 mmol) in 
DMF (13 mL) and the reaction stirred for 1 h (third reaction of Scheme 70, p.126). Water was added and 
the mixture extracted with diethyl ether. The organic layer was washed with water, LiCl (aq), brine, dried 
(Na2SO4), filtrated, concentrated and purified by flash column chromatography (silica gel, hexane:diethyl 
ether (4:1 – 1:1)) to give 205 as a white solid (1.8 g, 95%). 
1H NMR (600 MHz, CDCl3) δ 7.59 – 7.51 (m, 1H, CHarom), 7.49 – 7.41 (m, 1H, CHarom), 
7.34 (dd, J = 8.3, 1.2 Hz, 1H, CHarom), 5.81 (s, 1H, CaromCH(OCH3)2), 3.89 (s, 3H, 
CaromCOOCH3), 3.40 (s, 6H, CaromCH(OCH3)2). 
13C NMR (151 MHz, CDCl3) δ 168.09 (s, CaromCOOCH3), 148.03 (s, CaromCOTf), 134.47 
(s, CaromCH(OCH3)2), 130.82 (s, CaromCOOCH3), 130.32 (s, CHarom), 128.47 (s, CHarom), 124.42 (s, CHarom), 
118.59 (q, J = 320.0 Hz, - SO2CF3), 100.58 (s, CaromCH(OCH3)2), 54.99 (s, CaromCH(OCH3)2), 52.76 (s, 
CaromCOOCH3). 
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 Synthesis of compound 204 
Literature basis - Patent: Anacor Pharmaceuticals, Inc.; GlaxoSmithKline; US2010/256092; (2010); 
(A1) English; Ding, C.Z.; Zhang, Y.-K.; Li, X.; Liu, Y.; Zhang, S.; Zhou, Y.; Plattner, J.J.; Baker, S.J.; Liu, 
L.; Duan, M.; Jarvest, R.L.; Ji, J.; Kazmierski, W.M.; Tallant, M.D.; Wright, L.L.; Smith, G.K.; Crosby, R.M.; 
Wang, A.A.; Ni, Z.-J.; Zou. W.; Wright, J. Bioorganic & Medicinal Chemistry Letters 2010, 20, 7317 and 
Xia, Y.; Cao, K.; Zhou, Y.; Alley, M.R.K.; Rock, F.; Mohan, M.; Meewan, M.; Baker, S.J.; Lux, S.; Ding, 
C.Z.; Jia, G.; Kully, M.; Plattner, J.J. Bioorganic & Medicinal Chemistry Letters 2011, 21, 2533 
In a flame dried round bottom flask, under inert atmosphere, compound 205 (1.8 g, 5.1 mmol), 
bis(pinacolato)diboron (120, 2.6 g, 10.1 mmol), [1,1’-bis(diphenylphosphino)ferrocene]palladium (II) 
chloride (0.4 g, 0.51 mmol) and sodium acetate (1.2 g, 15.1 mmol) were flushed 3 times with Argon. Then, 
35 mL of previously distilled dioxane were added and degassed for 10 minutes with bubbling Argon. The 
reaction mixture was heated at 95 ºC for 4 days (fourth reaction of Scheme 70, p.126), after which the 
solvent was concentrated in vaccum and the crude product purified by flash column chromatography 
(silica gel, hexanedichloromethane:diethyl ether (9:0.5:0.5 – 8:1:1)) to give compound 204 as a yellowish 
solid (0.3 g, 20%). 
1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 7.7 Hz, 1H, CHarom), 7.52 (d, J = 7.2 Hz, 
1H, CHarom), 7.33 (t, J = 7.5 Hz, 1H, CHarom), 6.08 (s, 1H, CaromCH(OCH3)2), 3.86 (s, 
3H, CaromCOOCH3), 3.31 (s, 6H, CaromCH(OCH3)2), 1.36 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 168.78 (s, CaromCOOCH3), 141.49 (s, CaromB), 135.27 
(s, CHarom), 130.25 (s, CHarom), 129.79 (s, CaromCOOCH3), 127.68 (s, CHarom), 101.75 
(s, CaromCH(OCH3)2), 83.53 (s, C(CH3)2), 53.85 (s, CaromCH(OCH3)2), 52.22 (s, CaromCOOCH3), 25.09 (s, 
C(CH3)2). 
 
 Synthesis of compound 203 
Literature basis – Freskos, J.; Cynkowski, T.; Swenton J.S. Chemical Communications, 1984, 819 and 
Griffin, D.R.; Kasko, A.M. Journal of the American Chemical Society 2012, 134, 13103 
In a flame dried round bottom flask, under inert atmosphere, compound 204 (0.3 g, 0.89 mmol) was 
mixed with 2.5 mL of water. Then, 0.25 mL of trifluoroacetic acid were added and the reaction mixture 
was heated at 90 ºC for 18 h (fifth reaction of Scheme 70, p.126). At this point, a white solid had 
precipitated and a filtration under reduced pressure was performed to isolate compound 203 (0.17 g, 
67%). 
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1H NMR (400 MHz, Acetone) δ 8.01 (d, J = 7.2 Hz, 1H, CHarom), 7.94 – 7.80 (m, 1H, 
CHarom), 7.64 (t, J = 7.4 Hz, 1H, CHarom), 6.81 (s, 1H, CaromCHO(OH)), 2.06 (s, 1H, 
CaromCHO(OH)), 1.34 (s, 12H, 2xC(CH3)2). 
13C NMR (101 MHz, Acetone) δ 141.14 (s, CHarom), 130.78 (s, CHarom), 127.81 (s, 
CHarom), 85.21 (s, CaromCHO(OH)), 25.38 (s, C(CH3)2).  
Lack of solubility determined that Cquat couldn’t be detected. 
 
 Synthesis of compound 206 
Literature basis – Pennington, T.E.; Kardiman, C.; Hutton, C.A.; Tetrahedron Letters 2004, 45, 6657 
Treatment of compound 203 with 5 equiv of polystyrene–boronic acid (146) in acetonitrile/1 M HCl 
(9:1) for 20 h at 25 ºC (sixth reaction of Scheme 70, p.126), yielded 48% of compound 206, after 
evaporating solvents and performing a flash column chromatography (silica gel, hexane:acetone 1:9 – 
0:1 and 2% MeOH).  
1H NMR (400 MHz, D2O) δ 7.99 (d, J = 7.3 Hz, 1H, CHarom), 7.87 (d, J = 7.6 Hz, 1H, 
CHarom), 7.63 (t, J = 7.5 Hz, 1H, CHarom), 6.85 (s, 1H, CaromCHO(OH)). 
Lack of solubility determined that 13C NMR was not able to be achieved yet 
 
VI.5.1.2. Conjugation experiments with 1-butylamine 
VI.5.1.2.1. Preliminary reaction 
 + 
 
Aqueous Media 
 
25 ºC 
 
87  206  225 
Scheme 84 – Reaction between compound 206 and 1-butylamine 
 
Compound 206 (17 mg) was added to a 10 mL round bottom flask and then dissolved in 0.4 mL of 
deuterated water. Afterwards, 1-butylamine (87, 9 μL, 0.09 mmol) was added to the same flask and these 
compounds reacted for 18 h at 25 ºC (Scheme 84). At that time, the reaction mixture was transferred to 
a NMR tube and a 1H-NMR spectrum was collected to evaluate the product’s conversion based on the 
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comparison of the signal from α-protons of 1-butylamine and the same protons from imine/secondary 
amine. Evaluation of the 1H-NMR spectrum demonstrated a 32% conversion into the imine. 
 
VI.5.1.2.2. Fructose addition 
Based on the experience with vicinal diols and the reversibility assays performed with iminoboronates 
1 equivalent of D-fructose was added to the reaction mixture, in order to see whether or not the secondary 
amine formation could be catalysed. Unfortunately, the sugar completely hydrolysed the imine, but it is 
not clear that it boosted the cyclization. Further experiments on the subject have to be performed. 
 
VI.5.1.2.3. Influence of pH 
Compound 206 (6 mg) was added to an eppendorf and then dissolved in 0.15 mL of sodium acetate 
buffer (50.0 mM) at different pH’s. Afterwards, 1 equivalent of 1-butylamine (87, 3 μL) was added and 
these compounds reacted for 18 h at 25 ºC (Scheme 84). At that time, the reaction mixture was transferred 
to a NMR tube and diluted in D2O to collect a 1H-NMR spectrum and evaluate the product’s conversion.  
As a control, the same experiments following the same protocol were performed with a aboronated 
species (2-carboxybenzaldehyde) instead of compound 206, to demonstrate that the boronic acid’s 
presence is essential for imine formation. 
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